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Abstract 
 
Penicillin binding proteins (PBPs) are responsible for the final extracellular steps 
(transglycosylation and transpeptidation) in the biosynthesis of peptidoglycan, the 
essential cell-wall carbohydrate polymer, from its Lipid II precursor. They are 
excellent targets for antibiotics due to their essentiality for cell viability in most 
bacteria. Genus- and species-specific variation in the chemical structure of Lipid II 
can have significant consequences for the formation and metabolism of the 
peptidoglycan sacculus by the PBPs. Characterisation of these enzymes from Gram-
positive bacteria, including the substrate-enzyme interactions involved, is essential in 
both understanding the mechanisms of peptidoglycan biosynthesis and contributing 
to the development of new antimicrobials.   
 
The work presented in this thesis focuses primarily on the substrate specificity of the 
Streptococcus pneumoniae bifunctional PBPs; PBP1a and PBP2a; both 
recombinantly expressed and purified to a high level. The preference, by both 
enzymes, for amidated Lipid II as a transglycosylase substrate was identified by two 
complementary assay systems. A novel spectrophotometric assay was used to 
observe transpeptidation by S. pneumoniae PBP1a in a continuous manner; the first 
time this has been achieved for a Gram-positive PBP, and with potentially far-
reaching implications in the future of antibiotic discovery. Attempts were made to 
synthesise dipeptide branched Lipid II, implicated in β-lactam resistance, as 
substrates for the bifunctional PBPs. The role of amidation in Staphylococcus aureus 
peptidoglycan biosynthesis was also investigated, and variation in the requirement 
for this modification between the monofunctional transglycosylase MGT and 
bifunctional PBP2 identified. Two novel monosaccharide compounds were identified 
as inhibitors of transglycosylation.  
 
This thesis provides an important basis for understanding the peptidoglycan 
biosynthesis mechanisms of two globally important pathogens. This insight, and 
future work leading from it, could contribute to the development of new antibiotics, 
helping to reduce the global threat of antimicrobial resistance.  
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Chapter 1. Introduction 
 
1.1 Antimicrobial resistance 
 
The serendipitous discovery of penicillin by Alexander Fleming in 1928 (Fleming, 
1929) led to the global introduction of antimicrobials to treat bacterial infections, 
widely considered one of most significant developments in medical practice (Chopra, 
1998). The ‘Golden age’ of antimicrobial discovery between 1940-1960 (Walsh and 
Wright, 2005) saw the introduction of a large number of new classes, which were 
considered sufficient to keep bacterial infections at a low level. As a result, the 
pharmaceutical industry focused on more profitable areas, leading to a period of 
nearly 40 years in which no new classes of antimicrobials were introduced (von 
Nussbaum et al., 2006). This coincided with the gradual and eventually rapid 
increase in global prevalence of antimicrobial resistance due to overuse of existing 
drugs.  
 
Antimicrobial Resistance (AMR) is a major threat to both humans and animals, 
dramatically reducing the effectiveness of drugs that we have come to rely on in 
common medical practice.  Increasing resistance threatens to send us back to the dark 
ages of medicine, with minor infections becoming untreatable; simple operations 
could become extremely dangerous, and more complex procedures impossible. The 
most recent O’Neill report (O’Neill, 2015a) estimates that by 2050, ten million 
people may die annually, overtaking cancer death rates, at a worldwide economic 
cost of $100 trillion. It is crucially important that an interdisciplinary, multinational 
effort is made to exploit existing and identify new targets for antimicrobials. 
 
Note that the term antimicrobial is used to describe compounds active on all 
microorganisms including bacteria, parasites, viruses and fungi. The focus of this 
thesis is on bacteria, and therefore the term antibiotic will be used throughout to 
describe compounds that act specifically on bacteria. 
 
2 
 
1.2 Antibiotic targets 
 
Effective targets for antibiotic drugs are fundamental for bacterial cell viability but 
distinct from the equivalent eukaryotic process, enabling selective toxicity towards 
bacterial cells (Walsh, 2003). Most current antibiotics target one of the three main 
validated metabolic targets; DNA replication and repair, protein synthesis or 
bacterial cell wall biosynthesis (Walsh, 2003). The major classes of antibiotics are 
summarised in Table 1.1. 
 
1.2.1 DNA replication and repair 
 
The DNA double helix must be unwound for the genetic information within it to be 
accessed, and therefore complementary strands are separated temporarily for 
transcription, and permanently for replication. Transcription; the production of 
mRNA from DNA, is performed by RNA polymerase (Cramer, 2002) and is 
essential for viability. RNA polymerase is the target of the rifamycin class of 
antimicrobials, which bind close to the RNA polymerase active site and stop 
initiation of RNA synthesis (Floss and Yu, 2005). DNA topoisomerases are found in 
both prokaryotic and eukaryotic cells and are responsible for the control of DNA 
topology and relieving torsional stress during strand separation. DNA gyrase is the 
prokaryotic specific topoisomerase, responsible for introducing both negative and 
positive DNA supercoiling and is essential for bacterial viability (Champoux, 2001). 
The fluoroquinolone class of antibiotics forms a complex with DNA gyrase stopping 
re-ligation and therefore leading to the accumulation of double-stranded DNA breaks 
and subsequent cell death (Drlica et al., 2008).  
 
1.2.2 Protein synthesis 
 
A range of antibiotic classes target bacterial protein biosynthesis, an attractive target 
due to its complex nature and machinery that is sufficiently different from its 
eukaryotic counterpart. Central in protein synthesis is the ribosome, a 
ribonucleoprotein made of two subunits (30S and 50S), which associate to form a 
70S ribosome upon the initiation of protein synthesis (Nissen et al., 2000). The large 
3 
 
number of processes involved in initiation, elongation and termination provide ample 
possibilities for disruption, and examples of existing antimicrobials include 
streptogramins, macrolides and phenicols, which target the 50S ribosomal subunit, 
and aminoglycosides and tetracyclines that act on the 30S subunit (Kohanski et al., 
2010).  
 
1.2.3 Bacterial cell wall biosynthesis 
 
The bacterial cell wall is essential for viability, predominantly due to its main 
component, peptidoglycan. This forms a sacculus surrounding the cell providing 
mechanical strength to withstand the high internal turgor pressure, as well as acting 
as an anchor for cell wall associated proteins and carbohydrates. The peptidoglycan 
biosynthetic pathway is highly conserved between species, despite the variations in 
composition seen, and therefore antibiotic classes are able to inhibit homologous 
targets (Lazar and Walker, 2002). Peptidoglycan and its biosynthesis is the main 
focus of this thesis and is covered comprehensively in Sections 1.5 and 1.6.  
 
Class Example Target 
Quinolones Ciproflaxin DNA replication 
Rifamycins Rifampin Transcription 
Sulfonamides Sulfadimethoxine Folate synthesis 
Tetracyclines Minocycline Translation 
Aminoglycosides Streptomycin Translation 
Macrolides Erythromycin Translation 
Oxazolidinones Linezolid Translation 
β-lactams Penicillin Peptidoglycan biosynthesis 
Glycopeptides Vancomycin Peptidoglycan biosynthesis 
Lipopeptides Daptomycin Cell membrane 
Cationic peptides Colistin Cell membrane 
Table 1.1: Major classes of antibiotic. Examples of common antibiotics within the main clinically 
used classes of antibiotics, and their mode of action. Not intended to be an exhaustive list. Davies and 
Davies, 2010 
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1.3 Antibiotic resistance  
 
Resistance to antibiotics is a natural, evolutionary mechanism that all bacteria 
employ in order to survive (Normark and Normark, 2002). Low-level resistance, 
which exists for nearly all clinical antibiotics (Levy and Marshall, 2004), only 
becomes a problem when it increases to the point where widespread therapeutic 
failure occurs. However, the natural process of resistance development has been 
hugely accentuated by over 60 years of strong man-made selection pressure due to 
the underuse, overuse and misuse of antibiotics, and the vast quantities released into 
the environment (Davies and Davies, 2010). 
 
Resistance to many antibiotics exists before they are introduced to the clinic, such as 
pneumococcal resistance to optochin in lab animals, observed before it was used to 
treat infections in the early 1900s (Harwell and Brown, 2000). An entire species can 
be inherently resistant to large numbers of drugs such as Pseudomonas aeruginosa, 
which has an outer membrane impermeable to most hydrophobic antibiotics and a 
multidrug efflux pump that removes many that do enter (Lambert, 2002; Normark 
and Normark, 2002). Mycoplasma do not have a peptidoglycan layer in their cell 
wall, and therefore are inherently resistant to any antibiotics targeting it (Taylor-
Robinson and Bébéar, 1997) 
 
The development of resistance has a very broad time scale; it can be rapid such as the 
development of sulphonamide resistance, which was observed in the late 1930s 
following its clinical introduction in 1937, and was subsequently enhanced by gene 
amplification (Davies and Davies, 2010). It can be much slower in some cases, such 
as vancomycin resistance, which wasn’t detected for nearly 30 years (Johnson et al., 
1990). However, it is not always clear whether the antibiotic or resistance came first 
(Davies and Davies, 2010). The acquisition of resistance is generally through 
mutations or gene transfer, as a result of persistent selection pressure.  
 
Spontaneous mutations within the genome result in insertions, deletions, point 
mutations and inversions, and the frequency of these events vary hugely between 
bacteria. This mechanism is employed by Mycobacterium tuberculosis, which cannot 
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readily undergo genetic exchange (Riska et al., 2000), and has developed resistance 
to many drugs including rifampicin, streptomycin and macrolides (Ramaswamy and 
Musser, 1998). The stepwise build up of mutations resulting in high-level resistance 
is more clinically important than single-step mutations, as identification in the early 
stages should lead to steps being taken to slow down development. Fluoroquinolone 
resistance is a well-understood example of step-wise resistance, through mutation of 
genes causing increased expression of efflux pumps. This has the potential for high 
level multidrug resistance development as efflux pumps have a range of substrates 
(Normark and Normark, 2002). Resistance mutations can affect the natural function 
of the antibiotic target resulting in fitness costs and therefore compensatory 
mechanisms are required, often involving the target protein, and these prevent future 
mutational reversion (Normark and Normark, 2002).  
 
Horizontal gene transfer is common between bacteria within a genus, although it can 
occur in more evolutionary distinct organisms too (Alekshun and Levy, 2007) and is 
identifiable by the presence of DNA within bacterial genomes originating from 
different sources (Normark and Normark, 2002). Genetic transfer is either by 
transformation (uptake of environmental DNA by naturally competent bacteria), 
transduction (transfer via bacteriophages) or conjugation (direct transfer between 
bacterial cells) and involves a range of mobile genetic elements such as plasmids, 
transposons and integrons. Plasmids range in size from 1-100 kb and contain several 
genes including those encoding antibiotic resistance and those required for self-
replication. Transposons have their own transposase enabling them to insert into the 
host chromosome, and they encode specific resistance to one antibiotic. Integrons are 
incorporated into genetic elements and can further acquire exogenous gene cassettes 
which they turn into functional genes (Alekshun and Levy, 2007). 
 
1.3.1 Physiological mechanisms of antibiotic resistance 
 
Both inherent and acquired resistance manifest in three main physiological 
mechanisms of antibiotic evasion; inactivation of the drug, reduced uptake and 
accumulation in the cell or alteration of the drug target. Bacteria can use one or more 
of these mechanisms. 
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1.3.1.1 Antibiotic inactivation 
 
Inactivation of antibiotics can be by modification or hydrolysis, for both of which 
there are well-characterised examples. Modification of the ribosome targeting 
antibiotics chloramphenicol (50S) and aminoglycosides (30S) by the addition of 
functional groups dramatically reduces their affinity for the target (Blair et al., 2015). 
These modifications include O-phosphorylation, N-acetylation and O-adenylation 
catalysed by phosphoryltransferases, acetyltransferases and adenyltransferases 
respectively (Shaw et al., 1993). 
 
β-lactam antibiotics are inactivated by enzymatic hydrolysis of the β-lactam ring, 
which removes their functional group. β-lactamases are a large group of enzymes 
with active site similarity to the antibiotic target (Philippon et al., 1989), which are 
highly efficient in drug removal by hydrolysing up to 103 penicillin molecules/sec 
(Walsh, 2000). The β-lactamases are grouped into 4 classes; A, C and D comprising 
an active site serine, and class B which require zinc for activity and catalysis is 
through direct attack of a hydroxide ion rather than through a covalent intermediate 
(Palzkill, 2013). Thousands of enzymes exist that can hydrolyse a wide range of 
antibiotics such as macrolides, aminoglycosides and phenicols (Blair et al., 2015). 
 
1.3.1.2 Reduced uptake and accumulation 
 
Antibiotics must reach sufficient concentrations at the target site in order to be 
effective and there are several mechanisms by which this can be avoided. Gram-
negative bacteria are inherently more resistant to most antibiotics, due to the 
presence of an outer membrane in their cell wall that excludes both hydrophobic and 
large molecules. Antibiotics such as quinolones and β-lactams can enter the cell 
through outer membrane porins, which are required by the cell for nutrient uptake, 
although reduced absorption efficiency resulting in antibiotic resistance has been 
observed in a number of bacteria including P. aeruginosa and Escherichia coli 
(Fernández and Hancock, 2012).  
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If antibiotics enter the cell in sufficient quantities, they can be removed by active 
efflux. Efflux pumps are found in the cytoplasmic or outer membrane of all bacteria 
and are used for the energy-dependent transport of lipophilic and amphipathic 
molecules. They are also used as a protective mechanism to remove toxic 
compounds such as antibiotics (Webber and Piddock, 2003). Mutational removal of 
transcriptional repressors leads to overexpression and as pumps often exhibit wide 
substrate specificity this can results in high-level multidrug resistance such as that 
observed in P. aeruginosa (Blair et al., 2015; Fernández and Hancock, 2012) 
 
1.3.1.3 Alteration of the antibiotic target 
 
Alteration of the drug target is another effective mechanism, as observed in 
resistance to β-lactams and vancomycin. Mutations in Streptococcus pneumoniae 
penicillin-binding protein (PBP) active sites result in low affinity for β-lactam 
antibiotics but enables the bacterium to continue to build its cell wall effectively. As 
a main focus of this thesis, this is covered in more detail in Section 1.8. 
Staphylococcus aureus has acquired an additional PBP with low affinity for β-
lactams which can compensate for the lost activity of native proteins upon antibiotic 
treatment (Pinho et al., 2001).  
 
Vancomycin resistance is commonly achieved through target modification. 
Glycopeptide antibiotics such as vancomycin bind to the terminal D-Ala-D-Ala 
residues of the peptidoglycan precursor Lipid II (Nieto and Perkins, 1971). Substrate 
sequestration results in inhibition of peptidoglycan synthesis and consequently cell 
lysis. Resistant bacteria express the products of the vanHAX genes, which are 
responsible for incorporation of D-Ala-D-Lac instead of D-Ala-D-Ala into Lipid II 
(Walsh et al., 1996). The resulting loss of a single hydrogen bond in the 
vancomycin-Lipid II interaction reduces affinity by 1000-fold (McComas et al., 
2003).   
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1.3.2 Overcoming antibiotic resistance  
 
Antibiotic resistance will always exist, as it is a natural evolutionary mechanism. 
However, a coordinated, multinational and interdisciplinary approach is required to 
enable us to continue treating bacterial infections and to enable the medical 
profession to continue breaking boundaries. Efforts need to be focused towards 
conserving the lifespan and efficacy of existing drugs, and changes in behaviour 
resulting from this can help to ensure relative longevity of new antibiotics introduced 
in the future. The recent, and on-going O’Neill Reports highlight the importance of 
improved diagnostics (O’Neill, 2015), a problem that the longitude research prize 
hopes to solve (www.longitudeprize.org). The £10 million pound prize fund is 
offered to the first group to create a cheap, accurate, rapid and easy-to-use point of 
care test for infections with the aim of reducing the number of inappropriately 
prescribed antibiotics. 
 
In parallel with changes in behaviour it is important that we further exploit existing 
antimicrobial targets and identify new drugs. There are a huge number of possible 
approaches for the discovery of new antibiotics, which will not be covered here. 
These include, and are by no means restricted to rational and de novo drug design, 
high throughput screening, genomics based approaches as well as screening of 
compounds from natural sources. Natural products, or their derivatives make up a 
vast proportion of the antibiotic agents that currently exist (Brown et al., 2014). 
These are most often identified through screening of soil microorganisms and 
extraction of antibiotic compounds. However, only 1% of bacteria are culturable in 
laboratory conditions. A particularly exciting recent development in this area is the 
development of the Ichip by Nichols et al. (2010), which enables the growth of a 
range of previously unculturable microorganisms. Use of this method has already 
resulted in the discovery of a new cell wall inhibitor, teixobactin, to which no 
resistance has been detected (Ling et al., 2015). 
 
This thesis focuses on improved understanding of bacterial cell wall synthesis as a 
fundamentally interesting biological mechanism, as well as a validated target for 
antibiotics. Better understanding can help in the design of new drugs, which is just 
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one way in which we can help to ensure bacterial infections remain only a minor 
health problem for future generations. 
 
1.4 The bacterial cell wall 
 
Bacteria are classed as Gram-positive or Gram-negative based upon their reaction 
with the dye-iodine complex of Gram stain (Gram, 1884), which demonstrates the 
main difference in the cell wall structure of these two classes. The Gram stain reacts 
with the peptidoglycan polymer found exclusively in almost all eubacteria, with the 
exception of Mycoplasma. In Gram-positive bacteria, the stain interacts with the 20-
80 nm thick peptidoglycan layer, which makes up 30-70% of the overall cell wall 
structure (Bugg, 1999, Schleifer and Kandler, 1972). In contrast, in Gram-negative 
bacteria the thin 2-3 nm peptidoglycan layer surrounded by an outer membrane 
cannot interact with the stain (Gram, 1884, Bugg, 1999). The Gram-negative outer 
membrane is a complex layer made up of phospholipids, lipoproteins, 
lipopolysaccharides and porins (Bugg, 1999). The main features of the Gram-
positive and Gram-negative cell wall structure are illustrated in Figure.1.1. 
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Figure 1.1: The major features of the Gram-positive and Gram-negative cell wall. Major features are illustrated in schematic form. CM: cytoplasmic 
membrane, OM: outer membrane, P: periplasm. LP: Lipopolysaccharide, PG: peptidoglycan. Both cell walls have a peptidoglycan layer which is 10-20 layers 
thick in Gram-positive and 1-3 layers in Gram-negative. Adapted from Cabeen and Jacobs-Wagner (2005) 
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1.4.1 The Gram-positive cell wall 
 
The Gram-positive bacteria Streptococcus pneumoniae and Staphylococcus aureus 
are the particular focus of this thesis. Both have the structure of a typical Gram-
positive organism (Figure 1.1) with a thick layer of peptidoglycan (Section 1.5). 
Both also have a highly decorated cell surface with wall teichoic acids (WTA) and 
lipoteichoic acid (LTA), the former is anchored to the peptidoglycan sacculus and 
the latter to the cytoplasmic membrane. Teichoic acids are anionic glycopolymers 
consisting of phosphodiester-linked polyol units. WTA makes up approximately 90% 
of the S. pneumoniae cell wall teichoic acids (Vollmer, 2007), and are required for 
full expression of β-lactam resistance in methicillin resistant Staphylococcus aureus 
(MRSA) (Brown et al., 2013). They are involved in maintaining cell shape, cell 
division and the susceptibility to antibiotics of many Gram-positive bacteria (Brown 
et al., 2013). 
 
Pathogens (both Gram-positive and Gram-negative) responsible for invasive diseases 
often produce an extracellular polysaccharide capsule (CPS)(O’Riordan and Lee, 
2004)(not shown in Figure 1.1), which helps to resist phagocytosis and therefore is 
crucial for virulence. CPS range from linear polymers of two or more 
monosaccharides to complex branched polysaccharides with additional side chains 
(Paton and Morona, 2007), and distinct CPS types are used to define the serotype of 
bacteria. There are 90 known S. pneumoniae serotypes to date (Henrichsen, 1995), 
but relatively few strains of Staphylococcus aureus have been recognised as capsule 
positive (O’Riordan and Lee, 2004). CPS has successfully been targeted in the 
design of vaccinations against pneumococcal infections (World Health Organisation, 
2012), although the full mechanisms of CPS biosynthesis and expression are not 
fully understood (Paton and Morona, 2007).  
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1.5 Peptidoglycan 
 
1.5.1 The role of peptidoglycan 
 
Peptidoglycan is essential for bacterial survival and inhibition of its biosynthesis 
results in cell lysis. The polymer forms a sacculus surrounding the bacterial cell 
cytoplasmic membrane and its primary role is to withstand cellular turgor pressure 
(Vollmer et al., 2008), which can be up to 3 MPa in some Gram-positive bacteria 
(Bugg, 1999), due to its high mechanical strength. It is responsible for maintaining 
the defined cell shape (Young, 2003) through its close association with cell growth 
and division (Vollmer et al., 2008). Peptidoglycan also has a non-structural role as a 
scaffold to anchor extracellular structures such as lipoproteins in Gram-negative 
bacteria and proteins and teichoic acids in Gram-positive.  Proteins on the surface of 
Gram-positive bacteria are involved in adhesion, invasion and resistance to 
phagocytic killing and therefore are often crucially important in pathogenicity 
(Navarre and Schneewind, 1999).  
 
1.5.2 Peptidoglycan structure 
 
Peptidoglycan is a polymer of linear glycan strands cross-linked by short peptide 
stems. This basic structure is conserved but a high level of genus- and species-
specific diversity exists in the peptidoglycan sacculus. This variation is important in 
the interaction and action of cell wall synthesis and modification enzymes, as well as 
in resistance to antibiotics and sacculus degradation. Interspecies variation is used for 
the taxonomic classification of bacteria (Schleifer and Kandler, 1972).  
 
This section describes the conserved general structure of peptidoglycan, which is 
illustrated in Figure 1.2, with subsections detailing the main modifications observed. 
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1.5.2.1 The glycan backbone 
 
The glycan chain backbone of peptidoglycan is made up of alternating N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) sugar residues 
linked by β-1,4-glycosidic bonds. A pentapeptide stem is appended to the lactoyl 
side chain of the MurNAc residues (Section 1.5.2.2) (Bugg, 1999; Vollmer, 2008). 
This β-1,4-linked glycan backbone is found in all bacteria, although no known 
bacterial species possess an unmodified version (Section 1.5.2.1.1) in their mature 
peptidoglycan (Vollmer, 2008). Sugar residues are either linked to other cell-wall 
polymers or directly modified post synthesis.  
 
1.5.2.1.1 Variation in the glycan backbone 
 
The action of glycan strand-cleaving enzymes such as glucosaminidases and 
muramidases give variation in the terminal sugar residue of the polysaccharide 
backbone. Gram-positive Staphylococcus aureus may possess a GlcNAc residue at 
the reducing end rather than MurNAc due to cleavage by N-acetylglucosaminidase 
(Boneca et al., 2000), whereas the glycan chain of all Gram-negative bacteria and 
MurNAc 
L-Ala 
D-Glu 
L-Lys/ 
meso-DAP 
D-Ala 
D-Ala 
MurNAc 
L-Ala 
D-Glu 
L-Lys/ 
meso-DAP 
D-Ala 
D-Ala 
GlcNAc 
GlcNAc 
MurNAc 
L-Ala 
D-Glu 
L-Lys/ 
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D-Ala 
D-Ala 
MurNAc 
L-Ala 
D-Glu 
L-Lys/ 
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L-Ala 
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GlcNAc 
Figure 1.2: Basic structure of peptidoglycan. Glycan chains of alternating N-acetylglucosamine 
(GlcNAc) and N-acetylmuramic acid (MurNAc) linked by β-1,4-glycosidic bonds (red -). Peptide stems 
generally contain L-Lys in the third position in Gram-positive bacteria and meso-DAP in Gram-
negative. Cross-links between peptide stems (- - -) normally between position 3 and 4 of adjacent stems 
and are shown as direct links here. Variation exists in every component as discussed in the text. 
Adapted from Bugg et al., (1999). 
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some Gram-positive terminate with a 1,6-anhydrous-N-acetylmuramic acid (with an 
intramolecular ring) due to degradation by lytic transglycosylases (Section 
1.6.4)(Vollmer, 2008).  
 
Secondary modifications such as N-deacetylation, O-acetylation and N-glycolylation 
are observed frequently. N-deacetylation of GlcNAc and MurNAc to GlcN and MurN 
is responsible for lysozyme resistance, and are formed by peptidoglycan deacetylases 
acting on polymerised peptidoglycan (Vollmer, 2008). O-acetylation and de-O-
acetylation of MurNAc also occurs on newly polymerised peptidoglycan and have a 
role in resistance to most known muramidases. It is also associated with a range of 
other functions such as peptidoglycan cross-linking, autolysis and the recognition of 
peptidoglycan by host factors in infection (Vollmer, 2008). N-Glycolylation of the 
muramic acid 2-amino group to a glycolyl residue is found in most genera with 
mycolic acid, such as Rhodococcus, Gordonia and Mycobacterium (Azuma et al., 
1970; Sutcliffe, 1998), and also in some genera within the Acinomycetales 
(Evtushenko et al., 2002; Li et al., 2005; Matsumoto, 2003). This modification 
occurs on the final soluble cytoplasmic precursor, UDP-MurNAc pentapeptide, 
through the action of monooxygenases, and is believed to play a role in antibiotic 
and lysozyme resistance (Vollmer, 2008).  
 
The average glycan chain length varies significantly between bacteria, and at 
different locations within the cell (Wang et al., 2008), but surprisingly does not 
correlate with the thickness of the peptidoglycan layer. Gram-positive Bacilli spp. 
and Staphylococcus aureus have thick cell walls and glycan chains ranging in length 
from 50-250 disaccharides, and approximately 6 units respectively (Boneca et al., 
2000; Hughes, 1971). The model Gram-negative organism; E. coli has chains of 10-
40 disaccharide units (Vollmer, 2008).  
 
1.5.2.2 The pentapeptide stem 
 
A pentapeptide stem is attached to the MurNAc sugar and has the basic structure of  
L-Ala-γ-D-Glu-meso-DAP(or L-Lys)-D-Ala-D-Ala. The third position amino acid is 
meso-DAP in Gram-negative bacteria and L-Lys in Gram-positive (Schleifer and 
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Kandler, 1972). Several components of the pentapeptide structure are unusual, such 
as the γ linked D-Glutamic acid, with the only other documented occurrences in 
folate derivatives (Kislliuk, 1981) and bacterial exopolymers (Troy, 1973). D-amino 
acids are formed by racemisation of L-amino acids and are important in resistance to 
protease digestion of the cell wall (Bugg, 1999).  meso-DAP is a non-protein amino 
acid not found in animals, and together with the presence of D-amino acids provide 
interesting bacterial specific targets for antibiotics (Bugg, 1999). The pentapeptide 
stem is commonly described as the stem peptide as it is often lacking the terminal D-
Ala in mature peptidoglycan, and in some cases the penultimate D-Ala; resulting in 
tetra- and tripeptides.  
 
1.5.2.2.1 Variation in the stem peptide 
 
A large amount of variation occurs at every position on the stem peptide (Schleifer 
and Kandler, 1972), introduced through the action of Mur ligases (Section 1.6.1) or 
by modifications later in peptidoglycan biosynthesis. Most variation is in the cross-
linking third position amino acid, incorporated by the MurE ligase, where a wide 
variety of amino acids exist such as L-Lys, meso-DAP, LL-DAP and less commonly 
residues including L-homoserine, 2,4-diaminobutyric acid, L-ornithine and meso-
lanthionine (Vollmer et al., 2008). Of particular note is the presence of D-Lac or D-
Ser in the fifth position in strains resistant to the vancomycin antibiotic (Healy et al., 
2000).  
 
Post synthesis modifications such as hydroxylation, amidation, acetylation and 
attachment of proteins most commonly occur on position 2 or 3 at the lipid-linked 
stage of peptidoglycan synthesis, although many of the mechanisms involved are as 
yet unknown. D-Glu, meso-DAP and L-Lys have a hydroxylated hydrocarbon chain 
in some species, which in the case of D-Glu is dependent on oxygen supply during 
growth, and the ε-carboxyl of meso-DAP and α-carboxyl of glutamic acid are 
frequently amidated (see Section 1.5.2.2.2). Stem peptides act as a covalent anchor 
for many cell envelope proteins in both Gram-positive and Gram-negative bacteria 
(Dramsi et al., 2008).  
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1.5.2.2.2 Amidation of the stem peptide  
 
A particular focus of this thesis is the amidation of D-glutamate at position 2 to D-
isoglutamine, by the coordinated action of a glutamine amidotransferase like protein 
(GatD) and a Mur ligase homologue (MurT). These were first isolated from 
Staphylococcus aureus (Münch et al., 2012; Figueiredo et al., 2012), and more 
recently Streptococcus pneumoniae (Zapun et al., 2013). Amidation is frequently 
observed in Gram-positive bacteria (Schleifer and Kandler, 1972) and homologous 
transcriptional units have been identified in many bacteria of this class including 
Clostridium perfringens and Mycobacterium tuberculosis (Münch et al., 2012). Loss 
of amidation in Staphylococcus aureus results in a slower growth rate, increased 
sensitivity to lysozyme and reduced β-lactam resistance (Figueiredo et al., 2012), 
and is believed to play a role in innate immune signalling (Münch et al., 2012). 
Recent work has identified amidated peptidoglycan to be an optimal substrate for the 
late cell wall synthetic enzymes in S. pneumoniae (Zapun et al., 2013), and is 
investigated more fully in this thesis. 
 
A model for amidation by GatD/MurT has been proposed (Münch et al., 2012) 
(Figure 1.3), in which ammonia from glutamine (the primary nitrogen donor) is 
shuttled from GatD to the MurT synthetase active site, which subsequently amidates 
Lipid II in an ATP dependent manner. The exact timing of the process in 
peptidoglycan biosynthesis is not categorically confirmed, particularly with respect 
to peptide bridge formation (Section 1.5.2.3), but it has been demonstrated to be at 
the bactoprenol-bound stage.  
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1.5.2.3 Stem peptide cross-links 
 
Cross-links between pentapeptide stems are critical for peptidoglycan rigidity, and 
provide significant structural variation. The extent of cross-linking varies, typically 
between 25-50% in Gram-negative bacteria, and 70-90% in Gram-positive species 
(Glauner, 1988). Direct cross-links between the ε-amino group of meso-DAP (or L-
Lys) and the α-carbonyl of the position 4 D-Alanine in an adjacent peptide stem 
occur most commonly in Gram-negative bacteria with meso-DAP in the third 
position (but are also found in L-Lys containing stems). Gram-positive bacteria 
predominantly form indirect cross-links through an interpeptide bridge of 1-5 amino 
acids (Section 1.5.2.3.1). A peptide bond is formed between the α-amino group of 
the N-terminal amino acid in the peptide bridge and the α-carbonyl of the position 4 
D-Alanine in these cases (Vollmer et al., 2008). Interpeptide bridges exhibit a large 
amount of variation between bacterial species and are covered in more detail in the 
following section.  
 
Gln 
H2O 
Glu 
NH3 
ATP 
ADP 
Pi 
GatD 
MurT 
D-Glu D-isoGln 
Figure 1.3: Proposed mechanism of D-glutamate amidation by GatD/MurT.  Ammonia is 
shuttled from glutamine by the GatD glutaminase active site. MurT subsequently amidates D-
glutamate to D-isoglutamine in an ATP dependent manner. Diagram is a cartoon representation and 
not to scale. Lipid linker is shown as a representation and is not biologically correct. Adapted from 
Münch et al., (2012) 
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1.5.2.3.1 Variation in stem-peptide cross-links 
 
Intracellular membrane-associated ligases catalyse the addition of interpeptide 
bridges on the ε-amino group of the third position meso-DAP or L-Lys. Assembly is 
in the opposite direction to that of protein synthesis (Bugg, 1999) and uses 
aminoacyl-tRNAs as substrates. Bridge assembly occurs mostly at the lipid-linked 
stage, with the exception of Lactobacillus viridescens and Enterococcus faecalis 
(Hegde and Blanchard, 2003). Table 1.2 shows some examples of the peptide bridges 
formed in a range of bacteria. 
 
 
Bacterial species Peptide bridge composition 
Streptococcus pneumoniae L-Ser-L-Ala or L-Ala-L-Ala 
Staphylococcus aureus Gly-Gly-Gly-Gly-Gly 
Lactobacillus viridescens L-Ala-L-Ser or L-Ala-L-Ser-L-Ala 
Enterococcus faecium D-Asp, D-Asn 
Enterococcus faecalis L-Ala-L-Ala 
Streptomyces coelicolor Gly 
Table 1.2: Peptide bridge composition in Gram-positive branched peptidoglycan. (Vollmer et 
al., 2008) Sequence is carboxyl to amino terminal from left to right.  
 
 
Of particular interest in this project is the peptide bridge of S. pneumoniae (and 
Staphylococcus aureus to a lesser extent), both of which are essential in the 
expression of high level β-lactam resistance. The S. pneumoniae L-Ala-L-Ala or L-
Ser-L-Ala cross-link is assembled by the MurM and MurN tRNA-dependent ligases, 
which are non-essential but required for β-lactam resistance (Filipe et al., 2000), in 
which MurM plays a particularly important role (Lloyd et al., 2008). MurM is 
responsible for the addition of the first L-Ser or L-Ala and MurN the second L-Ala 
(De Pascale et al., 2008; Lloyd et al., 2008). Pentaglycine bridge formation in 
Staphylococcus aureus is catalysed by the FemX, FemA and FemB ligases, in which 
FemX adds the first glycine and FemA and FemB subsequently add two each 
(Rohrer and Berger-Bächi, 2003). FemX is essential (Tschierske et al., 1999) and all 
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three proteins must be present for full expression of β-lactam resistance (Ling and 
Berger-Bächi, 1998). 
 
Variation is also observed in direct cross-links. Peptide bonds between adjacent 
meso-DAP residues are important in β-lactam resistance; up to 10% of E. coli 
crosslinks are of this type (Glauner, 1988), and are found in high levels in non-
replicating Mycobacterium tuberculosis (Lavollay et al., 2008). Micrococcaceae 
peptidoglycan cross-linking is between the L-Ala at position one and D-Ala at 
position four (Ghuysen et al., 1968).  
 
1.5.3 Is peptidoglycan biosynthesis a viable antibiotic target? 
 
Peptidoglycan biosynthesis is validated as an antibiotic target as the success of two 
of the most clinically important classes of antibiotic, β-lactams and glycopeptides, 
have demonstrated (Bugg, 1999). The biosynthesis of peptidoglycan is a complex 
and essential process, making it an excellent target for antibiotics. The intracellular, 
membrane bound and extracellular steps provide a wide range of possible targets, 
and targeting the extracellular catalytic steps negates the structural difficulties 
associated with drug penetration of the cytoplasmic membrane. 
 
Understanding the biosynthesis of peptidoglycan is vitally important in the 
development of new antibiotics, as despite it being the target for key classes of drugs 
and its essentiality for cell survival, it has been underexploited as a target. Recent 
developments in structural biology, the in vitro synthesis of peptidoglycan 
biosynthetic intermediates and the development of high throughput screening (HTS) 
methods now makes detailed biochemical characterisation of the enzymes involved a 
possibility (Bugg et al., 2011). The insight obtained will progress the understanding 
of this fundamental process as well as aiding in the development of novel antibiotics 
to reduce the burden of antimicrobial resistance.  
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1.6 Peptidoglycan biosynthesis 
 
The biosynthesis of peptidoglycan is a complicated, multi-stage process, involving 
approximately 20 reactions and is under tight spatial and temporal control (Scheffers 
and Pinho, 2005). The biosynthetic steps can be split into three distinct stages; 
cytoplasmic, intracellular membrane bound and extracellular membrane bound. The 
first two stages are illustrated in Figure 1.4, and the final extracellular in Figure 1.5. 
 
1.6.1 Cytoplasmic steps 
 
The cytoplasmic steps of peptidoglycan synthesis are catalysed in a tightly ordered 
mechanism by six enzymes, MurA-F and involves the synthesis of UDP-MurNAc-
pentapeptide from UDP-GlcNAc (Figure 1.4). Several additional ‘side’ reactions are 
required to synthesise the D-glutamate and D-Ala-D-Ala substrates for MurD and 
MurF respectively (Barreteau et al., 2008).  
 
MurA forms the UDP-GlcNAc-enolpyruvate substrate for MurB by transfer of an 
enolpyruvate group to UDP-N-acetylglucosamine from PEP (phosphoenolpyruvate). 
MurB subsequently reduces this to UDP-N-acetylmuramic acid (UDP-MurNAc) in 
an NADPH dependent manner. ATP dependent amino acid ligases; MurC-F attach 
the pentapeptide stem to the UDP-MurNAc lactoyl group using an Mg2+ cofactor. 
Detailed analysis of the biochemical properties of MurC-MurF has shown that they 
have the same three-dimensional structure, reaction mechanism and six-amino acid 
ATP binding site. Variation at the N-terminus allows for the different lengths of the 
stem peptide substrates (Smith, 2006). 
 
1.6.2 Intracellular membrane associated steps 
 
The intracellular membrane associated steps of peptidoglycan biosynthesis are 
catalysed by MraY and MurG (Figure 1.4). MraY initially transfers the phosphor-
MurNAc-pentapeptide from the product of the cytoplasmic steps onto undecaprenyl 
phosphate (C55) to form Lipid I (Bouhss et al., 2004; Lloyd et al., 2004). The 
undecaprenyl phosphate carrier is produced by either dephosphorylation of 
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undecaprenyl pyrophosphate or kinase mediated phosphorylation of undecaprenol 
(Manat et al., 2014). The MraY catalysed reaction is coupled to MurG, which 
transfers N-acetylglucosamine from UDP-GlcNAc to Lipid I to form Lipid II 
(undecaprenyl pyrophosphoryl-MurNAc-(GlcNac)-pentapeptide)(Ha et al., 1999). 
Many of the amino acid based modifications in peptidoglycan structure (Sections 
1.5.2.2 and 1.5.2.3) occur at his point.  
 
1.6.2.1 Linking the intracellular and extracellular steps 
 
Lipid II must be flipped to the extracellular face of the cytoplasmic membrane before 
it can be incorporated into peptidoglycan by extracellular enzymes. The protein (or 
proteins) responsible remain a controversial research area, after more than 30 years 
of research. The main considered candidates have been MurJ, FtsW, RodA and 
SpoVE. In 2011, Mohammadi et al. demonstrated that FtsW could transport Lipid II 
across both proteoliposomes and membrane vesicles (Mohammadi et al., 2011) and 
later went on to demonstrate the substrate specificity of FtsW for Lipid II and 
suggested a mechanism for transport through a size-restricted pore-like structure 
(Mohammadi et al, 2014). This was widely considered to have solved the elusive 
flippase problem. However, almost coinciding evidence from elegant in vivo 
investigations has suggested that MurJ may actually be responsible for the 
translocation of Lipid II (Sham et al., 2014). The authors went so far as to 
demonstrate that FtsW does not flip Lipid II in vivo, going against the conclusions 
from previous in vitro work (Mohammadi et al., 2011). The real identity of the Lipid 
II flippase remains to be confirmed, with the possibility of multiple complementary 
or coordinated partners not discussed in the literature to date, and all work so far 
concerning E. coli, the flippase may in fact be a family of flippases with different 
roles at different points in the cell cycle.  
 
Page 22: Figure 1.4: The cytoplasmic and intracellular membrane associated steps in 
peptidoglycan biosynthesis. NAM = MurNAc, NAG = GlcNAc. UDP-GlcNAc converted to 
UDP-MurNAc by MurA and MurB. MurC-MurF sequentially add L-Ala, D-Glu, L-Lys (or meso-
DAP) and D-Ala-D-Ala to UDP-MurNAc. Side reactions required to make novel amino acids also 
shown. Gram-negative specific steps in green. MraY transfers UDP-MurNAc-pentapeptide to the 
undecaprenyl lipid carrier and MurG adds a final GlcNAc to form Lipid II. Lipid II is flipped to 
the extracellular (periplasmic in Gram-negative) space by FtsW or MurJ.. Figure adapted from 
unpublished figure by Dr Vita Godec 
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1.6.3 Extracellular membrane associated steps 
 
Lipid II is incorporated into peptidoglycan on the extracellular face of the 
cytoplasmic membrane by the penicillin-binding proteins (PBPs), which catalyse 
transglycosylation and transpeptidation (Figure 1.5). The PBPs are the focus of this 
thesis and are covered in more detail in Section 1.7.  
 
Transglycosylation is the elongation of glycan chains from Lipid II by incorporation 
of the disaccharide-pentapeptide into a growing polymer. A β-1,4-glycosidic bond is 
formed between the incoming GlcNAc and terminal MurNAc of the glycan chain, 
with the release of undecaprenyl pyrophosphate. The lipid carrier is translocated 
back across the cytoplasmic membrane either before or after dephosphorylation 
(Manat et al., 2014), resulting in undecaprenyl phosphate, the substrate for MraY 
(Section 1.6.2).  
 
The soluble glycan polymers are cross-linked by the transpeptidase activity of PBPs 
to form an insoluble sacculus, which can withstand the high internal turgor pressure 
of the cell. Cross-linking consists of direct or indirect peptide bonds between amino 
acids of adjacent peptide stems as described in Section 1.5.2.3. Both PBP catalysed 
reactions are covered in more detail in Section 1.7.  
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Figure 1.5: Extracellular membrane associated steps of peptidoglycan biosynthesis.  NAM = MurNAc, NAG = GlcNAc. Following the translocation of Lipid II to the 
extracellular (periplasmic in Gram-negative bacteria) side of the cytoplasmic membrane, the disaccharides are polymerised into glycan chains by transglycosylases. 
Transpeptidases form cross-links between pentapeptide stems to give structural rigidity. The lipid carrier is translocated back across the cytoplasmic membrane either before or 
after dephosphorylation. Figure adapted from unpublished figure by Dr Vita Godec 
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1.6.4 Processing and recycling of peptidoglycan 
 
Peptidoglycan biosynthesis is regulated at multiple levels in order to balance cell 
wall synthesis with cell growth, and in response to many factors including growth 
conditions, other bacteria and the cell cycle (Egan et al., 2015). The sacculus must be 
constantly remodelled and rebuilt in order to allow cell growth, separation of 
daughter cells and peptidoglycan turnover (Vollmer et al., 2008a). The 
peptidoglycan synthases are regulated by localisation and spatial regulation, 
precursor availability, environmental conditions and protein-protein interactions 
(Egan et al., 2015). In addition, the peptidoglycan hydrolases, made up of 
glycosidases (glycan strand cleaving) and peptidases (peptide stem cleaving) are 
responsible for the localised breakdown of the cell wall to allow modification of the 
sacculus. They have also been extensively used in the study of native peptidoglycan 
structure for many years (Vollmer et al., 2008a). This expansive class of enzymes 
possesses a large amount of redundancy, and many enzymes within it have multiple 
functions making the attribution of roles particularly difficult (Höltje and Tuomanen, 
1991; Smith et al., 2000). There is a known hydrolase for every bond in 
peptidoglycan, although only a subset is found in each bacterial species (Vollmer et 
al., 2008a). Table 1.3 summarises the roles of cell wall hydrolases in S. pneumoniae, 
and Figure 1.6 illustrates their hydrolytic activity on peptidoglycan. 
 
Cell wall hydrolase 
Pneumococcal 
protein 
Role 
DD-carboxypeptidase PBP3 Cell wall synthesis regulation 
N-acetylglucosaminidase LytB Daughter cell separation 
N-acetylmuramyl-L-alanine amidase LytA Major autolysin 
N-acetylmuramidase LytC Autolysin 
Peptidoglycan GlcNAc deacetylase PgdA Lysozyme resistance 
Table 1.3: S. pneumoniae peptidoglycan hydrolases.  Pneumococcal protein responsible for each 
hydrolytic activity illustrated in Figure 1.6, and cell cycle role of each enzyme (Vollmer, 2007) 
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Peptidoglycan recycling has been documented in Gram-negative but not Gram-
positive bacteria to date. A large degree of variation exists in the extent of 
peptidoglycan turnover between bacterial strains and also within them dependent on 
growth conditions (Reith and Mayer, 2011). Up to 50% of E. coli peptidoglycan is 
recycled and either used as an energy source, or to synthesise new peptidoglycan 
(Park and Uehara, 2008). Gram-positive bacteria shed 25-50% of its peptidoglycan 
per generation through outward expansion and the action of hydrolases, (Reith and 
Mayer, 2011). Following the identification of orthologs of recycling enzymes, and 
the massive loss of cell wall material involved, a Gram-positive peptidoglycan 
recycling system has been speculated but not proven (Reith and Mayer, 2011) 
 
 
 
 
MurNAc MurNAc GlcNac 
L-Ala 
D-Gln 
L-Lys 
D-Ala 
D-Ala 
DD-carboxypeptidase 
Peptidoglycan GlcNAc 
deacetylase 
N-acetylmuramyl-L-
alanine amidase 
N-acetylmuramidase N-acetylglucosaminidase 
Figure 1.6: S. pneumoniae peptidoglycan hydrolases. Arrows mark the point of cleavage of 
peptidoglycan hydrolases, illustrated with the basic structure of S. pneumoniae peptidoglycan. 
Adapted from Vollmer, 2007. 
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1.7 The penicillin-binding proteins 
 
The work in this thesis focuses on the activity of the penicillin-binding proteins 
(PBPs), which are responsible for polymerisation of the glycan chains of 
peptidoglycan (transglycosylation) as well as peptide stem cross-linking 
(transpeptidation), the final stages in the peptidoglycan biosynthesis pathway. PBPs 
are essential for cell viability due to their role in peptidoglycan tensile strength, and 
in addition to their lack of eukaryotic counterparts this makes them excellent 
antimicrobial targets (Bugg, 1999). Penicillin bears a structural resemblance to the 
natural PBP substrate: the D-Ala-D-Ala terminus of the stem pentapeptide precursor, 
thus they are sensitive to penicillin (where resistance is not found). This is the 
characteristic by which the class of enzymes were discovered, and subsequently 
named by Tipper and Strominger (1965). The term penicillin-binding proteins is 
misleading with regards to their function as the catalytic activities they are 
responsible for are transglycosylation, transpeptidation and carboxypeptidation.  
 
PBPs have been studied since they were first discovered in the 1960s (Tipper and 
Strominger, 1965), but despite this, relatively little is known about their enzymatic 
mechanisms and interactions with other cell wall proteins. Progress has been slow 
predominantly due to the nature of the enzymes and substrates involved. PBPs are 
integral membrane proteins, which are notoriously difficult to study, but the main 
barrier has been availability of the structurally complex Lipid II substrate. Recent 
advances in both areas have made their detailed study possible, and the biochemistry 
of these critical enzymes is beginning to be revealed.  
 
1.7.1 Nomenclature and classification of PBPs 
 
Most bacterial species express between three and eight different PBPs, which vary in 
relative abundance and constitute approximately 1% of their membrane protein 
population (Waxman and Strominger, 1983). Bacillus subtilis is unusual in its 
expression of sixteen distinct PBPs (Sauvage et al., 2008). PBPs are numbered 
within organisms based on their relative separation by SDS-PAGE (sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis) due to differences in molecular weight. 
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The gradual nature of identification means that some PBPs have an additional letter 
after the number. This nomenclature is confusing as PBPs of similar sizes and 
properties have different numbers in a range of organisms, making comparisons of 
function complicated.  
 
PBPs can be divided into two main classes; high molecular weight (HMW) and low 
molecular weight (LMW)(Waxman and Strominger, 1983) and their characterisation 
and topology is illustrated in Figure 1.7. HMW PBPs (60-140kDa) are integral 
membrane proteins consisting of a cytoplasmic tail, transmembrane spanning anchor 
and two extracellular domains joined by a β-rich linker. HMW PBPs are further sub-
classified into class A or class B depending on the characteristics of the N-terminal 
extracellular domain. In class A it is responsible for transglycosylase activity, and in 
class B it is thought to interact with cell cycle proteins to affect cell morphogenesis 
(Macheboeuf et al., 2006; Sauvage et al., 2008). The C-terminal extracellular domain 
has transpeptidase activity in both classes of HMW PBPs, and class A are known as 
bifunctional due to their dual transglycosylase and transpeptidase activity. LMW 
PBPs (40-50kDa) are commonly referred to as class C PBPs and have a single 
catalytic domain with either D,D-carboxypeptidase or endopeptidase activity 
(Denome et al., 1999), making up some of the peptidoglycan hydrolases covered in 
Section 1.6.4. Class C PBPs are membrane associated through a transmembrane or 
amphipathic helix (Macheboeuf et al., 2006). 
 
Monofunctional glycosyl transferases (MGTs) are expressed by some bacteria and 
have a complementary role to the transglycosylase activity of HMW class A PBPs 
(Di Berardino et al., 1996; Reed et al., 2011; Spratt et al., 1996; Wang et al., 2001). 
These differ from PBPs in that they have no penicillin-binding domain; however, 
they are integral membrane proteins with a crucial role in peptidoglycan 
polymerisation (Macheboeuf et al., 2006). 
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N
N
N
C
C
C
C
Class A: 
Bifunctional 
Class B: 
Monofunctional 
Class C 
Monofunctional 
Transglycosylase 
Transglycosylase 
Transpeptidase 
Transpeptidase 
Carboxypeptidase 
Endopeptidase 
Transpeptidase 
Transglycosylase 
High molecular 
weight (HMW) 
Low molecular 
weight (LMW) 
TM 
TM 
TM 
AH 
Penicillin-binding domain: 
Transpeptidase domain 
Penicillin-binding domain: 
Transpeptidase domain 
Transglycosylase domain 
Non penicillin-binding domain 
Penicillin-binding domain: 
Transpeptidase domain 
Transglycosylase domain 
Figure 1.7: Classification of the Penicillin-Binding Proteins: Classification shown on the left. Monofunctional transglycosylases are not PBPs but are shown for 
completeness due to their complementary role. Domain topology of each class shown where TM: transmembrane region, AH: amphipathic helix.  Enzymatic activity of each 
class shown on the right. 
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1.7.2 PBPs as part of the cell wall synthesis complex 
 
Some PBPs are unique and essential, whereas others demonstrate a level of 
functional redundancy within the cell. The interaction of a range of PBPs for 
localisation as well as functional and regulatory reasons has been shown. Cell wall 
metabolism during the cell cycle can be generally divided into two stages in rod 
shaped bacteria and the pneumococci; elongation and division, requiring tight 
temporal and spatial control of a range of essential proteins (Macheboeuf et al., 
2006) and increasingly recognised as involving two separate large multi-subunit 
complexes (Zapun et al., 2012). Variation exists in the mechanisms due to the 
different shapes of bacteria (Pinho et al., 2013), and the components of spatially 
distinct division and elongation complexes are best understood in the Gram-negative 
model organism Escherichia coli (Typas and Sourjik, 2015). 
 
The tightly regulated polymerisation of FtsZ (bacterial tubulin homologue) at the 
septum forms the Z ring and initiates cell division (Bi and Lutkenhaus, 1991; 
Errington et al., 2003) by recruitment of other members of the septal machinery to 
the division site, including the septal PBPs. In rod shaped bacteria, the PBPs 
involved in peripheral peptidoglycan synthesis co-localise with an actin-like 
cytoskeleton containing MreB in patches that move along the long axis of the cell 
powered by peptidoglycan synthesis (Domínguez-Escobar et al., 2011; Garner et al., 
2011; van Teeffelen et al., 2011). Cocci do not possess an MreB homologue and 
therefore the mechanism of peripheral cell wall synthesis is unclear (Pinho et al., 
2013).  
 
Immunoprecipitation, biochemical, immunofluorescence and genetic experiments in 
E. coli, Bacillus subtilis and Streptococcus pneumoniae have shown cell division and 
elongation to involve at least one Class A and Class B PBP, along with lytic 
transglycosylases and other cell wall proteins (Massidda et al., 2013; Popham and 
Young, 2003; Typas and Sourjik, 2015). 
 
This thesis focuses on the Gram-positive pathogens Staphylococcus aureus and S. 
pneumoniae and the following sections briefly summarise the current knowledge of 
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the role of PBPs in the cell wall synthetic machinery of these bacteria. Illustrated in 
Figure 1.8.  
 
1.7.2.1 Staphylococcus aureus cell wall synthesis machinery 
 
Spherical cocci such as Staphylococcus aureus build their cell wall using a single 
basic machinery that can be transient in some cases (Pinho et al., 2013). 
Staphylococcus aureus has an exceptionally minimal mechanism of cell wall 
synthesis which occurs only at the septum (Kuru et al., 2012; Pinho and Errington, 
2003) and requires only four PBPs (and one monofunctional transglycosylase), with 
an additional acquired transpeptidase in methicillin resistant strains. One each of 
Class A HMW, Class B HMW and LMW PBPs; PBP2, PBP1 and PBP4 localise at 
the septum (Pinho and Errington, 2003), and the localisation of the fourth HMW 
Class B PBP3 is not known to date. PBP1 is recruited to the mid-cell by an as yet 
unidentified divisome protein (Pereira et al., 2007; 2009), and PBP2 is recruited by 
its Lipid II substrate (Pinho and Errington, 2005). PBP4 as a LMW PBP is unusual in 
having transpeptidase activity and is responsible for forming highly cross-linked 
peptidoglycan. It is recruited by an intermediate of the wall teichoic acid (WTA) 
synthesis (pathway) (Atilano et al., 2010) after the initiation of peptidoglycan 
synthesis by PBP1 and PBP2.  
 
1.7.2.2 Streptococcus pneumoniae cell wall synthesis machinery 
 
The ovoccocal shape of pneumococcal cells suggests that the cell wall is formed by 
successive elongation and division processes, and therefore is likely to involve a 
distinct elongasome and divisome similar to that of rod shaped bacteria such as         
E. coli. However, the peripheral machinery in streptococci is adjacent to the septum 
instead of in the sidewall (Pinho et al., 2013), which may more resemble the recently 
identified FtsZ dependent preseptal elongation of E. coli (Typas et al., 2012). The 
current evidence suggests the presence of one large complex containing both sub-
machineries, which assembles at the midcell (reviewed excellently by Massidda et 
al., 2013). The currently favoured two-state model suggests that the peripheral 
machinery inserts new peptidoglycan between the septum and equatorial rings, 
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causing the cell to elongate, and the septal machinery synthesises the cross wall by 
following the leading edge of the septum (Pinho et al., 2013). Recent high-resolution 
microscopy of live cells following the incorporation of fluorescent probes into the 
growing cell wall has suggested that the apparatus may separate into two separate 
machineries in late cell division (Cadby and Lovering, 2014; Tsui et al., 2014), 
which would support this two state model. It is clear that the mechanisms of cell wall 
synthesis in ovococci such as S. pneumoniae are not fully understood, but new 
methods of observing live cells (Tsui et al., 2014) show real promise for future work. 
 
The current knowledge of the role of PBPs in the pneumococcal cell wall identifies 
that the Class B transpeptidases PBP2x and PBP2b are found in the septal and 
peripheral sub-machinery respectively (Massidda et al., 2013), however PBP2x may 
play a more exceptional role in an unusual form of septal closure as it locates 
separately from all other peptidoglycan synthesis proteins in the mid to late stages of 
cell division (Tsui et al., 2014). This may be mediated through the extracellular C-
terminal PASTA domains of PBP2x (Peters et al., 2014). The bifunctional Class A 
PBP1a has been observed in both the peripheral and septal machinery (Land and 
Winkler, 2011; Massidda et al., 2013), and it is believed to be important in creating 
the septum. The Class C carboxypeptidases are located across the entire cell surface 
(Barendt et al., 2011). The mechanism of PBP localisation is not well understood, 
but is believed to be substrate dependent (Hasper et al., 2006; Pinho et al., 2013) and 
mediated by the trimming activities of PBP3 restricting the correct substrate to the 
mid-cell (Morlot et al., 2004). Recent work has identified the importance of the 
StkP/DivIVA/GpsB triad in fine-tuning septal and peripheral peptidoglycan 
biosynthesis and therefore maintainance of the oval shape of S. pneumoniae (Fleurie 
et al., 2014). This is in keeping with the theory of a single large complex with sub-
machineries. 
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1.7.3 The transglycosylase domain of PBPs 
 
Monofunctional glycosyltransferases (MGTs) and Class A bifunctional PBPs possess 
a transglycosylase domain which is responsible for the polymerisation of Lipid II 
into glycan chains. Peptidoglycan transglycosylases are classified in the 
glycosyltransfer family 51 (GT51) according to the Carbohydrate-Active enzymes 
(CAZY) scheme (www.cazy.org). This class is characterised by being membrane 
bound, using undecaprenyl-based substrates and possessing a novel structural fold 
(Section 1.7.3.1). 
 
V
V
V
V
V
V
PBP1 PBP2 
Autolysin 
Septal 
growth 
PBP4 
Active 
autolysin 
PBP2x 
PBP1a 
PBP2b 
Autolysin 
PBP3 
Active 
autolysin 
Peripheral 
growth 
Septal 
growth 
Division site 
Equatorial 
ring 
Staphylococcus aureus Streptococcus pneumoniae 
Figure 1.8 Organisation of PBPs in cell wall synthesis of Staphylococcus aureus and S. 
pneumoniae. Staphylococcus aureus: PBP1 and PBP2 synthesise peptidoglycan at the septum. PBP4 is 
recruited later and is responsible for high levels of cross-linking. Autolysin (Atl) becomes active in the 
later stages of the cell cycle and causes septum splitting. S. pneumoniae: Septal peptidoglycan 
synthesis is catalysed by PBP1a and PBP2x. Peripheral insertion of new cell wall is by PBP2a. PBP3 is 
located throughout the cell and is thought to trim the terminal D-Ala from peptidoglycan stem peptides 
so that the correct substrate for PBPs is at the mid-cell. Adapted from Pinho et al., (2013). 
 34 
 
1.7.3.1 Structure of the transglycosylase domain 
 
Crystal structures of peptidoglycan transglycosylases from Staphylococcus aureus 
and Aquifex aeolicus (Lovering et al., 2007; Yuan et al., 2007) enabled the first 
structural identification of the catalytic domain, and further structures published 
since have confirmed the same common predominantly α-helical topological fold 
(Heaslet et al., 2009; Huang et al., 2012; Sung et al., 2009). 
 
The active site is found in a deep cleft between two lobes: a globular “head” region, 
which has low homology with λL lysozyme and a small hydrophobic region, termed 
the ‘jaw’ domain (Lovering et al., 2007; Yuan et al., 2007). The ‘jaw’ is thought to 
interact with Lipid II and the membrane by embedding or closely associating and is 
rich in hydrophobic residues (Lovering et al., 2007; Yuan et al., 2007). The λL 
lysozyme and transglycosylase active sites have secondary structure similarities, 
despite low sequence homology. The globular ‘head’ domain of both overlay well, 
with differences in the ‘jaw’ domain; which is composed mainly of β-sheets in 
lysozyme and α-helices in the transglycosylases. This structural similarity can be 
rationalised by the substrate similarity between the two and suggests a possible 
evolutionary acquisition of the GT51 fold by lysozyme (Lovering et al., 2007). The 
homology extends as far as the active site, with the essential catalytic glutamate of    
Staphylococcus aureus PBP2 and λL lysozyme oriented similarly, as well as the 
reaction products of lysozyme and reactants of PBP2 (Lovering et al., 2012a).  
 
Structures of E. coli PBP1b and Staphylococcus aureus MGT including the 
transmembrane (TM) spanning region, show that it is in close contact with the 
transglycosylase domain, but doesn’t affect the active site structure. Both structures 
show that the TM region maintains proper membrane orientation (Huang et al., 2012; 
Sung et al., 2009). Binding experiments showed the importance of the TM region in 
moenomycin interaction for both enzymes, and the transglycosylase activity of MGT 
(Huang et al., 2012). The overall structure of E. coli PBP1b, Staphylococcus aureus 
MGT and Staphylococcus aureus PBP2 transglycosylase domains are shown in 
Figure 1.9, bound to moenomycin as a substrate mimic (Section 1.7.3.2).  
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E. coli PBP1b S. aureus MGT S. aureus PBP2 
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Figure 1.9: Structural comparison of the transglycosylase domains of E. coli PBP1b, Staphylococcus aureus MGT and Staphylococcus aureus PBP2. Comparison of 
the structures of transglycosylase domains bound to moenomycin in the donor site as a substrate mimic (Section 1.7.3.2) Full domain is shown in ribbon form in cyan. 
Conserved motifs 1-5 are shown in red, magenta, green, dark blue and yellow respectively (Section 1.7.3.3). Conserved active site glutamate shown in stick form as part of 
motif 1. Moenomycin in stick form shown bound in the donor site. The globular ‘head’domain and flexible ‘jaw domain’ are labelled on the left of the figure. Structural 
alignments using moenomycin; Staphylococcus aureus PBP2 against Staphylococcus aureus MGT; RMSD: 0.856 Å for 71 atoms, E. coli PBP1b against Staphylococcus 
aureus MGT; RMSD: 1.14Å for 67 atoms. The transmembrane region of E. coli PBP1b and Staphylococcus aureus MGT can be seen extending from the bottom of the image. 
image. The structure of Staphylococcus aureus PBP2 was solved without the transmembrane region, and the linker and transpeptidase domain were removed for this image 
for both Staphylococcus aureus PBP2 and E. coli PBP1b. Credit: Dr Dean Rea for help in producing this figure. PDB accession codes; E. coli PBP1b:  3FWL; Staphylococcus 
aureus MGT: 3VMR; Staphylococcus aureus PBP2: 20LV. 
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A linker region known as the UB2H domain directly joins the transglycosylase and 
transpeptidase domains of E. coli PBP1b. It consists of five anti-parallel β-sheets and 
one α-helix, and is known to interact with LpoB, an outer membrane lipoprotein that 
stimulates transpeptidase activity (Paradis-Bleau et al., 2010; Typas et al., 2010). 
Linker regions exist in other bifunctional PBPs such as Staphylococcus aureus PBP2 
(Lovering et al., 2007), although have not been shown to functionally interact to 
date. 
 
1.7.3.2 Moenomycin: a transglycosylase inhibitor and structural tool 
 
The natural product moenomycin is the best characterised directly binding inhibitor 
of transglycosylase activity. The moenomycins are a family of glycolipid antibiotics 
produced by Streptomyces ghanaensis, and Moenomycin A is the main antimicrobial 
component (Ostash and Walker, 2010). Moenomycin A will be referred to as 
moenomycin throughout this thesis. Moenomycin is highly active against many 
Gram-positive bacteria, but due to its poor pharmacokinetic properties such as a long 
half-life and poor absorption, it cannot be developed as an antibiotic and has instead 
been used extensively in animal feed. The first crystal structure of a PBP bound to 
moenomycin (Lovering et al., 2007) gave direct evidence that it mimics the growing 
glycan chain (Lipid IV more specifically) in the donor site, an outcome predicted 
from its structural similarity (shown in Figure 1.10). This led to the conclusion that 
the growing glycan chain is the transglycosylase donor and Lipid II is the acceptor. 
Further crystal structures of transglycosylases bound to moenomycin have supported 
this (Heaslet et al., 2009; Huang et al., 2012; Sung et al., 2009; Yuan et al., 2008), 
and Perlstein et al. (2007) confirmed the donor and acceptor identities. Figure 1.9 
shows the crystal structures of E. coli PBP1b, Staphylococcus aureus MGT and 
Staphylococcus aureus PBP2 bound to moenomycin in the donor site.  
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1.7.3.3 Conserved residues of the transglycosylase domain 
 
The conserved residues of the transglycosylase domain are found in five motifs 
(Figure 1.9)(Lovering et al., 2008a), which have been shown to be essential in E. coli 
PBP1b, A. aeolicus PBP1a and Staphylococcus aureus MGT (Barrett et al, 2007; 
Heaslet et al., 2009; Terrak et al., 2008). Motifs 1-3 are central in the catalytic cleft, 
with motif 2 dividing the two substrate binding pockets; one for the growing glycan 
chain and the other for the incoming Lipid II. Motif 4 and 5 are proposed to play a 
more structural role; as motif 4 lines the back of the cleft, and motif 5 is found more 
peripherally in the globular ‘head’ domain. (Lovering et al., 2007). Mutational 
Figure 1.10: Structural comparison of moenomycin and peptidoglycan (Lipid IV). 
The structure of moenomycin (top) and Lipid IV (2 disaccharides) are shown. The glycan 
components of both are very similar, as well as the lipid anchor of peptidoglycan and 
lipid tail of moenomycin. Rings A-F are labelled on the structure. Peptide on the 
peptidoglycan structure represents the pentapeptide stem appended to the lactoyl group of 
the MurNAc sugar. 
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analyses have confirmed the role of the conserved residues, with motif 2 shown as 
essential for Lipid II recognition (Di Guilmi et al., 2003), and the catalytic glutamate 
identified as part of motif 1 (Terrak et al., 1999), with surrounding motif 1 conserved 
residues important in its positioning (Terrak et al, 2008). Positively charged lysine 
and arginines in motif 2 and 3 are predicted to be involved in substrate positioning 
(Lovering et al, 2007; Terrak et al., 2008).  
 
The first structure of a transglycosylase (Staphylococcus aureus MGT) bound to a 
Lipid II analogue in the acceptor site (Huang et al., 2012) identified the important 
acceptor interacting residues structurally for the first time (Figure 1.11). An 
unexpected observation was that the D-lactyl ether of MurNAc interacts with the 
transglycosylase domain, a region thought to only be involved in the transpeptidase 
reaction. This has implications for the role of the pentapeptide stem recognition in 
transglycosylase activity. Mutation of the proposed Lipid II contacting residues and 
activity analysis confirmed the crucial residues, in particular showing that K140 and 
R148 together stabilise the pyrophosphate leaving group, a departure from the 
previous prediction (Huang et al., 2012). 
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Figure 1.11: The MGT transglycosylase acceptor site. A: Natural substrate for the acceptor site: 
Lipid II. B: Lipid II analogue used for co-crystallisation with Staphylococcus aureus MGT FL by 
Huang et al .,(2012). Grey denotes the area observable on the electron density map. C: Schematic 
view of the interaction between Staphylococcus aureus MGT and Lipid II analogue showing 
hydrogen-bonding networks (black) and interactions around Mg2+ (red) of conserved resides (blue 
font). Interacting residues from sequence alignment and comparison of crystal structures shown for 
E. coli PBP1b (red) and Staphylococcus aureus PBP2 (green). Figure adapted from Huang et al., 
(2012).  
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1.7.3.4 Mechanistic features of transglycosylation 
 
Transglycosylation involves integration of the disaccharide units of Lipid II onto the 
reducing terminus of a growing glycan chain (Perlstein et al., 2007) as demonstrated 
by an elegant set of experiments in which the terminal GlcNAc of Lipid II was 
blocked with [14C]-labelled-galactose, preventing it from acting as a glycosyl 
acceptor at the non-reducing end. Chain extension by E. coli PBP1a, E. coli PBP1b, 
Staphylococcus aureus PBP2 and A. aeolicus PBP1a with this modified substrate 
demonstrated that chain extension occurs at the reducing terminus of the 
diphospholipid.   
 
Transglycosylation is a processive activity (Yuan et al., 2007), in such that the 
transglycosylase catalyses several rounds of polymerisation before releasing the 
glycan product. Time-course analysis of glycan products separated by SDS-PAGE 
identified long chains rather than the accumulation of short chains (Barrett et al., 
2007) supporting the model, along with the presence of an active site flap covering 
the A. aeolicus transglycosylase site observed in the crystal structure (Yuan et al., 
2007).  
 
Wang et al., (2008) demonstrated by SDS-PAGE separation of transglycosylase 
products, that PBPs from different organisms (and enzymes within the same 
organism) produce glycan chains of differing lengths, independent of the substrate: 
enzyme ratio. This is unsurprising given the variety of shapes and sizes of bacterial 
cells, and the presence of multiple transglycosylases in many organisms. E. coli 
PBP1a, E. coli PBP1b, E. faecalis PBP2a and Staphylococcus aureus PBP2 were 
found to produce chain lengths of approximately 30, 50, 15 and 15 disaccharide units 
respectively and S. pneumoniae PBP2a makes glycan chains of 20-30 units (Helassa 
et al., 2012). A mechanism for release of the product at the enzyme specific 
threshold length has not been elucidated to date. 
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1.7.3.5 Transglycosylase catalytic mechanism 
 
A catalytic mechanism for transglycosylation has been proposed based on crystal 
structures and accompanying biochemical analyses. The recent structure of 
Staphylococcus aureus MGT with a Lipid II analogue (Huang et al., 2012) has 
enabled the most detailed mechanistic insight to date supported by a comprehensive 
mutagenesis study (Illustrated in Figure 1.12), and has built on previous insight from 
the structures of Staphylococcus aureus PBP2, E. coli PBP1b and an earlier 
Staphylococcus aureus MGT structure (Heaslet et al., 2009; Lovering et al., 2007; 
2008; Sung et al., 2009). The binding of two Lipid II molecules, one in the donor and 
one in the acceptor site initiates transglycosylation, involving the interaction with 
several specific residues (detailed in Figure 1.12). E100 acts as a base to deprotonate 
the 4-OH of the GlcNAc in the acceptor site, which is stabilised by R241 and 
subsequently reacts with the C1 of the donor site Lipid II (or growing glycan chain). 
This results in a β-1,4-glycosidic bond and an inversion of the configuration of the 
C1 anomeric carbon. The displaced undecaprenyl pyrophosphate leaving group is 
stabilized by K140 and R148 of the donor site, an alteration from the previous 
suggestion of E156. The Lipid IV (or longer chain) is shuffled to the donor site, 
before a new Lipid II binds to the acceptor site in a mechanism proposed to be 
assisted by the higher affinity of the pyrophosphate-lipid moiety for the donor site 
(Lovering et al., 2007). The presence of a π-bulge on the edge of the jaw subdomain 
could allow local unfolding or disorder to allow this transition to occur (Lovering et 
al., 2008).  
 
Recently, positive cooperativity has been demonstrated between the acceptor and 
donor sites of the monofunctional transglycosylase (MGT) from Staphylococcus 
aureus (Bury et al., 2015). Binding of Lipid II analogues to the acceptor site causes 
an allosteric activation of the donor site leading to an increase in affinity for 
moenomycin. Bury and colleagues propose that Lipid II binds preferentially to the 
acceptor site causing a conformation change that stabilises the mobile region 
between motifs 1 and 2, previously implicated to be involved in acceptor binding 
(Lovering et al., 2008). This conformational change extends to the donor site, thus 
increasing its affinity for a second Lipid II (or maintaining the interaction with the 
growing glycan chain). This mechanism is likely to be particularly important in the 
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initiation of transglycosylation but also in processivity due to increased binding of 
the elongating chain. 
 
1.7.4 The penicillin-binding domain 
 
Class A and B high molecular weight (HMW) as well as the low molecular weight 
(LMW) PBPs, all possess a penicillin-binding domain. These were named following 
early experiments showing that penicillin blocked the formation of peptide cross-
links, leading to morphological differences in E. coli cells (Gardner, 1940; Tipper 
and Strominger, 1965). Tipper and Strominger (1965) proposed that penicillin 
formed a stable covalent penicilloyl enzyme by binding to the active site due to its 
H3 
H4 
H5 
Figure 1.12: Proposed mechanism for transglycosylation by PBPs. Illustrated with Staphylococcus 
aureus MGT. A: Donor (S2) and acceptor (S1) sites shaded in red. Binding of two Lipid II substrates 
represented by moenomycin (S2 site) and a Lipid II analogue (S1 site). The acceptor site Lipid II is 
stabilised through Mg2+ cations by S98, E102, R103, R117, S132, R241 and K248 and binding to the 
donor site by G130, Q137, K140, N141, R148 and N224. Helix 3,4 and 5 (labelled H3, H4 and H5 in 
brown) form the glycosyl acceptor site. B: E100 (red sticks) deprotonates the 4-OH of Lipid II 
GlcNAc in the S1 site, stabilised by R241 and this simultaneously reacts with the C1 of Lipid II in the 
S2 site. K140 and R148 (green sticks) stabilise the pyrophosphate leaving group and facilitate its 
departure. C: Lipid II (or the growing glycan chain) in the donor site (S2) is transferred to the Lipid II 
in the acceptor site with the formation of a β-1,4-glycosidic bond, and D: the product is shuffled to the 
S2 donor site. E: A new Lipid II molecule binds to the acceptor site (S1) and the cycle continues. 
Adapted from Huang et al., (2012). 
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structural similarity with the terminal D-Ala-D-Ala of the natural substrate (Figure 
1.16 (A and B)), which was later confirmed by binding of a [14C]-benzylpenicillin to 
be via a covalent linkage with a serine residue (Frère et al., 1976). The pentapeptide 
stem of the substrate was later shown to bind to this active site serine as well (Yocum 
et al., 1979).  
 
The penicillin-binding domain is found in both transpeptidases (HMW) and DD-
carboxypeptidases (LMW) (Section 1.7.4.2), the latter of which are less susceptible 
to β-lactam inhibition by comparison (Waxman and Strominger, 1983). This results 
in a bias towards hydrolase activity following antibiotic treatment leading to fragile 
peptidoglycan (Höltje, 1998). 
 
High levels of resistance to β-lactams has developed through several mechanisms, of 
particular importance in Staphylococcus aureus and Streptococcus pneumoniae, the 
latter of which is discussed in more detail in Section 1.8.  
 
1.7.4.1 The penicillin-binding domain active site 
 
Despite low overall sequence homology between the HMW and LMW penicillin-
binding domains, they exhibit similar overall structures consisting of two 
subdomains, as identified from crystal structures in both the apo and liganded state 
(liganded state of S. pneumoniae PBP1a and PBP2a as HMW and LMW PBPs 
respectively shown in Figure 1.13 bound to β-lactam antibiotics in the active site 
(Section 1.7.4.2)). A five-stranded β-sheet surrounded by three α-helices make up 
the first subdomain, and the second is completely α-helical. The active site is found 
at the bottom of an elongated cleft at the interface of the two subdomains, and inter-
domain flexibility is responsible for varied ligand affinity (Sauvage et al., 2008). The 
active site consists of three conserved sequence motifs (Figure 1.13); SXXK 
containing the catalytic serine and lysine general base, found in the centre of the 
catalytic cleft. Motif 2 and 3 lie on opposite sides of the catalytic cavity; motif 2; 
(S/Y)X(N/C) in a loop between α-helices 4 and 5, and motif 3; (K/H)(S/T)G inside 
β3 of the five-stranded β-sheet. An additional glycine found in the back of the 
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catalytic cleft is also highly conserved (Fonzé et al., 1999; Goffin et al., 1998; 
Macheboeuf et al., 2005). 
 
The analysis of several structures bound to substrate mimics has led to the 
identification of important regions and residues in substrate binding and catalysis 
(Sauvage et al., 2008). The amide of the donor stem-peptide terminal D-alanine is 
found between the second motif asparagine side chain and the β-3 backbone and the 
carbonyl (or β-lactam ring) hydrogen bonds with an oxyanion hole formed by the 
catalytic serine and residues following motif 3.  The methyl group of the same D-
A B 
C D 
S. pneumoniae PBP1a S. pneumoniae PBP2x 
Figure 1.13: Comparison of the transpeptidase domains of S. pneumoniae PBP1a (HMW) and S. 
pneumoniae PBP2x (LMW). Ribbon view of the overall transpeptidase domain of PBP1a (A) and 
PBP2x (B), and zoomed in view of the active site (PBP1a (C), PBP2x (D)). Conserved motifs 1-3 are 
shown in red, blue and yellow respectively. Active site serine can be seen (red sticks in motif 1) 
covalently bound to cefotaxime (PBP1a) and cefuroxime (PBP2x) both in grey stick form. Structures 
aligned through protein molecules. PBP2x aligned to PBP1a; RMSD: 3.3Å from 208 α-carbons. 
Credit: Dr Dean Rea for help in producing this figure. PDB accession codes; PBP1a: 2C5W; PBP2x: 
1QMF. 
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alanine inserts into a hydrophobic pocket, in which the conserved glycine is found 
and is important for binding specificity. The motif 3 hydroxyl is oriented towards the 
terminal D-alanine carboxyl, and the glycine is important for avoiding steric 
hindrance, and therefore allowing the substrate into the active site. The serine and 
lysine of motif 1 are important for catalysis; the serine is the catalytic residue, and 
lysine abstracts a proton and activates the serine as a nucleophile for acylation.  
 
A crystal structure of S. pneumoniae PBP1b showed that ligand binding led to a 
conformational change resulting in an ‘open’ active site (Macheboeuf et al., 2005), 
mediated through change from an antiparallel interaction between β-3 and β-4 to a 
parallel conformation through movement of an intervening loop. Substrate mediated 
activation was proposed in order to convert from a ‘closed’ inactivated state to an 
‘open’ active state (Figure 1.14). The same phenomena was discovered in 
Staphylococcus aureus acquired PBP2a, and shown to be due to the presence of an 
allosteric binding domain 60 Å away from the transpeptidase active site, which could 
be activated by muramic acid, peptidoglycan or the ceftaroline anti-MRSA antibiotic 
(Otero et al., 2013). This confirmed a previous prediction of allosteric regulation of 
PBP2a through activity studies (Fuda et al., 2005), and the Tipper-Strominger 
substrate mimicry hypothesis was later shown to exist at the allosteric site as well as 
the active site (Fishovitz et al., 2015). An allosteric site has not been demonstrate to 
date for other penicillin-binding domains, although the presence of a second 
cefuroxime molecule remote from the active site in the crystal structure of S. 
pneumoniae PBP2x suggests that they may exist (Gordon et al., 2000). 
 
1.7.4.2 Transpeptidation and DD-carboxypeptidation 
 
The penicillin-binding domain of PBPs is responsible for both transpeptidase and 
carboxypeptidase activity. The former is catalysed by the HMW-PBPs (PBP1a, 
PBP1b, PBP2a, PBP2b and PBP2x in S. pneumoniae) and results in cross-links 
between the pentapeptide stems of the glycan polymer (Sauvage et al., 2008). 
Carboxypeptidation involves the removal of the terminal D-Ala from non- cross-
linked stem peptides and is carried out by the LMW-PBPs (PBP3 in S. 
pneumoniae)(Morlot et al., 2005). Both are illustrated in Figure 1.15.   
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Both transpeptidation and carboxypeptidation proceed via a three-step mechanism, 
initiated by non-covalent binding of the donor stem peptide substrate to the active 
site. This is followed by attack of the penultimate D-Ala of the pentapeptide stem by 
the PBP active site serine, forming a covalent acyl-enzyme intermediate and 
displacing the terminal D-Ala from the donor pentapeptide stem. The nature of the 
‘acceptor’ determines the outcome of the third step; deacylation. In transpeptidation 
the primary amine on the third position L-Lys of the ‘acceptor’ pentapeptide stem (or 
the terminal amino acid of the branch) nucleophilically attacks the intermediate and 
forms a peptide bridge. H2O is the ‘acceptor’ in carboxypeptidation, which leads to 
hydrolysis and results in tetrapeptide stems (Figure 1.15) (Sauvage et al., 2008). 
 
 
 
 
 
 
 
Page 47: Figure 1.15: Proposed mechanism for transpeptidation and DD-carboxypeptidation. 
Only the pentapeptide stem of peptidoglycan is shown for simplicity. In both situations, Lys (motif 1) 
abstracts a proton from the catalytic Ser, which attacks the penultimate D-Ala in the “donor” stem 
peptide. An acyl-enzyme intermediate is formed and the terminal D-Ala released. During deacylation 
the acceptor ε-amino group of the third position L-Lys (or amino of branching amino 
acid)(transpeptidation) or a water molecule (DD-carboxypeptidation) forms a cross-link with the 
“donor” stem peptide or hydrolyses the acyl-enzyme intermediate respectively. Both result in 
regeneration of the active site serine and either cross-linked peptidoglycan or formation of a 
tetrapeptide stem. 
A B 
A499 A499 
N656 N656 
N158 
K463 
T654 
T652 
N158 
K463 
T652 
T654 
S460 S460 
Figure 1.14: Substrate mediated opening of the S. pneumoniae PBP1b transpeptidase active site. 
Zoomed in view of active site shown in ribbon style in cyan. Key interacting residues shown in stick 
form in magenta and hydrogen bonds in dashed black lines. A: ‘Closed’ non-liganded active site 
showing interaction between A499 and N656 blocking entrance to the catalytic cleft. B: ‘Open’ 
liganded active site with cefotaxime in stick form covalently bound to the active site serine (S460). 
Liganded aligned to non-liganded through protein molecules with an RMSD of 0.37 Å for 365 α-
carbons, showing no significant overall structural changes upon ligand binding. Credit: Dr Dean Rea 
for help in producing this figure. PDB accession numbers: “closed”: 2BG1; “open”: 2BG4 
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β-lactam antibiotics act as pseudosubstrates for the penicillin-binding domain of 
PBPs, as the β-lactam ring mimics the terminal D-Ala-D-Ala of the pentapeptide 
stem (Figure 1.16 A and B). The antibiotic is acylated by the active site serine, thus 
forming a covalent adduct, which is slow to deacylate and therefore prevents further 
reactions (Wise and Park, 1965), as illustrated in Figure 1.16 (C). 
 
 
A B 
C 
Figure 1.16: Structural comparison between β -lactams and the natural PBP substrate, and the β -
lactam mechanism of action. A: D-Ala-D-Ala terminus of the peptidoglycan pentapeptide stem. B: 
Generic structure of a β-lactam, showing the structural similarity with the natural substrate. The 
distribution of negative charge is similar in both structures and is shown by curves. C: β-lactams act as 
a suicide substrate by forming an inactive acyl-enzyme intermediate which has deacylation rate 
significantly slower than the rate of bacterial division. The PBP active site nucleophilic serine attacks 
the β-lactam ring carbon atom forming a covalent ester link.   Figure adapted from Zapun et al., (2008).  
 49 
 
1.8 Streptococcus pneumoniae 
 
Two chapters in this thesis (Chapters 4 and 6) focus on the Streptococcus 
pneumoniae PBPs, which play a particularly unusual and important role in antibiotic 
resistance. This section details the clinical significance of S. pneumoniae as a 
pathogen and its mechanisms of β-lactam antibiotic resistance.  
 
S. pneumoniae is a Gram-positive oval shaped coccus which can be both a 
commensal and a pathogen. In its carrier state it colonises the nasopharynx and is 
found in up to 4% of adults and 50% of children (Regev-Yochay et al., 2004). 
Pneumococci cause a range of diseases including otitis media, sinusitis and 
bronchitis and also pneumonia, meningitis and febrile bacteraemia invasive 
infections. The introduction of pneumococcal vaccines such as pneumococcal 
polysaccharide vaccine 23 (PPSV23) and pneumococcal conjugate vaccine 7 (PCV7) 
over the last 20 years has helped to lower the burden of invasive disease (Bocchini et 
al., 2010), however it still remains a major worldwide cause of mortality, particularly 
in developing countries and amongst children, the elderly and those with underlying 
health problems (World Health Organisation, 2012). WHO have previously 
estimated that 1.6 million deaths per year are caused by pneumococcal disease 
(World Health Organisation, 2007), with infants and young children particularly 
affected. An estimated 10% of global deaths of children under the age of 5 are due to 
pneumococcal infections (O’Brien et al., 2009). 
 
The remaining burden can be largely attributed to increasing levels of antibiotic 
resistance. S. pneumoniae is most commonly resistant to β-lactams such as penicillin, 
and macrolides, but also in some cases fluoroquinolones which are considered a drug 
class of last resort with serious side effects. Multidrug resistant strains are an 
increasing problem (Song et al., 2012).  
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1.8.1 Streptococcus pneumoniae β-lactam resistance 
 
β-lactam antibiotics have been particularly successful in the treatment of 
pneumococcal infections, due to its notable high susceptibility to these compounds 
(Hakenbeck et al., 2012). However, levels and frequency of penicillin-resistance in 
strains has increased rapidly worldwide since they were first isolated in the late 
1970s, predominantly due to the increasing use of antibiotics (Granizo et al., 2000), 
and now represent approximately 50% of isolates worldwide (Henriques-Normark, 
2007). Resistance to β-lactams in S. pneumoniae is not through the typical 
mechanism of β-lactamase production, but mainly due to modification of the PBPs, 
through expression of mosaic genes formed by recombination events both within 
pneumococci, and with other species (Hakenbeck et al., 2012; Zapun et al., 2008). 
The resulting PBPs in resistant strains have a lower affinity for β-lactams but 
maintain their natural physiological activity (Job et al., 2008). This is a remarkable 
mechanism given the similarity in structure of the β-lactams to the PBP substrate, 
and the way in which these PBPs are still able to cross-link peptidoglycan is 
unknown to date. Penicillin resistance in pneumococci is multifactorial, with several 
other known, and many more unknown factors playing a role (Hakenbeck et al., 
2012). 
 
S. pneumoniae peptidoglycan stem peptides are chemically modified by the addition 
of an L-Ala-L-Ala or L-Ser-L-Ala dipeptide branch (C- to N- terminus) on the ε-
amino group of the third position lysine (Filipe and Tomasz 2000; Fiser et al., 
2003)(Section 1.5.2.3), added to Lipid II during peptidoglycan biosynthesis by the 
MurM and MurN tRNA-dependant ligases (De Pascale et al., 2008; Lloyd et al., 
2008). Stem peptide bridges have been associated with β-lactam resistance, as some 
highly resistant strains have an increased level of branching compared to sensitive 
strains, due to expression of a mosaic murM gene (Garcia-Bustos and Tomasz, 1990; 
Smith and Klugman, 2001). This has been shown to be required for high-level 
resistance in clinical strains even in those already possessing low affinity PBPs 
(Filipe and Tomasz, 2000; Weber et al., 2000). Work within our lab has shown this 
‘resistant’ MurM to have a higher catalytic efficiency than its ‘susceptible’ 
counterpart, with a preference for incorporation of L-Ala over L-Ser (Lloyd et al., 
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2008). PBPs can function with either linear or branched peptides in the absence of β-
lactams, but in the presence of these antibiotics the murM product is essential for 
expression of resistance (Filipe and Tomasz, 2000; Severin et al., 1996; Weber et al., 
2000). It has been suggested that glycan chains with branched pentapeptides might 
be preferential substrates for the resistant PBPs and outcompete the β-lactam, 
allowing the cell wall to be synthesised in these resistant strains (Dessen et al., 2001; 
Pernot et al., 2004). Additionally they may serve as a signal for other cell wall 
processes involved in resistance (Filipe and Tomasz, 2000) 
 
Clinical isolates with identical MurM and PBP alleles can have significantly 
different resistance levels (Chesnel et al., 2005), suggesting the involvement of an 
additional factor or factors in high level β-lactam resistance. Other implicated 
mechanisms include the serine-threonine kinase StkP (Dias et al., 2009), and 
variations in enzymes catalysing glycan chain N-deacetylation and O-acetylation 
(Crisostomo et al., 2006; Tait-Kamradt et al., 2009) amongst others 
(comprehensively reviewed recently; Hakenbeck et al., 2012). Most recently, the 
cytoplasmic amino acid ligase, MurE has been implicated in clinical resistance in 
combination with low affinity PBP2b and PBP2x (Todorova et al., 2015).   
 
Lipid II with isoglutamine at position two in the stem peptide due to the action of the 
MurT/GatD amidase (Figueiredo et al., 2012; Münch et al., 2012)(Section 1.5.2.2.2) 
is required for efficient peptidoglycan cross-linking (Zapun et al., 2013). Non-
amidated peptides are rare in S. pneumoniae, making up 12.6 % of non cross-linked 
and only 1.8% of cross-linked peptides (Zapun et al., 2013), and resistant strains 
have a much greater proportion of cross-linked glycan chains (Garcia-Bustos and 
Tomasz, 1990). Stem peptide amidation is required for full expression of β-lactam 
resistance in Staphylococcus aureus, which may be due to substrate specificity of the 
PBPs, the FemXAB enzymes responsible for adding the pentaglycine stem or a 
combination of both (Discussed in Section 5.8.4.3). Therefore the importance of this 
peptidoglycan modification in the addition of the stem peptide bridge, as well as 
subsequent cross-linking is of great interest in understanding β-lactam resistance.  
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1.8.2 Streptococcus pneumoniae PBPs; key players in resistance 
 
Peptidoglycan chain polymerisation in Streptococcus pneumoniae is catalysed by the 
high molecular weight (HMW) Class A bifunctional penicillin-binding proteins 
(PBPs); PBP1a (79.7 kDa), PBP2a (80.7 kDa) and PBP1b (89.4 kDa); which catalyse 
both polymerisation of the glycan chain (transglycosylation) and cross-linking 
between them (transpeptidation). Either PBP1a or PBP2a must be functional for 
viability (Hoskins et al., 1999). S. pneumoniae also has two class B monofunctional 
transpeptidases; PBP2b (74.4 kDa) and PBP2x (82.2 kDa) which are essential for 
viability (Kell et al., 1993) and one Class C non essential regulatory PBP (PBP3 
(41.4 kDa) (Morlot et al., 2005). The general structure and activity of PBPs is 
covered in detail in Section 1.7.  
 
PBP2x, PBP2b and PBP1a are the main PBPs associated with β-lactam resistance in 
S. pneumoniae, although PBP2a is associated with low affinity in some strains 
(Hakenbeck et al., 2012). Resistance is mediated through mutations in the 
transpeptidase domain, although not necessarily the active site, that reduce the 
affinity for β-lactam antibiotics (Figure 1.17). PBPs in resistant strains have 
sequence blocks that vary by around 20%, compared to the highly conserved genes 
found in sensitive strains (Hakenbeck et al., 2012). The identification of mutations 
involved in resistance is complicated as compensatory mechanisms affecting 
enzymatic activity may also be present, and the mutations in clinical and laboratory 
strains differ significantly. Mutations in PBPs of clinically resistant S. pneumoniae 
strains associated with reduced affinity for β-lactams are shown in Figure 1.17.  
 
Low-level resistance is associated with mutations in the transpeptidase domain of 
PBP2x and PBP2b, which have different selective antibiotics (Hakenbeck et al., 
2012). Mutations in PBP1a confer high-level resistance, but only in the presence of 
low affinity PBP2b and/or PBP2x. The combined effect of PBP2x and PBP1a is 
particularly interesting in clinical isolates and suggests an interaction between the 
two in vivo (Zerfass et al., 2009). The proposed interactions of PBPs in cell wall 
synthesis in S. pneumoniae are covered in more detail in Section 1.7.2.2.  
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1.9 Staphylococcus aureus 
 
The PBPs from Staphylococcus aureus are the focus of Chapter 5 of this thesis. This 
section briefly describes the clinical significance of this pathogen with a particular 
focus on its resistance to antibiotics, highlighting the importance of research that 
may lead to the development of new compounds.  
 
Gram-positive Staphylococci account for 20% of all healthcare associated infections 
(Centres for Disease Control and Prevention, 2013). Of particular importance is 
Staphylococcus aureus, an opportunistic pathogen responsible for a range of 
conditions from minor skin infections to life threatening diseases such as pneumonia, 
septicaemia and infective endocarditis (Benfield et al., 2007; Deurenberg and 
Stobberingh, 2008). Staphylococcus aureus bacteraemia has become a leading cause 
of bloodstream infections in the world (Rasmussen et al., 2011) and these are 
becoming increasingly difficult to treat due to the rapid emergence of resistance to 
methicillin and vancomycin in particular (Rasmussen et al., 2011). 
PBP2x 
750 aa 
PBP2b 
680 aa 
266 616 
315 680 
N605T 
Y595F 
Q552E L546V 
T550A 
M400T 
H394Y 
R384G I371T M339F 
L364F T338A/G/P/S 
304 627 
PBP1a 
719 aa 
S337TMK S395SN K547SG 
S386TMK S443SN K614TG 
T615S M388A E476G 
S370TMK S446SN K557TG 
T371(A/S) L539W TSQF574-577NTGY 
Figure 1.17: S. pneumoniae PBP altered affinity for β-lactams. Transpeptidase domain of PBP2x, 
PBP2b and PBP1a shown in grey with first and last amino acid labelled at each end. Conserved active 
site motifs indicated by red arrow and bold text. Mutations within the transpeptidase domain 
associated with reduced β-lactam affinity in clinical strains labelled. Figure adapted from Hakenbeck 
et al., 2012 
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1.9.1 Staphylococcus aureus antibiotic resistance 
 
Within two decades of the introduction of penicillin, 80% of Staphylococcus aureus 
infections were resistant due to the production of a β-lactamase (Section 1.3.1.1) 
(Appelbaum, 2007) Soon after the introduction of methicillin to treat these 
infections, the first methicillin resistant Staphylococcus aureus (MRSA) strain was 
documented (Jevons, 1961), which arose through the acquisition of a non-native PBP 
with low affinity for β-lactams (Hartman and Tomasz, 1984; Utsui and Yokota, 
1985).  Incidences of MRSA increased rapidly worldwide, resulting in it becoming 
one of the main causes of hospital-acquired bacteraemia (Chambers et al., 2001). 
Community acquired MRSA is more virulent but currently more susceptible to 
antibiotics than its hospital acquired counterpart (Appelbaum, 2007), and is believed 
to be mediated in part by a native class C PBP with unexpected transpeptidase 
activity (Memmi et al., 2008). Interpeptide bridges (Section 1.5.2.3.1) and stem 
peptide amidation (1.5.2.2.2) are both associated with particularly high levels of β-
lactam resistance. Mandatory surveillance, amongst other measures, has led to a 
greater than 50% reduction in reported cases of MRSA within the UK healthcare 
system (Johnson et al., 2012). However, increasing cases of vancomycin-resistant 
Staphylococcus aureus (VRSA) (Howden et al., 2010) and insensitivity to antibiotic 
classes considered “drugs of last resort” such as daptomycin and linezolid (Mangili 
et al., 2005, Sorlozano et al., 2010), means that research into this globally important 
pathogen is as important as ever.  
 
1.10 Thesis aims 
 
Antimicrobial Resistance (AMR) poses an already severe and growing threat to 
modern healthcare. Coordinated, international efforts are required to prolong the 
clinical life of current and future antibiotics. In addition to this, new drug classes are 
required, and the design of these requires full characterisation of new and existing 
drug targets. 
 
The Staphylococcus aureus and S. pneumoniae penicillin-binding proteins (PBPs) 
are validated targets for antibiotics, and in the latter are responsible for the mediation 
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of resistance to β-lactam antibiotics. Chemical modifications to the Lipid II 
substrates are important in the activity and expression of resistance by these essential 
proteins, although the mechanisms involved are not well understood 
 
This thesis aims to contribute to current understanding of the enzymatic activity and 
substrate specificity of PBPs from these two globally significant pathogens, in 
particular the role of stem peptide amidation in their catalytic activity, and peptide 
branching in antibiotic resistance. A greater understanding could help to answer 
some fundamental biochemical questions and enable the future design of novel 
inhibitors against these excellent targets.  
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Chapter 2. Materials and Methods 
 
2.1 Buffers and solutions 
 
All chemicals were obtained as analytical grade from the following companies unless 
otherwise stated: Acros Organics (USA), Bachem (Germany), Calbiochem (USA), 
Fisher Scientific (USA), Novabiochem (Germany), Sigma (USA). 
 
MilliQ purified water was used to make all buffers. The pH of solutions was 
measured using a WPA pH meter CD720 from Hanna Instruments with pH 4, pH 7 
and pH 10 buffer standards. For chromatography, buffers were filtered prior to use 
with a 0.2 µm filter. 
 
2.2 Growth and maintenance of E. coli strains 
2.2.1 Bacterial strains 
 
The following bacterial strains are used throughout this thesis for DNA cloning and 
protein over-expression. 
 
E. coli strain Genotype Reference 
TOP 10 F-
 
mcrA Δ(mrr-hsdRMS-mcrBC) ϕ80lacZΔM15 ΔlacX74 
deoR recA1 araD139 Δ (ara-leu)7697 galU galK rpsL 
(StrR) endA1 nupG 
Grant et al. (1990) 
BL21 (DE3) F-ompT hsdSB(rB–, mB–) gal dcm (DE3) Studier and Moffatt, 
(1986) 
BL21 (DE3) 
pRosetta 
F-ompT hsdSB(rB–, mB–) gal dcm (DE3) and pRosetta 
plasmid for rare codon overexpression 
Studier and Moffatt, 
(1986) 
Table 2.1 Bacterial strains used for DNA cloning and protein over-expression  
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2.2.2 Bacterial growth media 
 
The following bacterial growth media and LB-agar plates were used throughout this 
project. 
 
2.2.2.1 LB-agar plates 
 
LB media with 1.5% (w/v) bacto-agar was sterilised by autoclaving, cooled to 50°C 
before the addition of appropriate antibiotics and 25 mL poured into sterile Petri 
dishes. Prepared plates were stored at 4°C.  
 
2.2.2.2 Super Optimal broth with Catabolite repression (SOC) media 
 
2% (v/v) peptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM glucose. 
 
2.2.2.3 Luria Bertani (LB) broth (Bertani, 1951) 
 
1% (w/v) tryptone, 0.5% (w/v) NaCl, 0.5% (w/v) yeast extract. 
 
2.2.2.4 ZY media (Studier, 2005) 
 
1% (w/v) N-Z amine, 0.5% (w/v) yeast extract. 
 
2.2.2.5 Autoinduction media (Studier, 2005) 
 
ZY media, 1 × NPS (giving final concentrations of 25 mM ammonium sulphate, 50 
mM potassium dihydrogen phosphate, 50 mM disodium hydrogen phosphate) and 1 
x 5052 (final 0.5% (v/v) glycerol, 0.05% (w/v) glucose, 0.2% (w/v) α-lactose), 1 
mM MgSO4 with appropriate antibiotics. 5052 made as 50 x stock and NPS as 20 × 
stock routinely. 
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2.2.3 Preparation of competent cells 
 
5 mL sterile Luria-Bertani (LB) broth 10:5:5 (tryptone:yeast extract:NaCl) 
containing the appropriate antibiotic was inoculated with the required E. coli strain 
from a glycerol stock, and incubated with 180 rpm shaking at 37°C overnight. 250 
mL sterile LB broth (plus 20 mM MgSO4 and appropriate antibiotics) was inoculated 
with 2.5 mL of the overnight culture and incubated at 37°C with shaking at 180 rpm 
until an optical density (A600nm (OD600nm)) of between 0.4 and 0.6 was reached. 
Centrifugation at 4500 × g for 10 min (Beckman JA-14 rotor) pelleted the cells, and 
this pellet was gently resuspended in 100 mL ice cold TFB1 buffer (30 mM 
potassium acetate, 10 mM calcium chloride, 50 mM manganese chloride, 100 mM 
rubidium chloride, 15% (v/v) glycerol, pH 5.8), incubated on ice for 5 min and then 
centrifuged at 4500 × g for 5 min (Beckman JA-14 rotor). The pellet was 
resuspended in 10 mL TFB2 buffer (10 mM MOPS, pH 6.5, 75 mM calcium 
chloride, 10 mM rubidium chloride, 15% (v/v) glycerol) and incubated on ice for 1 
hour. Competent cells were flash frozen in 50 µL aliquots in liquid nitrogen and 
stored at -80°C. 
 
2.2.4 Transformation of E. coli strains 
 
Competent cells (50 µL) were thawed on ice and incubated with 1 µL DNA (25-100 
ng) for 30 min on ice. Cells were heat-shocked at 42°C for 30 sec using a water bath 
and incubated on ice for 2 min. 250 µL of SOC media (Super optimal broth plus 
glucose)(Section 2.2.2.2) was added and the cells incubated at 37°C for 30-60 min 
with shaking. 100 µL of the transformed cells were plated using aseptic technique 
onto LB-agar plates containing the appropriate antibiotic and were incubated at 37°C 
overnight without shaking.  
 
2.2.5 Preparation of glycerol stocks 
 
5 mL sterile LB broth containing the appropriate antibiotic was inoculated with an  
E. coli colony from a fresh transformation and cultured overnight at 37°C with 
shaking at 180 rpm. 1 mL of this culture was mixed using aseptic technique with 1 
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mL sterile 100% (v/v) glycerol in a Corning cryo-vial, frozen in liquid nitrogen and 
stored at -80°C. 
 
2.3 DNA manipulation and cloning 
 
2.3.1 Oligonucleotides 
 
DNA oligonucleotides for PCR amplification were designed against the target gene 
and ordered from Integrated DNA Technologies (UK). 
 
2.3.2 Polymerase Chain Reaction (PCR) 
 
Q5® High-Fidelity DNA Polymerase (NEB) was used according to the 
manufacturer’s instructions to carry out DNA amplification. Unless otherwise stated, 
a 100 µL mix of reagents was made and divided into four 25 µL aliquots. PCR was 
in an Eppendorf Mastercycler Gradient thermocycler with an annealing temperature 
optimised according to the primers used (typically between 45-65°C).  
 
2.3.3 Restriction enzyme digestion of DNA 
 
Restriction enzymes (NEB) in the appropriate buffer (stipulated by the manufacturer) 
were used for restriction digests. 500 ng of plasmid DNA or PCR product was used 
and unless otherwise stated reactions were incubated at 37°C for 3 hours.  
 
2.3.4 Purification of DNA from PCR and restriction digests 
 
Polymerases and endonucleases were removed from DNA following PCR and 
restriction digests by purification with a QIAquick® PCR Purification kit (Qiagen) 
according to the manufacturer’s instructions. 
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2.3.5 Preparation of plasmid DNA 
 
Plasmid DNA was extracted from E. coli TOP10 cells following transformation and 
overnight culture using a Fermentas GeneJetTM miniprep extraction kit according to 
the manufacturer’s instructions. 
 
2.3.6 DNA concentration determination 
 
1.5 µL samples were quantified using a NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific). 
 
2.3.7 Ligation of DNA fragments with complementary ends 
 
Following restriction digestion of plasmid DNA and PCR-amplified genes to give 
DNA with complementary sticky ends, ligation was carried out with the NEB Instant 
Sticky-End Ligase Master Mix (containing T4 DNA ligase) and was used according 
to the manufacturer’s instructions. Ligations were in a final volume of 10 µL, 
incubated at room temperature for 5 min and 5 µL was used to transform E. coli 
TOP10 cells. The following day colonies were picked and grown overnight in 2 mL 
sterile LB broth before DNA was extracted using the Fermentas GeneJetTM miniprep 
extraction kit. 
  
2.3.8 Agarose gel electrophoresis 
 
0.8% (w/v) agarose gels were used to separate DNA fragments. Gels were prepared 
by dissolving 2 g of agarose (high-melting point agarose (GibcoBRL)) per 250 mL 
of 1 × Tris-acetate EDTA (TAE, 40 mM Tris acetate, 1 mM EDTA) buffer and 
heating in a microwave until dissolved. The agarose solution was cooled to hand-
heat and 1 µL of 10 mg.mL-1 Ethidium Bromide added per 30 mL solution, before 
pouring into a gel cast and allowing to set. The gel was submerged in a Geneflow gel 
tank containing 1 × TAE, and DNA samples were loaded into the wells with 1 × 
DNA loading dye solution (6 x stock: 0.25% (w/v) bromophenol blue, 0.25% (w/v) 
xylene cyanol FF and 15% (v/v) Ficoll 400) (Fermentas). 5 µL DNA standard 1 kb 
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ladder (Fermentas) (pre-mixed with loading buffer) was loaded as a size reference. 
Electrophoresis was at 100 V for 40 min and a Syngene GeneSnap G:Box gel 
illuminator and analysis system used to visualise the gel under ultraviolet light. 
 
2.3.9 DNA sequencing of plasmid constructs 
 
To confirm insertion of the cloned gene in the correct orientation, reading frame and 
with no PCR induced mutations; DNA constructs were sequenced. 80-100 ng.µL-1 
plasmid DNA and 5 pmol.µL-1 primer (either specific for the T7 promoter and 
terminator of the pET vector (Table 2.2) or the primers used for the original PCR 
amplification of the target gene) were used for each sequencing reaction in a final 
volume of 10 µL. Reactions were submitted to GATC Biotech (Germany), and 
resulting sequences were manually checked using ApE plasmid editor, blasted 
against a database (www.ncbi.nih.gov/BLAST; Altschul et al. (1990)) and aligned 
using ApE. 
 
 
Primer Sequence (5’-3’) 
T7 promoter TAATACGACTCACTATAGGG 
T7 terminator GCTAGTTATTGCTCAGCGG 
Table 2.2 Sequences of T7 promoter and terminator primers used for DNA sequencing 
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2.3.10 Gene constructs used in this project 
 
Construct Description Selection Affinity Tag Source 
pET21b::pbp2 
S. aureus pbp2 (full-
length) in pET21b vector 
Ampicillin 
Non-cleavable 
N-term 6-His 
N. Strynadka  
(UBC, Canada) 
pET41a::pbp2-Δ59 
S. aureus pbp2-Δ59 
(ΔTM domain) in 
pET41a vector 
Kanamycin Untagged 
N. Strynadka  
(UBC, Canada) 
pET15b::mgt 
S. aureus mgt-Δ27 (full-
length) in pET15b vector 
Ampicillin 
Thrombin 
cleavable N-
term 6-His 
Cloned for this project 
pET46::mgt-Δ67 
S. aureus mgt-Δ67 (ΔTM 
domain) in pET46 vector  
Ampicillin 
Enterokinase 
cleavable N-
term 6-His 
K. Abrahams  
(Warwick) 
pET15b::pbp2a-Δ22 
S. aureus D39 pbp2a-
Δ22 (ΔTM domain)in 
pET15b vector  
Ampicillin 
Thrombin 
cleavable N-
term 6-His 
N. Strynadka  
(UBC, Canada) 
pET30::pbp2a S. pneumoniae D39 
pbp2a (full-length) in 
pET 30 vector  
Kanamycin Untagged 
A. Zapun  
(Grenoble) 
pGEX-2T::pbp2a-Δ77 S. pneumoniae pbp2a-
Δ77 (ΔTM domain) in 
pGEX-2T vector  
Ampicillin 
Thrombin 
cleavable N-
term GST 
A. Zapun 
(Grenoble) 
pET46::pbp1a S. pneumoniae D39 
pbp1a (full-length) in 
pET46 vector  
Ampicillin 
Non-cleavable 
N-term 12-His 
K. Abrahams  
(Warwick) 
pET46::pbp1a-Δ30 S. pneumoniae D39 
pbp1a-Δ30 (ΔTM 
domain) in pET46 vector  
Ampicillin 
Non-cleavable 
N-term 12-His 
K. Abrahams 
(Warwick) 
pET26b::pbp1a S. pneumoniae D39 
pbp1a (full-length) in 
pET26b vector 
Kanamycin Untagged Cloned for this project 
Table 2.3 Gene constructs used for this project 
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2.4 Protein Expression and Purification 
 
Most proteins overexpressed and purified within this project were by pre-published 
methods, and there is a large amount of variation between protocols. References to 
the relevant literature are included throughout the text in each results chapter. This 
section covers the general methods for recombinant protein over-expression in        
E. coli, and details of modification from the published protocols for individual 
proteins are included for clarity, where significant deviations were made. 
 
2.4.1 Recombinant protein over-expression in E. coli 
 
A range of E. coli strains used for protein expression (Table 2.3) were used to over-
express recombinant proteins. Competent cells (Section 2.2.3) were transformed 
(Section 2.2.4) with an expression plasmid (Table 2.1) and plated onto selective 
media. Induction was either with IPTG or autoinduction.  
 
2.4.1.1 Isopropyl-β-D-thiogalactopyranoside (IPTG) induction  
 
5 mL LB (including appropriate antibiotic) was inoculated with a single colony from 
a fresh transformation, and cultured overnight at 37°C with shaking at 180 rpm. 1 L 
LB (with antibiotic selection) was inoculated with the whole overnight culture and 
incubated at 37°C with shaking at 180 rpm. At OD600nm of 0.6, cultures were induced 
with 1 mM IPTG and cultured at 25°C overnight (unless otherwise specified in this 
thesis or the published protocol). Cells were harvested in a Beckman JLA-8.100 rotor 
at 10,000 × g and the cell pellet stored at -20°C. 
 
2.4.1.2 Autoinduction 
 
Method adapted from the Studier Autoinduction System (Studier, 2005). 2 mL ZYP-
0.8G medium (ZY, 1 mM MgSO4, 0.8% (w/v) glucose, NPS) plus antibiotic 
selection was inoculated with a single colony from a fresh transformation. After 
overnight incubation at 37°C with shaking at 180 rpm, 1 mL was used to inoculate   
1 L of ZYP-5052 rich medium (ZY, 1 mM MgSO4, 5052, NPS) plus antibiotic 
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selection. Cells were cultured at 25°C for 22 h with shaking at 180 rpm, before 
harvesting at 10,000 × g in a Beckman JLA-8.100 rotor. Cell pellets were stored at    
-20°C. 
 
2.4.2 Preparation of cell lysates 
 
Frozen cell pellets (Section 2.4.1) were thawed on ice, resuspended in 3 mL.g-1 cell 
weight of phosphate buffered saline (PBS) supplemented with 2.5 mg.mL-1 hen egg-
white lysozyme and 20 µg.mL-1 DNAse and incubated with agitation at 4°C for 45 
min. Cells were lysed by sonication on ice for four bursts of 30 sec at 70% power 
using a Bandelin Sonoplus sonicator or passing three times through a continuous cell 
disruptor (Constant Cell Disruption Systems) at 30 kpsi at 4°C as specified in the 
text. Cell lysate was centrifuged at 20,000 × g using a Beckman JA-25.50 rotor for 20 
min at 4°C to pellet cell debris. Cellular localisation of the protein determines the 
next step used in the protocol.  
 
2.4.2.1 Soluble protein 
 
Supernatant following 20,000 × g centrifugation (Section 2.4.2) was clarified by 
further centrifugation at 50,000 × g for 45 min at 4°C (Beckman JA-25.50 rotor). The 
supernatant was used for purification. 
 
2.4.2.2. Insoluble protein 
 
The pellet from 20,000 × g centrifugation (Section 2.4.2) was resuspended in a buffer 
containing the detergent required for solubilisation (specified in text), and incubated 
at 4°C for 1 hour with agitation. Following centrifugation at 50,000 × g for 45 min at 
4°C (Beckman JA-25.50 rotor), the supernatant containing detergent-solubilised 
proteins was used for purification.  
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2.4.2.3 E. coli membranes 
 
Supernatant following 20,000 × g centrifugation was treated as for soluble proteins 
(Section 2.4.2.1). The resulting supernatant was centrifuged at 150,000 × g for 1 h at 
4°C to pellet the membrane fraction in an ultracentrifuge (Beckman Ti45 rotor in 
Beckman Coulter Optima L-90K). Membranes were resuspended in PBS (10 mL.L-1 
original cell culture) and stored at -20°C. 
 
2.4.3 Protein purification 
 
Basic methods for the main purification techniques used are covered here. Specific 
methods are included in the main text. 
 
2.4.3.1 Affinity chromatography 
 
Proteins with a hexa- or dodecahistidine affinity tag were purified by immobilised 
metal affinity chromatography (IMAC), using either TALON Metal Affinity Resin 
(Cobalt metal ions (Clontech)) and gravity flow, or a pre-packed column on an 
AKTA 10/100 system (GE Healthcare) in a cold cabinet at 4°C. Pre-packed columns 
were either HiTrap TALON crude 5 mL or HisTrap 5 mL (both GE healthcare).       
5 mL TALON Metal Affinity Resin was poured into an Econo-Pac® 
Chromatography column (BioRad) prior to purification and the basic development 
method employed was the same for all three types of column.  
 
Columns were washed with 10 column volumes (CV) sterile water, and equilibrated 
with a further 10 CV of purification buffer containing no imidazole. Protein solutions 
were loaded directly onto the column, and where necessary with TALON Metal 
Affinity Resin were incubated with agitation to increase binding. Flow-through was 
collected and columns washed with 10 CV equilibration buffer to remove unbound 
proteins. Columns were developed by washing with either a gradient (pre-packed 
columns) or step-wise increases in imidazole concentration (TALON Metal Affinity 
Resin) over 10 CV. The concentrations used were specific to the protein and its 
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affinity for the resin. 10 mL fractions were collected and protein elution from pre-
packed columns monitored by absorbance at 280 nm on the AKTA 10/100. 
 
Columns were washed with 10 CV of buffer containing 1 M imidazole, 10 CV sterile 
water, and 10 CV 20% (v/v) ethanol and stored at 4°C. 
 
2.4.3.2 Size exclusion chromatography 
 
2.4.3.2.1 Preparative size exclusion chromatography 
 
Proteins were separated according to size using a Superdex 200 (26/60) or Superose 
6 (10/300) size exclusion column (separation of proteins with mass range of 10-600 
kDa and 5-5000 kDa respectively) on an AKTA 10/100 purifier system (GE 
healthcare) in a cold cabinet at 4°C. Columns were equilibrated with 1.5 CV of the 
required buffer and samples loaded via an injection loop at a volume of <2% of the 
total column volume to ensure high resolution of separation. Elution was with 1 CV 
buffer at 1 mL.min-1 for Superdex 200 (26/60) and 0.4 mL.min-1 for Superose 6 
(10/300) with 1 mL and 0.5 mL fractions collected respectively. Protein elution was 
monitored by absorbance at 280 nm.  
 
2.4.3.2.2 Analytical size exclusion chromatography 
 
Analytical size exclusion chromatography was as described in Section 2.4.3.2.1 
using a Superdex 200 Increase 10/300 GL column (GE Healthcare) pre equilibrated 
with a Gel Filtration HMW Calibration Kit (GE Healthcare) to allow molecular 
weight estimation. 100 µL pure protein at 8 mg.mL-1 was loaded and elution was at 
0.3 ml.min-1 with the collection of 0.5 mL fractions. 
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2.4.3.3 Ion exchange chromatography 
 
Anion exchange was carried out using a ResourceQ 6 mL column (GE Healthcare) 
and cation exchange with a 5 mL HP SP Sepharose column (GE Healthcare) on an 
AKTA 10/100 purifier system (GE healthcare) in a cold cabinet at 4°C unless 
otherwise stated. The ResourceQ column contains 15 µm beads of Source 15Q resin, 
a strong anion exchanger due to its quaternary amine group, and SP Sepharose        
34 µm beads of sulfopropyl, a strong cation exchanger. Both maintain their charge 
over a large pH range. Columns were washed with 10 CV sterile water, 10 CV low 
salt buffer, 10 CV high salt buffer and finally a further 10 CV low salt buffer until 
the conductivity was observed at baseline. Protein was loaded in a low salt buffer 
with a pH selected to ensure a net negative (anion exchange) or positive (cation 
exchange) charge. Protein was eluted with a salt gradient of 0-1 M NaCl over 10 CV 
at a flow rate of 6 mL.min-1 or 2 mL.min-1 for ResourceQ and HP SP Sepharose 
respectively. Protein elution was monitored by an increase in absorbance at 280 nm 
and 1 mL fractions were collected.  
 
2.4.3.4 Buffer exchange and concentration 
 
Buffer exchange was either through the use of a PD-10 Desalting column (GE 
healthcare), used according to the manufacturer’s instructions, or with a Vivaspin® 
centrifugal concentrator (Sartorius) with a molecular weight cut-off of 10, 30 or 100 
kDa (specified in text) unless otherwise stated. Concentrators were centrifuged at 
3,000 × g in a bench-top centrifuge (Eppendorf Centrifuge 5810R) at 4°C, and if 
buffer exchange was required; refilled with exchange buffer until a sufficient dilution 
factor was reached. Protein solutions were concentrated until the required volume 
was achieved, and subsequently quantified (Section 2.5.1).  
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2.4.4 Specific protein purification protocols 
 
Where significant deviations are made from the published method for purification, 
the protocol is detailed here. More minor modifications are included in the text 
within the relevant chapter sections.  
 
 2.4.4.1 S. pneumoniae PBP2a-Δ77  (Section 4.3.4) 
 
Expression and purification was according to Di Guilmi et al., (1999) with the 
following modifications. Over-expression was in the BL21 (DE3) E. coli cell line but 
otherwise as described. Gel filtration chromatography was replaced with anion 
exchange chromatography (Section 2.4.3.3)(6 mL ResourceQ column). Fractions 
containing PBP2a-Δ77 after glutathione sepharose purification were concentrated to 
2.5 mL in a Vivaspin® centrifugal concentrator (10 kDa cut-off) and buffer 
exchanged into 50 mM HEPES pH 7.5, 10 mM MgCl2, 0.02% (v/v) TX-100 using a 
PD-10 Desalting column (GE healthcare). A 6 mL ResourceQ column was 
equilibrated as described in Section 2.4.3.3 with 50 mM HEPES pH 7.5, 10 mM 
MgCl2, 0.02% (v/v) TX-100 and 50 mM HEPES pH 7.5, 10 mM MgCl2, 0.02% (v/v) 
TX-100, 1M NaCl. The PBP2a-Δ77 sample was injected onto the column and eluted 
over a salt gradient as described in Section 2.4.3.3. Fractions were analysed by SDS-
PAGE (Section 2.5.2), concentrated (Section 2.4.3.4) and the protein concentration 
determined (Section 2.5.1). 
 
2.4.4.2 S. aureus PBP2a-Δ22 (Section 5.6.1) 
 
Several modifications were made from the original protocol by Lim and Strynadka 
(2002), and the protocol used is as follows. Harvested cells were resuspended in   25 
mL.L-1 cells lysis buffer (50 mM K2HPO4 pH 8, 1 mM EDTA) and soluble proteins 
obtained by sonication (Section 2.4.2 and 2.4.2.1). Lysate was applied to 5 mL 
DEAE Sepharose Fast Flow resin (GE Healthcare) in a falcon tube pre-equilibrated 
with Buffer A (50 mM K2HPO4 pH 8) and incubated on rollers at 4°C for 1 hour. 
Resin was spun at 2000 rpm for 5 min and supernatant taken as flow-through, before 
washing with 2 x 10 mL Buffer A. Flow-through containing PBP2a-Δ22 was 
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dialysed against Buffer B (50 mM K2HPO4 pH7) overnight and spun at 15,000 rpm 
for 30 min at 4°C before the supernatant was loaded onto a SP Sepharose (GE 
Healthcare) column (50 mL bed volume) pre-equilibrated with 10 CV Buffer B. This 
was washed with a further 10 CV Buffer B before eluting with a gradient over 10 CV 
of 0-100% Buffer C (50 mM K2HPO4 pH7, 1 M NaCl). Identified fractions after 
SDS-PAGE analysis were concentrated with a Vivaspin® centrifugal concentrator 
(30 kDa cut-off) to < 5 mL concomitant with buffer exchange before loading onto a 
Superdex 200 26/60 column pre equilibrated with 1 CV Buffer D (50 mM K2HPO4 
pH7, 150 mM NaCl). Fractions identified by SDS-PAGE were concentrated (Section 
2.4.3.4) and the protein concentration determined (Section 2.5.1) before storing at      
-80°C.  
 
2.5 Protein analysis and detection 
 
2.5.1 Protein quantification 
 
The concentrations of proteins purified without detergent were determined using the 
Bio-Rad colorimetric assay at 595 nm. 2 µL protein solution was added to 1 mL 
diluted Bio-Rad reagent in a plastic semi-micro cuvette, mixed and allowed to stand 
for 5 min. Absorbance at 595 nm was measured using a Jenway 6306 UV-visible 
spectrophotometer. Triplicate readings were taken and dilutions made if values were 
outside of the linear range.  
 
The protein concentration (µg.mL-1) was calculated using the following formula;  
 
[Protein] (µg.mL-1) = (A595nm/0.1) × 1.95 × dilution factor × (1000/volume assayed)  
 
The concentration of proteins purified in detergent (most of those within this thesis), 
were established using the bicinchoninic acid (BCA) assay (Pierce) as this is less 
affected by detergents. The assay was carried out according to the manufacturer’s 
instructions and absorbance at 562 nm was measured using a Jenway 6306 UV-
visible spectrophotometer. 
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2.5.2 SDS-Polyacrylamide Gel Electrophoresis 
 
Proteins were separated and visualised under denaturing conditions by discontinuous 
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) with the Tris-glycine buffer 
system (Laemmli, 1970). A 5 mL resolving gel (375 mM Tris pH 8.8, 0.4% (w/v) 
SDS, 12% acrylamide:bis-acrylamide (37.5:1)) was cast using the Hoeffer Mighty 
Small gel kit and polymerised with 100 µL 10% (w/v) APS (ammonium persulfate) 
and 10 µL N,N,N',N'-Tetramethylethylenediamine (TEMED). Prior to setting, the gel 
was overlaid with 100% (v/v) ethanol to ensure an even set. A 2 mL stacking gel 
(125 mM Tris pH 6.8, 0.4% (w/v) SDS, 4% acrylamide:bis-acrylamide (37.5:1)) 
polymerised with 50 µL 10% (w/v) APS and 10 µL TEMED, was poured on top of 
the polymerised resolving gel after removal of the overlaid ethanol, with the 
insertion of  a plastic comb to form wells. 
 
10 µg protein samples (or a maximum volume of 20 µL if the protein concentration 
was too low) were mixed with 1 × loading buffer (6 ×; 63.5 mM Tris pH 6.8, 0.4% 
(w/v) SDS, 5% (v/v) β-mercaptoethanol, 20% (v/v) glycerol, 2.5% (w/v) 
bromophenol blue) and were heat-denatured at 95°C for 10 min using an Eppendorf 
Mastercycler Gradient thermocycler. Samples were pipetted into the wells and the 
gel run in SDS-PAGE running buffer (25 mM Tris pH 8.3, 0.19 M glycine, 0.1% 
(w/v) SDS) at 180 V until the dye front reached the bottom of the gel. 
 
Proteins separated by SDS-PAGE were stained for 1 hour using Instant Blue stain 
(Expedeon). Gels were washed in water briefly and imaged using Syngene GeneSnap 
G:Box Gel Doc and analysis system. 
 
2.5.3 Microscale Thermophoresis (MST) 
 
NT-647 fluorescent label was covalently attached to the required protein using a 
MonolithTM  Protein Labelling Kit RED-NHS (Nanotemper Technologies, Germany) 
according to the manufacturer’s instructions and subsequently diluted to 150 nM. 
Non-labelled protein at final concentrations ranging from 64.95 µM to 2 nM were 
mixed in equal volumes with labelled protein to achieve 75 nM final concentration of 
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the dyed version. Assays were performed in protein storage or reaction buffer (as 
described in the text) plus 0.005% (v/v) Tween20 to reduce sticking to capillaries. 
MST analysis was in standard glass capillaries using the Monolith NT.115 
(Nanotemper Technologies, Germany) according to the manufacturer’s instructions.  
 
2.6 Synthesis of Lipid II intermediates 
 
2.6.1 UDP-MurNAc-pentapeptide biosynthesis  
 
Method adapted from Lloyd et al. (2008). 2 mL reaction volumes were used, 
containing 50 mM HEPES pH 7.5, 10 mM MgCl2, 200 mM PEP, 50 mM KCl, 10 
mM dithiothreitol, 10 mM UDP-GlcNAc, 30 mM L-Ala, 30 mM D-Glu (or 100 mM 
D-Gln), 30 mM L-Lys, 30 mM D-Alanyl-D-Ala, 200 µM NADPH, 6 mM ATP, 25 
mM isocitrate, 40 units isocitrate dehydrogenase (Sigma-Aldrich), 500 units of 
pyruvate kinase (Sigma-Aldrich), 300 µg MurA, 2000 µg MurB, 750 µg MurC, 1000 
µg MurD, 1250 µg MurE and 1500 µg MurF. This was incubated at 37°C overnight, 
before dilution with 5 mL sterile water, and filtration with a Vivaspin® centrifugal 
concentrator (10 kDa cut-off) to remove proteins.  
 
2.6.1.1 UDP-MurNAc-pentapeptide purification 
 
A Source 30Q column (26 x 120 mm) on an AKTApurifier 10 was used to purify the 
UDP-MurNAc-pentapeptides by anion exchange chromatography. Prior to use, the 
column was pre-equilibrated with 6 CV of 10 mM ammonium acetate pH 7.5, 6 CV 
of 1 M ammonium acetate pH 7.5, and a further 10 CV of 10 mM ammonium acetate 
pH 7.5 until conductivity was at baseline. Samples (Section 2.6.1) were diluted into 
100 mL of 10 mM ammonium acetate pH 7.5 and loaded onto the column. 10 mL 
fractions were collected during an ammonium acetate gradient from 10 mM to 300 
mM over 7 CV at 10 mL.min-1. Presence of the UDP-MurNAc-pentapeptide was 
determined by an increase in absorbance at 254 nm and 280 nm and fractions 
containing the required product were freeze dried 4 times and resuspended in a small 
volume of sterile water. 
 72 
2.6.1.2 UDP-MurNAc-pentapeptide further purification 
 
Size exclusion chromatography was used to remove residual ammonium acetate prior 
to subsequent reactions. A Biogel P2 column (89 cm x 2.6 cm) was equilibrated with 
2 CV of H2O at 1 mL.min-1. UDP-MurNAc-pentapeptide for desalting was injected 
via the injection loop and the column developed over one CV with H2O at                  
1 mL.min-1. 10 mL fractions were collected and absorbance at 254 nm and 280 nm 
used to identify the UDP-MurNAc-pentapeptide. The product peak was freeze dried, 
resuspended in 500 mM NaHCO3 pH 10  (or H2O depending on the next step) and 
frozen at -20°C. 
 
2.6.1.3 Quantification of UDP-MurNAc-pentapeptide 
 
The concentration of the final product was calculated by absorbance at 260 nm, by 
virtue of the uracil of UDP-MurNAc-pentapeptide (extinction coefficient of 10,000 
M-1cm-1). A quartz cuvette in a Jenway 6306 UV-visible spectrophotometer was 
used.  
 
2.6.1.4 Purity of UDP-MurNAc-pentapeptide 
 
The purity of UDP-MurNAc-pentapeptides was analysed by anion exchange 
chromatography using a 1 mL MonoQ HR 5/5 column (10 µM beads)(GE 
Healthcare). The column was pre-equilibrated with 10 CV 10 mM ammonium 
acetate pH 7.5, 10 CV 1 M ammonium acetate pH 7.5, and a further 10 CV 10 mM 
ammonium acetate pH 7.5 until conductivity was at baseline. A sample of 2 µL 
intermediate in a total of 1000 µL 10 mM ammonium acetate pH 7.5 was loaded 
through an injection loop and eluted over 10 CV at 1 mL.min-1 with a gradient of        
1-100% 1 M ammonium acetate pH 7.5. Elution was monitored by an increase in 
absorbance at 254 nm and 280 nm, and integration of the A254nm peak as a percentage 
of the total area using UNICORN (GE healthcare) software provided percentage 
purity.  
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2.6.2 Production of MurNAc-pentapeptide 
 
MurNAc-pentapeptide was made from UDP-MurNAc-pentapeptide by either acid or 
enzymatic hydrolysis as described. 
 
2.6.2.1 Acid hydrolysis of UDP-MurNAc-pentapeptide 
 
1 M HCl was added to 10 mg UDP-MurNAc-pentapeptide in H2O to give a final 
concentration of 0.1 M, and additional added dropwise if required until pH 1 was 
reached. Samples were boiled at 99°C for 30 min and subsequently neutralised to pH 
7.5 with 1 M NaOH. Samples were diluted to 5 mL in 10 mM ammonium acetate pH 
7.6 and purified as described in Section 2.6.2.3.  
 
2.6.2.2 Enzymatic hydrolysis of UDP-MurNAc-pentapeptide 
 
10 units of each of Phosphodiesterase from Crotalus adamanteus (Sigma-Aldrich) 
and Shrimp alkaline phosphatase (SAP)(NEB) were added to 10 mg UDP-MurNAc-
pentapeptide in H2O and Tris.HCl pH 8.5 added to a final concentration of 50 mM. 
This was incubated at 37°C overnight, before dilution with 5 mL sterile water, and 
filtration with a Vivaspin® centrifugal concentrator (10 kDa cut-off) to remove 
proteins. The flow-through was purified as described in Section 2.6.2.3.  
 
2.6.2.3 Purification of MurNAc-pentapeptide 
 
Purification was as described for UDP-MurNAc-pentapeptide (Section 2.6.1.1) with 
the additional monitoring of absorbance at 218nm to detect peptide bonds. MurNAc-
pentapeptide has no overall negative charge at pH 7.6 and therefore elutes in the 
flow-through. Fractions containing the required product were freeze dried 4 times 
and resuspended in a small volume of H2O. 
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2.6.2.4 Purity of MurNAc-pentapeptide 
 
The purity of MurNAc-pentapeptide was analysed by cation exchange 
chromatography using a 1 mL MonoS HR 5/5 column (10 µM beads)(GE 
Healthcare). The column was pre-equilibrated with 10 CV 20 mM phosphoric acid 
10 mM NaCl pH 4, 10 CV 20 mM phosphoric acid 1 M NaCl pH 4, and a further 10 
CV 20 mM phosphoric acid 10 mM NaCl pH 4 until conductivity was at baseline. A 
sample of 2 µL intermediate in a total of 600 µL 20 mM phosphoric acid 10 mM 
NaCl pH 4 was loaded through an injection loop and was subsequently washed with 
10 CV of the same buffer at 1 mL.min-1. Elution was with a gradient of 1-100% 20 
mM phosphoric acid 1 M NaCl pH 4 and was monitored by an increase in 
absorbance at 218 nm, 254 nm and 280 nm. Integration of the A218nm peak as a 
percentage of the total area using UNICORN software (GE healthcare) provided 
percentage purity of the MurNAc-pentapeptide. 
 
2.6.2.5 Quantification of MurNAc-pentapeptide 
 
MurNAc-pentapeptide was quantified by the Amplex Red assay for D-Ala release 
coupled to E. coli DacA (DD-carboxypeptidase to remove the terminal D-Ala).      
200 µL reactions in 50 mM HEPES pH 7.6, 5 mM MgCl2 containing 50 µM Amplex 
Red, 33.51 mM.min-1 Rhodotorula oracalis DAAO, 7.41 mM.min-1 horseradish 
peroxidase and 1 mg.ml-1 E. coli DacA were monitored in a quartz cuvette in a 
Varian Cary 100 spectrophotometer at 37°C, until a stable baseline at A555nm was 
reached. 2.5 µL of a 1/100 dilution of the MurNAc-pentapeptide stock was added 
and overall change in absorbance used to calculate the concentration of MurNAc-
pentapeptide in the cuvette. Note that the catalytic concentration of DAAO and HRP 
enzyme activity (mM.min-1) was calculated as described in Appendix 2 
 
2.6.3 Dansylation of UDP-MurNAc-pentapeptide 
 
Dansylation was carried out by Julie Todd or Anita Catherwood of BaCWAN (UK; 
Clarke et al., 2009; Lloyd et al., 2008), methods are included here for clarity. 
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Desalted UDP-MurNAc-pentapeptide (Section 2.6.1.2) in sterile water was mixed 
with an equal volume of acetone and reacted with a 42 × molar ratio of dansyl 
chloride (Sigma-Aldrich) in a tin foil covered glass vial. The reaction was allowed to 
proceed overnight at room temperature in the dark with stirring. A 10 × molar ratio 
of Tris pH 9 to dansyl chloride (previously added) was added and the reaction 
transferred to a round bottom flask. Quenching was for 1 hour at room temperature 
before rotary evaporation to remove solvents. Dried products were resuspended in 1 
mL sterile water and purified by size exclusion chromatography on a Superdex 
peptide 10/300 column (GE Healthcare) pre equilibrated with 1.5 CV   0.1 M 
ammonium bicarbonate. The sample was loaded via a 1 mL injection loop and 
elution monitored by absorbance at 254, 280 and 340 nm. Dansylated UDP-
MurNAc-pentapeptide is the first peak to elute with an absorbance at 340 nm. 
Fractions containing the required product were freeze dried 4 times and resuspended 
in a small volume of sterile water. Quantification (Section 2.6.1.3) and purity checks 
(Section 2.6.1.4) were as described previously.  
 
2.6.4 Branched UDP-MurNAc-pentapeptide derivatives 
 
2.6.4.1 Fmoc-dipeptide synthesis 
 
Synthesis of Fmoc-L-Ala-L-Ser was carried out using two methods (Section 
2.6.4.1.1. and 2.6.4.1.2), and Fmoc-L-Ala-L-Ala by one (Setion 2.6.4.1.1). 
 
2.6.4.1.1. Fmoc-OSu and dipeptide coupling 
 
Dipeptide (L-Ala-L-Ala-OH or L-Ala-L-Ser-OH) (620 µmol) was dissolved in 155 
mL H2O and 1550 µmol NaHCO3 added, before cooling to 0°C. A solution of Fmoc-
OSu (620 µmol) in 155 mL acetonitrile was made and also cooled to 0°C, before 
being added drop wise to the dipeptide solution, whilst stirring. This was allowed to 
warm to room temperature overnight whilst stirring before rotary evaporation to 
remove acetonitrile. The pH was adjusted to 10 with 5 M NaOH and 100 mL 
dichloromethane added in a separating funnel. The dichloromethane phase (bottom) 
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was decanted and stored, whilst the aqueous phase was acidified to pH 5 with 
concentrated HCl. The aqueous phase was washed with 100 mL ethyl acetate twice 
in the same way, and the resulting ethyl acetate phase (top) was rotary evaporated, 
before being dried under high pressure.  
 
2.6.4.1.2 Fmoc-L-Ala and O-tert-butyl-L-Ser tert-butyl ester 
 
235 mg Fmoc-L-Ala (755 µmol), 215 mg EDC (1375 µmol), 107 mg oxyma pure 
(750 µmol) and 163 mg O-tert-butyl-L-Ser tert-butyl ester (750 µmol) were added to 
5 mL CH2Cl2 and 2.15 mL triethylamine before stirring at room temperature 
overnight, and subsequently dried by rotary evaporation. The product was 
resuspended in 10 mL CH2Cl2 and 6 mL 5% (v/v) citric acid, the CH2Cl2 phase 
(bottom) decanted off and washed again with 5% (v/v) citric acid. 2 mL saturated 
NaHCO3 and 2 mL H2O were added to the remaining organic phase, the aqueous 
phase decanted off and the process repeated. 2 teaspoons of dried MgSO4 were added 
to the organic phase and the suspension filtered and dried by rotary evaporation. The 
product was purified by silica gel chromatography and de-protection of the Ot-butyl 
groups was carried out with 5 mL TFA and 5 mL dichloromethane (dried) for 5 
hours. The final product was dried by rotary evaporation and washed with diethyl 
ether before being dried under high pressure over night.  
 
2.6.4.2 UDP-MurNAc-hexa- and heptapeptide synthesis 
 
All reactions (Ser, Ala, Ser-Ala and Ala-Ala branching) were carried out in 2 mL of 
80% (v/v) acetonitrile. Added to this was Fmoc-X (24 µmol) where X is a peptide or 
dipeptide, N-hydroxysuccinimide (NHSu) (60 µmol), MES hydrate (10 µmol), 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC)(110 µmol), and 
the pH adjusted to 5.0. This was incubated at room temperature for 20 min (10 min 
for SerAla or Ser to reduce interaction of EDC with Ser side group) before the 
addition of UDP-MurNAc-pentapeptide (2 µmol) in 500 mM NaHCO3 at pH 10. 
Incubation, with stirring, was carried out for 3 hours before 100 µL ethanolamine 
was added, and 20 min later, 100 µL 20% (v/v) piperidine for a further 30 min. 2 mL 
reactions were diluted to 20 mL with sterile H2O and filtered with a 0.20 µm 
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nitrocellulose syringe filter. Filtrate was rotary evaporate to remove residual solvent, 
freeze-dried and stored at -20°C. 
 
2.6.4.3 UDP-MurNAc-hexa- and heptapeptides purification 
 
Purification was as described in Section 2.6.1.1. 
 
2.6.4.4 UDP-MurNAc-hexa- and heptapeptides quantification 
 
Quantification was as described in Section 2.6.1.3. 
 
2.6.5 Lipid II preparation 
 
2.6.5.1 Lipid II synthesis  
 
Method adapted from Breukink et al. (2003). Synthesis was in a glass vial in 3.5 mL 
buffer (100 mM Tris.HCl pH 8, 5 mM MgCl2, 1% (v/v) Triton X-100) and contained 
10.5 mg Micrococcus flavus membranes (Appendix 1) with 48 µmol UDP-GlcNAc 
(Sigma), 12 µmol UDP-MurNAc-pentapeptide (or branched/fluorescent derivative) 
and 4.8 µmol undecaprenyl phosphate, and was incubated at 37°C for 3 hours. Lipid 
was extracted with 3.5 mL 6 M pyridine-acetate pH 4.2 and 3.5 mL n-butanol. 
Centrifugation at 4500 × g for 10 min separated the phases and the n-butanol (top) 
phase was taken and washed with an equal volume of H2O. After a second 
centrifugation (4500 × g, 10 min), the top phase was collected, rotary evaporated and 
frozen at -80°C. 
 
2.6.5.2 Lipid II purification 
 
Lipid II purification was by anion exchange using DEAE-Sephacel. 8 mL resin was 
poured into a sawn-off 20 mL glass pipette with a glass wool fret, and washed with 5 
CV of 1 M ammonium acetate, 5 CV H2O and 10 CV of chloroform/methanol/water 
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(2:3:1) (solvent A). The sample was resuspended in 6 mL solvent A and loaded onto 
the column by pipette whilst collecting the flow through. The column was washed 
with 4 CV of solvent A and developed with stepwise increases in concentration of    
8 mL chloroform/methanol/1 M ammonium bicarbonate (2:3:1) using steps from    
50 mM ammonium bicarbonate to 1 M. Amidated Lipid intermediates required       
10 washes at 100 mM ammonium bicarbonate in order to separate the Lipid II from 
unused undecaprenyl phosphate.  
 
2.6.5.3 Analysis by thin layer chromatography (TLC) 
 
Fractions from anion exchange were analysed by Silica TLC.  Dried samples from 
purification were resuspended in 20 µL solvent A and loaded 2 cm apart and 1.5 cm 
from the bottom of the plate in 5 µL aliquots with air drying. TLC running buffer 
(chloroform/methanol/water/0.88 ammonia (88:48:10:1) was poured into the tank at 
a 1 cm depth and chromatography carried out at room temperature for approximately 
4 hours. Iodine vapour in a sealed tank was used to stain the TLC plate. A flat bed 
scanner was used to image results as iodine staining fades over time.  
 
2.6.5.4 Lipid II quantification 
 
Duplicate Lipid II samples (50 µL) and a chloroform/methanol/water 2:3:1 (v/v) 
control were dried down under nitrogen flow and resuspended in 50 µL 50 mM 
HEPES, 10 mM MgCl2, 30 mM KCl, 1.5% (w/v) CHAPS, pH 7.6. 50 µL. 1 M HCl 
was added to one Lipid II sample and the control, and both boiled for 20 min before 
centrifuging at 3,000 × g for 5 min. Samples were neutralised to pH 7.6 with 1 M 
NaOH. 
 
A Pi detection assay was used to quantify the inorganic phosphate released from 
Lipid II through acid hydrolysis. Purine nucleoside phosphorylase (PNP) converts 7-
methyl-6-guanosine (MESG) (strong A330nm) to ribose-1-phosphate and 7-methyl-6-
guanine (strong A360nm) in a Pi dependent manner. This increase in absorbance can be 
followed spectrophotometrically. Including inorganic pyrophosphatase (IPP) releases 
remaining phosphate from the inorganic pyrophosphate yielded by the acid 
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hydrolysis.  200 µL assays containing 50 mM HEPES pH 7.6, 10 mM MgCl2, 200 
µM MESG (Berry and Associates, USA), 1 unit PNP and 1 unit IPP are monitored 
for a stable baseline at 360 nm before the addition of 10 µL Lipid II sample. The 
extinction coefficient for the change in A360nm by 1 M Pi is 10,000 M-1cm-1 and is 
used to quantify the lipid taking into consideration that each Lipid II molecule has 
two Pi.  
 
2.6.6 Mass spectrometry 
 
Samples of UDP-MurNAc-peptide intermediates and Lipid II were analysed by the 
Proteomics Facility RTP (School of Life Sciences, University of Warwick) or by Dr 
Adrian Lloyd (School of Life Science, University of Warwick) unless otherwise 
stated. Masses were established by negative or positive ion electrospray ionisation 
mass spectrometry (ESI-MS), and positive ion fragmentation used to verify 
structures. Data analysis was by the Proteomics Facility RTP or Dr Adrian Lloyd 
using MassLynx (Waters, USA).  
 
2.7 Assays for transglycosylase activity 
 
Two assay systems were used in this project to analyse the transglycosylase activity 
of penicillin-binding proteins. These are illustrated diagrammatically for comparison 
along with alternative assay systems in Figure 2 of Galley et al., (2014) (attached in 
Appendix 8). 
 
2.7.1 Continuous spectrophotometric assay for transglycosylation 
 
The continuous spectrophotometric assay for transglycosylase activity was carried 
out as described in Helassa et al. (2012), based on the original assay reported by 
Schwartz et al. (2002). Modifications were made to the buffer conditions and 
additional components as well as Lipid II and enzyme concentrations, and these are 
detailed throughout the text. In general. 50 µL reactions consisted of 5 µL 100% 
dansylated Lipid II (Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) from a 10 × stock 
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and 40 µL of the specified reaction buffer containing any additional components 
required in a FLUOTRACTM 600 high binding 96-well plate (Greiner). Lipid stocks 
were made at 10 × the required Lipid II concentration in 10 × the desired detergent 
concentration by removal of chloroform/methanol/water (2:3:1) under nitrogen flow 
and resuspended by vortexing in the detergent buffer. Fluorescence measurements 
with excitation at 340 nm and emission at 521 nm were made in a Clariostar 
platereader (BMG Labtech) at the specified temperature until a steady baseline was 
observed. The reading was paused, plate ejected and 5 µL PBP at 10 × the required 
concentration, or 5 µL enzyme storage buffer (control) added to initiate the reaction 
with a multichannel pipette. A ThermalSeal RTTM film was applied to the plate to 
reduce evaporation. Fluorescence readings were continued for 100 minutes as 
standard.  
 
Fluorescence values were exported using MARS Data Analysis Software (BMG 
Labtech), rates were calculated in RFU/second and data plotted in GraphPad Prism 
(Version 6.0).  
 
2.7.2 SDS-PAGE analysis of transglycosylase products 
 
SDS-PAGE analysis of transglycosylase products was based on the method 
described by Helassa et al. (2012) and Barrett et al. (2007). Modifications were made 
to the buffer conditions, Lipid II and enzyme concentrations for individual 
experiments, and these are detailed throughout the text. In general, reactions were in 
a final volume of 15 µL in 0.6 mL low binding eppendorfs to minimise sticking.    
1.5 µL 100% dansylated Lipid II (Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) from 
a 10 × stock was added to 12 µL of the specified reaction buffer. 10 × stocks were 
made as described in Section 2.7.1. 1.5 µL PBP at 10 × the required concentration, or 
1.5 µL enzyme storage buffer (control) were added and reactions incubated in an 
Eppendorf Mastercycler Gradient thermocycler at a temperature and time specific to 
the experiment. Reactions were terminated with 0.5 mM moenomycin and                 
1 × loading buffer was added (6 × stock: 100 mM Tris pH 8.8, 4% (w/v) SDS, 40% 
(v/v) glycerol). 
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Polyacrylamide gels were prepared as previously described (Barrett et al., 2007) for 
the detection of glycan chain. Gels were cast using a Hoeffer Mighty Small gel kit 
with a 7.5 mL gel recipe of 2.5 mL gel buffer (1.25 M Tris pH 8.45, 0.4% (w/v) 
SDS), 3.3 mL H2O, 1.7 mL Acrylamide/Bis-acrylamide 37.5/1 40% and polymerised 
by the addition of 30 µL 10% (w/v) APS and 15 µL TEMED. Samples were loaded 
without heat denaturation. In a single lane, reaction buffer plus loading buffer with 
bromophenol blue was loaded to monitor migration. Gels were run in anode buffer 
(0.1 M Tris, pH 8.8) and cathode buffer (0.1 M Tris, 0.1 M Tricine, 0.1% (w/v) SDS, 
pH 8.25) at 100 V and 50 mA for 1 h. Imaging was in a Syngene GeneSnap G:Box 
Gel Doc under UV (302nm) transillumination with a SW06 filter (516-600 nm) 
(Syngene).  
 
2.8 Assays for transpeptidase activity 
 
Several methods were used for the detection of transpeptidase activity of PBPs 
throughout this thesis. 
 
2.8.1 BOCILLIN FL binding 
 
Fluorescently labelled BODIPY penicillin; BOCILLIN FL, was used to identify the 
correct folding of the penicillin-binding domain. 16 µg PBPs were incubated with 
200 µM ampicillin, 200 µM moenomycin or an equivalent volume of sterile water 
for 30 min at room temperature. A 5:1 molar ratio of BOCILLIN FL to PBP was 
then incubated at 37°C for 1 hour in the dark before the addition of 1 × loading dye 
and analysis by SDS-PAGE (Section 2.5.2). Samples were not heat denatured to 
preserve the interaction between the PBP and BOCILLIN FL. Fluorescence was 
detected using a Typhoon FLA 9500 laser scanner (GE Healthcare) with a Y520 
filter prior to Coomassie-staining of total protein.  
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2.8.2 SDS-PAGE analysis of transpeptidation products 
 
Polyacrylamide gel analysis of reaction products can detect transpeptidation using a 
modified version of the method in Section 2.7.2 (for transglycosylation). By use of a 
10:1 ratio (50 µM; 5 µM) dansylated to non-dansylated Lipid II, cross-linking is able 
to occur (dansylated Lipid II cannot be a transpeptidase acceptor), and fluorescence 
can be detected by the method described previously. Reactions in the presence and 
absence of 1 mM Penicillin G and 0.5 mM moenomycin were analysed by SDS-
PAGE as described in Section 2.7.2.   
 
2.8.3 N-acetylmuramidase digestion of SDS-PAGE gel bands for mass 
spectrometry 
 
The high molecular weight band remaining at the top of the SDS-PAGE gel was 
visualised by transillumination and removed with a scalpel. A band from the same 
location in a lane containing only reaction buffer was also removed as a negative 
control. Both samples were treated identically throughout. 150 µL 100% acetonitrile 
was added to gel bands in low binding eppendorfs and incubated at 40°C in an 
Eppendorf Mastercycler Gradient thermocycler for 40 min to dehydrate the 
acrylamide. Acetonitrile was aspirated and eppendorfs heated at 80°C with the lid 
open to remove residual solvent. Dehydrated acrylamide was crushed with tweezers 
and resuspended in 100 µL 50 mM Bis.Tris pH6.2. 10 µL 10 mg.mL-1 hen egg-white 
lysozyme or Mutanolysin from Streptomyces globisporus (both N-
acetylmuramidases) were added and mixtures incubated overnight at 37°C. A further 
10 µL N-acetylmuramidase was added for 2 hours at 37°C the following morning 
before centrifugation at 13,000 rpm for 4 min to pellet the acrylamide. The 
supernatant was carefully removed and the pellet washed in 100 µL 50 mM Bis.Tris 
pH 6.2 and centrifuged again. The supernatants from both spins were pooled and 
heated for 10 min at 100°C before centrifugation at 13,000 rpm for 10 min to remove 
proteins. 150 µL 10 mg.mL-1 NaBH4 was added for 30 min at room temperature to 
reduce the sugar rings following cleavage and finally 17.5 µL 20% (v/v) phosphoric 
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acid to cleave the lipid linker. Samples were analysed by liquid chromatography 
mass spectrometry (LC-MS) in positive mode by Dr A. Lloyd.  
 
2.8.4 Amplex Red assay for D-Ala release 
 
The Amplex Red assay for D-Ala release was used for the detection of 
transpeptidase and/or DD-carboxypeptidase activity. 200 µL reactions were 
performed in the specific buffer described in the text plus 50 µM Amplex Red, 33.51 
mM.min-1 Rhodotorula oracalis DAAO and 14.82 mM.min-1 horseradish peroxidase. 
The catalytic concentration of DAAO and HRP enzyme activity (mM.min-1) was 
calculated as described in Appendix 2. In a quartz cuvette; Lipid II or Lipid II 
storage buffer plus reaction buffer including the above coupling enzymes was 
monitored for absorbance at 555 nm for 2 min to ensure a stable baseline before the 
addition of PBP. The reaction was monitored until completion when using a Lipid II 
capable of being either a donor and an acceptor, or for 6 min before the addition of a 
transpeptidase acceptor if not. Assays were performed in a Varian Cary 100 
spectrophotometer at 30°C.  
 
2.8.5 N-acetylmuramidase digestion of cuvette contents for mass spectrometry 
 
Cuvette contents following a positive reaction were digested with Mutanolysin from 
Streptomyces globisporus prior to mass spectrometry in order to identify cross-linked 
products. 20 µL 2.2 M Bis.Tris pH 6.2 was added to the 200 µL cuvette contents plus 
20 µL 10 mg.mL-1 Mutanolysin and incubated for 2 h at 37°C. The reaction was 
incubated for a further 2 h with an additional 20 µL aliquot of Mutanolysin before 
boiling at 100°C for 10 min and centrifugation at 13,000 rpm for 10 min to remove 
proteins. 150 µL 10 mg.mL-1 NaBH4 was added for 30 min at room temperature to 
reduce the sugar rings following cleavage and finally 17.5 µL 20% (v/v) phosphoric 
acid added to cleave the lipid linker. Samples were analysed by liquid 
chromatography mass spectrometry (LC-MS) in positive mode, and subsequently by 
collision induced fragmentation by Dr A. Lloyd. 
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Chapter 3. Synthesis of Streptococcus pneumoniae specific 
Lipid II intermediates 
 
3.1 Introduction 
 
Peptidoglycan has the same basic structure, but is subject to many genus- and 
species-specific modifications, leading to variations in the chemical structure 
(covered in detail in Section 1.5.2). In order to study the in vitro enzymatic activities 
and substrate specificities of the Class A PBPs from Gram-positive pathogens 
(Chapter 4, 5 and 6), a range of substrate variants are required. These include Lipid II 
with species-specific modifications (Section 3.1.1), as well as fluorescently labelled 
variants for use in assays of transglycosylase activity (Sections 3.1.2, 4.1.4). Assay 
development to study the enzymes of the later stages of peptidoglycan biosynthesis 
has been hampered by lack of availability of the required lipid linked substrates. The 
extraction of Lipid II from bacteria is difficult as it has a low natural abundance and 
is structurally complex (Nakagawa et al., 1984; Van Heijenoort, 1992). However, 
several groups have developed chemical and chemo-enzymatic methods for synthesis 
of this important substrate, in sufficient yield for the development of assays 
(Breukink et al., 2003; Lloyd et al., 2008; Schwartz et al., 2001; VanNieuwenhze et 
al., 2002).  
 
3.1.1 Peptidoglycan modifications in Streptococcus pneumoniae 
 
S. pneumoniae peptidoglycan stem peptides are chemically modified by the addition 
of an L-Ala or L-Ser followed by L-Ala to form dipeptide branches on the ε-amino 
group of the third position lysine (Filipe and Tomasz, 2000; Fiser et al., 2003). These 
branches are described from their C-terminus to N-terminus as L-Ala-L-Ala and L-
Ser-L-Ala for the remainder of this thesis.  The stem peptide is also modified by 
amidation of the α-carboxyl of D-glutamate at position 2 in the stem peptide to 
isoglutamine by the amidase MurT/GatD (Zapun et al., 2013). Dipeptide branching 
and its involvement in S. pneumoniae β-lactam resistance is covered in more detail in 
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Chapter 6, and stem peptide branching more generally in Section 1.5.2.3. Amidation 
of the second or third position amino acid of the stem peptide is a common 
modification in Gram-positive bacteria (Vollmer et al., 2008; Section 1.5.2.2.2) and 
occurs on the second position D-glutamate in both S. pneumoniae and S. aureus. The 
role of this modification in both bacteria is studied and discussed in more detail in 
chapter 4 and 5 respectively.  
 
Glutamate amidation and the appendage of a dipeptide branch to the stem peptide 
occur at the lipid-linked stage of peptidoglycan biosynthesis, and therefore for 
further study of PBPs both the amidated and dipeptide branched Lipid II substrates 
are required. Specifically, these are; Lipid II (Gln), (and Lipid II (Glu)); to enable 
investigation into the effect of amidation on PBP activity (for both S. aureus and S. 
pneumoniae), as well Lipid II with the addition of either L-Ala-L-Ala or L-Ser-L-Ala 
branches (S. pneumoniae) (Figure 3.1 (X1, X2, R3 and R4). Synthesis of the Lipid II 
substrate with position 2 isoglutamine and a dipeptide branch has not been described 
to date, and thus this work is essential for the in vitro study of S. aureus and S. 
pneumoniae PBPs with their native substrate, and investigation into the role of 
branched substrates in peptidoglycan synthesis. Note that all Lipid II described in 
this thesis has lysine at the third position of the stem peptide unless stated otherwise.  
 
3.1.2 Fluorescently labelled Lipid II  
 
Lipid II can be modified to enable detection in assay systems. Historically, this was 
with radioactive [14C]GlcNAc (Bertsche et al., 2005), but more recently by covalent 
labelling with a fluorescent molecule, increasing the sensitivity and specificity of 
detection. A fluorescent group such as dansyl (excitation 340 nm, emission 521 nm; 
Schwartz et al., 2002) or 7-nitro-2,1,3-benzoxadiazol-4-yl (NBD; excitation 466 nm, 
emission 535 nm; van Dam et al., 2007) can be attached via a sulphonamide linkage 
to the ε-amino group of the lysine in the third position of the pentapeptide chain, or 
alternatively incorporated into the lipid chain (Liu et al., 2010). For use in the assay 
systems in this project (see section 4.1.4 for details), Lipid II with a dansyl group on 
the third position lysine was required (Figure 3.1 (R2)), with and without amidation 
of the second position glutamate α-carboxyl (Figure 3.1 (X1 and X2)). 
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3.1.3 In vitro Lipid II synthesis 
 
The synthesis of peptidoglycan intermediates, including Lipid II is well established 
within our group (BaCWAN, UK; Clarke et al., 2009; Lloyd et al., 2008). Lipid II 
can be made by either a chemical or enzymatic route (Breukink et al., 2003; Lloyd et 
al., 2008; Schwartz et al., 2001; VanNieuwenhze et al., 2002), the latter of which is 
detailed in Figure 3.2 (Illustrated for Lipid II (Glu/Gln)), and is the method used in 
this chapter (full method details in sections 2.6.1 and 2.6.5). In short, a single one-pot 
incubation containing the MurA-MurF enzymes mimics the cytoplasmic steps of 
peptidoglycan biosynthesis and produces UDP-MurNAc-L-Ala-γ-D-Glu/D-Gln-L-
Lys-D-Ala-D-Ala (UDP-MurNAc-pentapeptide (Glu/Gln)), which is then converted 
Figure 3.1: Lipid II variants. Structure of the Lipid II variants required for this project. Basic 
structure of lysine Lipid II is varied at two points (X and R). Lipid II is either X1: D-glutamate 
(non-amidated) in the second position or X2: D-isoglutamine (amidated) in the second position. 
The third position lysine is unchanged (R1), fluorescently labelled with a dansyl group (R2) or 
with the addition of a dipeptide branch; R3: L-Ala-L-Ala or R4: L-Ser-L-Ala. 
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to Lipid II by addition of undecaprenyl phosphate and UDP-GlcNAc using 
Micrococcus flavus membranes (Breukink et al., 2003).  
 
3.2 Experimental Aims 
 
• To synthesise UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys-D-Ala-D-Ala (UDP-
MurNAc-pentapeptide (Gln)) and adequately desalt for later reactions. 
• To develop a method for the chemical synthesis of UDP-MurNAc-
hexapeptide (Gln, Ala), UDP-MurNAc-hexapeptide (Gln, Ser), UDP-
MurNAc-heptapeptide (Gln, AlaAla) and UDP-MurNAc-heptapeptide (Gln, 
SerAla). 
• To convert these branched UDP-MurNAc-pentapeptide derivatives to Lipid 
II, with sufficient yield for use in enzymatic studies.  
• To obtain Lipid II (Glu), Lipid II (Gln) and their fluorescently labelled 
derivatives; Lipid II (Glu, Dans) and Lipid II (Gln, Dans) for assays of PBP 
activity 
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A 
B 
Figure 3.2: Enzymatic synthesis of Lipid II. .A: MurA-MurF one pot synthesis including substrates and cofactors for the Mur enzymes as well as recycling 
enzymes produces UDP-MurNAc-pentapeptide (Glu/Gln) from UDP-GlcNAc. B: UDP-MurNAc-pentapeptide converted to Lipid II by Micrococcus flavus 
membranes and the addition of UDP-GlcNAc and undecaprenyl phosphate. PK: Pyruvate kinase, IDH: Isocitrate dehydrogenase 
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3.3 Enzymatic biosynthesis of UDP-MurNAc-pentapeptide 
 
UDP-MurNAc-pentapeptide can be made in one step by enzymes MurA-MurF and 
their substrates (Section 2.6.1 and 3.1.3). UDP-MurNAc-pentapeptide (Glu) was 
made according to a published method (Lloyd et al., 2008). Work by Dr A. Lloyd 
established that MurD incorporates D-isoglutamine into position 2 of the 
pentapeptide when added in sufficient quantities (3 x excess required over natural D-
glutamate substrate). (Dr Adrian Lloyd, Personal communication), giving UDP-
MurNAc-pentapeptide (Gln). An alternative strategy is the enzymatic amidation of 
glutamate containing Lipid II using MurT/GatD in the presence of ATP and L-
glutamine (Zapun et al., 2013). However, this would require a purification step by 
anion exchange, reducing the final yield, as well as using costly Lipid II as a 
substrate. Additionally there is the possibility of incomplete purification, and thus a 
mix of final products, which can be avoided by ensuring that only isoglutamine can 
be incorporated at an early stage in the synthesis. Both UDP-MurNAc-pentapeptide 
(Glu) and UDP-MurNAc-pentapeptide (Gln) were synthesised by the one pot method 
(Section 2.6.1), purified by anion exchange (Section 2.6.1.1)(Figure 3.3) and freeze 
dried four times to remove the ammonium acetate required for elution from the 
Source30Q column.  
 
Elution of UDP-MurNAc-pentapeptide was monitored by absorbance changes at 254 
nm and 280 nm (2.6:1 A254nm:A280nm characteristic of the Uridine ring; Dawson et al., 
1986). Figure 3.3 shows a clear peak (A(i)) at the expected conductivity of 
approximately 13 mS.cm-1 (estimated based on previous work by Dr. A. Lloyd) and 
with clear separation from the ATP (A(ii)) required by MurC-MurF. UDP-MurNAc-
pentapeptide (Gln) was eluted at a lower conductivity than the non-amidated version 
(B(i)) at 12.6 mS.cm-1, due to the loss of a negative charge lowering the affinity for 
the anion exchange resin. The pentapeptide product was again well separated from 
ATP (B(ii)). No peaks were observed for contaminating ADP, suggesting proper 
functioning of the recycling system for ADP.  
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As residual ammonium acetate salt after Source30Q elution would inhibit subsequent 
carbodiimide coupling steps (Section 3.5.3), UDP-MurNAc-pentapeptide was 
desalted by size exclusion chromatography (Figure 3.4) using Bio-Gel P2 resin and 
H20 as described in Section 2.6.1.2. 
 
Despite the use of a large volume (475 mL) column, and elution in upflow, poor 
separation was observed between the UDP-MurNAc-pentapeptides and ammonium 
acetate (Figure 3.4), resulting in a significant loss of yield (discussed in Section 
3.7.2.2). Selected fractions containing UDP-MurNAc-pentapeptide separated from 
the salt peak were freeze-dried once and resuspended in a minimum volume of 500 
mM NaHCO3 pH 10. The product was quantified by absorbance at 260 nm (the 
A 
B 
(i) 
(i) 
(ii) 
(ii) 
Figure 3.3: Purification of UDP-MurNAc-pentapeptides (Glu/Gln) by anion 
exchange chromatography (Source30Q resin).  A: The purification of UDP-
MurNAc-L-Ala-γ-D-Glu-L-Lys-D-Ala-D-Ala (i) eluting at a conductivity of 13.3 
mS.cm-1. B: The purification of UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys-D-Ala-D-Ala 
(i) eluting at a conductivity of 12.6 mS.cm-1. A(ii) and B(ii) ATP (required by MurC-
MurF). Red trace is absorbance at 254 nm, blue trace: absorbance at 280 nm and 
black trace; conductivity. 
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uracil portion of the UDP-MurNAc-pentapeptide has an extinction coefficient of 
10,000 M-1cm-1; Dawson et al., 1986). A yield of ~20 mg per synthesis was achieved 
following both Source30Q and Bio-Gel P2 purification. 
 
Analytical anion exchange chromatography (MonoQ resin) was used to determine 
the final purity of UDP-MurNAc-pentapeptide (Glu) and UDP-MurNAc-
pentapeptide (Gln) (Section 2.6.1.4 and Figure 3.5). A 1 µL sample of each 
pentapeptide product variant in 1 mL 10 mM ammonium acetate was loaded onto a 1 
mL MonoQ column before elution over a 10 mL gradient from 10 mM to 1 M 
ammonium acetate. The D-Gln containing UDP-MurNAc-pentapeptide eluted earlier 
(14.4 mS.cm-1) than the D-Glu containing derivative (23.3 mS.cm-1), consistent with 
the structure. Integration of required peaks as a percentage of the overall area using 
A 
B 
(i) 
(ii) 
(i) 
(ii) 
Figure 3.4: Desalting of UDP-MurNAc-pentapeptides (Glu/Gln) by gel filtration 
chromatography (Bio-Gel P2 resin).  A: The desalting of UDP-MurNAc-L-Ala-γ-D-
Glu-L-Lys-D-Ala-D-Ala (i) (elution volume:104 mL) from ammonium acetate (ii) 
(elution volume:114 mL) B: The desalting of UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys-D-
Ala-D-Ala (i) (elution volume:108 mL) from ammonium acetate (ii) (elution volume:114 
mL). Red trace is absorbance at 254 nm, blue trace: absorbance at 280 nm. 
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UNICORN software (GE Healthcare) established the purity of UDP-MurNAc-
pentapeptide (Glu) as 98.4%, and UDP-MurNAc-pentapeptide (Gln) as 91.9%. 
Purity over 90% was deemed sufficient and taken forward and if purity was below 
this, the intermediate was re-purified by anion exchange (Source30Q).  
 
The synthesis of UDP-MurNAc-pentapeptide (Glu) and UDP-MurNAc-pentapeptide 
(Gln) was confirmed by negative ion mass spectrometry (carried out by the 
University of Warwick Proteomics Facility RTP) (Figure 3.6 and 3.7). Spectra are 
shown as full page images with embedded isotope profile predictions, which identify 
both variants to contain only UDP-MurNAc-pentapeptide (Glu) or UDP-MurNAc-
pentapeptide (Gln) respectively. All subsequent mass spectrometry in this chapter 
was carried out by the Proteomics Facility RTP unless otherwise stated.  
 
 
 
 
 
 
A B (i) 
(i) 
(ii) 
Figure 3.5: Purity checks of UDP-MurNAc-pentapeptides (Glu/Gln) by anion exchange 
chromatography (MonoQ resin) A: Purity check of UDP-MurNAc-L-Ala-γ-D-Glu-L-Lys-D-Ala-D-
Ala (i) (conductivity 23.3 mS.cm-1). Peak integration established purity as 98.4 %. B: Purity check of 
UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys-D-Ala-D-Ala (i) (conductivity 14.4 mS.cm-1) from a minor 
contaminant (ii). Peak integration established as 91.9 %. Red trace is absorbance at 254 nm, blue trace: 
absorbance at 280 nm. 
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[M-2H]2- A 
B 
C 
[M-H]- 
Figure 3.6: Negative ion mass spectra of UDP-MurNAc-pentapeptide (Glu) A: Mass spectra with [M-2H]2- (observed 573.6709, expected 573.6680), 
and [M-H]- (observed 1148.3422, expected 1148.3446) indicated. B: Predicted isotope distribution of [M-2H]2- based on the empirical formula of UDP-
MurNAc-pentapeptide (Glu) (predicted by MassLynxTM software (Waters, USA). C: Observed isotope distribution of [M-2H]2- (zoomed in view of [M-
2H]2- peak in A showing exact match with the predicted distribution in B.  
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[M-2H]2- 
[M-H]- 
Na[M-H]- 
A 
B 
C 
Figure 3.7: Negative ion mass spectra of UDP-MurNAc-pentapeptide (Gln) A: Mass spectra with [M-2H]2- (observed 573.1750, expected 573.1760),,  
[M-H]- (observed 1147.3568, expected 1147.3606) and sodiated [M-H]- (Na[M-H]-) indicated. B: Predicted isotope distribution of [M-2H]2- based on the 
empirical formula of UDP-MurNAc-pentapeptide (Glu) (predicted by MassLynxTM software (Waters, USA). C: Observed isotope distribution of [M-2H]2- 
(zoomed in view of [M-2H]2- peak in A showing exact match with the predicted distribution in B.  
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3.4 Synthesis of dansylated UDP-MurNAc-pentapeptide 
 
In order to obtain the fluorescently labelled Lipid II (Figure 3.1 (R2)) required for 
transglycosylase assays in later chapters (chapter 4 and 5), a dansyl group was 
covalently attached to the third position lysine by a sulphonamide linkage, as 
covered in Section 3.1.2, by Julie Todd or Anita Catherwood of BaCWAN (UK; 
Clarke et al., 2009; Lloyd et al., 2008), and is briefly covered here for completeness.  
 
Full methodological details are in Section 2.6.3 Briefly, desalted UDP-MurNAc-
pentapeptide (Gln/Glu) was incubated with a 42 × molar ratio of dansyl chloride 
(Sigma-Aldrich) in acetone overnight in the dark and with stirring. Unincorporated 
dansyl chloride was quenched with Tris pH 9 for 1 hour and rotary evaporation used 
to remove solvent. Dansylated UDP-MurNAc-pentapeptide (Glu/Gln) was purified 
from starting material by size exclusion chromatography on a Superdex Peptide 
column (GE Healthcare). Elution of dansylated product was identified by absorbance 
at 340 nm. Fractions were pooled, freeze dried and resuspended in a small volume of 
water. Purity was determined by anion exchange as before (Section 2.6.1.4) and 
negative ion mass spectrometry used to confirm identity. This was also used to 
confirm the presence of 100% dansylated product (and amidated where required) 
prior to Lipid II synthesis. Mass spectra are shown in Appendix 3.  
 
3.5 Chemical synthesis of branched UDP-MurNAc-pentapeptide 
derivatives 
 
3.5.1 Method choice 
 
A similar protocol to the enzymatic synthesis of the UDP-MurNAc-pentapeptides 
was considered for the synthesis of the S. pneumoniae branched pentapeptide 
derivatives. The amino acid ligases MurM and MurN use Lipid II and amino acids 
esterified to their cognate tRNAs as substrates to add the dipeptide branches in        
S. pneumoniae (Lloyd et al., 2008). This method was decided against due to the large 
quantities of Lipid II required, particularly at the method optimisation stage, and also 
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the low resolution of the Lipid II purification method, which is unable to separate 
branched and non-branched product sufficiently (Lloyd et al., 2008). Additionally 
due to the substrate specificity of MurM (Lloyd et al., 2008) it would not be trivial to 
separate the two products with either serine or alanine in the first position of the 
branch. Instead a chemical method for attachment of the amino acid was used. 
 
3.5.1.1 Chemo-enzymatic method 
 
The presence of the sole amino group present on the UDP-MurNAc-pentapeptide 
(Glu/Gln); on the ε-carbon of the third position L-Lys, has been exploited previously 
with the addition of fluorescent groups such as dansyl by sulphonamide linkage 
(Section 3.4) which can used to follow incorporation of the labelled Lipid II into non 
cross-linked peptidoglycan (Helassa et al., 2012; Schwartz et al., 2002). This ε-
carbon is also the position at which the species-specific branching amino acids are 
attached (Lloyd et al., 2008). Carbodiimide coupling chemistry was used to attach L-
Ala, L-Ser, L-Ala-L-Ala and L-Ser-L-Ala to the lysine of UDP-MurNAc-
pentapeptide (Glu/Gln) as shown in Figure 3.8 illustrated for UDP-MurNAc-
pentapeptide (Glu) and Fmoc-Ala-Ala.  
 
For coupling EDC (1) (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) was used 
to activate the free carboxyl of Fmoc-Ala-Ala (2) to form an O-acylisourea conjugate 
(3) of the latter. This was then displaced by N-hydroxysuccinimide (NHS) (4) with 
the displacement of the urea derivative of EDC (5) to yield the NHS ester of Fmoc-
Ala-Ala (6). This intermediate was attacked by the nucleophilic ε amino group of 
UDP-MurNAc-pentapeptide (7) to form a peptide bond between the two species and 
yield UDP-MurNAc-Ala-Glu-Lys(AlaAla-Fmoc)-Ala-Ala (8) which was 
subsequently deprotected with piperidine (9) to produce the final UDP-MurNAc-Ala-
Glu-Lys(AlaAla)-Ala-Ala (10) product, and the piperidine derivative of Fmoc (11). 
The presence of NHS in the reaction converted the amine-reactive O-acylisourea 
intermediate into an amine-reactive NHS ester, which made it more stable and has 
been reported to result in a more efficient coupling reaction (Staros et al., 1986). 
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Figure 3.8: Mechanism of coupling of peptides to UDP-MurNAc-pentapeptide (Glu). Reaction mechanism showing the carbodiimide coupling used to attach 
branching amino acids. Compounds labelled as described in the text. Illustrated for the coupling of Fmoc-L-Ala-L-Ala to UDP-MurNAc-pentapeptide (Glu). 
Mechanism identical for all other peptides.  
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3.5.2 Peptide and dipeptide branches 
 
For carbodiimide coupling, peptides to be added to the ε-amino group of the lysine 
must be protected on the primary amine with a group such as 
fluorenylmethyloxycarbonyl (Fmoc) to prevent side reactions between the amino 
acids and dipeptides, which would result in polymers (Carpino and Wu, 2000). Many 
amino acids can be purchased already attached to a Fmoc group, whereas others are 
prohibitively expensive and therefore it is more cost effective to add the protecting 
group to purchased peptides. Figure 3.9 illustrates the two methods used to produce 
Fmoc coupled peptides, as detailed in the remainder of this section. 
 
3.5.2.1 Fmoc-Ala and Fmoc-Ser 
 
Fmoc-Ala-OH and Fmoc-Ser-OH are available commercially and were purchased 
from Novabiochem (Germany). 
 
3.5.2.2 Fmoc-Ala-Ala 
 
Fmoc-Ala-Ala-OH is not available commercially and the cost of custom synthesis 
was prohibitively high, thus the protected dipeptide was synthesised as described in 
section 2.6.4.1.1, with the reaction of Ala-Ala-OH with Fmoc-OSu (Figure 3.9 (A); 
mechanism illustrated for Fmoc-Ala-Ser), before extraction with ethyl acetate. A 
57% yield was achieved; with 136 mg produced in a single reaction. Successful 
synthesis was confirmed by negative ion mass spectrometry (Figure 3.10 (A); [M-H]- 
expected 381.1459, observed 381.1494; dimeric species 2[M-H]- expected 763.2988, 
observed 763.3110).  
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B 
A 
Figure 3.9: Mechanism of dipeptide protection with Fmoc. Illustrated for Fmoc-L-Ala-L-Ser. A: Reaction of L-Ala-L-Ser (12) with Fmoc-OSu (13) to yield 
Fmoc-L-Ala-L-Ser (14) protected on the N-terminus. This method was also used for Fmoc-L-Ala-L-Ala (2); compound numbering contiguous from Figure 3.8. 
B: Carbodiimide coupling of Fmoc-L-Ala (15) and O-tert-Butyl-L-Ser tert-butyl ester (16) to yield Fmoc-L-Ala-L-Ser protected on the N-terminus with Fmoc 
and C-terminus with t-butyl (17). TFA hydrolysis removes the C-terminal protection to yield Fmoc-L-Ala-L-Ser (14). 
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3.5.2.3 Fmoc-Ala-Ser 
 
Similarly, the cost of custom synthesis of Fmoc-Ala-Ser-OH was prohibitive. Two 
methods were attempted and their yields compared. The first method was as 
illustrated in Figure 3.9 (A)(method Section 2.6.4.1.1), with the reaction of Ala-Ser-
OH with Fmoc-OSu. Extraction with ethyl acetate achieved a yield of 53% (126 mg 
per reaction). For the second, Fmoc-L-Ala was coupled to O-tert-Butyl-L-Serine 
tert-butyl ester using carbodiimide chemistry (Figure 3.9 (B))(full method section 
2.6.4.1.2); similar to that described for the addition of the branching peptides. The L-
Ala is protected on the amine by Fmoc, and the L-Ser on the carboxyl and β-
hydroxyl by t-butyl ester to prevent side reactions between the amino acids. EDC (1) 
and NHS (4) form an O-NHS ester intermediate with the carboxylic acid of the L-
Ala (Figure 3.9 (B)), thus activating it for nucleophilic attack by the O-tert-Butyl-L-
Serine tert-butyl ester (16) to form an amide bond. The product was extracted in 
dichloromethane and purified by silica gel chromatography. 
 
T-butyl removal from the seryl carboxyl was with TFA (trifluoroacetic acid). A 5 
hour hydrolysis was required as the standard 2 hour method yielded a mix of 
unprotected serine and some with 1 O-tert-Butyl group remaining. The yield from 
this method was substantially lower than the previous one, at 3%, most likely due to 
the large numbers of steps in the process.  
 
This could have been optimised further, but due to the high yield achieved with the 
first method and its simplicity, this was used to synthesise Fmoc-Ala-Ser for use in 
coupling. Again successful synthesis was confirmed by negative ion mass 
spectrometry (Figure 3.10 (B); [M-H]- expected 397.1408, observed 397.1278; 
dimeric species 2[M-H]- expected 795.2886, observed 795.2565). 
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3.5.3 Synthesis of branched UDP-MurNAc-pentapeptide intermediates 
 
Fmoc protected amino acids and dipeptides (Section 3.5.2) were reacted with EDC 
and NHS at pH 5 and the resulting O-acylisourea intermediates incubated with UDP-
MurNAc-pentapeptide (Glu) or UDP-MurNAc-pentapeptide (Gln) at pH10. The 
Fmoc protecting group was removed with piperidine and the products rotary 
evaporated to remove organic solvent and freeze-dried prior to purification.  The 
reaction scheme is detailed in Figure 3.8 and is described in more detail in section 
2.6.4.2. This method was derived from earlier work by Dr Gianfranco De Pascale 
(De Pascale, 2007), Dr Tom Clarke (Clarke, 2008) as well as De Pascale et al., 
(2008). Previous optimisation with single amino acid branches and UDP-MurNAc-
pentapeptide (Glu) established pH, incubation times and ratios of reagents; 45 eq. 
(equivalents) EDC, 30 eq. NHS, 12 eq. amino acid, 1 eq. 5P (De Pascale, 2007), that 
2[M-H]- 
[M-H]- 
2[M-H]- 
[M-H]- 
A 
B 
Figure 3.10: Negative ion mass spectrometry of Fmoc-Ala-Ala (A) and Fmoc-Ala-Ser (B). A: 
Negative ion electrospray time-of-flight mass spectra of Fmoc-Ala-Ala-OH. [M-H]- expected 
381.1459, observed 381.1494. Dimeric species 2[M-H]- expected 763.2988, observed 763.3110. B: 
Negative ion electrospray time-of-flight mass spectra of Fmoc-Ala-Ser-OH. [M-H]- expected 397.1408, 
observed 397.1278. Dimeric species 2[M-H]- expected 795.2886, observed 795.2565. 
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enabled the optimum yield. An important point to note with amidated pentapeptides 
is the presence of the amide group on the isoglutamine, which has the potential to act 
as a nucleophile in the EDC coupling reaction. Although, the relative lack of 
nucleophilic character of this amide nitrogen due to delocalisation of electrons with 
the adjacent carbonyl group makes this unlikely.   
 
Purification of branched intermediates was by anion exchange chromatography using 
Source30Q resin with a bed volume of 75 mL (Section 2.6.4.3). An ammonium 
acetate gradient from 10 mM to 300 mM over 7 column volumes was used to 
separate products, and the presence of UDP-MurNAc-pentapeptide derivatives were 
confirmed by absorbance at 254 nm and 280 nm. Fractions were freeze dried 4 times 
and resuspended in a small volume of H2O, prior to further analysis and 
identification of species. 
 
Figures 3.11 and 3.12 show both the purification and confirmation of synthesis by 
negative ion mass spectrometry of each of UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys-(L-
Ala)-D-Ala-D-Ala (Figure 3.11 (A) and (B)), UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys-
(L-Ser)-D-Ala-D-Ala (Figure 3.11 (C) and (D)), UDP-MurNAc-L-Ala-γ-D-Gln-L-
Lys-(L-Ser-L-Ala)-D-Ala-D-Ala (Figure 3.12 (A) and (B)), UDP-MurNAc-L-Ala-γ-
D-Gln-L-Lys-(L-Ala-L-Ala)-D-Ala-D-Ala (Figure 3.12 (C) and (D)). The addition of 
branching amino acids to amidated UDP-MurNAc pentapeptide is novel work, which 
has not been published to date. Dipeptide branching with non-amidated UDP-
MurNAc pentapeptide (Glu) was also attempted as shown in Table 3.1, but detailed 
results are not shown here as mass spectrometry confirmation of syntheses was not 
performed. Note that the mass spectrum shown in Figure 3.12 (B) was obtained on 
an open source machine for which raw data could not be obtained to produce a high-
resolution image. Therefore Figure 3.12 (B) is also reproduced in Appendix 4 as a 
full-page image for clarity.   
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A C 
[M-2H]2- 
[M-H]- 
[M-2H]2- 
[M-H]- 
B D 
Figure 3.11: Purification and characterisation of UDP-MurNAc-hexapeptides (Gln, Ala)(A,B) and (Gln, Ser)(C,D) by anion exchange chromatography 
(Source30Q resin) and negative ion mass spectrometry. A: Purification of UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys(L-Ala)-D-Ala-D-Ala (elution at 10.9 mS.cm-1 (A(ii)). 
(A(i)) is  a peak of organic reagents used in the coupling reaction. Red: A254nm; blue: A280nm, black: conductivity. B: Negative ion electrospray time-of-flight mass spectra 
of UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys(L-Ala)-D-Ala-D-Ala. [M-H]-expected 1218.3977, observed 1218.4017, [M-2H]2- expected 608.6954 observed 608.6997. C: The 
purification of UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys(L-Ser)-D-Ala-D-Ala (elution at 13.5 mS.cm-1 (C(ii)). (C(i)) is  a peak of organic reagents used in the coupling 
reaction. Red: A254nm; blue: A280nm, black: conductivity B: Negative ion electrospray time-of-flight mass spectra of UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys(L-Ser)-D-Ala-D-
Ala. m/z: [M-H]-expected 1234.3926 observed 1234.4128, [M-2H]2- expected 616.6928 observed 616.6984. 
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A 
B 
C 
D 
[M-2H]2- [M-2H]2- 
Figure 3.12: Purification and characterisation of UDP-MurNAc-heptapeptides (Gln, AlaAla)(A, B) and (Gln, SerAla) (C,D) by anion exchange chromatography 
(Source30Q resin) and negative ion mass spectrometry. A: Purification of UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys(L-Ala-L-Ala)-D-Ala-D-Ala (elution at 11.04 mS.cm-1) 
(A(ii)). (A(i)) is  a peak of organic reagents used in the coupling reaction. Red: A254nm; blue: A280nm, black: conductivity. B: Negative ion electrospray time-of-flight mass 
spectra of UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys(L-Ala-L-Ala)-D-Ala-D-Ala. [M-2H]2- expected 644.2139 observed 644.2. This spectra is reproduced as a full page in 
Appendix 4 due to low quality image. C: Purification of UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys(L-Ser-L-Ala)-D-Ala-D-Ala (elution at 11.4 mS.cm-1)(C(iii)). Unreacted UDP-
MurNAc-L-Ala-γ-D-Gln-L-Lys-D-Ala-D-Ala elutes at 8.5 mS.cm-1 (C(ii)) and (C(i)) is  a peak of organic reagents used in the coupling reaction. Red: A254nm; blue: A280nm, 
black: conductivity. B: Negative ion electrospray time-of-flight mass spectra of UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys(L-Ser-L-Ala)-D-Ala-D-Ala. [M-2H]2- expected 
652.2114 observed 652.2113. 
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Table 3.1 details the range of intermediates made using this method. Priority was 
given to the synthesis of the amidated variants (left-hand column) due to these being 
the in vitro synthetic precursor to the native substrate in S. pneumoniae, and 
therefore the more interesting for study (amidated Lipid II substrates are the 
preferred substrate of the S. pneumoniae PBPs (Zapun et al., 2013; and Chapter 4)). 
However, the overall aim was to produce all 8 variants, in order to provide a full 
range of substrates for studies now and in future work. Following confirmation of 
synthesis by negative ion mass spectrometry, the product was quantified by 
measuring absorbance at 260 nm (as in Section 3.3). Yields are shown in brackets in 
Table 3.1 where known. 
 
Branch UDP-MurNAc-pentapeptide (Gln) UDP-MurNAc-pentapeptide (Glu) 
Ala MS confirmed N/A 
Ser MS confirmed N/A 
Ala-Ala MS confirmed (14% yield) Attempted, no MS data 
Ser-Ala MS confirmed (22% yield) Attempted, no MS data 
Table 3.1. Branched UDP-MurNAc hexa- and heptapeptides synthesised. Branching amino acids 
described from C- to N-terminus 
 
Negative ion electrospray time-of-flight (TOF) mass spectrometry was used to 
confirm attachment of peptide and dipeptide branches (Figure 3.11 (B, D), Figure 
3.12 (B, D)). In all cases these were successful, although the observed species with a 
m/z of 573.6763 in Figure 6.11 (D) is consistent with the [M-2H]2- of UDP-
MurNAc-pentapeptide (Glu) (expected 573.6688). This suggests that in addition of 
the L-Ser branching amino acid, isoglutamine has become deamidated and the 
addition of the branch failed. This was not the case in any other reaction products 
analysed by mass spectrometry (discussed Section 3.7.2.1). UDP-MurNAc-
hexapeptide (Gln, Ser) was not used for conversion to Lipid II intermediates.  
 
Positive ion fragmentation was attempted in order to confirm that branching had 
occurred on the ε-amino of the third position lysine (carried out by Dr. Adrian 
Lloyd). UDP-MurNAc-hexapeptide (Gln, Ala), UDP-MurNAc-hexapeptide (Gln, 
Ser), UDP-MurNAc-heptapeptide (Gln, AlaAla) and UDP-MurNAc-heptapeptide 
(Gln, SerAla) were subjected to positive ion electrospray time-of-flight mass 
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spectrometry prior to fragmentation. The spectra of both hexapeptides showed the 
correct mass for the singly charged cations and were subsequently subjected to 
collision induced fragmentation (Appendix 5). The singly charged cation consistent 
with the mass of UDP-MurNAc-pentapeptide (Glu) ([M+H+] expected 1150.36 
observed 1150.36) was also detected in the UDP-MurNAc-hexapeptide (Gln, Ser) 
mass spectrum (Figure A5.2(A)) as expected following detection of the doubly 
charged anion in Figure 3.11(D). However, specific selection of the singly charged 
cation with a m/z consistent with that of UDP-MurNAc-hexapeptide (Gln, Ser) 
ensured that the deamidated product was not fragmented. Species specific to both 
hexapeptide structures were observed, conclusively showing that the Ser and Ala 
branching amino acids were attached correctly (Appendix 5). Despite observation of 
the correct species for UDP-MurNAc-heptapeptide (Gln, AlaAla) and UDP-
MurNAc-heptapeptide (Gln, SerAla) by negative ion mass spectrometry (Figure 3.12 
(B) and (D)), the corresponding singly, doubly or triply charged cations were not 
observed by analysis in positive mode. Therefore positive ion fragmentation could 
not be performed (Discussed further in Section 3.7.2.1) 
 
As the single amino acid branches were properly attached, and the correct mass was 
observed by negative ion TOF, the decision was made to take the prioritised 
heptapeptides forward for preparation of Lipid II.  
 
3.6 Preparation of Lipid II 
 
UDP-MurNAc-pentapeptides (and derivatives) can be converted into lipid linked 
intermediates enzymatically (Section 3.1.3 and Figure 3.2). This section covers the 
preparation of Lipid II derivatives; amidated, fluorescently labelled and branched 
(Figure 3.1), required for the study of Gram-positive PBPs throughout the rest of this 
thesis. 
 
3.6.1 Lipid II synthesis 
 
MraY and MurG are responsible for the conversion of UDP-MurNAc-pentapeptide 
into Lipid II (Bouhss et al., 2004; Ha et al., 1999; Lloyd et al., 2004) (Section 1.6.2). 
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These are not trivial to express and purify recombinantly, particularly MraY due to 
its ten transmembrane spanning helices (Lloyd et al., 2004). Therefore, Lipid II can 
be prepared from UDP-MurNAc-peptide precursors in vitro with Micrococcus flavus 
membranes supplemented with undecaprenyl phosphate and UDP-GlcNAc 
(Breukink et al., 2003). M. flavus membranes are used because they are rich in MraY 
and MurG. The routine synthesis of radiolabelled, fluorescently labelled and other 
Lipid II variants within our lab shows this system to be robust and able to accept a 
range of non-natural substrates. Lipid II variants in the forthcoming section were 
prepared with M. flavus membranes as described in Section 2.6.5, with any 
deviations from the protocol detailed. 
 
3.6.1.1 Lipid II purification 
 
Following synthesis, Lipid II, along with undecaprenyl phosphate, detergents and 
phospholipids were separated from proteins by solvent extraction. Lipid II was 
subsequently purified by anion exchange chromatography on DEAE-sephacel resin, 
pre-equilibrated with 1M ammonium acetate followed by chloroform/methanol/water 
(2:3:1) (solvent A). Lipid II was loaded in solvent A before a stepwise elution with 
increasing proportions of solvent B (chloroform/methanol/1 M ammonium 
bicarbonate (2:3:1)) was performed. This elution was modified for Lipid II variants 
with differing affinity for the resin. In particular, amidated versions of Lipid II have 
lower affinity for the DEAE Sephacel column and therefore required increased low 
buffer B concentration washes in order to elute undecaprenyl phosphate before the 
Lipid II and avoid overlap of the two components. This purification method is 
described in more detail in Section 2.6.5.2. Fractions from anion exchange were 
analysed by Silica thin layer chromatography (TLC) with the buffer 
chloroform/methanol/water/0.88 ammonia (88:48:10:1) (Section 2.6.5.3).  
 
3.6.2 Preparation of amidated and fluorescently labelled Lipid II 
  
Lipid II (Glu), Lipid II (Gln), Lipid II (Glu, Dans) and Lipid II (Gln, Dans) were 
prepared from UDP-MurNAc-pentapeptide derivatives by the method described in 
Section 2.6.5 by Julie Todd or Anita Catherwood (BacWAN, UK; Clarke et al., 
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2009; Lloyd et al., 2008). Purification of both Lipid II (Gln) and Lipid II (Gln, Dans) 
required additional washes with 100 mM ammonium bicarbonate (10% solvent B) in 
order to separate the Lipid II from the remaining undecaprenyl phosphate (Section 
2.6.5.2).  
 
Negative ion electrospray time-of-flight mass spectrometry was used to confirm the 
correct species, with particular attention paid to amidation (1 mass difference relative 
to non-amidated), and the number of dansyl groups present. The latter is important as 
the amide of isoglutamine could react with dansyl chloride and result in doubly 
dansylated Lipid II (although the difference in strength of the nucleophile makes it 
less likely). Detailed analysis of the mass spectra was consistent with 100% yield of 
the required species in each case (Appendix 6) and quantification was carried out by 
an assay of phosphate release (Section 2.6.5.4).  
 
3.6.3 Preparation of Lipid II (Gln, SerAla) 
 
Sufficient yield of UDP-MurNAc-heptapeptide (Gln, SerAla) was achieved in 
Section 3.5.3 to enable a small scale Lipid II synthesis to be performed. This was 
exactly the same method as described in Section 3.6.1 and Section 2.6.5, but with 
reagents reduced to 25% of a full reaction. This method has previously been shown 
to be scalable with no significant loss of relative yield (Dr A. Lloyd, Personal 
Communication).  
 
Products of the synthesis were purified by anion exchange chromatography and 
analysed by Silica TLC (Sections 2.6.5.2, 2.6.5.3 and 3.6.1.1). As described 
previously, further 100 mM ammonium bicarbonate (10% solvent B) washes were 
required when purifying amidated Lipid II variants due the lack of a negative charge 
on isoglutamine compared to glutamate. Figure 3.13 shows the Silica TLC of the 
purification of this synthesis. 
 
An initial TLC carried out with the routinely used 400 µL of each 4 mL eluted 
fraction showed no species behaving in a manner typical of Lipid II (not shown). 
Therefore the TLC in Figure 3.13 was performed with 3 mL of each 4 mL fraction 
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dessicated, resuspended in chloroform/methanol/water (2:3:1) (solvent A) and 
loaded. This suggests a very low yield of the possible Lipid species (c) (identified by 
behavior in this solvent system based on experience with other Lipid II derivatives). 
Despite additional 100 mM ammonium bicarbonate washes, overlap between the 
elution of undecaprenyl phosphate (b) and species (c) was seen. This suggests lower 
affinity for DEAE sephacel of the product of this synthesis than Lipid II (Gln), which 
could be due the addition of the branching amino acids. These are unlikely to cause 
significant difference in charge but the increased bulkiness could reduce its ability to 
bind to the resin. The smaller purification bed volume used in order to reduce losses 
may also have contributed to the poor separation. 
 
 
 
FT Solv
A 
50 100 
1 
100 
2 
100 
3 
100 
4 
100 
5 
100 
6 
100 
7 
(a) 
(b) 
(c) 
(d) 
(e) 
[ammonium bicarbonate] (mM)  
Figure 3.13: Thin-layer chromatography of fractions from initial anion exchange 
purification of Lipid II (Gln, SerAla). Silica gel TLC plate chromatography with 
Chloroform/methanol/water/ammonia (88:48:10:1) solvent. TLC plate staining was with iodine 
vapour. (a) undecaprenyl pyrophosphate, (b) is undecaprenyl phosphate, (c) is suspected Lipid II, 
(d) is the origin and (e) denotes the solvent front. 
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3.6.3.1 Re-purification of products of Lipid II (Gln, SerAla) synthesis 
 
In order to separate species (b) and (c) (Figure 3.13), the remainder of the fractions 
denoted (c) were pooled and re-purified on DEAE sephacel resin with ammonium 
bicarbonate at pH 9. Typically the pH of ammonium bicarbonate used in solvent B is 
not monitored but approximately neutral at the concentration used. This increase in 
pH was intended to increase binding of species (c) to the resin by increasing the 
number of negative charges due to deprotonation. A further Silica TLC was 
performed (Figure 3.14) 
 
Re-purification separated species (b) and (c) from Figure 3.13 to (a) and (b) on 
Figure 3.14, however, species (b) in the latter is barely visible. This suggests 
extremely low yield from re-purification. Fraction (b) (100 mM Ammonium 
(a) 
(b) 
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[ammonium bicarbonate] (mM) 
Figure 3.14: Thin-layer chromatography of fractions from anion exchange 
re-purification at pH 9 of Lipid II (Gln, SerAla). Silica gel TLC plate 
chromatography with Chloroform/methanol/water/ammonia (88:48:10:1) solvent. 
TLC plate staining was with iodine vapour. (a) undecaprenyl phosphate, (b) is 
suspected lipid II, (c) is the origin and (d) denotes the solvent front. 
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bicarbonate fraction 7) was freeze-dried three times and submitted to negative ion 
mass spectrometry. The correct species could not be identified.  
 
It was hypothesised that salt may have remained following freeze-drying, which may 
prevent the Lipid II from being observed by mass spectrometry. Therefore, samples 
were re-extracted in organic solvent as used at the beginning of Lipid II purification 
(Section 2.6.5.2). Any remaining salt would separate into the aqueous phase, and 
Lipid II into the organic phase. Despite this, the correct species were still not 
observed. 
 
3.6.3.2 Acid hydrolysis of suspected Lipid II (Gln, SerAla) product 
 
Negative ion time-of-flight mass spectrometry of UDP-MurNAc-heptapeptide (Gln, 
SerAla) prior to Lipid II preparation was successful (Figure 3.12 (D)). The behaviour 
of species (b) (Figure 3.14) suggests that it is a Lipid II derivative, due to its location 
on the TLC, and further separation from undecaprenyl phosphate at pH 9. Therefore, 
acid hydrolysis was attempted, as if this hypothesis is correct, the undecaprenyl 
pyrophosphate would be removed, yielding MurNAc-heptapeptide (Gln, SerAla), 
which could be observed by mass spectrometry. Acid hydrolysis was performed as 
for Lipid II quantification (Section 2.6.5.4), with a parallel non-hydrolysed control. 
Samples were subsequently desiccated, resuspended in Solvent A 
(chloroform/methanol/water (2:3:1)) and centrifuged at 13,000 rpm for 1 minute in 
silicised eppendorfs to remove insoluble material. Both samples were split, with half 
submitted to negative ion electrospray time-of-flight mass spectrometry and the 
remainder analysed by TLC (Section 2.6.5.3) (Figure 3.15). Hydrolysis of confirmed 
Lipid II (Gln, Dans) was used as a positive control. 
 
Species (c) was attributed to Lipid II (Gln, Dans) based on previous TLC and mass 
spectrometric analysis of the stock the sample came from. Acid hydrolysis of the 
positive control yielded species (d), which migrates in a manner consistent with 
undecaprenyl phosphate, the product of acid hydrolysis of Lipid II. No species that 
migrated in this solvent system was observed in the sample of suspected Lipid II 
(Gln, SerAla) prior to acid hydrolysis, apart from species (a) which was also found in 
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the positive control and is likely due to a solvent component. Following acid 
hydrolysis species (b) was observed suggesting that the suspected Lipid II (Gln, 
SerAla) species was acid hydrolysed. However, species (b) did not migrate similarly 
to species (d), the expected product of acid hydrolysis of Lipid II. The results of this 
acid hydrolysis were inconclusive.  
 
Negative ion time-of-flight mass spectrometry was carried out on all samples, and 
the expected species corresponding to either MurNAc-pentapeptide derivative or 
undecaprenyl phosphate were not observed. The lack of success with the positive 
control suggests that sample preparation may be to blame. Insufficient sample 
(a) 
(b) 
(c) 
(d) 
(e) 
(f) 
- + - + 
Lipid II (Gln, 
Dans) 
Suspected 
Lipid II (Gln, 
SerAla) 
Figure 3.15: Thin-layer chromatography of suspected Lipid II (Gln, SerAla) and 
Lipid II (Gln, Dans) acid hydrolysis. Silica gel TLC plate chromatography with 
Chloroform/methanol/water/ammonia (88:48:10:1) solvent. -; non-hydrolysed, +; acid 
hydrolysed. TLC plate staining was with iodine vapour. (a) suspected solvent 
contamination b) product of acid hydrolysis of suspected Lipid II (Gln, SerAla), (c) Lipid 
II (Gln, Dans) , (d) product of acid hydrolysis of (c). (e) is the origin and (f) denotes the 
solvent front.  
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remained to repeat the analysis and therefore no conclusion could be made regarding 
the synthesis of Lipid II (Gln, SerAla) following these results (discussed further in 
Section 3.7.4). 
 
3.6.4 Preparation of Lipid II (Gln, AlaAla) 
 
Sufficient UDP-MurNAc-heptapeptide (Gln, AlaAla) was produced to carry out a 
Lipid II preparation scaled down to 10% of that described in Section 3.6.1 and 2.6.5. 
Based on the knowledge acquired in Section 3.6.3.1, the anion exchange purification 
was carried out at pH 9 initially, in order to avoid the loss of yield associated with re-
purification. Despite this, and the subsequent loading of the entire eluted fractions 
onto a TLC plate, no species suggestive of Lipid II could be observed. This is likely 
due to very low yield, particularly in a reaction 1/10th of the size normally carried 
out.  
 
3.7 Discussion and further work 
 
The methods used throughout this chapter are discussed in detail in this section, and 
future work required is detailed.  
 
3.7.1 UDP-MurNAc-pentapeptides 
 
UDP-MurNAc-pentapteptide (Glu) and (Gln) were successfully synthesised 
enzymatically and purified. The former was made according to a published protocol 
(Lloyd et al., 2008), and the latter by a modified version. The importance of 
incorporating only D-isoglutamine at this point (through the activity of MurD) is 
significant in later comparisons of the substrate specificity of S. pneumoniae and S. 
aureus PBPs. 
 
The final yield achieved was significantly affected by poor separation of peaks 
during gel-filtration chromatography intended to remove ammonium ions from UDP-
MurNAc-pentapeptides prior to addition of branching amino acids (Figure 3.4). This 
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was despite a low loading volume (<1 mL) onto a large (475 mL) column and elution 
in upflow, all steps taken to improve separation. Due to the significant effect of salt 
in later coupling stages, any fractions in the region of overlapping peaks were 
discarded. Re-purification by gel-filtration of these peaks did not achieve sufficient 
yield to be economical. Therefore to obtain a higher final yield, an alternative 
method for desalting will be required. Sephadex G-10 resin (GE healthcare) in a 200 
mL bed volume, and a Superdex Peptide 10/300 GL column (GE Healthcare) were 
trialled as alternative size exclusion matrices. Separation of salt from UDP-MurNAc-
pentapeptide was greater with Superdex Peptide than BioGel-P2, however the 
column size only enables small quantities of material to be loaded at once. Sephadex 
G-10; a resin specifically optimised for desalting of small biomolecules, showed a 
slight increase in separation from BioGel-P2 although has a lower loading capacity 
due to the bed volume, and therefore made negligible difference in resulting yield 
relative to desalting with BioGel-P2. The multiple runs required did not make this an 
option in the development of an efficient synthesis method. An alternative strategy of 
anion exchange could be used, which has been optimised within the group since this 
work was carried out. Here, the sample is bound to the anion exchange resin Q 
sepharose (53 mL bed volume) in a small fraction, before being washed in water to 
remove ammonium ions and subsequently eluted in upflow into a small volume in 
the buffer required (500 mM NaHCO3 pH 10). This method allows tens of mgs to be 
loaded and freed from ammonium ions, removing any possibility of contamination 
with species that could hinder further manipulation of the pentapeptide.  
 
3.7.2 Branched hexa- and heptapeptides 
 
UDP-MurNAc-heptapeptides (Gln, AlaAla) and (Gln, SerAla) were synthesised for 
the first time. This is an important step in the aim of producing the S. pneumoniae 
specific Lipid II variants. The main focus of this work was on these as precursors to 
the PBP substrates, although the UDP-MurNAc-hexapeptides (Gln, Ala) and (Gln, 
Ser) are also of interest on conversion to Lipid II species in the study of the substrate 
specificity of the MurM and MurN amino acid ligases. These are responsible for the 
in vivo addition of dipeptide branches and all work so far has been with non-
amidated Lipid II precursors (De Pascale et al., 2008; Lloyd et al., 2008). It is to date 
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unknown whether branching occurs before or after amidation, and therefore these 
hexapeptides are of use in future work should they be converted into Lipid II species.  
 
3.7.2.1 Limitations of the chemo-enzymatic method for synthesis of branched 
UDP-MurNAc-pentapeptide derivatives 
 
The chemo-enzymatic method used for the synthesis of branched UDP-MurNAc-
pentapeptide derivatives was successful for all of the variants attempted and analysed 
by mass spectrometry, however it was unreliable, with varied and generally low 
yield, and often no branched product observed. There are many possible explanations 
for this, some of which are covered in this section.  
 
Fmoc-L-Ala and Fmoc-L-Ser were purchased from Novabiochem (Germany) at 99% 
purity (assured by rigorous HPLC analysis), ensuring negligible free-amino acid 
content as well as <0.02% acetic acid, both of which significantly affect coupling 
reaction yield. Conversely, purity checks were not performed on the Fmoc-L-Ala-L-
Ala and Fmoc-L-Ser-L-Ala (Section 3.5.2). Negative ion mass spectrometry 
identified no other peaks of significance, suggesting (although not categorically 
proving) the absence of non-protected dipeptides. However, the presence of acetic 
acid, which will be activated by EDC coupling, cannot be ruled out. Therefore HPLC 
purification using a C18 reversed-phase column and desalting of the Fmoc protected 
dipeptides should be carried out in future to optimise the experimental yield.  
 
The optimal reaction volume for branched peptide coupling to UDP-MurNAc-
pentapeptide (Glu) was established previously (De Pascale, 2007) as 2 mL, with 
scaling up of this volume associated with significant reductions in yield. Therefore 
the percentage yields quoted in Table 3.1 are misleading in terms of absolute 
quantities of product made. Approximately 1-1.5 mg of UDP-MurNAc-pentapeptide 
(Gln, AlaAla) and (Gln, SerAla) were produced per 2 mL reaction, meaning a large 
number of syntheses would be required to obtain reasonable quantities for later steps. 
This is laborious and time consuming, and therefore if this method is to be used in 
the synthesis of large quantities of branched Lipid II for future enzymatic studies, a 
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renewed effort is required to scale up this process (discussed further in section 
3.7.2.2). 
 
The attachment of branching peptides to the isoglutamine of UDP-MurNAc-
pentapeptide (Gln) could not a priori be ruled out. However, the lack of nucleophilic 
character of the amide nitrogen due to delocalisation of electrons with the adjacent 
carbonyl group, makes it is unlikely to form a peptide bond. Negative ion mass 
spectrometry (Figure 3.11 (B,D) and 3.12 (B,D)) would not distinguish between 
branching on the isoglutamine or lysine, which could only be categorically 
determined by positive ion fragmentation. However, it could be expected that if the 
isoglutamine amide were reactive then so would the L-lysine ε-amino group and 
consequently some double branching would occur, which would be separated in the 
anion exchange purification (note the clear separation between branched and non-
branched in Figure 3.12 (C)). Additionally, the positive ion fragmentation of UDP-
MurNAc-hexapeptide (Gln, Ser) and (Gln, Ala) showed the branching to have 
occurred on the lysine side chain, which is suggestive of the same situation with the 
L-Ser-L-Ala and L-Ala-L-Ala branched UDP-MurNAc-heptapeptides (Gln). These 
arguments make a compelling case suggesting that the isoglutamine residue of the 
stem peptide did not undergo peptide coupling to L-Ala, L-Ser or the dipeptides.  
 
It was noted that following the synthesis of UDP-MurNAc-hexapeptide (Gln, Ser), 
that some UDP-MurNAc-pentapeptide (Glu) was observed by both negative and 
positive ion mass-spectrometry (Section 3.5.3). The pentapeptide used for the 
coupling reaction was confirmed to be fully amidated before use and therefore this 
deamidation occurred either during synthesis or in the mass spectrometer. De Pascale 
et al., (2008) showed that UDP-MurNAc-hexapeptide (Glu, Ser) was separated from 
UDP-MurNAc-pentapeptide (Glu) by anion exchange performed in the same way as 
it was here. However, amidated pentapeptides elute earlier on a salt gradient as they 
are less negatively charged than the non-amidated variants. Therefore it is possible 
that the elution of UDP-MurNAc-pentapeptide (Glu) and UDP-MurNAc-hexapeptide 
(Gln, Ser) overlapped in Figure 3.11 (C) if deamidation had occurred prior to 
purification. The reason for deamidation in only this case is unknown but shows a 
potential significant limitation of this method. This issue also highlights the 
requirement for a higher resolution purification method such as HPLC.  
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The reason for the failure of positive ion mass spectrometry with UDP-MurNAc-
heptapeptides (Gln, SerAla) and (Gln, AlaAla) is unknown. It is unlikely that the 
difference in one amino acid between the single and double branch is responsible, 
but is a possibility. An alternative explanation is a by-product of the synthesis of 
Fmoc protected dipeptides brought through the coupling and purification, which 
masks the observed signal (any by-product from the coupling reaction would also be 
present in the hexapeptides). It was assumed due to the success with fragmentation of 
the hexapeptides that branching was in the correct position, and therefore these 
heptapeptides were taken forward to Lipid II synthesis with the intention to repeat 
the positive ion fragmentation on the final Lipid II product. However, NMR should 
be considered in the future for detection of the products of coupling reactions as it is 
both non-destructive and relative proportions of products can be seen.  
 
An important point to note is that chiral conversion during amino acid activation 
cannot be ruled out with EDC and NHS coupling (Kuefner et al., 1990). This would 
result in diastereoisomers, and therefore in future work HPLC media such as 
immobilised vancomycin or teicoplanin, should be used as they can resolve 
diastereroisomers.  
 
3.7.2.2 Improving the UDP-MurNAc-hexa- and hepta- peptide yield of the 
chemo-enzymatic method 
 
The majority of identified limitations of the chemo-enzymatic method could be 
improved or overcome with an increase in yield of the coupling step. Several 
suggestions for this were made throughout Section 3.7.2.1 and further proposals are 
made in this section. 
 
The desalting of UDP-MurNAc-pentapeptides (Glu) and (Gln) was associated with a 
significant reduction in final yield due to poor separation from the salt peak. 
Fractions were selected to ensure no salt was taken forward to the coupling step, 
however, an improved desalting method as discussed in section 3.7.1 would be more 
thorough. Additionally, Nessler’s reagent (Dipotassium tetraiodomercurate(II) in 
dilute sodium hydroxide) (Vanselow, 1940) can be used to qualitatively detect the 
 118 
 
presence of ammonium compounds. This would form a useful test to ensure 
complete desalting before EDC coupling, and thus limit the effect on yield.  
 
It was proposed that purification of the amine-reactive NHS ester prior to coupling 
could improve the yield, as non-activated peptides and other reagents are removed 
before UDP-MurNAc-pentapeptide is added. However, Dr Aleš Žula (University of 
Ljubljana, Slovenia) isolated the activated esters of Fmoc-L-Ala-L-Ser and Fmoc-L-
Ala-L-Ala and subsequently reacted them with UDP-MurNAc-pentapeptide (Glu) in 
dimethylformamide (DMF). Products were purified by reverse-phase 
chromatography (mobile phase 99%/1% H20/CH3CN) and the Fmoc group was 
removed with morpholine before a second reverse-phase step. On arrival at the 
University of Warwick, further purification by gel filtration chromatography 
(Superdex Peptide 10/300 (GE Healthcare)) was performed and peaks analysed by 
negative ion mass spectrometry. Only starting UDP-MurNAc-pentapeptide (Glu) was 
observed, showing that coupling was unsuccessful. An improvement of conditions 
may be required in order for this method to be pursued further, 
 
3.7.3 Confirmation that amidation and dansylation of Lipid II species was 
complete 
 
Lipid II (Glu), Lipid II (Gln), Lipid II (Glu, Dans) and Lipid II (Gln, Dans) were 
synthesised by Julie Tod or Anita Catherwood (BacWAN, UK: Clarke et al., 2009; 
Lloyd et al., 2008) by methods described in the text, purified, quantified and their 
identity confirmed by negative ion mass spectrometry. Its inclusion was important in 
this chapter, as many conclusions throughout the remainder of this thesis rely on the 
assurance that the Lipid II substrate was 100% amidated, 100% dansylated (or both). 
This was ensured by modification of the UDP-MurNAc-pentapeptide precursor 
synthetic scheme prior to purification, confirmation by mass spectrometry and a 
sensitive purity check. Modification at this stage results in only the required soluble 
intermediate being put into a Lipid II synthesis, the purification of which would not 
distinguish different final products so clearly. The identity was again confirmed at 
this point by negative ion mass spectrometry and this evidence supports many of the 
conclusions in the following chapters.  
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3.7.4 Preparation of S. pneumoniae specific Lipid II variants 
 
Unsuccessful attempts were made to convert UDP-MurNAc-heptapeptide (Gln, 
AlaAla) and (Gln, SerAla) into Lipid II. The availability of M. flavus membranes and 
undecaprenyl phosphate led to the prioritisation of these particular variants, as the 
native, and therefore more interesting substrates for the PBPs. The failure of the 
Lipid II (Gln, AlaAla) synthesis (Section 3.6.4) is most likely due to the very small-
scale reaction carried out in addition to the poor conversion by M. flavus membranes 
(discussed later in this section). The results for Lipid II (Gln, SerAla) synthesis 
(Section 3.6.3), and reasons for the lack of success, are discussed in more detail in 
this section. 
 
Unlike after the synthesis of UDP-MurNAc-pentapeptide (section 3.3), desalting and 
purity check by anion exchange were not carried out on the UDP-MurNAc-
heptapeptides. This was due to very low yield, which would be significantly reduced 
even further by these additional steps. In future experiments, when sufficient yield is 
achieved, these purification steps should be performed prior to Lipid II synthesis, to 
ensure no contaminants are present which may affect the subsequent reaction.  
 
It is possible that amidated and branched S. pneumoniae specific UDP-MurNAc-
heptapeptides are not transferred to undecaprenyl phosphate efficiently by M. flavus 
MraY. MurG is unlikely to be the limiting factor as it has been shown to use a wide 
range of substrates including those with large fluorescent groups (Liu et al., 2003; 
van Dam et al., 2007; Dr A. Lloyd, Personal Communication). Additionally, an 
accumulation of Lipid I would be expected if this was the case, and this was not 
observed. Fluorescence and radioactivity based assay systems exist for MraY activity 
(Brandish et al.,1996; Solapure et al., 2005), however the former relies on a dansyl 
group on the third position lysine, and is therefore not suitable for the testing of 
branched substrates. Therefore, the radiolabel exchange assay could be used to 
compare the transfer of UDP-MurNAc-heptapeptides (Gln, SerAla) by M. flavus 
membranes and E. coli membranes with overexpression of recombinant                     
S. pneumoniae MraY, a method previously successful for E. coli, P. aeruginosa,            
S. aureus, M. flavus and B. subtilis MraY using the fluorescence assay (Rodolis et 
al., 2014). 
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An important observation to note is the result of repurification at pH 9. The resulting 
spot (b) (Figure 3.14) is not convincing but the separation of the original spots (b) 
and (c) (Figure 3.13) suggests that purification at pH 9 is a useful strategy for further 
experiments. The alteration was successful in achieving better separation between 
undecaprenyl phosphate and Lipid II (Gln) (Rebecca Bolton, Personal 
Communication) and therefore is an important modification to the method for 
subsequent experiments.  
 
TLC analysis of the products of UDP-MurNAc-heptapeptide (Gln, SerAla) 
incubation with M. flavus membranes is suggestive of a successful synthesis. The 
position of spot (c) in Figure 3.13 and (b) in 3.14 is consistent with the behaviour of 
other Lipid II variants.  However, negative ion mass spectrometry data could not be 
obtained to confirm this. Due to the high sensitivity of mass spectrometry it is 
unlikely that the low yield observed was responsible. Attempts to remove any 
contaminating salt, and the undecaprenyl phosphate did not alleviate the issue. Lipid 
II (Gln, SerAla) would be expected to fly in negative ion mass spectrometry, as data 
is routinely obtained for Lipid II (Gln, Dans), predominantly the same structure but 
with a higher molecular weight due to the dansyl group.  
 
Coupled with this, the behaviour of the suspected Lipid II (Gln, SerAla) upon acid 
hydrolysis was unusual. TLC analysis suggests that undecaprenyl phosphate was 
yielded by hydrolysis of Lipid II (Gln, Dans) and an unknown product from Lipid II 
(Gln, SerAla). The expected products were not observed by negative ion mass 
spectrometry for either Lipid II (Gln, SerAla) or the Lipid II (Gln, Dans) control. 
This may have been due to plasticisers in the sample due to use of eppendorfs (albeit 
silicised) for the removal of insoluble material. This experiment could not be 
repeated in the time available, as no material remained from the synthesis.  
 
3.7.5 Future direction 
 
Efforts to synthesis the S. pneumoniae specific branched Lipid II substrates (Lipid II 
(Gln, AlaAla) and (Gln, SerAla)) have been unsuccessful to date. This is 
predominantly due to poor absolute yield of the EDC coupling step to produce UDP-
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MurNAc heptapeptides. Therefore the main priority for further work in the first 
instance is the optimisation of this protocol to enable scaling up. This is crucial in 
establishing a viable method to produce sufficient quantities of this valuable 
substrate. Previous attempts were unsuccessful (Clarke, 2008; De Pascale, 2007), 
however, alterations in the ratios of reaction components may be essential in 
achieving this, as chemical syntheses of this type are not always directly scalable (Dr 
Vita Godec, Personal Communication). Additionally, ensuring adequate desalting of 
both UDP-MurNAc-pentapeptide (Gln) and purification of Fmoc protected 
dipeptides will limit side reactions and thus improve the yield.  
 
Once sufficient quantities of UDP-MurNAc-heptapeptide have been synthesised, 
detailed optimisation of Lipid II conversion can be carried out. As mentioned 
previously (Section 3.7.4), confirmation that MraY is able to transfer the amidated 
and branched substrates to the lipid carrier should be carried out. Several strategies 
could be employed to overcome a low turnover by MraY if required. For example, 
addition of a larger excess of membranes or a longer incubation period.  
 
If the yield by this method cannot be increased to adequate levels, the alternative 
enzymatic method could be employed (Section 3.5.1). This has been successful for 
the enzymatic addition of the S. aureus pentaglycine interpeptide bridge to non-
amidated (Schneider et al., 2004) and amidated Lipid II (Rebecca Bolton, Personal 
Communication) using the FemXAB peptidyltransferases. The presence of either L-
Ser or L-Ala on the first position of the S. pneumoniae branch makes this more 
complicated than for the pentaglycine stem. The addition of a L-Ala-L-Ala branch 
could in theory be performed in one pot with Lipid II, alanyl-tRNAAla, L-alanine and 
both MurM and MurN followed by purification. However, in order to achieve an L-
Ser-L-Ala branch, seryl-tRNASer, L-Serine and MurM from the Pn16 penicillin 
sensitive strain (MurMPN16), shown to preferentially alanylates the Lipid II (Lloyd et 
al., 2008) would need to be incubated with Lipid II first. Purification would be 
required before the addition of alanyl-tRNAAla, L-alanine and MurN. This method 
requires large quantities of Lipid II for optimisation and HPLC purification may be 
essential to ensure that the final product has the branching required. However, if 
insufficient yield is achieved by the chemical method then this may be a suitable 
strategy. Alternatively, the L-Ser and L-Ala single amino acid branches could be 
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added chemically to UDP-MurNAc-pentapeptide as was previously performed by De 
Pascale et al., (2008) for the non-amidated version and in this chapter for the 
amidated. The product of this could be incubated with M. flavus membranes 
followed by MurN, alanyl-tRNAAla and L-alanine to add the second amino acid to 
the branch.  
 
Of particular note is that for the study of transpeptidase activity of the S. pneumoniae 
PBPs, MurNAc-pentapeptide should be able to act as an acceptor (see chapter 6 for 
more details). This is made by acid or enzymatic hydrolysis of UDP-MurNAc-
pentapeptide (Section 6.4.2). Therefore, the role of substrate branching in 
transpeptidation can be studied to a certain extent without the requirement for Lipid 
II conversion, should this continue to be unsuccessful. 
  
3.8 Conclusion 
 
The dipeptide branched, amidated UDP-MurNAc-heptapeptides (Gln, AlaAla) and 
(Gln, SerAla) have been synthesised chemo-enzymatically for the first time. These 
are important precursors to the Lipid II substrates that will enable detailed enzymatic 
study of S. pneumoniae PBP substrate specificity, and analysis of the role of Lipid II 
branching in β-lactam resistance. Steps were taken to convert these to Lipid II, which 
have been unsuccessful to date, but further work informed by the data within this 
chapter, holds promise for the future availability of these substrates. The synthesis of 
amidated and fluorescently labelled Lipid II (Dans) was covered briefly, and 
confirmed to be 100% the required Lipid II variant, crucially important in the 
experiments throughout Chapters 4, 5 and 6.   
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Chapter 4. Enzymology of transglycosylation: the effect of 
Lipid II amidation on the transglycosylation activity of 
Streptococcus pneumoniae Class A PBPs 
 
4.1 Introduction 
 
Streptococcus pneumoniae is responsible for a range of diseases from bronchitis to 
endocarditis and meningitis (Section 1.8 for more detail). The spread of multi-drug 
resistant strains is making treatment increasingly difficult, highlighting the 
requirement for new lines of intervention. Instrumental in this is a greater 
understanding of the biochemistry of the pneumococcal cell wall.  
 
4.1.1 S. pneumoniae penicillin-binding proteins 
 
Peptidoglycan chain polymerisation in Streptococcus pneumoniae is catalysed by the 
high molecular weight (HMW) Class A bifunctional penicillin-binding proteins 
(PBPs); PBP1a, PBP2a and PBP1b (Hoskins et al., 1999); which catalyse both 
polymerisation of the glycan chain (transglycosylation) and cross-linking between 
them (transpeptidation). PBPs generally, and specifically to S. pneumoniae are 
reviewed comprehensively in Section 1.7 and 1.8.2 respectively.  
 
Efforts to study the enzymatic activity of the PBPs have focused predominantly on 
their transpeptidase function, and in particular the development of resistance to the β-
lactam family of antibiotics (See Section 1.8 and Chapter 6 for more detail). 
Relatively little focus has been placed on the transglycosylase function, which is 
necessary to provide the polymerised substrate for the cross-linking reaction, 
although the hydrophobic transmembrane region of PBP2a was previously shown to 
be important (Helassa et al., 2012).  In order to understand the mechanisms of 
peptidoglycan synthesis more fully and aid future development of novel antibiotics, 
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the study of transglycosylation is essential. The transglycosylase domain, its 
enzymatic activity and proposed catalytic mechanism are covered in Section 1.7.3.   
 
4.1.2 Assays for transglycosylation 
 
Transglycosylase assay development has been slow due to the requirement for the 
complex Lipid II substrate, which has previously been difficult to synthesise. 
Additionally, PBPs are mainly integral membrane proteins, interacting with a lipid-
linked substrate, making them particularly difficult to study in vitro. However, due to 
advances in membrane protein isolation in recent years and progress at the 
University of Warwick and elsewhere in the production of the complex substrate 
intermediates (Breukink et al., 2003; Lloyd et al., 2008; Schwartz et al., 2001; 
VanNieuwenhze et al., 2002), assays with these substrates are now possible. 
 
The main assay methods for transglycosylase activity have recently been 
comprehensively reviewed (Galley et al., 2014) (attached in Appendix 8). Two 
complementary assay systems were selected for this project. 
 
The SDS-PAGE assay system is unique in allowing the processivity of a 
transglycosylase to be studied by providing qualitative data on chain length although 
calibration of gels is problematic given the lack of suitable standards. Glycan 
products of in vitro reactions have a net negative charge and can be separated by 
Tris-Tricine SDS-PAGE (Barrett et al., 2007; Lesse et al., 1990; Schägger et al., 
1987). Initial studies with this technique used radiolabelled substrates (Barrett et al., 
2007), and more recently, Lipid II substrate with a fluorescent dansyl group (Lipid II 
(Dans)) linked via a sulphonamide linkage to the ε-amino group of the stem peptide 
lysine side chain (Section 3.1.2)(Helassa et al., 2012). This substrate serves two 
purposes in the study of transglycosylase activity. Firstly, a GeneSnap Gel Doc 
transilluminator with a blue light convertor and short-pass filter enables the dansyl 
fluorescence at 521 nm to be detected to visualise the products, more rapidly than 
imaging by autoradiography required with radiolabelled substrate. Secondly, due to 
the location of the fluorescence group, the use of 100% dansylated Lipid II prevents 
transpeptidation as the third position lysine on the donor stem is blocked. Previous 
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studies have suggested that transglycosylase kinetic parameters are only marginally 
affected by the addition of fluorescence side groups (Schwartz et al., 2002; Zhang et 
al., 2007). 
 
Unlike the SDS-PAGE assay, an assay for transglycosylase activity coupled to N-
acetylmuramidase digestion with dansylated Lipid II provides complementary 
quantitative initial rate data (Schwartz et al., 2002), and optimisation for a 96-well 
plate format (Offant et al., 2010) enables the rapid screening of conditions. Lipid II 
is presented in detergent micelles, and upon polymerisation by PBPs and subsequent 
digestion by N-acetylmuramidase, aqueous soluble monomers are produced, 
accompanied by a reduction in the quantum yield of fluorescence of the dansyl 
fluorophore due to the change in environment from a lipid bilayer to an aqueous 
solution. This fluorescence decrease is used to follow transglycosylation. To date, 
full incorporation of Lipid II into glycan chains over the assay time-course has been 
assumed, and kinetic values established from the initial rate of fluorescence decrease 
(Helassa et al., 2012; Offant et al., 2010; Schwartz et al., 2002). This is discussed 
further in Section 4.6.2.2 
 
4.1.3 Amidation of Lipid II in S. pneumoniae 
 
S. pneumoniae peptidoglycan stem peptides are chemically modified by the addition 
of a L-Ala-L-Ala or L-Ser-L-Ala dipeptide branch on the ε-amino group of the stem 
peptide lysine (Filipe and Tomasz, 2000; Fiser et al., 2003) and by amidation of 
glutamate at position 2 to isoglutamine by the amidase MurT/GatD (Zapun et al., 
2013) (Sections 1.5.2.3 and 1.5.2.2 for more details). Dipeptide branching is covered 
in more detail in Chapters 3 and 6. Amidated peptidoglycan makes up > 90% of the 
S. pneumoniae cell wall; (Bui et al., 2012) and is likely to be essential for S. 
pneumoniae PBP2a and optimal for S. pneumoniae PBP1a transpeptidase activity 
(Zapun et al., 2013; Chapter 6). However, the effect of this modification on the 
crucial preceding transglycosylase activity has not been studied to date.   
 
This chapter focuses on the effect of the amidation of Lipid II on the 
transglycosylase activity of S. pneumoniae bifunctional Class A PBPs; PBP1a and 
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PBP2a. These two class A PBPs are of particular interest as at least one of them must 
be active for viable cells. PBPs were recombinantly expressed from the D39 
penicillin-susceptible strain, the progenitor of the commonly used avirulent, 
unencapsulated R6 lab strain (Williams et al., 2007). There are no nucleotide level 
differences between the pbp genes in D39 and R6 (Job et al., 2008).  
 
Understanding the substrate-enzyme interactions involved in transglycosylation is 
important since it has significant consequences in the formation and metabolism of 
the peptidoglycan sacculus of this important pathogen and may be crucial in the 
design of novel antibacterial compounds targeting transglycosylation. 
 
 
4.2 Experimental Aims 
 
• To express and purify PBP1a and PBP2a from S. pneumoniae with and 
without the transmembrane spanning domain. 
• To study the effect of stem peptide amidation on transglycosylation activity 
of S. pneumoniae PBP1a and PBP2a by SDS-PAGE separation of the 
products and continuous fluorescence assay.  
• To examine the role of the transmembrane region in processivity of S. 
pneumoniae PBP1a and PBP2a transglycosylation. 
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4.3 Expression and purification of S. pneumoniae D39 PBP1a and 
PBP2a 
 
In order to investigate the transglycosylation activity of PBP1a and PBP2a, they 
were expressed and purified as both the full-length protein and devoid of the 
transmembrane spanning domain from the penicillin-susceptible D39 strain. The 
constructs for expression of PBP1a were obtained from Dr K. Abrahams, and for 
PBP2a from Dr A. Zapun (IBS, Grenoble) (Table 4.1). Expression and purification 
are described in this section.  
 
Construct Selection Source 
pET46::pbp1a Ampicillin Dr K. Abrahams (University of Warwick) 
pET46::pbp1aΔ30 Ampicillin Dr K. Abrahams (University of Warwick) 
pET30b::pbp2a Kanamycin Dr A. Zapun (IBS, Grenoble) 
pGEX-2T::pbp2aΔ77 Ampicillin Dr A. Zapun (IBS, Grenoble) 
Table 4.1: Gene constructs provided for expression and purification of S. pneumoniae D39 Class 
A PBPs 
 
4.3.1 Expression and purification of S. pneumoniae D39 PBP1a FL 
 
Full-length PBP1a was expressed and purified as described previously (Abrahams, 
2011). Briefly, pET46::pbp1a was expressed in BL21 Star (DE3) pRosetta cells and 
grown under autoinduction at 25°C, solubilised in 1% (w/v) sodium deoxycholate 
and purified by IMAC (Section 2.4.3.1) in 0.1% (w/v) DDM. DDM is a mild, non-
denaturing detergent, often used for membrane protein purification (Privé, 2007), 
which has been demonstrated to maintain PBP1a in an active state (Abrahams, 
2011). IMAC fractions were analysed by SDS-PAGE (Figure 4.1(a)). PBP1a that 
eluted at 250 mM imidazole was concentrated using a 100 kDa cut-off centrifugal 
concentrator before further purification by injection onto an analytical Superose 6 
10/300 GL gel filtration column pre-equilibrated and eluted in 20 mM Tris pH 7.5, 
150 mM NaCl, 0.03% (w/v) DDM in order to separate aggregated and non-
aggregated protein (Figure 4.1(b)). Lowering the detergent concentration to slightly 
above the CMC reduces excessive micelle formation, which could interfere with 
128 
 
future structural and activity studies. Final selected fractions were concentrated in a 
100 kDa cut-off centrifugal concentrator before storage in 20 mM Tris pH 7.5, 150 
mM NaCl, 0.03% (w/v) DDM, 50% (v/v) glycerol at -20 °C (previously determined 
to be optimal (Abrahams, 2011). 
4.3.2 Expression and purification of S. pneumoniae D39 PBP1a-Δ30 
 
PBP1a-Δ30 was expressed and purified from pET46::pbp1a-Δ30 as described in 
(Abrahams, 2011), and in an identical manner to PBP1a FL (Section 4.3.1). Despite 
the protein lacking the transmembrane spanning region, detergent is required for 
solubilisation due to the presence of a membrane interaction site in the 
transglycosylase domain of bifunctional PBPs (Di Guilmi et al., 1999; Lovering et 
al., 2007; Sung et al., 2009). Figure 4.2 shows the purification and final purity of 
PBP1a-Δ30. The yield of purified protein was substantially lower than that for the 
full-length PBP1a, due to a significantly lower expression level, as observed 
previously (Abrahams, 2011) 
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Figure 4.1: Purification of S. pneumoniae D39 PBP1a FL by IMAC and size exclusion 
chromatography. (a) 12% SDS-PAGE Coomassie-stained gel showing the isolation of membranes, 
solubilisation in 1% (w/v) sodium deoxycholate and subsequent IMAC purification of PBP1a FL. Mr, 
molecular weight markers (kDa); TM, total membrane fraction; P, ultracentrifugation pellet following 
sodium deoxycholate solubilisation; S, ultracentrifugation supernatant containing soluble protein; FT, 
unbound protein following 3 h incubation of supernatant with cobalt-chelated sepharose resin; 15, wash 
with buffer containing 15 mM imidazole; 50 (fractions) 1-4, elution with buffer containing 50 mM 
imidazole; 250 (fractions) 1-4, elution with buffer containing 250 mM imidazole. (b) Size exclusion 
chromatogram using the Superose 6 10/300 GL column. Red: absorbance at 254nm, Blue: absorbance 
at 280 nm (i) shows the elution of aggregated material in the column void volume and (ii) the elution of 
PBP1a FL. (c) 12% SDS-PAGE Coomassie-stained gel of the final purity of PBP1a FL. Mr, molecular 
weight markers (kDa); 1a FL, purity of PBP1a FL following both purification steps. 
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4.3.3 Expression and purification of S. pneumoniae PBP2a FL 
 
Expression and purification of pET30b::pbp2a was as described in Helassa et al., 
(2012) with the addition of a 50,000 × g centrifuge spin prior to the first affinity 
purification to remove insoluble material, and is shown in Figure 4.3. PBP2a is 
purified without an affinity tag by successive anion and cation exchange steps by 
exploitation of the differing predicted isoelectric points (pI) of the cytoplasmic and 
extracellular regions of the protein (Helassa et al., 2012). A high level of purity was 
achieved by this method (Figure 4.3 (c)).  
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Figure 4.2: Purification of S. pneumoniae D39 PBP1a-Δ30 by IMAC and size exclusion 
chromatography. (a) 12% SDS-PAGE Coomassie-stained gel showing the isolation of membranes, 
solubilisation in 1% (w/v) sodium deoxycholate and subsequent IMAC purification of PBP1a-Δ30. Mr, 
molecular weight markers (kDa); TM, total membrane fraction; SN, ultracentrifugation supernatant 
containing soluble protein; P, ultracentrifugation pellet following sodium deoxycholate solubilisation; 
FT, unbound protein following 3 h incubation of supernatant with cobalt-chelated sepharose resin; 15, 
wash with buffer containing 15 mM imidazole; 50 (fractions) 1-4, elution with buffer containing 50 
mM imidazole; 250 (fractions) 1-4, elution with buffer containing 250 mM imidazole. (b) Size 
exclusion chromatogram using the Superose 6 10/300 GL column. Red: absorbance at 254nm, Blue: 
absorbance at 280 nm (i) Elution of aggregated material in the column void volume and (ii) Elution of 
PBP1a-Δ30 (c) 12% SDS-PAGE Coomassie-stained gel of the final purity of PBP1a-Δ30. Mr, 
molecular weight markers (kDa); -, empty lane; 1a-Δ30, purity of PBP1a-Δ30 following both 
purification steps. 
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4.3.4 Expression and purification of S. pneumoniae PBP2a-Δ77 
 
Expression and purification of PBP2a-Δ77 was as described in Di Guilmi et al., 
(1999) with the addition of an anion exchange step on a 6 mL ResourceQ column 
and full methodological details are in Section 2.4.4.1 . Briefly, the PBP2a-Δ77 GST 
fusion protein was overexpressed and purified on a glutathione Sepharose column 
followed by cleavage of the GST tag by thrombin digestion. Eluted protein was 
analysed by SDS-PAGE (Figure 4.4 (a)). Remaining bound GST was eluted with 10 
mM reduced L-glutathione, and the presence of three bands in this lane indicates that 
thrombin cleavage proceeded almost to completion, with little GSTPBP2a-Δ77 
eluted and a large band of GST. All fractions containing PBP2a-Δ77 were buffer 
exchanged and purified by anion exchange chromatography (ResourceQ) (Figure 4.4 
(b)).  
 
A good level of purity was achieved for PBP2a-Δ77 (Figure 4.4 (c)), with a single 
lower molecular weight contaminant not removed by the two purification steps. This 
is likely an interacting protein, or proteolytically cleaved PBP2a and is too close in 
molecular weight to remove by the addition of an additional size exclusion 
chromatography step. 
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Figure 4.3: Purification of S. pneumoniae D39 PBP2a FL by successive cation and anion 
exchange chromatography. (a) Cation exchange chromatogram of the elution from a 5 mL HP SP 
Sepharose column. Red: absorbance at 254nm, Blue: absorbance at 280 nm (i) Peak of unbound 
material eluted in no salt wash following column loading (ii) Shoulder of main peak consisting of 
PBP2a FL and a large number of other proteins (iii) Main peak elution of PBP2a FL taken forward to 
anion exchange chromatography  (b) Anion exchange chromatogram showing the elution from a 6 mL 
ResourceQ column. Red: absorbance at 254nm, Blue: absorbance at 280 nm (i) The single peak of pure 
PBP2a FL eluted (c) 12% SDS-PAGE Coomassie-stained gel of the final purity of PBP2a FL. Mr, 
molecular weight markers (kDa); sp2a, PBP2a FL following successive cation and anion exchange 
steps. 
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4.3.5 Final purity of S. pneumoniae D39 PBP1a and PBP2a  
 
S. pneumoniae PBP1a FL, PBP1a-Δ30, PBP2a FL and PBP2a-Δ77 were expressed 
and purified by previously determined methods with modifications where required. 
The final purity of each of the variants is shown in Figure 4.5. 
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Figure 4.5: 12% Coomassie–stained gel of the final purity of  
the S. pneumoniae Class A PBPs to be studied. Mr, Molecular 
weight markers (kDa). Lanes are labelled with the PBP  
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Figure 4.4: Purification of S. pneumoniae D39 PBP2a-Δ77 by Glutathione Sepharose and anion 
exchange chromatography (a) 12% SDS-PAGE Coomassie-stained gel of the elution of PBP2a-Δ77 
following thrombin cleavage on a 5 mL glutathione sepharose column. Mr, molecular weight markers 
(kDa); Eluted fractions 1-10, 1 mL fractions eluted from column; -, empty lane; GST, Elution of 
cleaved GST from column with reduced L-glutathione. Location of GST-PBP2a-Δ77, PBP2a-Δ77 and 
GST indicated on the gel. .(b) Anion exchange chromatogram showing the elution from a 6 mL 
ResourceQ column. Red: absorbance at 254nm, Blue: absorbance at 280 nm (i) The single peak of pure 
PBP2a FL eluted (shoulder excluded from selected fractions) (c) 12% SDS-PAGE Coomassie-stained 
gel of the final purity of PBP2a-Δ77. Mr, molecular weight markers (kDa); 2a-Δ77, purity of PBP2a-
Δ77 following both purification steps. Small arrow indicated location of PBP2a-Δ77 on the gel. 
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4.4 Analysis of transglycosylase products by SDS-PAGE 
 
Tris-tricine SDS-PAGE can be used to separate the products of glycan chain 
polymerisation with fluorescently labelled dansylated Lipid II substrate (Sections 
4.1.2 and 2.7.2), providing valuable insight into the processivity of the 
transglycosylase domain of PBPs. This section describes the study of peptidoglycan 
chain synthesis by S. pneumoniae PBP1a and PBP2a, in particular focusing on the 
specificity for the amidated stem peptide variant of the Lipid II substrate (Section 
4.1.3). 
 
4.4.1 Conditions for observation of transglycosylase activity of S. pneumoniae 
PBP1a and PBP2a by SDS-PAGE 
 
In vitro transglycosylase activity is critically affected by buffer conditions including 
divalent cations, detergent and dimethylsulfoxide (DMSO) concentration (Barrett et 
al., 2007; Offant et al., 2010; Schwartz et al., 2002). Transglycosylation by PBP1a 
and PBP2a has previously been observed by the SDS-PAGE technique with the non-
amidated Lipid II variant, and non-dansylated in the case of PBP1a (Abrahams, 
2011; Helassa et al., 2012; Zapun et al., 2013) and thus optimised conditions 
amenable to in vitro activity are known.  
 
The method used for SDS-PAGE is detailed in Section 2.7.2, and specific buffer 
requirements, temperatures and incubation times are indicated in the following 
sections. Dansylated Lipid II, both amidated and non-amidated (Lipid II (Glu, Dans) 
and Lipid II (Gln, Dans)) were synthesised by the BaCWAN facility (University of 
Warwick, Coventry, UK), and confirmed by mass spectrometry to be 100% 
fluorescently labelled (and 100% amidated where required)(Section 3.6.2 and 
Appendix 6). Lipid II substrate was stored in 3:2:1 chloroform:methanol:water and 
required evaporation under nitrogen flow before resuspension by vigorous vortexing 
in the required buffer. Consequently, pipetting of small volumes and evaporation of 
the organic solvent affected the accuracy with which solutions of known 
concentration could be prepared. Therefore larger stocks of Lipid II at 500 µM in 
0.1% (v/v) TX-100 were made routinely and diluted to the concentration of Lipid II 
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and detergent required for assays. Where higher TX-100 concentrations were 
required, or alternative detergents, a master stock with a suitable detergent 
concentration was made. Lipid II solutions in TX-100 are stable on storage at -80°C 
for at least 6 months (Dr Adrian Lloyd, Personal Communication). 
 
It should be noted for this assay format that a true replicate is represented by the use 
of different enzyme preparations and separate reactions run on a different gel. Exact 
replicates were not always performed but comparisons made with comparable 
reactions performed for different experiments where possible. Where exact replicates 
were performed the number of repeats are indicated in the figure legend.  
 
4.4.2 Comparison of transglycosylation products of S. pneumoniae PBP1a and 
PBP2a with Lipid II (Glu, Dans) and Lipid II (Gln, Dans) 
 
As described in Section 4.1.3, the amidation of Lipid II is necessary for PBP2a and 
optimal for PBP1a in order to observe high molecular weight material attributed to 
cross-linking (Zapun et al., 2013). However, this study did not directly analyse the 
effect of the stem peptide chemical modification on transglycosylase activity. 
Therefore single time point reactions were carried out to compare the substrate 
specificity of PBP1a FL and PBP2a FL. 10 µM Lipid II (Lipid II (Glu, Dans) or 
Lipid II (Gln, Dans)) in either 50 mM HEPES pH 7.5, 10 mM MgCl2, 150 mM 
NaCl, 25% (v/v) DMSO, 0.02% (v/v) Triton X-100 (PBP1a) or 50 mM HEPES pH 
7.5, 25 mM MgCl2, 200 mM NaCl, 25% (v/v) DMSO, 0.02% (v/v) Triton X-100 
(PBP2a) was incubated with 1 µM PBP1a FL, 1 µM PBP2a FL or an equivalent 
volume of enzyme storage buffer at 30°C overnight. Overnight incubations were 
used to ensure reactions proceeded to completion. Reaction products were analysed 
by SDS-PAGE as described in Section 2.7.2 (Figure 4.6). Reaction buffers described 
here are used for the rest of this chapter unless specified. 
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Under the conditions used it is evident due to the presence of dansylated material 
higher up the gel, that with both Lipid II (Glu, Dans) and Lipid II (Gln, Dans), 
PBP2a FL produces larger products than PBP1a FL. This suggests that PBP2a FL is 
more processive than PBP1a FL. Amidation of Lipid II does not appear to have an 
effect on the length of glycan products of PBP1a FL as material is seen at equivalent 
positions in the lanes containing Lipid II (Glu, Dans) and Lipid II (Gln, Dans). 
However, the distribution of product lengths of PBP2a FL with Lipid II (Gln, Dans) 
are higher up the gel than that with Lipid II (Glu, Dans), and more material is not 
able to enter the gel (as seen by the band of material indicated by (iii)). This shows 
that PBP2a produces longer glycan chains with amidated substrate, and therefore that 
amidation has an effect on the processivity of the enzyme.  
 
 
10 µM Lipid II 
(Glu, Dans) 
10 µM Lipid II 
(Gln, Dans) 
C 1 µM 
PBP1a 
C 1 µM 
PBP1a 
i 
ii 
iii 
10 µM Lipid II 
(Glu, Dans) 
10 µM Lipid II 
(Gln, Dans) 
C 1 µM 
PBP2a 
C 1 µM 
PBP2a 
(a) (b) 
Figure 4.6: Comparison of the effect of Lipid II amidation on the transglycosylase products 
of S. pneumoniae PBP1a (a) and PBP2a (b). Products of transglycosylation separated on a 8.5% 
T/2.7% C SDS-PAGE gel. Representative of n=2. Dansyl fluorescence at 521 nm was detected 
using a blue light converter and short pass filter on a GeneSnap Gel Doc. All reactions contained 
10 µM total Lipid II (either Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) as labelled below the gel 
and 1 µM PBP1a or 1 µM PBP2a where indicated. C, –enzyme: 10 µM Lipid II with enzyme 
replaced with an equal volume of enzyme storage buffer. Reactions in a final volume of 15 µL 
were incubated at 30°C overnight. (i) denotes unpolymerised Lipid II; (ii) glycan chains of varying 
lengths and (iii) the location of very high molecular weight material if present, which does not 
enter the gel. 
135 
 
4.4.3 The effect of Triton X-100 concentration on processivity of S. pneumoniae 
PBP1a and PBP2a transglycosylation 
 
The presence of detergent (TX-100 in the case of PBP1a and PBP2a) in the assay 
buffer is important for the solubility of the Lipid II substrate, and the full-length PBP 
possessing a hydrophobic transmembrane region. Previous studies have identified a 
combined effect of detergent and DMSO, where increasing DMSO concentration 
rescues transglycosylase activity at high detergent concentrations, which would 
otherwise be inhibitory (Helassa et al., 2012, Offant et al., 2010, Schwartz et al., 
2002). This effect has been attributed to DMSO mediated increase in solubility of the 
lipid substrate and more rapid exchange between detergent micelles, allowing Lipid 
II and PBP to come into contact (Schwartz et al., 2002). The effect of TX-100 
concentration on PBP1a FL and PBP2a FL transglycosylase activity was analysed by 
SDS-PAGE whilst maintaining DMSO at a set concentration. 
 
10 µM Lipid II (Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) was incubated with 1 
µM PBP1a FL, 1 µM PBP2a FL or an equivalent volume of enzyme storage buffer in 
either 50 mM HEPES pH 7.5, 10 mM MgCl2, 150 mM NaCl, 25% (v/v) DMSO 
(PBP1a) or 50 mM HEPES pH 7.5, 25 mM MgCl2, 200 mM NaCl, 25% (v/v) DMSO 
(PBP2a) both with a range of TX-100 concentrations ranging from 0.2 × CMC to 
10.7 × CMC (CMC = 0.015% (v/v)). 15 µL reactions were incubated at 30°C 
overnight before analysis by SDS-PAGE (Section 2.7.2) (Figure 4.7) 
 
PBP1a exhibited transglycosylase activity until 2.7 × CMC (0.04% (v/v)) with both 
Lipid II substrates, with little effect on processivity. Above 2.7 × CMC, activity is 
severely inhibited, showing that the DMSO concentration used is not able to rescue 
this inhibition. Below the TX-100 CMC, a faint band of unpolymerised Lipid II was 
observed after overnight incubation indicating poor transglycosylase activity.  
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10 µM Lipid II (Glu, Dans): 1 µM PBP2a 10 µM Lipid II (Gln, Dans): 1 µM PBP2a 
i 
ii 
iii 
- enzyme 0.003 0.005 0.01 0.02 0.04 0.08 0.16 - enzyme 0.003 0.005 0.01 0.02 0.04 0.08 0.16 
Final Triton X-100 concentration (%) Final Triton X-100 concentration (%) 
10 µM Lipid II (Glu, Dans): 1 µM PBP1a 10 µM Lipid II (Gln, Dans): 1 µM PBP1a 
i 
ii 
iii (a) 
(c) 
(b) 
(d) 
0.3 0.2 0.7 1.3 2.7 5.3 10.7 [TX-100] relative to CMC 0.3 0.2 0.7 1.3 2.7 5.3 10.7 
0.3 0.2 0.7 1.3 2.7 5.3 10.7 [TX-100] relative to CMC 0.3 0.2 0.7 1.3 2.7 5.3 10.7 
Figure 4.7: Effect of Triton X-100 concentration on the processivity of S. pneumoniae PBP1a 
((a) and (b)) and PBP2a transglycosylase activity ((c) and (d)). Products of transglycosylation 
separated on a 8.5% T/2.7% C SDS-PAGE gel. Dansyl fluorescence at 521 nm detected using a blue 
light converter and short pass filter on a GeneSnap Gel Doc. All reactions contain 10 µM total Lipid II 
(either Lipid II (Glu, Dans)((a),(c)) or Lipid II (Gln, Dans)((b),(d)) as labelled above the gel and 1 µM 
PBP1a ((a), (b)) or 1 µM PBP2a ((c),(d)) where indicated. –enzyme: 10 µM Lipid II with enzyme 
replaced with an equal volume of enzyme storage buffer. Control reactions at 0.02% (v/v) TX-100). 
Reactions in a final volume of 15 µL were incubated at 30°C overnight. (i) denotes unpolymerised 
Lipid II; (ii) glycan chains of varying lengths and (iii) the very high molecular weight material, if 
present, which does not enter the gel. 
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PBP2a FL is less affected by TX-100 concentration than PBP1a FL, as activity 
observed at all concentrations used. The polymerisation of Lipid II (Glu, Dans) was 
mainly unaffected by varying the TX-100, with only minor inhibition at 10.7 × 
CMC. However, with Lipid II (Gln, Dans), 2.7 × CMC (0.04% (v/v)) TX-100 causes 
a shortening in the glycan chain length; observed by a reduction in the band at the 
top of the gel (iii), and a shortening of the chain lengths towards the bottom of the 
gel. At TX-100 concentrations above this, short chains are observed but not full 
inhibition as was seen with PBP1a.  
 
4.4.4 Time-course studies of the transglycosylase activity of S. pneumoniae 
PBP1a and PBP2a  
 
Whilst the SDS-PAGE method is predominantly useful for obtaining qualitative 
information on the processivity of PBP transglycosylase activity, it can also indicate 
relative rates between enzymes and conditions through time-course studies. This 
approach was used to investigate differences in substrate preference between Lipid II 
(Glu, Dans) and Lipid II (Gln, Dans) of PBP1a and PBP2a. 0.02% (v/v) TX-100 was 
used, as good activity was observed in all cases previously at this concentration 
(Section 4.4.3), and it is above the CMC (0.015% (v/v)).  
 
10 µM Lipid II (Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) in 120 µL reaction 
buffer (PBP1 or PBP2a (Section 4.4.2) containing 0.02% (v/v) TX-100) was 
incubated with 1 µM PBP1a FL or PBP2a FL at 30°C. 15 µL samples were removed 
after 0, 1, 2, 4, 7 and 24 hours (PBP1a)(Figure 4.8) or 0, 1, 2, 4 and 8 hours 
(PBP2a)(Figure 4.9) and the reaction stopped with 0.5 mM moenomycin 
(transglycosylase inhibitor). Products were analysed by SDS-PAGE (Section 2.7.2). 
 
As observed in Figure 4.6, amidation of Lipid II does not affect PBP1a processivity.  
Figure 4.8 indicates that Lipid II (Gln, Dans) is polymerised more rapidly than Lipid 
II (Glu, Dans), although the difference in fluorescence intensity suggests more Lipid 
II (Glu, Dans) is present. However, all Lipid II (Gln, Dans) visible by eye is used 
within the first hour of reaction, whereas an appreciable amount of Lipid II (Glu, 
Dans) remains after 7 hours.  
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Amidation of Lipid II increases the processivity of S. pneumoniae PBP2a 
transglycosylation (Figure 4.6). Figure 4.9 demonstrates that Lipid II (Gln, Dans) is 
also polymerised more rapidly than Lipid II (Glu, Dans) by PBP2a, with all visible 
amidated Lipid II used within the first hour. This also shows that PBP2a is more able 
to use Lipid II (Glu, Dans) than PBP1a as all substrate is polymerised within 4 hours, 
compared to over 7 hours by PBP1a. 
 
24 hour and 8 hour controls in Figures 4.8 and 4.9 respectively were included with 
the addition of 0.5 mM moenomycin. This demonstrates that the activity observed is 
inhibited by the specific transglycosylase inhibitor, and confirms the rationale for 
stopping each time point aliquot with 0.5 mM moenomycin.  
 
 
0 1 2 4 7 24 
Time (hours) 
Moe 0 1 2 4 7 24 
Time (hours) 
i 
ii 
iii 
10 µM Lipid II (Glu, Dans): 1 µM PBP1a 10 µM Lipid II (Gln, Dans): 1 µM PBP1a 
Figure 4.8: A time-course comparison of Lipid II (Glu, Dans) and Lipid II (Gln, Dans) as 
substrates for S. pneumoniae PBP1a. Products of transglycosylation separated on a 8.5% 
T/2.7% C SDS-PAGE gel. Representative of n=2. Dansyl fluorescence at 521 nm detected using 
a blue light converter and short pass filter on a GeneSnap Gel Doc. Parallel reactions containing 
10 µM Lipid II (Glu, Dans) or 10 µM Lipid II (Gln, Dans) (as indicated above gel) were 
incubated at 30°C. 15 µL aliquots removed at time points shown, and reaction stopped with 0.5 
mM moenomycin. Moe, control reaction of 10 µM Lipid II (Gln, Dans), 1 µM PBP1a FL and 
0.5 mM moenomcyin incubated at 30°C for 24 hours (i) denotes unpolymerised Lipid II; (ii) 
glycan chains of varying lengths and (iii) the location of very high molecular weight material if 
it were present, which does not enter the gel. 
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4.4.5 The role of the S. pneumoniae PBP2a transmembrane region in 
transglycosylase activity 
 
Helassa et al., (2012) identified that the transmembrane spanning (TM) region of 
PBP2a has a significant influence on the length of glycan polymers produced, with 
its removal resulting in a 4-fold decrease in chain length. Chemical cross-linking 
experiments suggested an involvement of the TM region in dimerisation of PBP2a 
and the increased processivity was attributed to either this or a more direct 
interaction between the Lipid II substrate and the PBP transmembrane helix. The TM 
region of E. coli PBP1b is crucial in its affinity for moenomycin, and this has led to 
10 µM Lipid II (Glu, Dans), 1 µM PBP2a  10 µM Lipid II (Gln, Dans), 1µM PBP2a  
0 2 4 
Time (hours) 
8 1 0 2 4 
Time (hours) 
8 1 Moe Moe 
i 
ii 
iii 
Figure 4.9: A time-course comparison of Lipid II (Glu, Dans) and Lipid II (Gln, Dans) as 
substrates for S. pneumoniae PBP2a-FL. Products of transglycosylation separated on a 8.5% 
T/2.7% C SDS-PAGE gel. Dansyl fluorescence at 521 nm was detected using a blue light converter 
and short pass filter on a GeneSnap Gel Doc. Parallel reactions containing 10 µM Lipid II (Glu, 
Dans) or 10 µM Lipid II (Gln, Dans) and 1 µM PBP2a FL were incubated at 30°C, aliquots were 
removed at time points shown, and reaction stopped with 0.5 mM moenomycin. Moe, control 
reaction of 10 µM Lipid II (Lipid II (Glu, Dans) or Lipid II (Gln, Dans) as indicated), 1 µM PBP2a 
FL and 0.5 mM moenomycin were incubated at 30°C for 24 hours (i) denotes unpolymerised Lipid 
II; (ii) glycan chains of varying lengths and (iii) the very high molecular weight material, which does 
not enter the gel. 
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the suggestion that it is important in binding of Lipid II and moenomycin (Cheng et 
al., 2008; Sung et al., 2009). Additionally these effects could be due to differences in 
interaction of enzyme and substrate due to the presence of a detergent micelle 
surrounding the hydrophobic TM region (Helassa et al., 2012). 
 
Helassa and co-workers conducted their experiments at a TX-100 concentration of 
0.04% (v/v) with non-amidated dansylated Lipid II, therefore an obvious comparison 
to make is the effect of removal of the TM helix (Δ77) on the processivity of PBP2a 
with Lipid II (Gln, Dans), compared to that displayed by the complete protein. This 
experiment was conducted at the lower TX-100 concentration of 0.02% (v/v), to 
keep the concentration sufficiently below that observed to be inhibitory in Figure 4.7 
(D).  
 
10 µM Lipid II (Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) was incubated with      
1 µM PBP2a FL or 1 µM PBP2a-Δ77 in PBP2a reaction buffer at 30°C overnight 
before analysis by SDS-PAGE (Section 2.7.2)(Figure 4.10). A parallel set of 
reactions were identical but with the addition of 1 mM moenomycin.  
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Figure 4.10 shows a reduction in chain lengths from Lipid II (Gln, Dans) to Lipid II 
(Glu, Dans) for both the full-length and -Δ77 enzyme, further demonstrating the role 
of Lipid II amidation on PBP2a processivity (see Figure 4.6 and 4.9). Processivity is 
also reduced with both substrates following removal of the TM region as observed 
by Helassa et al., (2012) with Lipid II (Glu, Dans).  
PBP2a FL PBP2a-Δ77 
Gln Glu Gln Glu 
PBP2a FL PBP2a-Δ77 
Gln Glu Gln Glu 
i 
ii 
iii 
10 µM Lipid II (Dans), 1 µM PBP2a 
(FL/-Δ77) 
10 µM Lipid II (Dans), 1 µM PBP2a 
(FL/-Δ77), 1 mM Moenomycin 
Figure 4.10: Comparison of PBP2a FL and PBP2a-Δ77 processivity with Lipid II (Glu, 
Dans) and Lipid II (Gln, Dans). All reactions contain 10 µM total Lipid II (either Lipid II (Glu, 
Dans) indicated by Glu below the gel or Lipid II (Gln, Dans) indicated by Gln) and 1 µM PBP2a 
FL or 1 µM PBP2a-Δ77 where indicated. Control reactions on the right of the gel containing an 
additional 1 mM moenomycin are labelled. Reactions in a final volume of 15 µL were incubated at 
at 30°C overnight and products of transglycosylation separated on a 8.5% T/2.7% C SDS-PAGE 
gel. Representative of n=2. Dansyl fluorescence at 521 nm detected using a blue light converter 
and short pass filter on a GeneSnap Gel Doc. (i) denotes unpolymerised Lipid II; (ii) glycan chains 
of varying lengths and (iii) the very high molecular weight material, which does not enter the gel. 
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In order to test the possibility that the processivity effect between full-length and 
truncated enzyme could be due to differences in the detergent micelle surrounding 
the hydrophobic TM region, the effect of TX-100 concentration on PBP2a-Δ77 
transglycosylase activity was investigated as in Section 4.4.3 for PBP2a FL. As 
before, 10 µM Lipid II (Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) was incubated 
with 1 µM PBP2a-Δ77 or an equivalent volume of enzyme storage buffer in PBP2a 
reaction buffer with a range of TX-100 concentrations from 0.2 × CMC to 10.7 × 
CMC. 15 µL reactions were incubated at 30°C overnight before analysis by SDS-
PAGE (Section 2.7.2)(Figure 4.11). 
A more significant effect on processivity was observed with truncated PBP2a (Figure 
4.11) at increasing TX-100 concentrations than for the full-length enzyme (Figure 
4.7). Inhibition was first observed at just above the CMC (0.02% (v/v) TX-100) for 
both Lipid II (Glu, Dans) and Lipid II (Gln, Dans), with severe inhibition at 2.7 × 
CMC (0.04% (v/v)) and above (Figure 4.11). Activity was observed with PBP2a FL 
at all TX-100 concentrations tested with both substrates. A possible explanation for 
- enzyme 0.003 0.005 0.01 0.02 0.04 0.08 0.16 - enzyme 0.003 0.005 0.01 0.02 0.04 0.08 0.16 
Final Triton X-100 concentration (%) Final Triton X-100 concentration (%) 
10 µM Lipid II (Gln, Dans), 1 µM PBP2a-Δ77 
 
10 µM Lipid II (Glu, Dans), 1 µM PBP2a-Δ77 
i 
ii 
iii (a) (b) 
Figure 4.11: Effect of Triton X-100 concentration on the processivity of S. pneumoniae PBP2a-
Δ77. All reactions contain 10 µM total Lipid II (either Lipid II (Glu, Dans)(a) or Lipid II (Gln, 
Dans)(b)) as labelled above the gel and 1 µM PBP2a-Δ77 PBP2a reaction buffer with various TX-100 
concentrations. –enzyme: 10 µM Lipid II with enzyme replaced with an equal volume of enzyme 
storage buffer. (Control reactions at 0.02% (v/v) TX-100). Reactions in a final volume of 15 µL were 
incubated at 30 °C overnight and products of transglycosylation separated on a 8.5% T/2.7% C SDS-
PAGE gel. Dansyl fluorescence at 521 nm detected using a blue light converter and short pass filter on 
a GeneSnap Gel Doc. (i) denotes unpolymerised Lipid II; (ii) glycan chains of varying lengths and (iii) 
the very high molecular weight material, which does not enter the gel. 
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this is a difference in detergent-micelle interaction between the two protein variants, 
reducing the likelihood of PBP and Lipid II interactions with the truncated version at 
increasing TX-100 concentrations. PBP2a possesses a membrane association site 
within the transglycosylase domain between Lys 78 and Ser 156 (Di Guilmi et al., 
1999) and therefore this hydrophobic region is likely to interact with TX-100, and 
this could affect vital protein-substrate interactions.  
 
An interesting point arising from these observations is that the study on glycan chain 
length conducted by Helassa et al., (2012) was with TX-100 at 0.04% (v/v), and in 
Figure 4.10 at 0.02% (v/v). The comparison of Figures 4.7 and 4.11 shows that at the 
detergent concentrations used previously (in both cases), which are both above the 
CMC (0.015% (v/v)), the chain lengths produced by PBP2a-Δ77 are shorter than at 
0.01% (v/v)(Figure 4.11). The effect is more significant at 0.04% (v/v) TX-100. 
Conversely, full-length PBP2a is not as affected by these TX-100 concentrations 
(Figure 4.7 (c) and (d)). Therefore the shortening of chains observed with PBP2a-
Δ77 is a result of the TX-100 concentrations used.  
 
A time-course analysis was conducted for PBP2a-Δ77 transglycosylase activity at 
two TX-100 concentrations, to identify any further effects of the detergent 
concentration on enzyme activity. 0.01% (v/v) and 0.04% (v/v) were selected due to 
the significant difference seen between enzyme activities at these concentrations in 
Figure 4.11. 
 
10 µM Lipid II (Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) in 120 µL PBP2a 
reaction buffer, with either 0.01% (v/v)(a) or 0.04% (v/v)(b) TX-100 was incubated 
with 1 µM PBP2a-Δ77 at 30°C. 15 µL samples were removed after, 0, 1, 2, 4, 7 and 
24 hours and reactions stopped with 0.5 mM moenomycin. Products were analysed 
by SDS-PAGE (Section 2.7.2)(Figure 4.12). 
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Lipid II (Gln, Dans) was polymerised more rapidly by PBP2a-Δ77 at both TX-100 
concentrations than Lipid II (Glu, Dans), as was seen previously with PBP2a FL 
(Figure 4.9). The main difference identified was a slowing of the rate of 
transglycosylation of Lipid II (Glu, Dans) with a TX-100 concentration of 0.04% 
(v/v) compared to that at 0.01% (v/v).  
 
4.4.6 Requirement for the TM region in PBP2a oligomerisation 
 
In vitro cross-linking experiments with EGS (ethylene glycol bis(succinic acid) N-
hydroxysuccinimide ester) by Helassa et al., (2012) identified apparent dimerisation 
of full-length PBP2a, but not PBP2a-Δ77. Several experiments were performed to 
confirm this.  
 
Firstly, Microscale thermophoresis (MST) was used to investigate the dimerisation 
of PBP2a. Changes in molecule size are identified by movement in a temperature 
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0.04% Triton X-100 0.01% Triton X-100 
10 µM Lipid II (Glu, Dans),  
1 µM PBP2-Δ77 
Time (hours) Time (hours) Time (hours) 
10 µM Lipid II (Gln, Dans),  
1 µM PBP2-Δ77 
10 µM Lipid II (Glu, Dans),  
1 µM PBP2-Δ77 
10 µM Lipid II (Gln, Dans),  
1 µM PBP2-Δ77 
(a) (b) 
i 
ii 
iii 
Figure 4.12: A time-course comparison of Lipid II (Glu, Dans) and Lipid II (Gln, Dans) as 
substrates for S. pneumoniae PBP2a-Δ77 and the effect of TX-100 concentration. Parallel 120 uL 
reactions containing 10 µM Lipid II (Glu, Dans) or 10 µM Lipid II (Gln, Dans) (as indicated above gel) 
in PBP2a reaction buffer containing 0.01% (v/v) TX100 (a) or 0.04% (v/v) TX-100 (b) and 1 µM 
PBP2a-Δ77 were incubated at 30°C. 15 µL aliquots were removed at time points shown, and reaction 
stopped with 0.5 mM moenomycin. Products of transglycosylation were separated on a 8.5% T/2.7% C 
SDS-PAGE gel. Representative of n=2. Dansyl fluorescence at 521 nm detected using a blue light 
converter and short pass filter on a GeneSnap Gel Doc. (i) denotes unpolymerised Lipid II; (ii) glycan 
chains of varying lengths and (iii) the very high molecular weight material, which does not enter the 
gel. 
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gradient (thermophoresis) with the titration of non-fluorescent molecules against a 
constant concentration of fluorescent molecule (for detection). Changes in 
thermophoresis can be used to monitor binding (Jerabek-Willemsen et al., 2011; 
Seidel et al., 2013; Wienken et al., 2010).  
 
Experiments were performed by Dr James Wilkinson as part of a demonstration from 
NanoTemper Technologies (Germany) GmbH (methodological detail Section 2.5.3). 
NT-647 fluorescent label was covalently attached to primary amines on PBP2a-FL 
and PBP2a-Δ77 and non-labelled proteins subsequently titrated (64.95 µM to 2 nM) 
against a constant concentration of 75 nM labelled PBP. Assays were performed in 
PBP2a-FL and PBP2a-Δ77 storage buffers (Section 4.3.3 and 4.3.4 respectively) at 
30°C plus 0.005% (v/v) Tween20 to reduce sticking to capillaries. MST analysis was 
in standard glass capillaries using the Monolith NT.115 (NanoTemper GmbH). Data 
analysis performed by Dr James Wilkinson established a Kd of 500 nM for PBP2a 
FL and no indication of binding for PBP2a-Δ77.  
 
Experiments were subsequently repeated in PBP2a assay buffer for both PBP2a-FL 
and PBP2a-Δ77 but data was not obtained due to protein aggregation affecting the 
fluorescence signal. This has important implications in the discussion of assay 
conditions used to observe transglycosylase activity (Discussed section 4.6.2).  
 
Dimerisation of PBP2a-FL was further probed by analytical size exclusion 
chromatography (Section 2.4.3.2.2). 100 µL of pure protein (Section 4.3.3) at 8 
mg.ml-1 was loaded onto a Superdex 200 Increase 10/300 GL (GE Healthcare) 
column and eluted with 1 column volume (CV) of PBP2a storage buffer at 0.3 
ml.min-1 (Figure 4.13(a)). SDS-PAGE analysis of the two peaks identified them to 
contain only PBP2a-FL (Figure 4.13(b)), suggesting two oligomerisation states. Pre-
equilibration of the column with a Gel Filtration HMW Calibration Kit (GE 
Healthcare) enables a rough estimation of molecular weight. This is not very 
accurate due to the presence of large TX-100 detergent micelles, and the assumption 
of globular protein required for this calculation. However, the estimate suggested 
peak (i) to be 280 kDa and (ii) 141 kDa in size. The molecular weight of PBP2a-FL 
at 80 kDa and TX-100 at approximately 90 kDa suggests that peak (ii) may be a 
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monomer and at (i) a dimer of PBP2a-FL. An interesting observation is the intensity 
of peak (ii) in correspondence with the amount of protein present (Figure 4.13(b). 
The higher intensity of absorbance signal at 280 nm and 254 nm of the less abundant 
protein may suggest interaction with a molecule with absorbance at this wavelength 
(such as tightly bound TX-100), or a reduction in absorbance observed due to 
dimerisation.  
 
Re-injection of peak (i) onto the Superdex 200 Increase column resulted in a 
chromatogram of the same peaks and relative intensities of that observed in Figure 
4.13. This suggests an equilibrium state between monomeric and dimeric PBP2a-FL.  
 
4.4.7 Role of the S. pneumoniae PBP1a transmembrane region in 
transglycosylase activity 
 
The effect of TM helix removal on PBP1a activity was also investigated. A 
comparable experiment to that shown in Figure 4.10 was performed. Here, 10 µM 
Lipid II (Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) was incubated with 1 µM 
PBP1a FL or 1 µM PBP1a-Δ30 in PBP1a reaction buffer at 30°C overnight before 
analysis by SDS-PAGE (Section 2.7.2)(Figure 4.14)(control reactions also included 
1 mM moenomycin).  
(i) 
(ii) 
(a) (b) Mr 
97 
45 
30 
20 
66 
Peak (i) Peak (ii) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Figure 4.13: Gel filtration analysis of oligomeric state of S. pneumoniae PBP2a-FL. (a) Superdex 
200 Increase 10/300 FL chromatogram showing the elution of 2 peaks of PBP2a-FL at (i) 11.0 mL and 
(ii) 12.3 mL. Red: absorbance at 254nm, Blue: absorbance at 280 nm (b) 12% SDS-PAGE Coomassie-
stained gel showing the analysis of these peaks and showing they both contain pure PBP2a-FL with no 
contaminants or break-down products. Mr, molecular weight markers (kDa); Peak (i) 1-7 Samples from 
fractions in peak (i); Peak (ii) 8-14 Fractions in peak (ii). All samples 10 µL from 500 µL fractions. 
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Figure 4.14 suggests there may be a reduction in glycan chain lengths between Lipid 
II (Glu, Dans) and Lipid II (Gln, Dans) for both full-length and truncated enzymes, 
which contradicts the previous observation (Figures 4.6 and 4.8) that PBP1a-FL 
processivity is unaffected by Lipid II amidation. However, it is clear that less Lipid II 
(Glu, Dans) is present, and therefore strong conclusions cannot be drawn. The 
comparison between Figures 4.6, 4.8 and 4.14 also highlights an issue with 
reproducibility between gels (Discussed Section 4.6.2.1). It is clear that removal of 
the TM region affects PBP1a transglycosylase activity, as with both substrates 
unpolymerised Lipid II substrate remains after an overnight incubation.  
 
MST experiments as in Section 4.4.6 were performed for PBP1a-FL and PBP1a-Δ30 
in reaction buffer, but aggregation prevented data analysis.  
PBP1a FL PBP1a-Δ30 
Gln Glu Gln Glu 
PBP1a FL PBP1a-Δ30 
Gln Glu Gln Glu 
i 
ii 
iii 
10 µM Lipid II, 1 µM PBP1a 
(FL/-Δ30) 
10 µM Lipid II, 1 µM PBP1a (FL/-Δ30),  
1 mM Moenomycin 
Figure 4.14: Comparison of PBP1a FL and PBP1a-Δ30 processivity with Lipid II (Glu, 
Dans) and Lipid II (Gln, Dans). All reactions contained 10 µM total Lipid II (either Lipid II 
(Glu, Dans) indicated by Glu below the gel or Lipid II (Gln, Dans) indicated by Gln) and 1 µM 
PBP1a FL or 1 µM PBP1a-Δ30 where indicated. Control reactions on the right of the gel 
containing an additional 1 mM moenomycin are labelled. Reactions in a final volume of 15 µL 
were incubated at 30°C overnight and products of transglycosylation separated on a 8.5% 
T/2.7% C SDS-PAGE gel. Dansyl fluorescence at 521 nm was detected using a blue light 
converter and short pass filter on a GeneSnap Gel Doc. (i) denotes unpolymerised Lipid II; (ii) 
glycan chains of varying lengths and (iii) the very high molecular weight material, which does 
not enter the gel. 
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4.5 Continuous coupled fluorescence assay for transglycosylase 
activity  
 
As described in Section 4.1.2, the polymerisation of fluorescent Lipid II (Dans) can 
be coupled to digestion by N-acetylmuramidase to obtain quantitative data on 
transglycosylation. In Section 4.4, it was established by SDS-PAGE analysis that 
amidated Lipid II (Lipid II (Gln, Dans)) is an optimal substrate for S. pneumoniae 
PBP1a and PBP2a transglycosylation, and time-course studies suggest that it is 
polymerised more rapidly by both enzymes than the non-amidated variant (Lipid II 
(Glu, Dans)). This section details the study of the effect of amidation of Lipid II on 
the rate of transglycosylation in a quantitative manner by the continuous 
transglycosylation assay in a 96-well plate assay format (Helassa et al., 2012; Offant 
et al., 2010). The standard methodology for this assay is detailed in Section 2.7.1. 
 
4.5.1 Optimisation of conditions for PBP1a and PBP2a transglycosylase activity 
 
As described in Section 4.4.1, optimal buffer conditions are known for PBP1a and 
PBP2a (Abrahams, 2011; Helassa et al., 2012). As for the gel assays, larger, more 
concentrated stocks of Lipid II were made to improved accuracy. In initial 
experiments a gradual reduction in fluorescence over the experimental time-course 
was observed in all reactions including controls. This was attributed to evaporation 
over time leading to a change in buffer conditions and was overcome by the use of 
optically transparent ThermalSeal RTTM film to seal the plate upon reaction 
initiation. A reduction in dansyl fluorescence yield of  ~8%, but no effect on the 
fluorescent properties was observed (Figure 4.15). This was acceptable as the 
reduction in fluorescence due to evaporation was more significant.  
 
Reaction buffers used in this section were, PBP1a: 50 mM HEPES pH 7.5, 10 mM 
MgCl2, 150 mM NaCl, 25% (v/v) DMSO, 0.02% (v/v) TX-100 and PBP2a: 50 mM 
HEPES pH 7.5, 25 mM MgCl2, 200 mM NaCl, 25% (v/v) DMSO, 0.02% (v/v) TX-
100 unless stated otherwise. 
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4.5.1.1 Fluorescent properties of Lipid II (Dans) 
 
The published optimal excitation and emission wavelengths of the dansyl 
fluorophore appended to Lipid II are 340 nm and 521 nm respectively (Schwartz et 
al., 2002). In order to ensure the highest signal, any effect of the assay buffer system 
on the dansyl fluorescent properties was investigated (Figure 4.15). 10 µM Lipid II 
(Glu, Dans) or Lipid II (Gln, Dans) in 50 µL PBP1a or PBP2a reaction buffer plus 
0.1 mg.ml-1 N-acetylmuramidase (mutanolysin from Streptomyces globisporus), in a 
Greiner FLUOTRACTM 600 96-well plate was scanned for wavelength maxima in a 
CLARIOstar® platereader (BMG Labtech). Emission from 400-600 nm was 
measured after excitation at 340 nm and emission at 521 nm with excitation over the 
320-400 nm range. All measurements were performed with and without a seal, and 
with buffer only controls, in duplicate. No difference was observed between the two 
buffer systems or between Lipid II (Glu, Dans) and Lipid II (Gln, Dans), therefore 
Figure 4.15 demonstrates the effect of the seal and shows buffer only controls, with 
Lipid II (Gln, Dans) in PBP1a buffer for simplicity. 
 
The emission maxima observed with excitation at 340 nm was 521 nm, and the 
intensity was reduced slightly by the inclusion of a seal. An increase in emission at 
lower wavelengths was observed due to the seal, but not in the region that may affect 
the monitored wavelengths. Similarly, a reduction in intensity was seen when 
emission was measured at 521 nm. The optimal excitation wavelength was 359 nm, 
higher than that expected. In both cases, the buffer control confirms that the 
fluorescence observed is due to the presence of the Lipid II (Dans). A test reaction 
was performed with excitation at 359 nm and emission at 521 nm, with more noise 
observed than the usual parameters of 340 nm and 521 nm. Therefore, the published 
conditions of excitation at 340 nm and emission at 521 nm were taken forward with 
the use of a plate seal to prevent evaporation.  
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An additional control, with the removal of Lipid II, but the inclusion of 1 µM PBP1a 
or PBP2a in their respective reaction buffer plus 0.1 mg.ml-1 mutanolysin showed no 
signal at 521 nm following excitation at 340 nm, which rules out a fluorescence 
effect due to the protein (data not shown).  
 
All assays hereafter were carried out in the reaction buffers stated above (Section 
4.5.1) in a CLARIOstar® platereader (BMG Labtech) with Greiner FLUOTRACTM 
600 black 96-well plates, at 30°C with excitation at 340 nm, emission at 521 nm and 
with a ThermalSeal RTTM film unless specified otherwise. Basic experimental 
methods for the assay system are detailed in Section 2.7.1. 
 
4.5.1.2 Lysozyme as an alternative N-acetylmuramidase coupling enzyme 
 
N-acetylmuramidases are responsible for cleavage of the β-1,4-linkage between 
MurNAc and GlcNAc of the peptidoglycan polysaccharide backbone. Mutanolysin 
from Streptomyces globisporus has been used in all published work to date using this 
fluorescence assay (including Helassa et al., 2012; Offant et al., 2010; Schwartz et 
al., 2002). It was hypothesised that the cheaper, more readily available, Lysozyme 
from hen egg-white could replace mutanolysin as this catalyses the same reaction 
and is also active against Gram-positive peptidoglycan (Nakimbugwe et al., 2006). A 
(a) (b) 
Figure 4.15: Optimal emission and excitation wavelengths of Lipid II (Dans). 10 µM Lipid II (Gln, 
Dans) in 50 µL 50 mM HEPES pH 7.5, 10 mM MgCl2, 150 mM NaCl, 25% (v/v) DMSO, 0.02% (v/v) 
TX-100 in a Greiner FLUOTRACTM 600 96-well plate. a) Excitation at 340 nm, emission measured at 
400 nm-600 nm. Black solid, Lipid II; Red solid; Lipid II + seal, Black dashed; Buffer control, Red 
dashed; Buffer control + seal. Emission maxima observed at 521 nm. b) Excitation at 320 nm – 400 
nm, emission at 521 nm. Black solid, Lipid II; Red solid; Lipid II + seal, Black dashed; Buffer control, 
Red dashed; Buffer control + seal. Excitation maxima observed at 359 nm.  
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search of the literature revealed no information on the minimum length of glycan 
chain required by mutanolysin as a substrate, and that the minimum requirement for 
optimal activity of lysozyme is 6 saccharides (Vocadlo et al., 2001). Parallel assays 
were carried out with 0.1 mg.ml-1 lysozyme and mutanolysin to test the hypothesis. 
Both Lipid II (Glu, Dans) and Lipid II (Gln, Dans) were tested to ensure no 
difference in N-acetylmuramidase specificity was observed between the two (Figure 
4.16). 
 
Emission at 521 nm following excitation at 340 nm was followed for 2000 seconds 
with measurements at 30 second intervals. Reactions consisted of 10 µM Lipid II 
(Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) and 1 µM PBP1a or PBP2a in the 
enzyme specific reaction buffer. Parallel reactions contained either 0.1 mg.ml-1 
mutanolysin from Streptomyces globisporus or 0.1 mg.ml-1 hen egg-white lysozyme 
and were initiated with the addition of enzyme. Relative fluorescence measurements 
were plotted against time. Initial rates were not calculated at this point as the raw 
data is shown for direct comparison to ensure linearity of response, and full analysis 
of the effect of enzyme and substrate concentrations is carried out in Section 4.5.2. 
 
(a) (b) 
Figure 4.16: Comparison of lysozyme and mutanolysin as coupling enzymes in the continuous  
fluorescence assay for S. pneumoniae PBP1a (a) and PBP2a (b) transglycosylase activity 10 µM 
Lipid II ((Lipid II (Glu, Dans) (Blue lines) or Lipid II (Gln, Dans)(Red lines)) a) In 50 mM HEPES pH 
7.5, 10 mM MgCl2, 150 mM NaCl, 25% (v/v) DMSO, 0.02% (v/v) TX-100 with 0.1 mg.ml-1 lysozyme 
(dashed lines) or 0.1 mg.ml-1 mutanolysin (solid lines) plus 1 µM PBP1a. b) In 50 mM HEPES pH 7.5, 
25 mM MgCl2, 200 mM NaCl, 25% (v/v) DMSO, 0.02% (v/v) TX-100 with 0.1 mg.ml-1 lysozyme 
(dashed lines) or 0.1 mg.ml-1 mutanolysin (solid lines) plus 1 µM PBP2a. Controls in both a) and b) 
solid black lines, 10 µM Lipid II (Gln, Dans) in mutanolysin containing reaction buffers as before with 
PBP storage buffer replacing PBP. Dashed black lines, 10 µM Lipid II (Gln, Dans) in lysozyme 
containing reaction buffers as before with PBP storage buffer replacing PBP. Reaction volume ; 50 µL 
in a Greiner FLUOTRACTM 600 96-well plate. Excitation at 340 nm, emission at 521 nm. Readings at 
30 second intervals. Plotted lines are averages of 3 repeats.  
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This initial comparison of Lipid II (Glu, Dans) and Lipid II (Gln, Dans) by 
continuous assay agrees with previous results by SDS-PAGE analysis, showing that 
the amidated substrate is preferred. For PBP1a, no difference was observed between 
mutanolysin and lysozyme, and for PBP2a lysozyme performed better. A greater 
fluorescence drop was observed over the time-course, suggesting that the glycan 
chains were digested more fully. In both cases a linear response was observed 
between fluorescence change and time showing that the coupling enzyme is not 
limiting. The difference between PBP1a and PBP2a may be due to the greater 
processivity of the latter, as observed in Section 4.4, and the differences in substrate 
specificity of the two N-acetylmuramidases. However it could be due to the 
mutanolysin stock used.  
 
The rationale for using lysozyme as a coupling enzyme in the assay system has been 
demonstrated here, and therefore 0.1 mg.ml-1 lysozyme was used hereafter for 
continuous fluorescence transglycosylase assays of PBP1a and PBP2a, unless stated 
otherwise. 
 
4.5.2 Do S. pneumoniae PBP1a and PBP2a polymerise Lipid II (Gln, Dans) more 
rapidly than Lipid II (Glu, Dans)? 
 
A simple comparison between the two substrates with 10 µM Lipid II and 1 µM 
enzyme suggested that both PBP1a and PBP2a polymerise Lipid II (Gln, Dans) more 
rapidly than Lipid II (Glu, Dans)(Figure 4.16). This section describes a more 
thorough investigation of this difference.  
 
4.5.2.1 Continuous fluorescence assay for transglycosylation of Lipid II (Gln, 
Dans) 
 
Due to substrate availability, initial experiments were performed with Lipid II (Gln, 
Dans). A range of enzyme concentrations was tested against a single substrate 
concentration in order to establish direct proportionality between the amount of 
enzyme assayed and the rate measured. 1 µM Lipid II was chosen, as sufficient 
signal was observed and by significantly reducing the amount of Lipid II per 
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reaction, a greater number of experiments could be performed with the stock 
available. This is pertinent as the Lipid II substrates are costly to produce. 
 
50 µL reactions containing 1 µM Lipid II (Gln, Dans) in either PBP1a or PBP2a 
reaction buffer plus 0.1 mg.ml-1 hen egg-white lysozyme were initiated with the 
addition of 0, 0.02, 0.06, 0.1, 0.2, 0.4, 0.8 or 1 µM enzyme in triplicate. The reaction 
was monitored for 100 min and the rate in fluorescence change per second of the 
initial linear portion calculated (with the background rate of the control reaction 
without PBP subtracted). This was plotted against enzyme concentration to establish 
the relationship between enzyme concentration and transglycosylation rate (Figure 
4.17 black data points). 
 
A linear increase in rate was observed with increasing concentrations of PBP1a and 
PBP2a, to 0.2 µM PBP1a and 0.1 µM PBP2a (Figure 4.17 (b) and (d)). The 
relationship becomes non-linear at this point, dropping for PBP1a and more 
significantly with increasing PBP2a concentrations. To test whether this was due to 
lysozyme insufficiency, the same reaction was repeated in an identical manner, with 
an increase in lysozyme concentration to 0.5 mg.ml-1 (Figure 4.17 red data points). 
 
Increasing the lysozyme concentration had no significant effect on the relationship 
observed between enzyme concentration and reaction rate with 1 µM Lipid II (Gln, 
Dans) for either enzyme, thus demonstrating that the coupling enzyme was not the 
limiting factor at higher enzyme concentrations. 
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4.5.2.2 Comparison between transglycosylation rates with Lipid II (Glu, Dans) 
and Lipid II (Gln, Dans) 
 
Once sufficient Lipid II (Glu, Dans) was obtained, the same enzyme dependency 
experiments could be repeated. Reactions were exactly as previously described for 
the 0.1 mg.ml-1 lysozyme experiments in Section 4.5.2.1 but with a substrate 
concentration of 2 µM for both Lipid II (Glu, Dans) and Lipid II (Gln, Dans). This 
increased substrate concentration allows a greater range of enzyme concentrations (0, 
0.02, 0.06, 0.1, 0.2, 0.4, 0.8, 1, 1.5 and 2 µM) to be tested, and to observe whether 
the phenomenon observed in Section 4.5.2.1 applies at the higher substrate 
(a) 
(c) 
(b) 
(d) 
Figure 4.17: Rate of Lipid II (Gln, Dans) transglycosylation by S. pneumoniae PBP1a (a), (b) 
and PBP2a (c), (d) 1 µM Lipid II Lipid II (Gln, Dans) a) In 50 mM HEPES pH 7.5, 10 mM MgCl2, 
150 mM NaCl, 25% (v/v) DMSO, 0.02% (v/v) TX-100 with 0.1 mg.ml-1 lysozyme (black) or 0.5 
mg.ml-1 lysozyme (red) plus 0, 0.02, 0.06, 0.1, 0.2, 0.4, 0.8 or 1 µM PBP1a. b) In 50 mM HEPES pH 
7.5, 25 mM MgCl2, 200 mM NaCl, 25% (v/v) DMSO, 0.02% (v/v) TX-100 with 0.1 mg.ml-1 
lysozyme (black) or 0.5 mg.ml-1 lysozyme (red) plus 0, 0.02, 0.06, 0.1, 0.2, 0.4, 0.8 or 1 µM PBP2a. 
Reaction volume; 50 µL in a Greiner FLUOTRACTM 600 96-well plate. Excitation at 340 nm, 
emission at 521 nm with readings at 30 second intervals. RFU (relative fluorescence unit) change per 
second calculated from initial linear portion of time-course. Values represent mean ± standard 
deviation of triplicate reactions. Linear regression fitted to region with linear relationship (b) PBP1a: 
Black, 0.1 mg.ml-1 lysozyme Slope 125.8 ± 9.556, R2: 0.9612 ; Red, 0.5 mg.ml-1 lysozyme Slope 91.7 
± 9.531, R2: 0.9297 (d) PBP2a: Black, 0.1 mg.ml-1 lysozyme Slope 495.2 ± 42.36, R2: 0.9513 ; Red, 
0.5 mg.ml-1 lysozyme Slope 415.7 ± 64.35, R2: 0.8925 
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concentration. Reactions with both substrates were performed in the same 96-well 
plate to ensure comparable starting fluorescence values were measured, and therefore 
Lipid II concentrations. Two replicates were performed in each of two plates. Rate in 
RFU change per second of the initial linear portion of the reaction were calculated. 
This was plotted against enzyme concentration in µM (Figure 4.18). 
 
The same relationship between rate and enzyme concentration was observed as 
previously (Figure 4.17), with both Lipid II (Glu, Dans) and Lipid II (Gln, Dans) 
(Figure 4.18 (a) and (c)). An initial linear relationship was observed with increasing 
concentrations of PBP1a and PBP2a, to 0.4 µM PBP1a and 0.2 µM PBP2a (Figure 
4.18 (b) and (d)), double that observed with 1 µM Lipid II, thus implicating an 
(a) (b) 
(c) (d) 
* 
* 
* 
* 
Figure 4.18: Dependency of Lipid II (Glu, Dans) and Lipid II (Gln, Dans) transglycosylation on 
S. pneumoniae PBP1a ((a)and(b)) and PBP2a ((c)and(d)) concentration 2 µM Lipid II (Lipid II 
(Glu, Dans)(black) or Lipid II (Gln, Dans)(red)) (a) In 50 mM HEPES pH 7.5, 10 mM MgCl2, 150 
mM NaCl, 25 % (v/v) DMSO, 0.02 % (v/v) TX-100 with 0.1 mg.ml-1 lysozyme plus 0, 0.02, 0.06, 0.1, 
0.2, 0.4, 0.8, 1, 1.5 or 2 µM PBP1a. (b) In 50 mM HEPES pH 7.5, 25 mM MgCl2, 200 mM NaCl, 25 
% (v/v) DMSO, 0.02 % (v/v) TX-100 with 0.1 mg.ml-1 lysozyme plus 0, 0.02, 0.06, 0.1, 0.2, 0.4, 0.8, 
1, 1.5 or 2 µM PBP2a. Reaction volume; 50 µL in a Greiner FLUOTRACTM 600 96-well plate. 
Excitation at 340 nm, emission at 521 nm with readings at 30 second intervals. RFU change per 
second calculated from initial linear portion of time-course. Values represent mean ± standard 
deviation of 4 reactions. Initial linear portion of reaction fitted by linear regression (b) PBP1a: Black, 
Lipid II (Glu, Dans) Slope 7.418 ±3.077, R2: 0.8090 ; Red, Lipid II (Gln, Dans) Slope 89.79 ± 5.243, 
R2: 0.9302 (d) PBP2a: Black, Lipid II (Glu, Dans) Slope 75.33 ± 9.672, R2: 0.7654 ; Red, Lipid II 
(Gln, Dans) Slope 268.3 ± 13.69, R2: 0.9532. Students’ two-tailed t-test performed on (b) and (d) to 
determine statistical significance. * indicates a p value below 0.001. 
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importance of enzyme:substrate ratio in this phenomenon (below 5:1 Lipid II:PBP1a 
and 10:1 Lipid II:PBP2a). With  PBP1a and PBP2a enzymes, and both substrates, a 
reduction in rate was observed at higher enzyme concentrations (below 2:1 Lipid 
II:PBP1a and 5:1 Lipid II:PBP2a). These results are discussed further in Section 
4.6.3.1.1. 
 
4.5.3 Moenomycin inhibition of S. pneumoniae PBP1a and PBP2a 
 
Inhibition with the specific transglycosylase inhibitor, moenomycin, was confirmed 
for both PBP1a and PBP2a under the conditions for which the maximum rates were 
obtained in Section 4.5.2.2. 1 µM PBP1a or 400 nM PBP2a was added to initiate a 
reaction with 2 µM Lipid II (Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) in the 
relevant enzyme reaction buffer including 0.1 mg.ml-1 lysozyme and increasing 
concentrations of moenomycin (0, 0.2, 0.4, 0.5, 0.8, 5, 10 or 50 µM) in triplicate. 
Initial rates as RFU/second were calculated and percentage inhibition compared to 
the no moenomycin control determined. The data were fitted to a simple saturation 
model of inhibitor binding to a single site (Equation 1), which enabled IC50 values to 
be extracted (Figure 4.19) 
 
Equation 1:      %𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = !"".[!]!"!"![!] 
 
The IC50 values (Table 4.2) obtained are consistent with tight binding nature of 
moenomycin as an inhibitor. Perfect results would establish the IC50 as 50% of the 
enzyme concentration, which is close to the values seen for PBP1a. IC50 values for 
PBP2a were also within a range consistent with moenomycin as a tight inhibitor. No 
difference was observed between inhibition of Lipid II (Glu, Dans) and Lipid II (Gln, 
Dans). The difference in PBP2a is likely due to experimental error. 
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Substrate 
IC50 (µM) 
PBP1a PBP2a 
Lipid II (Glu, Dans) 0.373 ± 0.107 0.644 ± 0.242 
Lipid II (Gln, Dans) 0.431 ± 0.092 0.117 ± 0.117 
Table 4.2 IC50 values for moenomycin inhibition of S. pneumoniae PBP1a and PBP2a 
transglycosylation 
(a) 
(b) 
Figure 4.19: Inhibition of S. pneumoniae PBP1a (a) and PBP2a (b) activity by moenomycin. 2 µM 
Lipid II (Lipid II (Glu, Dans)(red) or Lipid II (Gln, Dans)(black)) (a) In 50 mM HEPES pH 7.5, 10 
mM MgCl2, 150 mM NaCl, 25% (v/v) DMSO, 0.02 % (v/v) TX-100 with 0.1 mg.ml-1 lysozyme plus 0, 
0.2, 0.4, 0.5, 0.8, 1, 1.5, 2, 5, 10 or 50 µM moenomycin and 1 µM PBP1a. (b) In 50 mM HEPES pH 
7.5, 25 mM MgCl2, 200 mM NaCl, 25% (v/v) DMSO, 0.02% (v/v) TX-100 with 0.1 mg.ml-1 lysozyme 
plus 0, 0.2, 0.4, 0.5, 0.8, 1, 1.5, 2, 5, 10 or 50 µM moenomycin and 400 nM PBP2a. Reaction volume; 
50 µL in a Greiner FLUOTRACTM 600 96-well plate. Excitation was at 340 nm, emission was at 521 
nm with readings at 30 second intervals. Inhibition was calculated as a percentage relative to rate 
without inhibitor and plotted against moenomycin concentration in µM. Values represent mean ± 
standard deviation of 3 reactions. R2 values of regression fit: a) Lipid II (Glu, Dans)(red): 0.8841, Lipid 
II (Gln, Dans)(black): 0.7873. b) Lipid II (Glu, Dans): 0.7274, Lipid II (Gln, Dans): 0.8211  
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4.5.4 Establishing kinetic parameters for Lipid II (Glu, Dans) and Lipid II (Gln, 
Dans) polymerisation by S. pneumoniae PBP1a and PBP2a  
 
In section 4.5.2 it was clearly established that amidated Lipid II is a preferable 
transglycosylase substrate for S. pneumoniae PBP1a and PBP2a. In order to 
investigate this further, the dependency on substrate concentration was investigated. 
Enzyme concentrations at which an appreciable rate (although not necessarily 
maximal) was detected in Figure 4.18 were chosen. A substrate ((Lipid II (Glu, 
Dans) or Lipid II (Gln, Dans)) concentration range from 1/2 to at least 20 times the 
enzyme concentration was tested where possible.  
 
Reactions were exactly as previously described for the 0.1 mg.ml-1 lysozyme 
experiments in Section 4.5.2, but with a range of substrate concentrations (made 
from larger stocks for accuracy)(methods Section 2.7.1). Initial rates of the linear 
portion of the time-course were calculated in RFU/sec/µg protein and plotted against 
substrate concentration (Figures 4.20 (PBP1a) and 4.21 (PBP2a)). Data were initially 
fitted to the Michaelis-Menten equation (Equation 2) using GraphPad Prism. Vmax 
and Km could be extracted from this. Note that Kcat could not be established by this 
method as the fluorescence change could not be accurately correlated with an amount 
of substrate used (Discussed in Section 4.6.2.2). 
 
Equation 2:     𝑉! = !!"#[!]!!![!] 
 
A sigmoidal relationship between substrate concentration and rate was noted in all 
but the PBP1a reaction with Lipid II (Glu, Dans). This may be because one catalytic 
cycle involves the consumption of two substrates, or indicate some cooperativity in 
activity. Therefore, the data were also fitted to two variations of the Michaelis-
Menten equation using GraphPad prism; one considering the binding and turnover of 
two substrates per reaction (Equation 3)(Zawadzke et al., 1991) and one taking into 
account cooperativity in activity (Equation 4)(Copeland, 2000). Although two Km 
values for the consumption of 2 molecules of substrate per catalytic turnover could 
be extracted (Equation 3), only S0.5 values could be quoted for the cooperative 
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equation (4) because the true meaning of this parameter is more obscure. The R2 
value for the equation fit to the data was used to determine the best fit. 
 
Equation 3:     𝑉! = !!"#[!]!!!(!)(!!(!)! ! )![!]! 
 
Equation 4:     𝑉! = !!"#[!]!!!.!![!]! 
 
In Figure 4.20 and 4.21, where data are best fitted to Equation 2 the curve is in black, 
Equation 3 in blue, and Equation 4 in red. Kinetic parameters extracted are detailed 
in Tables 4.3 and 4.4. The kinetic profiles for each enzyme are shown on the same 
Y-axis scale in Figure 4.22 for ease of comparison.  
 
 
The data could not be accurately fitted for 1 µM PBP1a with Lipid II (Glu, Dans) 
(Figure 4.20 (a)) as the substrate concentration tested were not high enough to allow 
the rate to plateau. However, it was fitted to equation 2 with an R2 value of 0.784 
indicating poor fit. Rates obtained with Lipid II (Gln, Dans) (Figure 4.20 (b)) were 
fitted to all three equations. Comparison within GraphPad Prism rejected the null 
hypothesis that Equation 2 was a better fit than Equation 3, however the null 
hypothesis that Equation 4 was a better fit than Equation 3 was neither accepted or 
(a) (b) 
Figure 4.20: Dependency of PBP1a transglycosylation on Lipid II (Glu, Dans)(a) and Lipid II 
(Gln, Dans)(b) concentrations. Reactions in 50 mM HEPES pH 7.5, 10 mM MgCl2, 150 mM NaCl, 
25% (v/v) DMSO, 0.02% (v/v) TX-100 with 0.1 mg.ml-1 lysozyme. Excitation at 340 nm, emission at 
521 nm with readings at 30 second intervals. RFU change per second per µg PBP1a calculated from 
initial linear portion of time-course. Values represent mean ± standard deviation of 3 reactions. Data 
best fitted to either Equation 2 (a) or Equation 3 (b).  (a) 1.5 µM – 30 µM Lipid II (Glu, Dans) and 1 
µM S. pneumoniae PBP1a. Fitted to equation 2. R2 = 0.784. (b) 0.1 µM – 8 µM Lipid II (Gln, Dans) 
and 0.1 µM S. pneumoniae PBP1a. Fitted to equation 3. R2 = 0.898. Note the different X and Y axis 
scales 
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rejected. Therefore it can be concluded that the data does not fit standard Michaelis-
Menten kinetics but there is no strong evidence for cooperativity. Values for Vmax 
and S0.5 extracted from Figure 4.20 are shown in Table 4.3. 
 
The data obtained with PBP2a were analysed in the same way (Figure 4.21). For 
both Lipid II (Glu, Dans) (a) and Lipid II (Gln, Dans) (b) a sufficient range of 
substrate concentrations were tested to observe a plateau in rate. In both cases a clear 
sigmoidal relationship was observed between substrate concentration and initial rate. 
Neither set of data would fit to equation 3 but both fitted to Equation 4 with high R2 
values. This is consistent with cooperativity in the dependency of PBP2a activity on 
Lipid II. The kinetic values extracted are shown in Table 4.4.  
 
Kinetic parameters for all four enzyme and substrate combinations are shown in 
Tables 4.3 and 4.4. Data for PBP1a with Lipid II (Glu, Dans) substrate is poor and 
therefore it cannot be used with much certainty. However, given that a maximal rate 
has not been reached at 30 µM, the Km will be at least 15 µM.  
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Figure 4.21: Dependency of PBP2a transglycosylation on Lipid II (Glu, Dans)(a) and Lipid II 
(Gln, Dans)(b) concentrations. Reactions in 50 mM HEPES pH 7.5, 10 mM MgCl2, 150 mM NaCl, 
25% (v/v) DMSO, 0.02% (v/v) TX-100 with 0.1 mg.ml-1 lysozyme. Excitation at 340 nm, emission at 
521 nm with readings at 30 second intervals. RFU change per second per µg PBP2a calculated from 
initial linear portion of time-course. Values represent mean ± standard deviation of 3 reactions. Data 
fitted to either Equation 4.  (a) 1 µM – 20 µM Lipid II (Glu, Dans) and 1 µM S. pneumoniae PBP2a. 
R2 = 0.962. (b) 0.1 µM – 8 µM Lipid II (Gln, Dans) and 0.06 µM S. pneumoniae PBP2a.. R2 = 0.984. 
Note the different X and Y axis scales. 
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Lipid II 
Vmax 
(RFU/sec/µg) 
Km (µM) Vmax/Km R2 of fit 
Glu, Dans* 2.22 ± 0.50 31.91 ± 11.70 0.07± 0.03 0.784 
Gln, Dans 9.18 ± 0.42 
1: 0.76 ± 0.70 
2: 1.55 ± 1.96 
5.92 ± 7.49^ 0.898 
Table 4.3: Kinetic parameters for PBP1a transglycosylase activity. Values for Vmax and Km 
extracted from the fits shown in Figure 4.20 and Vmax/Km calculated as a measure of catalytic 
efficiency. R2 of fit shown. * fit is poor and therefore the values are not very accurate for this row.^ 
value calculated using Km2 
Lipid II 
Vmax 
(RFU/sec/µg) 
S0.5 (µM) Vmax/S0.5 
Hill 
coefficient 
R2 of fit 
Glu, Dans 1.89 ± 0.05 4.85 ± 0.20 0.39 ± 0.02 3.20 ± 0.42 0.962 
Gln, Dans 46.85 ± 1.50 1.67 ± 0.17 28.05± 2.99 2.04 ± 0.17 0.984 
Table 4.4:  Kinetic parameters for PBP2a transglycosylase activity. Values for Vmax, K0.5 and the 
hill coefficient for cooperativity (h) extracted from the fits shown in Figure 4.21 and Vmax/K0.5 
calculated as a measure of catalytic efficiency. R2 of fit shown. 
 
Note that Km2 for PBP1a with amidated Lipid II is used for subsequent comparisons, 
as binding of the second substrate molecule is required for formation of the active 
enzyme complex. A lower S0.5(PBP2a) or Km2(PBP1a) for Lipid II (Gln, Dans) 
compared to Lipid II (Glu, Dans) was calculated showing that both have a higher 
affinity for the amidated substrate. The S0.5 (PBP2a) and Km2 (PBP1a) values for 
Lipid II (Gln, Dans) show comparable affinity and Vmax values identify the 
transglycosylation rate to be higher for both PBP1a and PBP2a with amidated Lipid 
II (notably so for PBP2a).  The difference in rates can be seen clearly in Figure 4.22 
with both substrates plotted on the same Y axis scale. Kcat/Km cannot be calculated 
without confirmation of the amount of Lipid II consumed in the time-course 
(discussed in Section 4.6.2.2), however Vmax/Km and Vmax/S0.5 were calculated as 
measures of catalytic efficiency, and are 85 and 72 fold greater with amidated 
substrate relative to the non-amidated substrate for PBP1a and PBP2a respectively.  
162 
 
The Hill coefficient (h) is used as a measure of cooperativity. When the value of h is 
greater than 1 this indicates positive cooperativity, where the binding of one 
molecule of substrate increases the affinity of another site for further binding (Segel, 
1993). The data were fitted to Equation 4 for PBP2a which gave a positive value for 
the hill coefficient irrespective of substrate amidation. There is uncertainty regarding 
cooperativity of PBP1a towards Lipid II (Gln, Dans) binding as the data fitted 
equally well to Equation 3. Equation 4 accounts for cooperativity between molecules 
of enzyme (discussed in Section 4.6.3.1.2).  
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Figure 4.22: Comparison of transglycosylation rates of Lipid II (Glu, Dans) and Lipid II (Gln, 
Dans). Data from Figure 4.20 and 4.21 plotted on the same Y-axis scale for each enzyme: (a) PBP1a 
(b) PBP2a. Lipid II (Gln, Dans) shown in red and Lipid II (Glu, Dans) in black  
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4.6 Discussion and future work 
 
This chapter has demonstrated the clear preference for amidated Lipid II by the 
bifunctional Class A PBPs from S. pneumoniae. The importance of the 
transmembrane spanning domain and dimerisation in this activity were also 
investigated. This section discusses the data in the context of its biological 
implications, and highlights the required future work leading from the findings.  
 
4.6.1 Expression and purification of S. pneumoniae PBP1a and PBP2a 
 
PBP1a and PBP2a from S. pneumoniae D39 were both expressed and purified 
successfully according to previously established protocols with minimal 
modifications as described in Section 4.3. The final purity was shown in Figure 4.5. 
The use of existing protocols gave confidence in the activity of proteins due to earlier 
experiments. 
 
4.6.2 Limitations of the assay systems used 
 
Before the results are discussed it is important to consider the limitations of the assay 
systems used. The methodological limitations of these assay systems were covered in 
a recent review (Galley et al., 2014; attached in Appendix 8). They apply here and 
are briefly mentioned throughout this section. However, further limitations were 
identified in the course of this investigation:  
 
Firstly, the use of a fluorescently labelled substrate variant may affect the observed 
results. It has previously been established that the use of substrates with 
modifications of the third position amino acid does not significantly affect the kinetic 
parameters measured (Schwartz et al., 2002; Zhang et al., 2007). However, given the 
findings here that modification to the second position amino acid has a significant 
effect on transglycosylase activity, and a recent crystal structure of Staphylococcus 
aureus MGT showing that the lactoyl group of the MurNAc sugar interacts with 
active site residues (Huang et al., 2012), a large dansyl fluorescence group on the 
third position may have more of an effect than first thought. The effect of this on the 
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results is mitigated slightly by the use of 100% dansylated Lipid II in all 
experiments. This allows relative comparisons between the amidated and non-
amidated substrates as the fluorescence group is present in both cases. 
 
An important observation was made during the MST experiment, with respect to 
stability of enzymes in the buffer conditions used for both assay types. The MST 
assays of PBP2a were successful in enzyme storage buffer, but protein aggregation 
was detected by this sensitive technique in the buffers used for transglycosylase 
assays. This could have been due to use of different enzyme preparations than for 
previous experiments, although aggregation was observed for both PBP1a and 
PBP2a, which makes this explanation less likely. The high DMSO concentration 
used in assays is the most probably reason for protein aggregation, although this is 
necessary for the observation of activity by the continuous assay (Section 6.4.4). 
Further work should test whether the DMSO concentration can be reduced for the 
SDS-PAGE assay to see if this is the case. 
 
The following sections detail the assay specific limitations identified.  
 
4.6.2.1 SDS-PAGE analysis of transglycosylase products 
 
This assay system is unique as it allows visualisation of complete reaction products 
and comparisons between enzymes and conditions, providing vital information 
regarding transglycosylase processivity. This quantitative data is very useful and has 
been used in many studies, including a comprehensive analysis of the chain lengths 
made by different transglycosylases (Wang et al., 2008). However, the method does 
have a number of limitations, which should be considered when interpreting results. 
 
• Samples are loaded with no colour dye as bromophenol blue affects the 
mobility of products. However, loading clear samples into clear wells can 
lead to loading errors, which cannot be seen. Using combs that make wider 
wells can help to overcome this, however it limits the number of samples 
possible on one gel.  
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• Reproducibility between gels can be problematic. This is particularly an issue 
with longer glycan chains that may not be able to enter the gel. Additionally, 
the distinct separation of short glycan chains is highly dependent on the 
voltage the gel is run at. Despite this, meaningful comparisons can still be 
made between samples on the same gel. 
• No standards for glycan chain length are available to date. Therefore 
quantification of polymer lengths is an estimate based on known values with 
the use of controls, unless very short chains are observed and distinguishable. 
• The resolution of longer chains is not possible with a standard gel system, in 
the same way that it is for the shorter chains. A smear is typically seen 
towards the top of the gel, and distinct chain lengths cannot be observed. This 
may be overcome using larger SDS-PAGE gels, or gradient gels.  
• Finally, quantitative data on reaction rates are not possible, apart from 
observations of relative rates using a time-course experiment, with low 
temporal resolution 
 
Despite these limitations the qualitative data available are incredibly useful, and have 
been used for many studies. Recent advancements at Warwick, with the availability 
of Dansylated Lipid II substrate (Section 3.6.2) and the installation of a more specific 
wavelength filter to the Syngene GeneSnap G-Box Gel Doc system, allows the 
detection of significantly lower quantities of polymerised product than previously 
possible (Abrahams, 2011). This has significantly reduced the Lipid II concentration 
required in assays with a subsequent reduction in enzyme, thus enabling more 
efficient use of the costly substrate.   
 
4.6.2.2 Continuous fluorescence assay 
 
Several assumptions must be made for the use of the continuous assay to follow 
transglycosylation. 
 
Using this assay for the study of processive enzymes adds a level of complication 
and uncertainty to the analysis. Lysozyme recognises heptasaccharide units as 
preferential substrates (ie. Lipid VI) and cleaves off two disaccharides (Vocadlo et 
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al., 2001). However, it is not known how the muramidase interacts with the 
extending chain whilst it is being polymerised. It is likely that the glycan chains are 
extended to a certain length out of the catalytic site of the PBP before the 
muramidase begins to cleave, which complicates analysis. However, the initial linear 
rate is measured to try to overcome this. A reduction in fluorescence is observed in 
assays if the muramidase is omitted (not shown) which could be due to the increased 
distance between dansyl groups and the lipid linker surrounded by a detergent 
micelle. It may also be as a result of quenching of dansyl groups on adjacent 
pentapeptide stems. The buffer conditions, particularly the presence of DMSO may 
have an effect on the fluorescence as well (Section 4.6.2).  
 
The full conversion of Lipid II to soluble disaccharide pentapeptide was not 
assumed, and therefore Kcat  (and subsequently Kcat/Km) could not be extracted from 
the data. Initial publication of this method (Schwartz et al., 2002), optimised with    
E. coli PBP1b was accompanied with a parallel HPLC analysis of products showing 
full conversion of Lipid II. However, subsequent studies (Helassa et al., 2012; Offant 
et al., 2010) have assumed full conversion based upon this, despite using different 
conditions. This assumption should be confirmed by HPLC methods for each 
enzyme tested. Particularly with the use of TX-100 as a detergent, both in this study 
and work by Helassa et al., (2012), as some Lipid II may be located inside the large 
detergent micelle and therefore is not available for polymerisation.  An attempt was 
made to analyse the starting and end products of reactions by TLC (not shown), 
which could simply and sensitively determine if all Lipid II has been used. However 
the presence of detergent (DDM) affected the mobility of species and no conclusions 
could be made. In order for Kcat to be calculated by this method, the full conversion 
of Lipid II should be confirmed by HPLC analysis. S0.5 or Km and Vmax values were 
calculated as ratios for comparison of substrates, but Kcat/Km would be a preferential 
comparison. 
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4.6.3 Characterisation of S. pneumoniae PBP1a and PBP2a transglycosylase 
activity 
 
4.6.3.1 The effect of Lipid II amidation on PBP1a and PBP2a activity 
 
Lipid II amidation has previously been shown to be important for S. pneumoniae 
PBP1a and PBP2a transpeptidase activity (Zapun et al., 2013). This study focused on 
the transpeptidase activity of the enzyme and did not separate the two enzyme 
activities of the bifunctional PBPs. The generally accepted theory is that ongoing 
transglycosylase activity is required for transpeptidation (Zapun et al., 2013) and 
therefore understanding the crucial first reaction is important in understanding the 
full assembly of peptidoglycan. The study reported in this chapter aimed to assay 
solely the transglycosylase activity of PBP1a and PBP2a to investigate substrate 
specificity.  
 
4.6.3.1.1 Amidated Lipid II is a preferential substrate for PBP1a and PBP2a 
transglycosylation 
 
Both assay systems showed a clear substrate specificity for amidated Lipid II as a 
transglycosylase substrate for PBP1a and PBP2a. Amidated Lipid II was 
polymerised more rapidly by both enzymes as demonstrated by both SDS-PAGE 
analysis and the continuous fluorescence assay (Figures 4.8, 4.9, 4.12, 4.17, 4.18, 
4.21, 4.22 and 4.23). The processivity of PBP1a catalysed transglycosylation was not 
affected as demonstrated by SDS-PAGE analysis of reaction products (Figure 4.6, 
4.7 and 4.8). PBP2a exhibited greater processivity with the preferred substrate, as 
demonstrated by SDS-PAGE analysis of reaction products (Figures 4.6, 4.7, 4.9, 4.10 
and 4.11). The faster rate observed could suggest that the increased processivity may 
be partly due to the speed of polymerisation.  
 
A linear relationship was observed between rate and PBP1a concentration up to a 5:1 
Lipid II:PBP ratio and up to 10:1 Lipid II:PBP for PBP2a (Figures 4.17 and 4.18). At 
ratios below this, the linear relationship was lost which may be because the 
transglycosylation reaction requires 2 substrates for every enzyme molecule. This 
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mechanism suggests several possible explanations for the relationship observed. 
Firstly, with high enzyme concentrations, a large proportion (approaching all) of the 
substrate will be bound to enzyme, which could result in quenching of the dansyl 
group. Alternatively, and perhaps additionally, the binding of 1 molecule of Lipid II 
to each enzyme molecule as the ratio approaches 1:1 would result in the insufficient 
formation of an active enzyme complex which requires 2:1 Lipid II: enzyme, and 
thus an inhibition of rate would be observed. The coupling system is unlikely to 
explain the reduction in rate seen at higher enzyme concentrations as a sigmoidal 
relationship between fluorescence and time was not observed, which would suggest 
that it is limiting, and increasing the lysozyme concentration in Figure 4.17 had no 
effect.   
 
There is evidence to suggest that PBP2a oligomerises above 500 nM (Section 4.4.6), 
in which case two enzyme molecules with a donor and an acceptor site each could 
bind up to 4 molecules of Lipid II at once to form an active complex. This may 
explain the reduction in rate as the Lipid II:PBP2a ratio approaches 4:1 (Figure 4.18 
(c). It may also explain the reduction in rate observed above 500 nM PBP2a 
generally, as a higher substrate concentration may be required to maintain sufficient 
levels of activity. The data presented in Figure 4.17 (c) support this hypothesis. This 
could be studied further by repeating the same experiment presented in Figure 4.18 
((c) and (d)) with a number of substrate concentrations.  
 
4.6.3.1.2 Extraction of kinetic parameter for PBP1a and PBP2a transglycosylase 
activity 
 
Analysis of the relationship between rate and substrate concentration enabled kinetic 
parameters to be extracted for both PBP1a and PBP2a (Figures 4.20, 4.21, 4.22 and 
Tables 4.3 and 4.4). An insufficient range of substrate concentrations was tested for 
PBP1a with Lipid II (Glu, Dans), which restricted the ability to fit the data to the 
Michaelis-Menten equation with high accuracy (Table 4.3). The Km value extracted 
of 31.91 µM, is much higher than that of 0.76 and 1.55 µM for the binding of the 
first and second substrate with amidated Lipid II, showing that PBP1a has a much 
higher affinity for the amidated substrate. The Vmax increase and catalytic efficiency 
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(measured by Vmax/Km) increase of approximately 5-fold and 85-fold respectively 
confirm Lipid II (Gln, Dans) to be a preferential substrate. The Lipid II (Glu, Dans) 
data could be fitted to standard Michaelis-Menten kinetics (Equation 2), but the 
binding and turnover of two substrates or cooperativity could not be distinguished 
between for Lipid II (Gln, Dans)(Equation 3 or 4). No published Km value of PBP1a 
transglycosylase activity exists for either substrate for comparison. The data 
presented for PBP1a with both substrates (Figures 4.20 and 4.22), has a reasonably 
high level of variation in it, possibly due to the errors associated with calculating 
rates of slow reactions in particular. This in addition to the need for higher substrate 
concentrations for Lipid II (Glu, Dans) means that kinetic parameters cannot be 
confidently extracted and compared for PBP1a. The experiments should be repeated, 
with higher enzyme concentrations if necessary, to confirm the findings.  
 
The data for PBP2a activity were fitted to a modified Michaelis-Menten equation 
taking into account cooperativity of substrate binding (Equation 4). The data fit to 
this very well, as opposed to the standard Michaelis-Menten equation (Equation 2) or 
a modified version taking into account each kinetic cycle involves consumption of 
two substrates (Equation 3). The inability to fit the data to Equation 3 may be due to 
cooperativity in activity, although sigmoidal data may also be observed because the 
substrate is not pure and the enzyme exhibits distinct catalytic efficiencies with 
different components within the substrate preparation. The method of synthesis of 
amidated and dansylated Lipid II, plus confirmation of the products be mass 
spectrometry (Appendix 6) suggest this is not the case. Additionally, a sigmoidal 
relationship was seen with 100% non-amidated Lipid II. The data fitted very well to 
the equation assuming cooperativity, as determined by the R2 values (Table 4.4). The 
Hill coefficient (h) of both were calculated as >1 showing positive cooperativity. 
This coefficient can also be used to estimate the number of binding sites involved in 
cooperativity (Segel, 1993). Interestingly, PBP2a at 1 µM was used for the Lipid II 
(Glu, Dans) test (h=3.20 ± 0.42) and at 60 nM for the Lipid II (Gln, Dans) study 
(h=2.04 ± 0.17). This could suggest the involvement of two sites in cooperativity at 
concentrations below the proposed Kd and 3 or 4 above it, although the error 
associated with the data should lead to caution with this theory. A fuller test of 
enzyme concentrations either side of the Kd for both Lipid II (Glu, Dans) and Lipid II 
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(Gln, Dans) transglycosylation could be carried out to investigate whether 
dimerisation affects cooperativity, or vice versa.  
 
The S0.5 values extracted show the amidated Lipid II substrate to have a higher 
affinity for PBP2a, and the Vmax demonstrates the much higher rate observed (almost 
25-fold faster with Lipid II (Gln, Dans)). Vmax/Km as a measure of catalytic 
efficiency was 72-fold higher for amidated Lipid II. This clearly demonstrates how 
preferential amidated Lipid II is as a substrate. Only Kcat values are available in the 
literature for PBP2a and therefore direct comparisons cannot be made. These values 
were also obtained by assuming full consumption of Lipid II, which affects their 
reliability (Di Guilmi et al., 2003; Helassa et al., 2012) (discussed in Section 
4.6.2.2).  
 
An interesting area of further work in relation to this data is the modelling of Lipid II 
concentrations within the pneumococcal cell and correlation with the exponential 
region of the graphs, where transglycosylase rate is increasing rapidly with respect to 
substrate concentration. This could elucidate methods of PBP regulation through 
substrate availability. However, analysis would not be trivial as Lipid II 
concentration is likely to vary between the inner and outer leaflet of the inner 
membrane and throughout the cell generally. Detailed modelling alongside 
microscopy to identify the location of Lipid II may enable this study to be 
performed.  
 
4.6.3.2 Role of the transmembrane region in PBP1a and PBP2a transglycosylase 
activity 
 
A previous study by Helassa et al., (2012) showed that removal of the 
transmembrane (TM) region of PBP2a gave a 4-fold decrease in glycan chain length 
produced with non-amidated Lipid II. This was replicated, and additionally shown to 
be the case with amidated Lipid II (Figure 4.10). However, both results were 
subsequently shown to be at least in part a result of the TX-100 concentrations used 
(Section 4.4.5). This could be explained by the presence of a membrane interacting 
region within the PBP2a transglycosylase domain (Di Guilmi et al., 1999), which 
171 
 
was shown to be hydrophobic and is therefore likely to be the part of the protein to 
interact with TX-100 detergent micelles following removal of the TM region. 
Therefore, the TX-100 micelle will surround the TM region in full-length PBP2a and 
the hydrophobic part of the transglycosylase domain in PBP2a-Δ77. This second 
interaction may affect the Lipid II-PBP2a interactions required for activity, and 
appears to lead to early release of product.  
 
The role of the PBP1a transmembrane spanning region (TM region) in 
transglycosylase activity was briefly investigated by SDS-PAGE analysis of reaction 
products (Figure 4.14). This has not been investigated to date, although the TM 
region has previously been demonstrated to be important for substrate interaction in 
Staphylococcus aureus MGT and E. coli PBP1b transglycosylase activity (Huang et 
al., 2012; Sung et al., 2009), and possibly S. pneumoniae PBP2a as discussed above. 
Removal of the TM region of PBP1a resulted in poor transglycosylase activity as 
identified by incomplete use of substrate in an overnight incubation. This was the 
case for both Lipid II (Glu, Dans) and Lipid II (Gln, Dans), despite the observed 
difference in the amount of substrate present (Section 4.4.7). This suggests that the 
TM region is important for PBP1a transglycosylase activity. Although a change in 
the interaction of the TX-100 detergent micelle with the ΔTM protein compared to 
full-length cannot be ruled out as for PBP2a above. The presence of a hydrophobic 
membrane interacting domain has not been demonstrated for PBP1a as for PBP2a 
and other bifunctional PBPs (Di Guilmi et al., 1999; Lovering et al., 2007; Sung et 
al., 2009). Further investigation is required to elucidate the importance of the TM 
region in PBP1a substrate interaction and transglycosylase activity.   
 
Since TX-100 is a mixture of molecular species and thus heterogeneous in nature, 
future studies of PBP1a and PBP2a may benefit from a more defined detergent-
protein in vitro system where the direct effects of the detergent relative to the 
enzyme activity may be investigated. 
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4.6.3.3 Oligomerisation of PBP2a  
 
In vitro cross-linking experiments and limited proteolysis suggest a self-association 
of PBP2a dependent on the TM spanning region, which stabilises the 
transglycosylase domain (Helassa et al., 2012). PBP2a oligomerisation was probed 
by a further two methods in this chapter (Section 4.4.6). A Kd of 500 nM was 
established by MST for full-length protein, and a value could not be obtained for 
PBP2a-Δ77 despite testing up to 64.95 µM. The Kd value is comparable to that of 
~100 nM measured for the Class A bifunctional E. coli PBP1b (Bertsche et al., 
2005), for which dimerisation has been shown by SPR to stimulate transglycosylase 
activity. Dimerisation has also been observed for E. coli PBP1a (Charpentier et al., 
2002). In this study, size exclusion chromatography was also performed for PBP2a 
FL and this identified a dynamic equilibrium between two species, estimated to be a 
dimer and a monomer. No peak was observed in the column flow-through showing 
that no higher order oligomers or aggregation products were present.  
 
The effect of dimerisation on PBP2a activity was not studied. This would be an 
interesting experiment in further work, particularly given the stimulated E. coli 
PBP1b transglycosylase activity upon dimerisation (Bertsche et al., 2005), and the 
possible cooperativity of the dependence of PBP2a on its Lipid II substrate (Section 
4.5.4.  
 
4.6.4 Comparison of PBP1a and PBP2a transglycosylase activity 
 
Differences were observed between the transglycosylase activities of PBP1a and 
PBP2a, and the effect of substrate modifications on each.  
 
SDS-PAGE analysis showed that PBP2a is a more processive transglycosylase under 
the conditions used. It produces longer glycan chains with both substrate variants 
than PBP1a and is further stimulated with the use of Lipid II (Gln, Dans) as a 
substrate.  
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Similarly the continuous fluorescence assay data (Section 4.5) shows that PBP2a 
transglycosylation is more efficient than PBP1a. Figure 4.18 shows that at a fixed 
substrate concentration of 2 µM, a similar maximal initial rate was measured for 
PBP2a and PBP1a, but at a much lower concentration of PBP2a (400 nM compared 
to 1 µM). Over double the amount of PBP1a is required to an equivalent rate with the 
same amount of substrate. PBP2a initial rates are severely affected at high enzyme 
concentrations with a fixed substrate concentration (Figure 4.18), whereas PBP1a 
rates are similarly affected but to a much lesser extent. This could be because PBP2a 
dimerises at higher concentrations and substrate binding leads to increased 
quenching or depletion of substrate required for the second substrate binding event 
required for catalysis (Section 4.6.3.1.1).  
 
Both enzymes have a higher affinity for Lipid II (Gln, Dans) than Lipid II (Glu, 
Dans), reflecting the situation in vivo where amidation is known to be essential 
(Zapun et al., 2013), and both PBP1a and PBP2a have a similar affinity for the 
amidated substrate. However, the increase in observed Vmax was much greater for 
PBP2a with Lipid II (Gln, Dans) than PBP1a, and the reduction in Km more 
significant for PBP1a.  
 
The relationship between substrate concentration and rate (Figures 4.20, 4.21 and 
4.22) gives evidence of cooperativity in PBP2a transglycosylase activity. 
Cooperativity of the donor and acceptor sites with respect to substrate binding has 
recently been observed for a monofunctional transglycosylase from Staphylococcus 
aureus (Bury et al., 2014), and dimerisation has been seen to stimulate E. coli PBP1b 
transglycosylase activity (Bertsche et al., 2005) although the recent crystal structure 
of E. coli PBP1b (Sung et al., 2009) shows the protein in a monomer form without 
the possibility for dimer formation within the crystal packing (Dr D. Roper, Personal 
Communication). There is no evidence of cooperativity of PBP1a activity with either 
Lipid II substrate. The possibility of dimerisation was not studied for PBP1a, and 
would be an interesting investigation for further work.  
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4.6.5 Biological implications 
 
The results discussed in Sections 4.6.3 and 4.6.4 show that the preference for 
amidated substrate by the S. pneumoniae Class A PBPs extends to their 
transglycosylase activity.  90% of the peptidoglycan in the pneumococcal cell wall is 
amidated (Bui et al., 2012) and the lipid II amidase is essential (Zapun et al., 2013), 
therefore this is clearly a physically small but highly significant chemical 
modification. Amidation has been shown to be essential for efficient peptidoglycan 
synthesis in vitro (Zapun et al., 2013) and also in vivo as non-amidated peptides were 
only found in monomeric muropeptides (Bui et al., 2012).  
 
The data in this chapter show that the recognition of amidated pentapeptides is 
important at the transglycosylation stage, and this increased catalytic rate may also 
have a subsequent effect on transpeptidation. Cross-linking enzymes may 
preferentially recognise amidated stem peptides, and this would be unsurprising 
given the proximity of the cross-linking reaction to the second position amino acid. 
However, the increased rate of glycan chain polymerisation (and processivity in the 
case of PBP2a) may also help to increase transpeptidation efficiency. An assessment 
of the influence on transpeptidase activity will be possible following the 
development of suitable transpeptidase assay technology. 
 
Differences were observed between PBP1a and PBP2a activity both generally, and in 
their response to amidated substrates (Sections 4.6.3 and 4.6.4). Current evidence 
suggests that PBP2a is the transglycosylase responsible for peripheral insertion of 
Lipid II into peptidoglycan and PBP1a for creation of the septum, although it has 
also been found peripherally (Massidda et al., 2013; Morlot et al., 2003). The greater 
processivity of PBP2a suggests it continuously inserts Lipid II into the sacculus to 
grow the cell. PBP2a was also a faster transglycosylase than PBP1a in this study, and 
this may suggest that a faster rate of peripheral insertion is required to elongate the 
cell sufficiently before the septum is formed. However, the presence of a histidine 
tag on the N-terminus of PBP1a should lead to care in making this comparison. The 
third non-essential transglycosylase in S. pneumoniae, PBP1b, has been shown to 
catalyse transglycosylation in vitro (Liu et al., 2006) but its location within the cell 
has not been identified. It would be of interest to see whether it functionally interacts 
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with PBP1a, PBP2a or both and whether each produces its own chains or extends 
those made by one of the other transglycosylases as seen for MGT and PBP2 in 
Staphylococcus aureus (Rebets et al., 2014).  
 
The recent identification of cooperativity between substrate binding in the donor and 
acceptor site in Staphylococcus aureus MGT (Bury et al., 2014) is of great interest 
and was suggested to be particularly important in initiation of transglycosylation and 
processivity. The identification of cooperativity in PBP2a suggests interaction 
between molecules in an oligomer. Both Staphylococcus aureus MGT (Chapter 5) 
and S. pneumoniae PBP2a make particularly long glycan chains in vitro, so a more 
detailed study into PBP1a cooperativity would help to identify if this is a mechanism 
used by more processive enzymes to maintain interaction with the growing chain, or 
for transglycosylation generally. 
 
4.6.6 Further work 
 
Despite the limitations of the methods used, interesting comparisons and conclusions 
with regards to S. pneumoniae transglycosylation could be made in the context of the 
current literature. However, it is clear that a better assay system that does not rely on 
fluorescence is required in parallel to confirm the findings. Previous attempts have 
coupled the release of undecaprenyl pyrophosphate during transglycosylation to a 
specific phosphatase PgpB (Touze et al., 2008) with subsequent detection of 
phosphate release (Abrahams, 2011). However, this was only possible in a stopped 
assay format due to the limiting activity of the phosphatase. Optimisation of 
conditions for PgpB activity may enable this to be developed into a continuous assay. 
Detection of the undecaprenyl pyrophosphate product of transglycosylation is a 
promising option for a continuous assay without the requirement for a fluorescently 
labelled substrate. One strategy could be through the use of compounds that bind to 
undecaprenyl pyrophosphate such as bacitracin (Manat et al., 2014). Modification of 
bacitracin with a fluorophore reporter could allow indirect monitoring of 
transglycosylation by binding to the released product. Alternatively, the 
undecaprenyl lipid linker could be modified, to directly follow release. Modifications 
to this part of the substrate have less of an effect on substrate recognition than those 
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on the pentapeptide (Liu et al., 2010). Although significant modifications to the lipid 
substrate, such as the replacement of undecaprenyl-pyrophosphate with para-
Nitrophenyl phosphate (p-NPP) (Liu et al., 2006), result in a complete loss of 
activity.  
 
Several lines of further work have been proposed throughout this section. The 
priority is to complete the analysis of PBP1a by the continuous fluorescence assay by 
extension of the substrate concentrations used, to enable full comparisons between 
the PBP1a and PBP2a activities. Testing the relationship between rate and substrate 
concentration at a range of enzyme concentrations above and below the Kd will allow 
the effect of PBP2a dimerisation on cooperativity to be elucidated. Using comparable 
enzyme concentrations for both enzymes and substrates will identify whether 
cooperativity is substrate or enzyme specific, or a general property of 
transglycosylases. So far, cooperativity in substrate binding for a monofunctional 
transglycosylase has been shown (Bury et al., 2014), but it has not been observed in 
kinetic studies. A repeat of this experiment for PBP2a could allow cooperativity 
within and between molecules to be distinguished. 
 
By confirming the level of conversion of Lipid II to soluble disaccharide, a full range 
of kinetic parameters could be obtained enabling differentiation between the effect of 
amidation on substrate interaction and turnover. Linked to this it would be interesting 
to structurally characterise the enzyme-substrate interactions involved. The crystal 
structure of Staphylococcus aureus MGT (Huang et al., 2012) shows the lactoyl 
group of the MurNAc sugar to interact with the active site, but no more is known 
about the interaction of the stem peptide given the limitations of the density for the 
lipid II substrate mimetic in the active site. This could be modelled computationally 
to identify possible interacting residues, which could be subsequently mutated to test 
their role. Additionally, the creation of a substrate analogue with at least the first two 
amino acids in the stem peptide could enable co-crystallisation with S. pneumoniae 
PBPs to identify important residues or regions.  
 
Further investigation into the role of the TM region on oligomerisation and enzyme 
activity is important. The evidence from this thesis and previous work by Helassa et 
al., (2012) suggests that PBP2a forms a dimer but the same investigation was not 
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performed for PBP1a. A study of the oligomeric state of PBP1a and the effect of 
both on transglycosylation (and subsequent transpeptidation) will be of great interest. 
It should be remembered that PBPs do not work in isolation and are likely to interact 
with a number of other cell division proteins, which may modulate their activity 
(Noirclerc-Savoye et al., 2013; Phillipe et al., 2014) 
 
Several lines of evidence implicate interactions between various PBPs (Section 
1.7.2.2) in vivo, and it is likely that the TM region as well as other parts of the 
protein, are involved in these interactions. An ultimate aim is the in vitro 
reconstitution of the cell wall synthetic complexes in S. pneumoniae. A crucial first 
step in this is investigation of the combined activities of PBPs and other cell wall 
proteins in peptidoglycan synthesis. For example, the effect of PBP2x activity on 
PBP1a transglycosylase activity could be investigated, as these have been shown to 
co-localise at points in the cell cycle. The combined functional role of 
Staphylococcus aureus transglycosylases has been identified (Rebets et al., 2014). 
Although evidence suggests PBP1a and PBP2a localise separately in the 
pneumococcal cell (Morlot et al., 2003), this investigation only looked at a snapshot 
in the cell division cycle, and recent studies have suggested that the cell wall 
complex is more mobile (Tsui et al., 2014). There are likely a plethora of 
coordinated interactions both spatially and temporally regulated throughout the cell 
cycle. 
 
Although Kcat values could not be calculated for the enzymes in this study, previous 
work has shown the in vitro activity of PBPs to be far below that required to support 
life. For example, E. coli PBP1b catalyses 0.8 transglycosylase 
reactions/minute/molecule in vitro, whereas 300 would be required to support growth 
and division (Vollmer and Höltje, 2004). Whilst this is not surprising given the 
removal of the enzyme from its usual interacting partners, many of which are not 
known (Section 7.1.4), a movement towards a more biologically relevant assay 
system is paramount. Several methods could be attempted to achieve this;  
 
The inclusion of the S. pneumoniae cytoplasmic membrane phospholipids; 
cardiolipin and phosphatidyl glycerol (Brundish et al., 1967) into assays could help 
to stimulate PBP activity by providing a more biologically relevant system. This 
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method has been successful for E. coli PgpB (Abrahams, 2011) and S. pneumoniae 
tRNA-dependent ligase MurM (Dr A. Lloyd, Unpublished work) previously. 
 
Purification of PBPs using the novel Styrene Maleic Acid copolymer Lipid Polymer 
(SMALP) technique could help to stimulate their activity by removing the 
requirement for detergent extraction for study. SMALP under the correct conditions 
can form discoidal nanostructures and encapsulate the protein from the membrane, a 
more biologically relevant system than detergent micelles. This has been used to 
purify active proteins from liposomes (Jamshad et al., 2011; Knowles et al., 2009; 
Orwick-Rydmark et al., 2012), overexpressed eukaryotic and prokaryotic proteins, as 
well as functional complexes from intact drug resistant staphylococcal cells (Paulin 
et al., 2014 (Appendix 8)). This could be used to isolate complexes of PBPs with the 
rest of the associated cell wall synthetic machinery following overexpression in E. 
coli strains, or from pneumococcal strains. Proteins purified in this way could then 
be reconstituted into defined vesicles with known and controlled lipid components, 
mimicking the in vivo environment.  
 
4.6.7 Conclusions 
 
The results shown in this chapter add significantly to the knowledge of 
transglycosylation by the S. pneumoniae Class A PBPs. Either PBP1a or PBP2a must 
be present in pneumococcal cells for viability, and are proposed to have different 
roles in cell growth and division. This study has shown for the first time that the 
activity of Gram positive Class A transglycosylase activity is affected by amidation 
of the position two stem peptide amino acid and that PBP2a is both more processive 
and more efficient under the conditions used. Amidation of the stem peptide 
glutamate has more of an effect on transglycosylase processivity and rate of PBP2a , 
but a greater impact on the Km of PBP1a which further supports the theory of their 
varied roles. The relatively minor modification of glutamate to glutamine in the stem 
peptide has a very significant role in PBP activity.  
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Chapter 5. Enzymology of transglycosylation: the 
characterisation of Staphylococcus aureus transglycosylases 
and novel inhibitors of their activity 
 
5.1 Introduction 
 
Staphylococcus aureus is a globally important opportunistic pathogen (Section 1.9). 
A greater understanding of the mechanisms by which this bacterium builds its cell 
wall is of fundamental interest, and could aid in the development of new antibiotics 
in the future. 
 
5.1.1 Peptidoglycan modifications in Staphylococcus aureus 
 
Three main chemical modifications have been identified in mature peptidoglycan of  
Staphylococcus aureus;  
• O-acetylation of glycan chain muramyl sugar ring C6 hydroxyl groups by the 
oatA gene product (Bera et al., 2005),  
• Addition of a pentaglycine interpeptide bridge by the FemXAB 
peptidyltransferases (Ling and Berger-Bächi, 2003; Rohrer and Berger-Bächi, 
2003; Schneider et al., 2004; Strandén et al., 1997; Tschierske et al., 1999),  
• Stem peptide modification (amidation) of D-glutamate at position 2 to D-
isoglutamine by the MurT/GatD complex (Figueiredo et al., 2012; Münch et 
al., 2012).  
 
Both amidation and the interpeptide bridge are essential for full expression of 
methicillin resistance in MRSA (Münch et al., 2012; Rohrer and Berger-Bächi, 
2003). Depletion of amidation, from the normally almost completely isoglutamine 
containing state (Schleifer and Kandler, 1972) reduces growth rate and increases 
susceptibility to both β-lactams and lysozyme in MRSA strains (Figueiredo et al., 
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2012). This relatively minor chemical modification has hugely significant effects on 
Staphylococcus aureus viability and antibiotic resistance. 
 
5.1.2 Staphylococcus aureus penicillin-binding proteins 
 
β-lactam sensitive strains of Staphylococcus aureus possess 4 PBPs; one class A 
bifunctional (PBP2), two class B monofunctional transpeptidases (PBP1, 
PBP3)(Pereira et al., 2007; Pinho et al., 2000; Sauvage et al., 2008) and one low 
molecular weight type 5 PBP (PBP4), which is unusual in displaying transpeptidase 
activity (Kozarich and Strominger, 1978; Qiao et al., 2014; Wyke et al., 1981). This 
is important for maintenance of the high level of cross-linking (up to 95%) observed 
in Staphylococcus aureus peptidoglycan (Gally and Archibold, 1993) and is 
suggested to be the mechanism by which PBP4 contributes to β-lactam resistance in 
community acquired MRSA infections (Kozarich and Strominger, 1978; Memmi et 
al., 2008). Methicillin resistant strains have an additional acquired Class B 
transpeptidase, PBP2a, the expression of which is induced in the presence of β-
lactams and it subsequently forms peptidoglycan in a cooperative manner with PBP2 
(Pinho et al., 2001). This interaction is important for the enzymatic activities of both 
proteins as demonstrated by the dramatically reduced MIC for methicillin upon 
inhibition of PBP2 transglycosylase activity (Pinho et al., 2001).  
 
The single bifunctional penicillin-binding protein; PBP2 along with two additional 
monofunctional transglycosylases; MGT and SgtA catalyse polymerisation of Lipid 
II into the glycan chains of peptidoglycan (Reed et al., 2011; Wang et al., 2001). 
PBP2 is essential for viability in susceptible strains and in resistant strains upon β-
lactam treatment (Pinho et al., 2001). MGT and SgtA have been shown to be 
nonessential in methicillin susceptible Staphylococcus aureus (MSSA). However, 
MGT becomes essential for viability in the absence of PBP2 transglycosylase 
activity where SgtA remains nonessential (Reed et al., 2011). This may be due to the 
inability of SgtA to compensate for MGT or PBP2 activity due to differential 
expression in the cell cycle.  
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The current catalytic model for transglycosylation by PBPs (Section 1.7.3) is that the 
formation of long carbohydrate polymers of β-1,4-linked N-acetylglucosamine 
(GlcNAc) and N-acetylmuramic acid (MurNAc) involves an initiation phase (two 
Lipid II molecules bind to the donor and acceptor active sites) and an elongation 
phase (the addition of further Lipid II monomers). The processivity demonstrated by 
the transglycosylases appears to be tightly regulated between different enzymes and 
species, by a yet unknown mechanism. The interactions of Staphylococcus. aureus 
PBP2, MGT and SgtA, along with other cell wall synthetic enzymes (PBP1 and 
PBP2a) has been demonstrated (Reed et al., 2011). These have recently been shown 
to include interactions with wall teichoic acid (WTA) (Farha et al., 2013) providing 
further evidence for the existence of a large complex responsible for the highly 
coordinated process cell wall synthesis in vivo (Leski and Tomasz, 2005).  
 
5.1.3 Studying the Staphylococcus aureus PBPs 
 
The importance of Lipid II amidation in Staphylococcus aureus cell wall viability is 
clear (Figueiredo et al., 2012; Münch et al., 2012), and therefore delineation of the 
interaction between cell wall biosynthetic enzymes and amidated Lipid II is 
imperative for an understanding of staphylococcal peptidoglycan synthesis. Now, 
particularly given the identification of the crucial role of amidation in the 
transglycosylase activity of S. pneumoniae PBPs, the parallel investigation in 
Staphylococcus aureus is of great interest.  
 
5.1.4 Transglycosylase inhibitors 
 
Several comprehensive reviews of transglycosylase inhibitors have been published to 
date, including Halliday et al. (2006),  Ostash and Walker (2005) and recently Galley 
et al. (2014), all highlighting these enzymes as promising targets for future 
antimicrobial discovery. Inhibition of the extracellular steps in cell wall synthesis has 
been a successful strategy historically, with the well-known β-lactam class of 
antibiotics targeting transpeptidation. Transglycosylases can be inhibited by direct 
targeting of the enzyme, or through limiting the availability of the Lipid II substrate 
(Figure 5.1). Several classes of antibiotics bind to the peptidoglycan precursor, Lipid 
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II, inhibiting cell wall synthesis, such as glycopeptides, ramoplanin, type B 
lantibiotics, mannopeptimycins and recently identified, teixobactin (Breukink et al., 
2003; Chatterjee et al., 2005; Ling et al., 2015; Kahne et al., 2005; Ruzin et al., 
2004; Walker et al., 2005).  
 
No compounds that directly bind to transglycosylases have been developed for 
human use to date, although the natural product inhibitor moenomycin strongly 
validates the classification of these enzymes as antibiotic targets (Figure 5.1). 
Moenomycin, is a glycolipid antibiotic produced by various Streptomyces species. It 
is active against a large number of Gram-positive bacteria (Welzel, 2005) and 
recently identified as active against the Gram-negative multidrug resistant 
Helicobacter pylori (Tseng et al., 2014). Moenomycin mimics the structure of the 
product of a transglycosylation reaction between two molecules of lipid II (referred 
to as Lipid IV) and blocks the donor site of the transglycosylase. However, its poor 
pharmacokinetic properties including a long half-life and poor absorption have 
prevented clinical development for use in humans. The use of moenomycin in animal 
feed as a growth promoter, has not resulted in development of resistance to the drug 
in contrast to the use of other antimicrobials which has commonly resulted in rapid 
resistance development. In vitro selection of moenomycin resistance has been shown 
to occur at only very low frequency (Rebets et al., 2014) and even then, without 
horizontal gene transfer between organisms (Butaye et al., 2003). The structure of 
LII 
TP 
TG 
Moenomycins 
Glycopeptides 
Ramoplanin Nisin 
Mannopeptimycins* 
Type B 
lantibiotics 
Teixobactin* 
Figure 5.1: Inhibitors of transglycosylation. Known inhibitors of bacterial transglycosylases 
illustrated for a bifunctional penicillin-binding protein. TG; transglycosylase domain. TP; 
transpeptidase domain. LII: Lipid II. Arrow indicates presumed stage of intervention where known. 
* indicates unknown position of intervention  
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moenomycin along with its biosynthesis and chemical properties has recently been 
extensively reviewed (Ostash and Walker, 2010).  
 
The lack of natural resistance to moenomycin, plus the theory that antibiotics 
targeting the transglycosylase step of peptidoglycan synthesis may be less prone to 
the development of resistance as the polysaccharide backbone is not altered between 
wild-type and antibiotic resistant strains (Ritter and Wong, 2001), suggest 
transglycosylases to be good antibiotic targets. Additionally the 5 motifs of the 
transglycosylase domain are highly conserved (Huang et al., 2012). These reasons 
make the transglycosylases very promising leads for drug development, as shown 
recently by Zuegg et al. (2015) (Section 5.7) 
 
A better understanding of the mechanisms by which Staphylococcus aureus 
synthesises the carbohydrate polymer of its cell wall by transglycosylation will 
enable the future design of novel inhibitors against this promising target. This 
chapter details efforts to understand the substrate specificity of the Staphylococcus 
aureus transglycosylases PBP2 and MGT, and identifies two new inhibitors of MGT 
glycan chain polymerisation. 
 
5.2 Experimental Aims 
 
• To express and purify MGT and PBP2 from Staphylococcus aureus Mu50. 
• To establish optimal conditions for the study of MGT and PBP2 
transglycosylase activity by SDS-PAGE separation.  
• To examine the role of Lipid II amidation on transglycosylase activity of 
MGT and PBP2.  
• To establish conditions for observation of transglycosylase activity of MGT 
by a continuous fluorescence assay. 
• To characterise novel carbohydrate based putative transglycosylase inhibitors 
in vitro  
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5.3 Expression and purification of the Staphylococcus aureus Mu50 
transglycosylases; MGT and PBP2 
 
In order to study the enzymatic activity of the Staphylococcus aureus 
transglycosylases, the extracellular domains of MGT and PBP2 from the methicillin- 
and vancomycin intermediate (VISA) resistant Mu50 strain (Hiramatsu et al., 1997) 
were expressed and purified. Constructs for expression were obtained from Dr K. 
Abraham (University of Warwick) and Dr N. Strynadka (UBC, Canada), and are 
detailed in Table 5.1. 
 
Construct Selection Source 
pET46::mgt-Δ67 Ampicillin Dr K. Abrahams (University of Warwick) 
pET41a::pbp2-Δ59 Kanamycin Dr N. Strynadka (UBC, Canada) 
Table 5.1 Gene constructs provided for expression and purification of Staphylococcus aureus 
Mu50 transglycosylases 
 
5.3.1 Expression and purification of Staphylococcus aureus MGT-Δ67 
 
Expression and purification of MGT-Δ67 was as described in (Abrahams, 2011), 
with a single modification. Here, IMAC (Section 2.4.3.1) was on a 5 mL HiTrap 
TALON® crude column (GE Healthcare) on an ÄKTApurifier 100 (GE Healthcare) 
pre-equilibrated and washed with PBS + 150 mM NaCl before elution with a linear 
gradient of 0 – 300 mM imidazole in the same buffer. A high level of purity was 
achieved as shown in Figure 5.4.  
 
5.3.2 Expression and purification of Staphylococcus aureus PBP2-Δ59 
 
Expression and purification of PBP2-Δ59 was as previously described in Lovering et 
al., (2007) with the following alterations: a second Superdex 200 gel filtration 
purification was carried out by pooling fractions from the first fractionation on this 
column, concentrating them to a small volume and reapplying to the column. 
Following buffer exchange to remove salt using a PD-10 desalting column (Section 
2.4.3.4), a 1 mL ResourceQ column (GE Healthcare) was used as a replacement for 1 
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mL MonoQ anion exchange and run in an identical manner, with a salt gradient from 
0-600 mM NaCl. Despite the modification of the protocol to include the addition of 
cOmplete™ EDTA-free Protease Inhibitor Cocktail (Roche), and all steps being 
carried out at 4°C, a high level of protein degradation was observed (Figure 5.2). A 
large amount of PBP2-Δ59 did not bind to the ResourceQ column, which may 
suggest it is incorrectly folded, as this method of purification has been used 
previously for this protein. 
 
Due to these issues, and as PBP2-Δ59 was required for activity assays rather than 
structural analysis, the gel filtration and anion exchange steps were excluded, and 
protein purified by a single IMAC step (Section 2.4.3.1) in order to minimise 
handling, shortening the overall time period of purification that may have contributed 
to the protein degradation observed. IMAC was conducted on a 5 mL HiTrap column 
(GE Healthcare) at 4°C as described by Lovering et al., (2007) with a stepwise 
elution at 20 mM, 50 mM and 100 mM imidazole (Figure 5.3). The second eluted 
peak (ii) was selected as the first did not bind as strongly to the resin, and the third 
peak contained very little PBP2-Δ59. Peak (ii) was buffer exchanged by PD-10 
Desalting column (GE Healthcare) to remove imidazole. The final protein in 10 mM 
Tris pH 8, 0.2 M NaCl and 0.28 mM LDAO was flash frozen in liquid nitrogen and 
stored at -80°C. 
 
L FT Mr 1 2 3 4 5 6 7 8 9 10 11 
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45 
30 
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(a) (b) 
(i) 
(ii) (iii) 
(i) (ii) (iii) 
Figure 5.2: Purification of Staphylococcus aureus Mu50 PBP2-Δ59 with a final anion exchange 
step. (a) Anion exchange chromatogram using a ResourceQ column with a stepwise elution up to 600 
mM NaCl. 3 main peaks were identified by (i), (ii) and (iii). The blue and red traces refer to absorbance 
at 280 and 254 nm respectively.b) 12% SDS-PAGE Coomassie-stained gel showing the three main 
peaks from anion exchange. Mr, molecular weight markers (kDa); L, protein loaded onto column 
following IMAC, and 2 rounds of gel filtration; FT, protein which did not bind to the ResourceQ 
column; (i) 1,2, peak (i) from (a); (ii) 3-7, peak (ii) from (a); (iii) 8-11, peak (iii) from (a). Location of 
PBP2-Δ59 indicated by arrow on the gel. 
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Figure 5.4: 12% Coomassie–stained gel of the final 
purity of Staphylococcus aureus transglycosylases to 
be studied. Mr, Molecular weight markers (kDa). Lanes 
are labelled with the relevant PBP.  
 
 
5.3.3 Final purity of Staphylococcus aureus Mu50 MGT-Δ67 and PBP2-Δ59 
 
Staphylococcus aureus MGT-Δ67 and PBP2-Δ59 were expressed as above. The final 
purity of both recombinant proteins is shown in Figure 5.4. 
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(iii) 
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Figure 5.3: Purification of Staphylococcus aureus Mu50 PBP2-Δ59 by a single IMAC step. (a) 
IMAC chromatogram using a 5 mL HiTrap column with a stepwise elution with 20 mM (i), 50 mM (ii) 
and 100 mM (iii) imidazole. The blue and red traces refer to absorbance at 280 and 254 nm 
respectively. b) 12% SDS-PAGE Coomassie-stained gel showing the three main peaks from IMAC 
purification. Mr, molecular weight markers (kDa); W, elution from extensive buffer exchange washing 
step; (i) 1-6, fractions from peak (i) at 20 mM imidazole; (ii) 7-10, fractions from peak (ii) at 50 mM 
imidazole; (iii) 11-13, fractions from peak (iii) at 100 mM imidazole. Location of PBP2-Δ59 indicated 
by arrow on the gel. 
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5.4 Analysis of Staphylococcus aureus MGT-Δ67 transglycosylase 
products by SDS-PAGE and continuous fluorescence assay 
 
Observation of MGT-Δ67 transglycosylase activity was documented previously 
(Abrahams, 2011; Terrak and Nguyen-Distèche, 2006) and as a result, conditions 
were available as a starting point for this study. MGT-Δ67 was expressed and 
purified in the same manner as before (Abrahams, 2011) and therefore it was 
expected that transglycosylation would be observed under the same conditions.  
 
The conditions used previously for transglycosylase assays (Abrahams, 2011; Terrak 
and Nguyen-Distèche, 2006), and initially here were 20 mM Tris pH 8.0, 10 mM 
MgCl2, 0.1% (w/v) DDM, 20% (v/v) DMSO, 0.05% (v/v) decyl PEG. Enzyme and 
Lipid II were incubated at 20°C for 1 hour followed by 60°C for ten minutes at 
which point samples were centrifuged at 13,000 rpm to remove protein.  
 
5.4.1 SDS-PAGE separation of MGT-Δ67 transglycosylase products 
 
The products of Lipid II polymerisation were initially analysed by SDS-PAGE 
separation. Previous work was conducted with [14C]-Lipid II, with detection by 
tritium phosphor screen (Abrahams, 2011). The use of dansylated Lipid II (Section 
3.6.2) as in Chapter 4, enabled more rapid observation of results, and the use of a 
short-pass filter and blue light convertor within a Syngene GeneSnap G-Box Gel Doc 
system allowed small quantities of Lipid II to be used. Previous experiments required 
the use of 4.4 mM Lipid II to enable a signal to be observed following 
autoradiography. Initial fluorescence assays were carried out with Lipid II (Glu, 
Dans) at a concentration of 130 µM.  
 
5.4.1.1 Dansylated Lipid II as a substrate for Staphylococcus aureus MGT-Δ67 
  
Previous work has demonstrated the ability of the S. pneumoniae transglycosylases 
to polymerise Lipid II (Glu, Dans) (Chapter 4 and references therein). Therefore it 
was initially surprising that preliminary assays with MGT-Δ67 demonstrated no 
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transglycosylase activity with the same substrate. An assay was subsequently 
conducted using varying ratios of labelled and non-labelled Lipid II in order to 
identify whether the lack of activity was enzyme or substrate specific. Reactions 
containing 130 µM total Lipid II in 30 µL reaction buffer including 45 µM MGT-
Δ67 were incubated as described above. Lipid II was either 100% Lipid II (Glu, 
Dans), 50:50 Lipid II (Glu, Dans):Lipid II (Glu), 20:80 Lipid II (Glu, Dans):Lipid II 
(Glu), 10:90 Lipid II (Glu, Dans):Lipid II (Glu), or 100% Lipid II(Glu). The dansyl 
group enabled the fluorescent lipid II to be detected, and a fluorescent analogue of 
vancomycin (which binds to the terminal D-Ala-D-Ala of the pentapeptide stem 
(Nieto and Perkins, 1971)): VanFL (BODIPY FL conjugate of vancomycin) was 
used post reaction to detect the non-labelled Lipid II in polymers. This was shown 
previously to be sufficiently sensitive for detection of glycan polymers of MGT-Δ67 
(Abrahams, 2011).  
Reactions were split into two 15 µL aliquots, and half treated with 24 µM VanFL for 
5 min at room temperature in the dark. The VanFL treated and un-treated samples 
were analysed by SDS-PAGE and fluorescence of both dansyl and VanFL detected 
by blue light converter and short-pass filter for fluorescence at 521 and 512 nm 
respectively.   
(a) (b) 
A B C D E F A B C D E F 
i 
iii 
ii 
Figure 5.5: Lipid II (Glu, Dans) as a substrate for MGT-Δ67 transglycosylation. 130 µM total 
Lipid II was polymerised with 45 µM MGT-Δ67: A, 100% Lipid II (Glu, Dans); B, 50:50 Lipid II (Glu, 
Dans):Lipid II (Glu); C, 20:80 Lipid II (Glu, Dans):Lipid II (Glu); D, 10:90 Lipid II (Glu, Dans):Lipid 
II (Glu); E, 10:90 Lipid II (Glu, Dans):Lipid II (Glu) no enzyme control; F, 100% Lipid II(Glu). 
Reactions were split and products of transglycosylation were separated on a 8.5% T/2.7% C SDS-
PAGE gel with (b) or without (a) treatment with 24 µM VanFL. Dansyl fluorescence at 521 nm, and 
VanFL at 512 nm was detected using a blue light converter and short pass filter on a GeneSnap Gel 
Doc. (i) denotes unpolymerised Lipid II; (ii) glycan chains of varying lengths (iii) denotes where high 
molecular weight material, unable to enter the gel would be found. 
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Figure 5.5 demonstrates that MGT-Δ67 will not use 100% dansyl labelled Lipid II as 
a substrate (Figure 5.5(a) A and (b) A), but will polymerise it when mixed with non-
labelled Lipid II (Lane B, C, D). Lane F shows that MGT will polymerise the more 
native non-fluorescent Lipid II. S. pneumoniae bifunctional Class A PBPs; PBP1a 
and PBP2a (with and without the transmembrane spanning region) will polymerise 
100% labelled Lipid II, and this suggests that the larger two domain PBPs are able to 
accommodate the dansyl fluorescence group more easily. Previous work 
demonstrating that fluorescently labelled Lipid II does not significantly affect 
transglycosylation kinetic parameters was only with bifunctional PBPs (Schwartz et 
al., 2002; Zhang et al., 2007), which makes this an important observation for the use 
of fluorescently labelled substrates.  
 
The detection of both dansyl and VanFL fluorescence in Figure 5.5 (b) (as 
wavelengths for detection are close so both would be detected) and detection of only 
a proportion of all material through dansyl fluorescence in Figure 5.5 (a) does not 
allow direct comparisons between amounts of Lipid II polymerised to be made 
between all of the conditions. However, it is clearly demonstrated that 100% Lipid II 
(Glu, Dans) was not polymerised into glycan chains by MGT-Δ67. 
 
5.4.1.2 Requirement of MGT-Δ67 for DDM in transglycosylase assay buffer 
 
The use of different detergents for Lipid II and enzyme will lead to mixed micelles 
which may result in mixing effects such as those observed in Section 6.4.4, which 
could affect future continuous fluorescence assays. Therefore, the requirement for 
0.1% (w/v) DDM in the assay buffer in addition to 0.05% (v/v) decyl PEG was 
tested in 15 µL assays performed as in Section 5.4.1.1 with a 50:50 mix of Lipid II 
(Glu, Dans): Lipid II (Glu). Reaction buffers were as before (Section 5.4) with and 
without 0.1% (w/v) DDM and control reactions without the addition of 45 µM MGT 
were included (Figure 5.6). Gel imaging was by detection of dansyl fluorescence.  
 
DDM was found to have little difference on the extent of polymerisation (Figure 
5.6). Slightly more starting material was present in the absence of DDM, however, 
the smear of product towards the top of the gel is more intense also, suggesting an 
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inaccuracy in gel loading. Consequently, DDM was omitted from reaction buffers as 
its removal did not impact upon transglycosylase activity and removed the unknown 
potential for complication of the results by the formation of mixed micelles which 
could have  significant effects on assay read-outs. 
 
5.4.1.3 Cloning and expression of  Staphylococcus aureus Mu50 MGT-Δ28 
 
Following unsuccessful attempts to polymerise neat Lipid II (Glu, Dans) with MGT-
Δ67 (Section 5.4.1.1), and the discovery that a construct containing the amino-
terminal membrane spanning region of MGT starting at residue 28 has catalytic 
activity ten times faster than the -Δ67 version (Huang et al., 2012), a “full-length” 
MGT construct was cloned, expressed and purified. The sequence encoding residues 
i!
iii!
ii!
+DDM -DDM 
LII 
only  
LII & 
MGT  
LII 
only  
LII & 
MGT  
Figure 5.6: Requirement of DDM for MGT-Δ67 transglycosylation. 130 µM total Lipid II 
(50:50 Lipid II (Glu,Dans): Lipid II (Glu)) was polymerised with 45 µM MGT-Δ67 with or 
without 0.1% (w/v) DDM as indicated below the gel. LII only: 130 µM Lipid II mix plus enzyme 
storage buffer. LII & MGT; 130 µM Lipid II mix plus 45 µM MGT-Δ67. Products of 
transglycosylation were separated on a 8.5% T/2.7% C SDS-PAGE gel. Dansyl fluorescence at 
521 nm was detected using a blue light converter and short pass filter on a GeneSnap Gel Doc. (i) 
denotes unpolymerised Lipid II and (ii) glycan chains of varying lengths . (iii) denotes where high 
molecular weight material, unable to enter the gel would be found. 
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Q28-R269 from Staphylococcus aureus Mu50 mgt was cloned into the pET15b 
vector as described in Section 2.3 and by Huang et al. (2012). Successful cloning 
was confirmed by sequencing. Residues 1-27 were not included as the full-length 
protein was easily degraded. pET15b::mgt-Q28-R269 will be referred to as 
pET15b::mgt for the remainder of this thesis. Expression and purification was as 
described by Huang et al., (2012) with a Superose 6 10/300 GL (GE Healthcare) 
column used instead of Superdex 200 10/300 GL (GE Healthcare) and yielded highly 
pure MGT(-Δ28) (Figure 5.7). 
 
5.4.1.4 Demonstration of full-length Staphylococcus aureus MGT(-Δ28) 
transglycosylase activity by SDS-PAGE 
 
The transglycosylase activity of MGT-Δ28(FL)  was compared to that of MGT-Δ67 
(Section 5.4.1.2). Huang et al., (2012) observed MGT-Δ28(FL) activity by HPLC, 
and their assay conditions were amended for SDS-PAGE analysis, by the removal of 
14% (v/v) MeOH necessary for HPLC and addition of 20% (v/v) DMSO as required 
by MGT-Δ67. Conditions used were 50 mM Tris.HCl pH 8, 10 mM MnCl2, 0.08% 
97 
66 
45 
30 
MGT Mr (a) (b) 
(i) 
(ii) 
Figure 5.7: Purification of Staphylococcus aureus Mu50 MGT-Δ28(FL) by size 
exclusion chromatography and final purity. (a) Size exclusion chromatogram using the 
Superose 6 10/300 GL column. (i) shows the elution of aggregated material in the column 
void volume and (ii) the elution of MGT FL.  The blue and red traces refer to absorbance at 
280 and 254 nm respectively. (b) 12% SDS-PAGE Coomassie-stained gel showing the final 
purity of MGT FL following IMAC and size exclusion chromatography. Mr, molecular 
weight markers (kDa);; MGT, 10 µg MGT FL. 
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(v/v) decyl PEG, 20% (v/v) DMSO. Reactions were incubated at 20°C for 1 hour 
before removal of protein (Section 5.4).  
 
15 µL assays were performed as in Section 5.4.1.2 with a 50:50 mix of Lipid II (Glu, 
Dans):Lipid II (Glu). Reaction buffers were as described in this section for MGT-
Δ28(FL) and Section 5.4.1.2 (without DDM) for MGT-Δ67. The total Lipid II 
concentration was halved to 65 µM to reduce the quantity of costly substrate 
required, given that sufficient signal was observed under transillumination previously 
(Figure 5.6), and the 50:50 ratio of labelled to non-labelled Lipid II was maintained. 
The Lipid II:enzyme ratio was also preserved by reducing the enzyme concentration 
to 22.5 µM. Reaction products were separated by SDS-PAGE and detected by dansyl 
fluorescence at 521 nm (Figure 5.8). 
 
MGT-Δ67 MGT-FL 
LII 
only  
LII + 
MGT  
LII 
only  
LII + 
MGT  
i 
iii 
ii 
Figure 5.8: SDS-PAGE separation of MGT-Δ67 and MGT-Δ28(FL)  
transglycosylase products 65 µM total Lipid II (as 32.5 µM Lipid II (Glu, Dans) 
and 32.5 µM Lipid II (Glu)) were polymerised with 22.5 µM MGT-Δ67 or MGT-
Δ28(FL) (MGT-FL) as indicated below the gel. LII only, 65 µM Lipid II mix in 
reaction buffer plus enzyme storage buffer in replacement of enzyme; LII + MGT, 
65 µM Lipid II mix plus 22.5 µM MGT-Δ67 or MGT-Δ28(FL) (MGT-FL) as 
indicated. Products of transglycosylation were separated on an 8.5% T/2.7% C SDS-
PAGE gel. Dansyl fluorescence at 521 nm was detected using a blue light converter 
and short pass filter on a GeneSnap Gel Doc. (i) denotes unpolymerised Lipid II and 
(ii) glycan chains of varying lengths, (iii) denotes where high molecular weight 
material, unable to enter the gel would be found.  
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Figure 5.8 demonstrates that MGT-Δ28(FL) was active as a transglycosylase under 
the conditions used and with a 50:50 mix of fluorescently labelled:non-labelled Lipid 
II (Glu). The glycan chain lengths observed were more variable in length with MGT-
Δ28(FL) than MGT-Δ67. The lower intensity of fluorescence observed for MGT-
Δ28(FL) products may be due to a greater distribution of glycan chain lengths being 
produced, leading to the fluorescence detected being more dispersed. Despite this, it 
has been clearly shown that MGT-Δ28(FL) demonstrates transglycosylase activity 
under these conditions.  
 
5.4.1.5 Role of Lipid II amidation in Staphylococcus aureus MGT 
transglycosylase activity 
 
It was hypothesised that if amidated Lipid II was a preferential substrate for MGT as 
for all other Gram-positive PBPs tested so far in this study, and with MGT-Δ28(FL) 
shown to be 10 times more active than MGT-Δ67 (Huang et al., 2012), then the -Δ28 
enzyme may polymerise 100% dansylated Lipid II. This was tested with 10 µM 
Lipid II (Glu, Dans) or Lipid II (Gln, Dans), as sufficient fluorescent signal was 
observed at this concentration previously (Section 4.4.2). Lipid II in reaction buffer 
was incubated with 1 µM MGT-Δ67 or MGT-Δ28(FL) at 20°C for 1 hour, at which 
point, protein was removed and products were analysed by SDS-PAGE (Figure 5.9). 
 
An apparent error in loading of the Lipid II (Gln, Dans), MGT-Δ28(FL) reaction, 
means that conclusions could not easily be made from this result. Although MGT-
Δ28(FL)(MGT-FL) was able to polymerise Lipid II (Glu, Dans), showing it can use 
fully labelled substrate. It was unexpected that MGT-Δ67 was able to use Lipid II 
(Gln, Dans) as well. It is interesting to note that MGT-Δ28(FL) is capable of 
polymerising 100% Lipid II (Glu, Dans) whereas MGT-Δ67 does not appear to 
exhibit this activity. This is discussed further in Section 5.8.1.2.1. 
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5.4.2 Continuous fluorescence assay of Staphylococcus aureus MGT 
transglycosylation 
 
Following the observation of transglycosylation by MGT-Δ28(FL) with 100% 
fluorescently labelled Lipid II, the same experiment was performed by the 
continuous assay system described in Section 4.1.2 (Methods Section 2.7.1).  
Reaction buffer was as described in Section 5.4.1; 50 mM Tris. HCl pH 8, 10 mM 
MnCl2, 0.08% (v/v) decyl PEG, 20% (v/v) DMSO with the addition of 0.1 mg.ml-1 
hen egg-white lysozyme for initial comparisons. This concentration of lysozyme was 
determined sufficient for the coupled assay of S. pneumoniae PBP1a and PBP2a 
(Section 4.5.1.2), and is discussed further in Section 5.7.1.3.  
MGT-Δ67 MGT-FL 
i 
iii 
ii 
Glu C Glu  Gln C Gln Glu C Glu  Gln C Gln 
Figure 5.9: Comparison of the effect of Lipid II amidation on the transglycosylase products 
of Staphylococcus aureus MGT-Δ67 and MGT-Δ28(FL): Products of transglycosylation were 
separated on a 8.5% T/2.7% C SDS-PAGE gel. Dansyl fluorescence at 521 nm was detected using 
a blue light converter and short pass filter on a GeneSnap Gel Doc. All reactions contained 10 µM 
total Lipid II (either Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) labelled as Glu and Gln below 
the gel respectively, and 1 µM MGT-Δ67 or 1 µM MGT-Δ28(FL)(MGT-FL) where indicated. Glu 
C, –enzyme: 10 µM Lipid II (Glu, Dans) with enzyme replaced by enzyme storage buffer. Gln C, 
–enzyme: 10 µM Lipid II (Gln, Dans) with enzyme replaced by enzyme storage buffer. (i) denotes 
unpolymerised Lipid II; (ii) glycan chains of varying lengths and (iii) the very high molecular 
weight material, which does not enter the gel. 
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1 µM, 0.5 µM or 0.25 µM MGT-Δ28(FL) was added to initiate reactions with 2.5 
µM, 5 µM or 10 µM Lipid II (Lipid II (Glu, Dans) or Lipid II (Gln, Dans)). 
Reactions were monitored for 100 min at 25°C. Rates in RFU change per second of 
the initial linear portion of the reaction were calculated. The observed initial rate 
increased proportionally with enzyme concentration for both substrates, however, no 
significant difference was established between rates with Lipid II (Glu, Dans) and 
Lipid II (Gln, Dans) as demonstrated for 5 µM Lipid II (Figure 5.10).  
 
Unlike the bifunctional PBPs studied in Chapter 4, no difference was observed 
between the MGT-Δ28(FL) transglycosylation rate with Lipid II (Glu, Dans) and the 
rate with  Lipid II (Gln, Dans).. This may suggest a different substrate specificity of 
MGT or the Staphylococcus aureus transglycosylases more generally. The lowest 
enzyme concentration used was 0.25 µM and previous HPLC assays (Huang et al., 
2012) used enzyme concentrations of 60 nM, so a more detailed study of the effect of 
enzyme concentration and other Staphylococcus aureus transglycosylases is required 
to further investigate this. 
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5.5 Analysis of Staphylococcus aureus PBP2-Δ59 transglycosylase 
products by SDS-PAGE  
 
The data in Section 5.4, indicated that amidation of the lipid substrate made no 
difference to the transglycosylation rate of MGT-Δ28(FL). Therefore, the  
bifunctional PBP2 was also investigated. 
 
5.5.1 Demonstration of PBP-Δ59 transglycosylase activity by SDS-PAGE 
 
Due to substrate availability, initial assays of PBP2-Δ59 transglycosylase activity 
were with Lipid II (Gln, Dans). Staphylococcus aureus PBP2 activity had previously 
been demonstrated (Barrett et al., 2005) by HPLC with [14C]-Lipid II (C35). The 
buffer system (‘HPLC assay buffer’) used in this assay; 50 mM acetic acid, 50 mM 
MES, 10 mM CaCl2, 20% (v/v) DMSO at pH 5, was compared to a detergent-
omitted S. pneumoniae PBP2a reaction buffer (Section 4.4): 50 mM HEPES pH 7.5, 
(a) (b) (c) 
Figure 5.10: Comparison of MGT-Δ28(FL) transglycosylation rates by continuous 
fluorescence assay with Lipid II (Glu, Dans) and Lipid II (Gln, Dans). 5 µM Lipid II (Glu, 
Dans)(Black) or Lipid II (Gln, Dans)(Grey) and 1 µM, 0.5 µM or 0.25 µM MGT-Δ28(FL)  as 
labelled on x-axis.. Excitation was at 340 nm, emission was at 521 nm with readings at 30 second 
intervals. RFU change per second was calculated from initial linear portion of time-course. Values 
represent the mean ± standard deviation of triplicate reactions. Student’s two-tailed t-test was 
performed to test for statistical significance. p-values: (a) 0.225, (b) 0.054, (c) 0.937 where p-
>0.05 was considered not significant. 
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200 mM NaCl, 25 mM MgCl2, 25% (v/v) DMSO. 10 µM Lipid II (Gln, Dans) was 
incubated with or without 1 µM PBP2-Δ59 at 30°C overnight in these buffers, to 
ensure the reaction proceeded to completion. Reaction products were analysed by 
SDS-PAGE (Section 2.7.2) (Figure 5.11). 
No activity was observed in the HPLC assay buffer (Barrett et al., 2005), and short 
glycan chains were produced after overnight incubation in the pneumococcal PBP2a 
reaction buffer. Detergent was not present in the reaction buffer used by Barrett et 
al., (2005), and its omission is likely to have not affected transglycosylase activity 
given the presence of 20% (v/v) DMSO to enhance solubility of the lipid substrate. 
Significantly, the Lipid II substrate previously (Barrett et al., 2005) also did not have 
a dansyl fluorescence group, which may be more important in observation of 
transglycosylase activity than previously thought (Section 5.4). C35 Lipid II has 
LII only LII + PBP2 LII only LII + PBP2 
i 
iii 
ii 
Buffer A Buffer B 
10 µM Lipid II (Gln, Dans) 
Figure 5.11: SDS-PAGE separation of PBP2-Δ59 transglycosylase products. LII only, 10 
µM Lipid II (Gln, Dans) plus PBP2-Δ59 storage buffer; LII+PBP2, 10 µM Lipid II (Gln, Dans) 
and 1 µM PBP2-Δ59. Buffer A, 50 mM HEPES pH 7.5, 200 mM NaCl, 25 mM MgCl2, 25% 
(v/v) DMSO; Buffer B, 50 mM acetic acid, 50 mM MES, 10 mM CaCl2, 20% (v/v) DMSO pH 
5. Products of transglycosylation were separated on a 8.5% T/2.7% C SDS-PAGE gel. Dansyl 
fluorescence at 521 nm was detected using a blue light converter and short pass filter on a 
GeneSnap Gel Doc. (i) denotes unpolymerised Lipid II; (ii) glycan chains of varying lengths 
(iii) denotes where high molecular weight material, unable to enter the gel would be found. 
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previously been shown to be a more optimal substrate in vitro than the C55 variant 
(Ye et al., 2001), however, C35 Lipid II was not available for this study.  Another 
way to manipulate the availability of the Lipid II for transglycosylation, distinct from 
lipid prenyl chain length was to vary the TX-100 concentrations added to the 
reaction buffer to determine any effect on the enzyme activity, given the use of C55 
Lipid II. The reaction was exactly as for Figure 5.11 (buffer A) with the addition of 
1/3 – 10 x CMC TX-100 (CMC = 0.015% (v/v)). Products were analysed by SDS-
PAGE (Figure 5.12).  
 
No difference in processivity was observed with the addition of increasing TX-100 
concentrations, suggesting that the 25% (v/v) DMSO present is sufficient for PBP2-
Δ59 activity. Activity was observed up to a TX-100 concentration just above CMC 
(0.015% (v/v)), but above this full inhibition occurred. Mis-orientation of PBP2 in 
the detergent micelle due to the absence of the hydrophobic transmembrane domain 
-enz 0.005% 0.01% 0.02% 0.04% 0.08% 0.16% 
Final Triton X-100 concentration (v/v)  
0% 
i 
iii 
ii 
Figure 5.12: Effect of TX-100 concentration on PBP2-Δ59 transglycosylase 
processivity. –enz, 10 µM Lipid II (Gln, Dans) plus PBP2-Δ59 storage buffer in 
reaction buffer with 0% TX-100. Remaining lanes, 10 µM Lipid II (Gln, Dans) and 1 
µM PBP2-Δ59. Buffer; 50 mM HEPES pH 7.5, 200 mM NaCl, 25 mM MgCl2, 25% 
(v/v) DMSO with increasing TX-100 concentrations as labelled. Products of 
transglycosylation were separated on a 8.5% T/2.7% C SDS-PAGE gel. Dansyl 
fluorescence at 521 nm was detected using a blue light converter and short pass filter 
on a GeneSnap Gel Doc. (i) denotes unpolymerised Lipid II and (ii) glycan chains of 
varying lengths. (iii) denotes where high molecular weight material, unable to enter the 
gel would be found.  
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of the PBP may have been responsible for this, as seen with S. pneumoniae PBP2a 
(Section 4.4.5). This result shows that TX-100 is not required for PBP2-Δ59 activity 
in the presence of 25% (v/v) DMSO.  
 
5.5.2 Effect of Lipid II amidation on PBP2-Δ59 transglycosylase activity 
 
The transglycosylase activity of PBP2-Δ59 with amidated and non-amidated 
substrate was compared by separation of the reaction products by SDS-PAGE. 10 
µM Lipid II (Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) was incubated with 1 µM 
PBP2-Δ59 or an equivalent volume of enzyme storage buffer in 50 mM HEPES pH 
7.5, 25 mM MgCl2, 200 mM NaCl, 25% (v/v) DMSO at 30°C overnight. Glycan 
products were analysed by SDS-PAGE (Figure 5.13) 
Figure 5.13 shows a clear difference between the activity of PBP2-Δ59 with 
amidated and non-amidated Lipid II. After overnight incubation, unpolymerised 
Lipid II (Glu, Dans) was observed at the base of the gel, demonstrating a distinct 
preference for the amidated Lipid II substrate by PBP2-Δ59, as identified previously 
LII only LII only LII + PBP2 LII + PBP2 
Lipid II 
(Glu, Dans) 
Lipid II 
(Gln, Dans) 
i 
iii 
ii 
Figure 5.13: Effect of Lipid II amidation on the transglycosylase products of 
Staphylococcus aureus PBP2-Δ59. Products of transglycosylation separated on a 8.5% T/2.7% 
C SDS-PAGE gel. Dansyl fluorescence at 521 nm was detected by using a blue light converter 
and short pass filter on a GeneSnap Gel Doc. Reactions contained 10 µM total Lipid II (either 
Lipid II (Glu, Dans) or Lipid II (Gln, Dans)) as labelled below the gel. LII only, plus enzyme 
storage buffer; LII +PBP2, plus 1 µM PBP2-Δ59. (i) denotes unpolymerised Lipid II and (ii) 
glycan chains of varying lengths.. (iii) denotes where high molecular weight material, unable to 
enter the gel would be found. 
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for the S. pneumoniae bifunctional PBPs (Section 4.4.2).  This phenomenon was not 
observed for the Staphylococcus aureus monofunctional transglycosylase MGT 
(Section 5.4.1.5 and 5.4.2). 
 
5.5.3 Continuous fluorescence assay of PBP2-Δ59 transglycosylase activity 
 
In order to kinetically characterise and accurately quantitate the changes in activity 
of PBP2-Δ59 in response to modifications of its assay conditions or substrate, the 
enzyme was assayed with 10 µM Lipid II (Gln, Dans) by the continuous 
fluorescence assay system (Section 2.7.1). The buffer for observation of activity by 
SDS-PAGE was used; 50 mM HEPES pH 7.5, 25 mM MgCl2, 200 mM NaCl, 25% 
(v/v) DMSO with the addition of 0.1 mg.ml-1 lysozyme as a coupling enzyme 
(Section 4.5.1.2), and the assay performed at 30°C for 150 min as described in 
Section 2.7.1. 
 
No activity was observed by this assay system (data not shown). Transglycosylase 
activity previously observed by overnight incubation and SDS-PAGE may have been 
too slow to identify activity within the continuous assay timeframe.  
 
5.5.4 Expression and purification of full-length Staphylococcus aureus PBP2 
 
S. pneumoniae bifunctional PBP2a was shown to be less processive after the removal 
of the TM region (Section 4.4.5), and Staphylococcus aureus MGT was able to 
polymerise 100% Lipid II (Glu, Dans) only in the presence of its TM region (Section 
5.4.1.5). Both of these findings, and extensive literature (Section 5.8.1.2), suggested 
a critical role of the TM region in substrate interaction. This, together with the 
inability to follow PBP2-Δ59 activity continuously in a kinetic assay prompted 
attempts to express and purify full-length PBP2, in order to elucidate the importance 
of the TM region on PBP2 processivity and to allow more detailed characterisation 
of its enzymology.  
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The pET21b::pbp2 plasmid expressing the full-length PBP2 gene was obtained from 
Dr N. Strynadka (UBC, Canada) and expression and purification was attempted as 
described by Barrett et al., (2005). Very poor yield was achieved following 
solubilisation of the post lysis pellet with 0.5% (w/v) Sarkosyl for 1 hour. Several 
adjustments to the protocol were made, including the addition of cOmplete™ EDTA-
free Protease Inhibitor Cocktail (Roche) and an additional ultracentrifugation step of 
the soluble fraction at 150,000 × g to specifically pellet membranes (Section 2.4.2.3). 
Both the low speed and high speed pellets were solubilised for longer (3 hours) with 
0.5% (w/v) Sarkosyl, resulting in a detectable quantity of protein; mainly in the 
50,000 × g pellet (as used in Barrett et al., 2005) rather than the 150,000 × g pellet. 
Loose Ni2+ bound chelating Metal Affinity Resin (Section 2.4.3.1) was used rather 
than a pre-packed 5 mL HisTrap HP (GE Healthcare) column in order to achieve 
higher binding, and soluble protein was allowed to incubate with the resin, stirring 
for 3 hours at 4°C. Despite this, a significant quantity of PBP2 was present in the 
column flow through from the solubilised 50,000 × g pellet, suggesting mis-folded 
protein. A stepwise elution from 10 mM to 500 mM imidazole was carried out to 
develop gravity flow columns. PBP2 containing fractions were concentrated in a 10 
kDa cut-off centrifugal concentrator with subsequent buffer exchange to remove 
imidazole. Protein concentration was not detectable by Bio-Rad assay (Section 2.5.1) 
for protein solubilised from the ultracentrifuge pellet. A very poor yield of 0.04 
mg.L-1 was achieved from the low speed pellet, and included a high amount of 
contaminating protein (Figure 5.14).  
 
PBP2-FL purity was compared to PBP2-Δ59 by SDS-PAGE analysis of the same 
quantity of loaded protein. Insufficient yield and purity was achieved for PBP2-FL 
despite alterations to the published protocol. 
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5.6 Analysis of Staphylococcus aureus PBP2-PBP2a Interactions 
 
5.6.1 Expression and purification of Staphylococcus aureus Class B PBP2a 
 
Increasing evidence has accumulated to support that PBPs function within larger 
complexes containing other PBPs as well as other proteins responsible for the 
growth, maintenance and turnover of the cell wall (Section 5.8.4.2). One mechanism 
of methicillin resistance in Staphylococcus aureus is due to the acquisition of the 
monofunctional Class B PBP2a with low affinity for β-lactams, which compensates 
for the lost transpeptidase activity of the methicillin susceptible PBP2 (Pinho et al., 
2001). Therefore, it was hypothesised that PBP2 and PBP2a may form a complex in 
vivo, which may stimulate the transglycosylase activity of PBP2. 
  
PBP2
-Δ59 Mr 
97 
66 
45 
30 
20 
14 
PBP2
-FL 
Figure 5.14: 12% SDS-PAGE Coomassie–stained 
gel to analyse the final purity of Staphylococcus 
aureus PBP2-Δ59 and PBP2-FL. Mr, Molecular 
weight markers (kDa). Lanes are labelled with the 
relevant PBP. Position of PBP2-Δ59 on the gel 
indicated by arrow. 
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To test this hypothesis, Staphylococcus aureus PBP2a was expressed and purified 
from the pET15b::pbp2a-Δ22 plasmid (obtained from Dr N. Strynadka (UBC, 
Canada)). Expression of the full-length PBP2a including the TM region has 
previously been unsuccessful despite extensive efforts within our group (Dr David 
Roper, Personal Communication). Expression of the -Δ22 PBP2a was as described in 
Lim and Strynadka, (2002) and purification followed the same basic scheme with 
modifications, with all steps at 4°C (Section 2.4.4.2). The final high level of purity of 
PBP2a-Δ22 is shown in Figure 5.15 and a yield of 7 mg.L-1 was achieved.  
 
 
A sample of very pure PBP2a-Δ22 was then sent to Professor Simon Foster 
(University of Sheffield) for anti-PBP2a antibody production in mice, which was 
subsequently used by Dr Sarah Paulin (UCL, London) to show the co-purification of 
PBP2/PBP2a as a complex from intact Staphylococcus aureus cells (Paulin et al., 
2014 (appended to the end of this thesis; Appendix 8)). This further supports the 
hypothesis for a multi-PBP complex in vivo. 
 
97 
45 
30 
66 
20 
Mr PBP2a-Δ22 
Figure 5.15: 12% SDS-PAGE Coomassie-stained 
gel showing the final purity of PBP2a-Δ22. Mr, 
molecular weight markers (kDa); TM, total 
membrane fraction; PBP2a-Δ22, 10 µg PBP2a-Δ22. 
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5.6.2 Can PBP2-Δ59 processivity be stimulated by other Staphylococcus aureus 
PBPs?   
 
Staphylococcus aureus PBP2a compensates for the loss of methicillin susceptible 
PBP2 transpeptidase activity during β-lactam treatment (Pinho et al., 2001). It was 
hypothesised that the complex of PBP2 and PBP2a formed may also stimulate PBP2 
transglycosylase activity. E. coli Class A PBP1a transglycosylase activity has been 
shown to be stimulated by monofunctional E. coli Class B transpeptidase PBP2 
(Banzhaf et al., 2012). The ability of PBP2a-Δ22 to stimulate the transglycosylase 
activity of PBP2-Δ59 was tested. It was anticipated that utility of Lipid II (Gln, 
Dans) and the solely transpeptidase nature of PBP2a would eliminate any 
contribution of PBP2a catalysis to the results of this experiment because the third 
position of the stem peptide was (i) dansylated and therefore blocked for 
transpeptidase activity and (ii) not appended to a branched stem, which PBP2a 
requires (Strandén et al. 1997). Therefore, overnight incubation of 10 µM Lipid II 
(Gln, Dans) in PBP2 reaction buffer (Section 5.5.2) at 30°C with 1 µM of each 
enzyme to be tested was performed. The subsequent reaction products were analysed 
by SDS-PAGE (Figure 5.16).    
 
PBP2a-Δ22 was shown to not affect the mobility of Lipid II (Gln, Dans) through the 
gel. However, no increase in processivity of PBP2-Δ59 transglycosylase activity was 
observed with the addition of PBP2a-Δ22 (Figure 5.16). Any alteration in rate of 
glycan chain polymerisation cannot be determined in this experiment, as a single 
overnight time point was conducted. A time-course experiment or continuous 
fluorescence assay would allow this to be studied.  
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This result suggests that the interaction of PBP2 and PBP2a does not increase the 
processivity of the transglycosylation observed, although there are many caveats to 
this. For example, the transmembrane spanning region of one, or both enzymes may 
be crucial for interaction and/or processivity, as might the pentaglycine moiety 
appended to the third position of the stem peptide of the native staphylococcal lipid 
II substrate of these enzymes.  
 
5.7 Characterisation of novel carbohydrate based transglycosylase 
inhibitors 
 
The need for novel inhibitors of the transglycosylase activity of PBPs was discussed 
in Section 5.1.4. To address this urgent clinical requirement, the groups of Professor 
LII only PBP2a PBP2 + 2a PBP2 
i 
iii 
ii 
Figure 5.16: Transglycosylase activity of Staphylococcus aureus PBP2-Δ59 in the presence or 
absence of PBP2a-Δ22. 10 µM Lipid II (Gln, Dans) in PBP2 reaction buffer was present in all 
assays. LII only, plus enzyme storage buffer; PBP2, plus 1 µM PBP2-Δ59. PBP2a, plus 1 µM 
PBP2a-Δ22; PBP2 + 2a, plus 1 µM PBP2-Δ59 and 1 µM PBP2a-Δ22. Products of transglycosylation 
were separated on a 8.5% T/2.7% C SDS-PAGE gel. Dansyl fluorescence at 521 nm was detected 
using a blue light converter and short pass filter on a GeneSnap Gel Doc. (i) denotes unpolymerised 
Lipid II and (ii) glycan chains of varying lengths  (iii) denotes where high molecular weight 
material, unable to enter the gel would be found. 
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Matthew Cooper (University of Queensland, Australia) and Dr Wim Meutermans 
(Alchemia, Australia) synthesised a 500 compound library based on the structure of 
moenomycin (Zuegg et al., 2015). All 500 compounds were tested against 
methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) Staphylococcus 
aureus, three enterococcal strains and E. coli.  
 
Non-haemolytic compounds demonstrating activity against Gram-positive strains 
were tested and two of these (Figure 5.17). displayed activity against a broad range 
of drug resistant Staphylococcus aureus strains as well as multi-drug resistant S. 
pneumoniae (Table 1 in Zuegg et al., 2015; attached in Appendix 8) One of these, 
ACL202015 showed a spontaneous mutation frequency of less than 2.5 × 10-10 at 4 × 
MIC against Staphylococcus aureus (ATCC 13709). 
 
As the compounds were based originally on the structure of moenomycin and are 
carbohydrate based, it was predicted that their mode of action is inhibition of 
transglycosylase activity. This section details the investigation of these inhibitors as 
transglycosylase inhibitors of Staphylococcus aureus MGT-Δ28(FL). Part of this 
section (Figure 5.21) has been published in Zuegg et al., (2015) (attached at the end 
of this thesis; Appendix 8)).  
 
Figure 5.17: Novel carbohydrate based transglycosylase inhibitors.: Structures of two 
most active inhibitors taken forward; ACL20215 and ACL20964. Adapted from Zuegg et 
al., (2015). 
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5.7.1 A continuous fluorescence assay for MGT-Δ28(FL) transglycosylase 
activity and inhibition. 
 
MGT-Δ28(FL) transglycosylase activity was previously analysed by the continuous 
fluorescence assay system (Section 2.7.1 and Section 5.4.2), where no significant 
difference was observed between the rate of polymerisation of Lipid II (Glu, Dans) 
and Lipid II (Gln, Dans). Due to this and substrate availability, Lipid II (Glu, Dans) 
was used as a substrate for the remainder of this chapter. Initial conditions for the 
assay were as in Section 5.4.2; 50 mM Tris. HCl pH 8, 10 mM MnCl2, 0.08% (v/v) 
decyl PEG, 20% (v/v) DMSO, 0.1 mg.ml-1 hen egg-white lysozyme, at 25°C and the 
assay was performed as in Section 2.7.1.  
 
5.7.1.1 Fluorescent properties of Lipid II (Dans) 
 
The effect of the MGT-Δ28(FL) assay buffer system on the fluorescent properties of 
Lipid II (Glu, Dans) was investigated as it was for the S. pneumoniae PBPs in 
Section 4.5.1.1. 10 µM Lipid II (Glu, Dans) in 50 µL MGT-Δ28(FL) reaction buffer 
in a Greiner FLUOTRACTM 600 96-well plate was scanned for wavelength 
excitation and emission optima in a CLARIOstar® platereader (BMG Labtech). 
Emission from 400-600 nm was measured after excitation at 340 nm and emission at 
521 nm with excitation over the 320-400 nm range. All measurements were 
performed with and without ThermalSeal RTTM film (Section 4.5.1), and with buffer 
only controls. 
 
As seen previously (Figure 4.16) the emission maxima was observed at 521 nm after 
excitation at 340 nm (Figure 5.18 (a)). The optimal excitation wavelength for 
emission at 521 nm was again 359 nm (Figure 5.18 (b)), higher than the published 
value of 340 nm, and both maxima were reduced marginally by the inclusion of a 
seal. Other seal induced spectral changes were outside of the range used to follow the 
assay. Excitation at 359 nm and emission at 521 nm resulted in a high level of noise 
(seen previously in Section 4.5.1.1), and therefore assays were performed with 
excitation at 340 nm and emission at 521 nm to achieve the optimal fluorescence 
signal, with a ThermalSeal RTTM seal to stop evaporation. 
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5.7.1.2 Optimisation of conditions for the continuous fluorescence assay of 
MGT-Δ28(FL) transglycosylation.  
 
Initiation of the continuous fluorescence assay by addition of substrate rather than 
enzyme was investigated. Parallel reactions of 10 µM Lipid II (Glu, Dans) and 1 µM 
MGT-Δ28(FL)  were initiated by addition of either enzyme or substrate. No effect on 
reaction rate was observed, however a lag period of approximately 1 minute was 
observed before fluorescence decrease began when Lipid II was added last, 
presumed to be due to mixing of Lipid II containing micelles with decyl PEG 
micelles. Therefore, reactions were initiated by the addition of enzyme.  
 
Greiner FLUOTRACTM 600 96-well black plates have been used for all assays in this 
report. These are treated to make them hydrophilic and therefore have a higher 
binding capacity for polar molecules. FLUOTRACTM 200 96-well black plates are 
more hydrophobic and may mimic the membrane environment more closely. 
(Greiner website). A standard assay of 10 µM Lipid II (Glu, Dans) and 1 µM MGT-
Δ28(FL) was carried out in both plate types and initial rate of transglycosylase 
activity determined in RFU change per second. A higher rate was observed in the 
hydrophilic plate (14.36 RFU/second) compared to the hydrophobic plate (9.13 
(a) (b) 
Figure 5.18: Optimal emission and excitation wavelengths of Lipid II (Glu, Dans) in MGT-
Δ28(FL)  reaction buffer. 10 µM Lipid II (Glu, Dans) in 50 µL 50 mM Tris. HCl, 10 mM MnCl2, 
0.08% (v/v) decyl PEG, 20% (v/v) DMSO, 0.1 mg.ml-1 hen egg-white lysozyme in a Greiner 
FLUOTRACTM 600 96-well plate. a) Excitation was at 340 nm, emission was measured at 400 nm- 600 
nm. Black solid line, Lipid II; Red solid line; Lipid II + seal, Black dashed line; Buffer control, Red 
dashed line; Buffer control + seal. Emission maximum was observed at 521 nm. b) Excitation at 320 
nm – 400 nm, emission at 521 nm. Black solid line, Lipid II; Red solid line; Lipid II + seal, Black 
dashed line; Buffer control, Red dashed line; Buffer control + seal. Excitation maximum was observed 
at 359 nm.  
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RFU/second). It is likely that the hydrophobic surfaces of the FLUOTRACTM 200 
plates bound, and removed from the bulk solution of the assay, lipid II, detergent 
and/or MGT-Δ28(FL). 
 
The effect of pH on MGT-Δ28(FL) transglycosylation rate was investigated. 10 µM 
Lipid II (Glu, Dans) and 1 µM MGT-Δ28(FL) were assayed in 10 mM MnCl2, 
0.08% (v/v) decyl PEG, 20% (v/v) DMSO, 0.1 mg.ml-1 hen egg-white lysozyme, 
with the replacement of 50 mM Tris.HCl pH 8.0, by 50 mM HEPES at pH values 
spanning the full range of the HEPES buffering capacity (pKa = 7.6; pH 6.8-8.2) 
(Dawson et al. 1986). Assays were monitored by the standard method (Section 2.7.1) 
and the initial rate of transglycosylase activity determined at each pH. (Table 5.2). 
 
pH Rate (RFU/second) 
6.8 5.56 
7 9.27 
7.5 7.90 
8 14.19 
Table 5.2. Effect of pH on MGT-Δ28(FL)  transglycosylase activity 
 
Within the pH range tested, the optimal pH for activity was pH 8, with a 2-fold faster 
initial rate than any of the other pH conditions tested. The rate observed with HEPES 
pH 8, was comparable to that with Tris.HCl buffer at the same pH, used so far for 
MGT-Δ28(FL) assays. (eg. 14.36 RFU/second in hydrophilic plate test earlier in this 
section) 
 
Efforts to further improve the transglycosylase rate observed by the methods in this 
section and 5.7.1.1 were unsuccessful. Based on results in this, and the previous 
section, assays were subsequently performed in 50 mM Tris.HCl pH 8.0, 10 mM 
MnCl2, 0.08% (v/v) decyl PEG, 20% (v/v) DMSO, 0.1 mg.ml-1 hen egg-white 
lysozyme in Greiner FLUOTRACTM 600 96-well black plates at 25°C. Reactions 
were initiated by the addition of enzyme and dansyl fluorescence monitored by 
excitation at 340 nm and emission at 521 nm.  
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5.7.1.3 Lysozyme as the N-acetylmuramidase coupling enzyme in the continuous 
fluorescence assay for transglycosylase activity 
 
0.1 mg.ml-1 hen egg-white lysozyme was shown to be sufficient and non-limiting as 
the N-acetylmuramidase coupling enzyme in the continuous fluorescence assay of S. 
pneumoniae Class A PBP transglycosylase activity (Section 4.5.1.2). This was 
assumed in Section 5.4.2, and is tested more fully in this section. 0.01, 0.05 and 0.1 
mg.ml-1 hen egg-white lysozyme were tested with 1 µM, 0.5 µM or 0.3 µM MGT-
Δ28(FL) and 10 µM Lipid II (Glu, Dans) under the optimised assay conditions for 
MGT-Δ28(FL). At all lysozyme concentrations, reactions containing 0.5 µM and 0.3 
µM MGT-Δ28(FL) did not reach a plateau in 100 min. The fluorescence decrease 
over time with 1 µM MGT-Δ28(FL) was sigmoidal with both 0.01 and 0.05 mg.ml-1 
lysozyme, suggesting that the coupling enzyme is limiting at these concentrations. 
An initial linear phase followed by a plateau was observed with 1 µM MGT-
Δ28(FL), 0.1 mg.ml-1 and 10 µM Lipid II (Glu, Dans), allowing calculation of initial 
rate (not shown). 
 
The results described here support the rationale for using 1 µM MGT-Δ28(FL) and 
0.1 mg.ml-1 in assays with 10 µM Lipid II (Glu, Dans). 
 
5.7.2 Determination of kinetic parameters for MGT-Δ28(FL) transglycosylase 
activity 
 
In order to investigate the impact of ACL20215 and ACL20964 on the activity of  
MGT-Δ28(FL), the relationship between Lipid II (Glu, Dans) concentration and 
MGT-Δ28(FL) transglycosylation rate was first investigated. 1-10 µM Lipid II (Glu, 
Dans) was assayed with 1 µM MGT-Δ28(FL) in 50 mM Tris.HCl pH 8.0, 10 mM 
MnCl2, 0.08% (v/v) decyl PEG, 20% (v/v) DMSO, 0.1 mg.ml-1 hen egg-white 
lysozyme. Triplicate reactions were performed, and the initial rate was plotted 
against substrate concentration (Figure 5.19).  
 
211 
 
For the substrate range used the relationship between rate and substrate concentration 
did not plateau. The data best fit to a modified Michaelis-Menten equation 
considering cooperativity (Equation 4 in Section 4.5.4), and allowed extraction of 
Vmax: 92.88 ± 14.86 µM, S0.5: 6.64 ± 1.25 µM with a hill coefficient of 1.91 ± 0.27. 
The R2 of the fit was 0.9911. Although care should be taken extracting kinetic 
parameters as the data rate did not plateau.  
 
As substrate availability did not allow higher concentrations to be tested, the 
published Km value for MGT-Δ28(FL) of 9.6 ± 0.76 µM (Huang et al., 2012) was 
used to calculate the concentration of substrate for subsequent inhibitor assays. This 
fits closely to the S0.5 value calculated here as well. A Lipid II (Glu, Dans) 
concentration at approximately 1/6 Km (1.45 µM) was used to test for inhibition. This 
low concentration was selected in order to make the assay more sensitive to 
inhibition competitive with respect to lipid II.. 
 
5.7.3 Inhibition of MGT-Δ28(FL) transglycosylase activity by moenomycin 
 
To validate the MGT-Δ28(FL) assay for detection of inhibitors, the specific inhibitor 
of transglycosylase activity, moenomycin, was used as a positive control for 
Figure 5.19: Dependence of Staphylococcus aureus MGT-Δ28(FL) 
transglycosylase rate on Lipid II (Glu, Dans) concentration.  Initial 
rate in RFU/second (based on three data sets) plotted against [Lipid II 
(Glu, Dans)]. Error bars represent standard deviation of triplicate 
measurements. Data fitted to modified Michaelis-Menten considering 
cooperativity with an R2 value of 0.9911. 
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inhibition. The moenomycin IC50 (the inhibitor concentration at which half maximal 
inhibition occurs) for MGT-Δ28(FL) inhibition was determined in the presence of 1 
µM MGT-Δ28(FL) and 1.45 µM Lipid II (Glu, Dans (Sections 5.7.2 and 2.7.1), 
between 1 µM and 50 µM moenomycin. Initial rates were used to compute 
percentage inhibition relative to the no inhibitor control. The data were fitted to a 
simple saturation model of inhibitor binding (Equation 1) which enabled IC50 values 
to be extracted. Maximum inhibition was fixed at 100% for fitting of the non-linear 
regression (Figure 5.20). 
 
Equation 1: %  𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 100. 𝐼𝐼𝐶!" + 𝐼  
 
The calculated IC50 for moenomycin inhibition of MGT-Δ28(FL) was 5.1 ± 0.729 
µM. This is higher than expected given the tight binding nature of moenomycin, 
although the lack of a full TM region may reduce the affinity of MGT for 
moenomycin as observed for Class A PBPs (Cheng et al., 2008) However, it 
demonstrated clear inhibition of MGT-Δ28(FL) transglycosylase activity and was 
therefore a positive control for testing of inhibition by ACL20215 and ACL20964. 
Figure 5.20: Inhibition of Staphylococcus aureus MGT-Δ28(FL) transglycosylase activity 
by moenomycin. Assays of 1.45 µM Lipid II (Glu, Dans) and 1 µM MGT-Δ28(FL) with 
increasing [moenomycin] from 1 – 50 µM. Excitation was at 340 nm, emission was at 521 nm 
with readings at 30 second intervals.. Values represent mean ± standard deviation of 4 
reactions. R2 value of regression fit: 0.929 
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5.7.4 in vitro study of transglycosylase inhibition by ACL20215 and ACL20964 
 
ACL202015 and ACL20964 exhibited poor solubility, which could be overcome by 
reduced pH or the addition of DMSO (Dr Wim Meutermans, Personal 
communication). pH was previously shown to have a significant effect on MGT-
Δ28(FL) transglycosylase activity (Section 5.7.1.2) and therefore the compounds 
were resuspended at stock concentrations in 100% (v/v) DMSO. The DMSO 
concentration contributed by the addition of inhibitors to the assay was accounted for 
in the total concentration of 20% (v/v) in the assay.  
 
The use of a fluorescence assay to test for inhibition requires the screening of 
inhibitors as a control, to identify any intrinsic fluorescence in the region monitored 
in the assay. ACL202015 and ACL20964 at 20, 100 and 400 µM in MGT-Δ28(FL)  
reaction buffer, plus buffer controls were scanned for fluorescence at the 
wavelengths monitored in the continuous fluorescence assay. No signal was 
observed above that from buffer alone with either compound (not shown).   
 
1 – 300 µM ACL202015 and ACL20964 were tested for inhibition of MGT-Δ28(FL)  
in an identical manner to moenomycin in Section 5.7.3. Percentage inhibition data 
were again fitted to a simple saturation model of inhibitor binding to a single site 
(Equation 1) with maximum inhibition fixed as 100% (Figure 5.21). 
 
(a) (b) 
Figure 5.21: Inhibition of Staphylococcus aureus MGT-Δ28(FL) transglycosylase activity by 
ACL20215 (a) and ACL20964 (b). Assays of 1 µM MGT-Δ28(FL) in the presence of 1.45 µM Lipid 
II (Glu, Dans) with increasing [ACL20215] or [ACL20964] from 1 – 300 µM. Reaction volume was 50 
µL. Excitation was at 340 nm, emission was at 521 nm with readings at 30 second intervals. Inhibition 
was calculated as a percentage relative to rate without inhibitor and plotted against inhibitor 
concentration in µM. Values represent mean ± standard deviation of 4 reactions. R2 value of non-linear 
regression fits were: (a) 0.804 (b) 0.705. 
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IC50 values of 26.1 ± 2.7 µM and 15.6 ± 2.0 µM were calculated for ACL202015 and 
ACL20964 respectively (compared to 5.1 ± 0.729 µM for moenomycin seen 
previously). These correspond to 17 and 11 µg.ml-1 respectively (8 µg.ml-1 for 
moenomycin). This data identifies these compounds as inhibitors of transglycosylase 
activity. The impact of these inhibitors on lysozyme activity was discounted as no 
sigmoidal relationship was observed suggestive of coupling enzyme limitations 
(Section 5.8.2.1).  
 
5.8 Discussion and future work 
 
This chapter has provided a good basis for understanding of the substrate specificity 
of the Staphylococcus aureus transglycosylases. Additionally, the characterisation of 
novel inhibitors of transglycosylase activity is pertinent in the discovery of new 
antimicrobials. This section discusses the data presented and its biological 
implications and details future work leading from the findings described. For 
discussion of the limitations of the SDS-PAGE and continuous fluorescence assay 
for transglycosylase activity, see Section 4.6.2. 
 
5.8.1 Characterisation of Staphylococcus aureus MGT transglycosylase activity 
 
5.8.1.1. Role of the transmembrane domain in MGT transglycosylation 
 
In agreement with Huang et al. (2012), the importance of the hydrophobic TM 
region of MGT in transglycosylation was demonstrated. The inability of MGT-Δ67 
to use non-amidated fully dansylated lipid II as a substrate (Figure 5.9) suggests that 
some of the additional 39 residues in the MGT-Δ28 protein are crucially important in 
substrate interaction, made more obvious in the presence of a sizeable dansyl group 
on the pentapeptide. The role of the TM region in the interaction of Staphylococcus 
aureus MGT and E. coli PBP1b with moenomycin has previously been documented 
(Cheng et al., 2008; Huang et al., 2012), and its importance in substrate interaction 
observed in S. pneumoniae PBP2a and E. coli PBP1b (Cheng et al., 2008; Helassa et 
al., 2012; Sung et al., 2009). The results presented here led to the hypothesis that 
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increased affinity of MGT for amidated Lipid II overcame the loss of substrate 
affinity due to removal of a crucial interacting domain in the MGT-Δ67 protein, thus 
enabling it to polymerise 100% Lipid II (Gln, Dans) (Figure 5.9). This could be 
confirmed by isothermal calorimetry experiments comparing amidated and non-
amidated Lipid II binding to MGT with and without the TM region, although this 
would require removal of detergent micelles, which would complicate analysis. A 
modified MGT or Lipid II substrate would be required for this experiment to ensure 
the substrate isn’t polymerised. With this in mind, current focus in the laboratory is 
directed towards synthesis of lipid II analogues where the pyrophosphate bridge 
between the undecaprenyl and MurNAc moieties has been replaced by non-
hydrolysable pyrophosphate mimetics.  
 
An additional explanation for the inability of MGT-Δ67 to use 100% dansylated non-
amidated Lipid II is incorrect orientation of the enzyme in detergent micelles due to 
the truncation of the protein. This has been inferred from the X-ray crystal structures 
of Staphylococcus aureus MGT and E. coli PBP1b (Huang et al., 2012; Sung et al., 
2009). Alternatively, the oligomeric state of MGT-Δ67 and MGT-Δ28(FL) may 
differ, and this could have implications for substrate access to the active site. Both 
MGT-Δ67 and MGT-Δ28(FL) have been identified as oligomers of uncertain 
multiplicity (Reed et al., 2011; Wang et al., 2001). Both of these suggestions are 
only possible if amidation leads to a sufficiently large increase in affinity to allow the 
substrate to enter the active site and offset the poor orientation of the truncated 
protein relative to its substrate. 
 
The detection of dansyl containing glycan chains with a mixture of labelled and non-
labelled Lipid II Glu substrate (Figure 5.5) suggests that MGT-Δ67 is incorporating 
some of the fluorescent Lipid II presented, despite being unable to polymerise it 
alone (Section 5.4.1.1). This observation may be due to differential binding of 
labelled and non-labelled lipid II in the donor and/or acceptor sites of the 
transglycosylase. With neither the isoglutamine in the pentapeptide or TM region to 
aid affinity for the substrate, the presence of two dansyl groups within the active site 
may be too unfavourable for the formation of a catalytically competent 
donor/acceptor/ transglycosylase complex. Occlusion of the active site by detergent 
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or incorrect orientation of Lipid II binding may have the same outcome. The 
presence of the TM region or amidation is apparently sufficient to overcome this as 
in both cases the enzyme can use 100% dansylated Lipid II.  
 
The results seen here suggest that if most enzyme molecules bind one labelled and 
one non-labelled substrate then an active complex is formed. This finding is unique 
to MGT so far, and has not been described for any bifunctional PBPs studied by the 
same method (Helassa et al., 2012; Offant et al., 2010; Schwartz et al., 2002; Chapter 
4). Despite the fact that dansylation and other modifications of Lipid II do not affect 
the PBP kinetic parameters (Schwartz et al., 2002; Zhang et al., 2007) the findings 
presented here have implications in the use of these labelled substrates. A full 
investigation using amidated and non-amidated Lipid II with fluorescent tags at 
different positions or with radioactive labelling could enable this to be investigated. 
 
The effect of the TM region on transglycosylation rates was not investigated. 
Following the observation that MGT-Δ67 can polymerise 100% Lipid II (Gln, Dans), 
a continuous assay could be carried out comparing the relative rates of 
transglycosylation of this amidated substrate by MGT-Δ67 and MGT-Δ28(FL). 
Considering the work by Huang and colleagues (2012) as well as complementary 
studies on E. coli PBP1b (Barrett et al., 2004; Terrak et al., 1999) it is expected that 
a higher transglycosylation rate would be observed with the full-length protein.  
 
This is the first analysis of MGT processivity towards Lipid II polymerization in 
vitro and the role of the TM region on this process. The lack of suitable standards 
means that the length of glycan chains produced cannot be accurately calculated but 
comparison with S. pneumoniae PBP2a (Chapter 4) known to produce polymers of 
20-30 disaccharide units in length, suggests that the disaccharide polymers generated 
by MGT are in excess of 20-25 units in length. However, this is likely to be an 
underestimate:  More polymerised material is found in a band at the top of the gel in 
MGT-Δ28(FL) reactions (Figure 5.9), identifying material too large to enter the 
acrylamide and suggesting that MGT-Δ28(FL) is more processive than its truncated 
Δ67 counterpart. This is consistent with literature demonstrating the involvement of 
the TM region in transglycosylase processivity (Helassa et al., 2012). However, this 
conclusion should be made with care as interaction of the detergent micelle with the 
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different MGT variants may also have an effect on the substrate usage discussed in 
this section (see Section 4.6.3.2, regarding the impact of detergent in S. pneumoniae 
PBP2a processivity).   
 
5.8.1.2 Effect of Lipid II amidation on MGT transglycosylation 
 
The experiments described in this chapter suggest differential effects of amidated 
substrate on the transglycosylase activity of monofunctional and bifunctional 
transglycosylase enzymes (discussed further in Section 7.1.1). This chapter detailed 
the first investigation of the effect of amidation on a monofunctional 
transglycosylase to date.  
 
Non-amidated Lipid II was clearly shown to be a less optimal substrate than in its 
amidated form for MGT-Δ67 by SDS-PAGE analysis, and comparisons of 
transglycosylation rates could not be made as 100% non-amidated dansylated Lipid 
II, required for the continuous assay, was not a viable substrate. A mixture of 
labelled and non-labelled Lipid II could be used as an alternative, however due to the 
unknown specificity of the donor and acceptor sites for the dansylated substrate 
(Section 5.8.1.1), data analysis would be complicated by the productive or inhibitory 
interactions of mixtures of dansylated and non-dansylated substrates at either binding 
site.  
 
No impact of Lipid II amidation in either processivity or rate was observed with the 
Δ28(FL) enzyme. This could suggest that the transmembrane domain has an 
important role in substrate interaction, and has a greater effect than the presence of 
isoglutamine in the second position. MGT-Δ28(FL) is a significantly more active 
transglycosylase than MGT-Δ67 (Huang et al., 2012). Therefore the rates of 
transglycosylation with both amidated and non-amidated substrates may have been 
too high to observe any difference. Therefore, continuous fluorescence assays with a 
much greater range of enzyme concentrations could be performed to test this 
hypothesis.  
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The only literature to date covering the substrate specificity of PBPs for amidated 
Lipid II concerns the bifunctional enzymes from S. pneumoniae (Zapun et al., 2013), 
in which the requirement for amidated substrate for the formation of a cross-linked 
peptidoglycan species (but not specifically the transglycosylase activity) was studied.  
  
5.8.2 Characterisation of Staphylococcus aureus PBP2 transglycosylase activity 
 
The effect of Lipid II amidation on the transglycosylase activity of the bifunctional 
Staphylococcus aureus PBP2 was also investigated by SDS-PAGE analysis of 
reaction products.  
 
5.8.2.1 PBP2 purification  
 
PBP2 was successfully purified in the absence of its hydrophobic transmembrane 
spanning domain (Section 5.3.2), however purification of full-length PBP2 was less 
successful (Section 5.5.4) where a poor yield of impure protein was achieved. This 
was mainly due to inefficient solubilisation of protein with detergent. This 
observation suggests that a screen of alternative detergents might enable more 
efficient solubilisation of this protein. Furthermore, whether or not the expressed 
protein was correctly folded was unknown. This point could be addressed by 
analysing Bocillin FL binding of the expressed protein to establish the integrity of 
the transpeptidase active site and binding of the protein to immobilised moenomycin 
(Bury et al., 2015; Stembera et al., 2002).  
 
5.8.2.2 PBP2-Δ59 activity 
 
The transglycosylase activity of PBP2 observed previously (Barrett et al., 2005; 
Wang et al., 2008) could not be repeated under the same conditions. There are 
several possible reasons for this: Firstly, Barrett and colleagues conducted their 
experiments with full-length PBP2, which may be more active than the ΔTM version. 
This theory is supported by both the literature (Helassa et al., 2012; Huang et al., 
2012; Sung et al., 2009, Wang et al., 2001) and previous work in this chapter 
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(Section 5.8.1.1). Significantly, the previous assays (Barrett et al., 2005) with PBP2-
FL use a heptaprenyl (C35) Lipid II variant rather than the native undecaprenyl (C55) 
version. This had been identified to be a more amenable substrate for in vitro study 
(Ye et al., 2001) but may interact with the enzyme differently to natural C55 Lipid II.  
 
The Lipid II used previously by Barrett and colleagues was 14C labelled unlike the 
dansylated substrate used here, and this may account for the lack of activity under 
the conditions. The buffer system in which activity was observed was as used for     
S. pneumoniae PBP2a in Chapter 4, and may require further optimisation for this 
particular protein. Additionally, C35 dansylated Lipid II could be synthesised and 
tested to identify the role of this shorter lipid chain on the observed activity 
differences.  
 
It is likely that efforts to observe PBP2-Δ59 transglycosylase activity by the 
continuous fluorescence assay were unsuccessful due to a poor rate undetectable by 
the time-course used for the SDS-PAGE assay. This may be due to the enzyme 
truncation, presence of the dansyl group on the substrate, or the buffer conditions 
used. Therefore successful purification of PBP2-FL and an extensive optimisation of 
the buffer system are important steps in the understanding of PBP2 transglycosylase 
activity, and are a priority for further work. 
 
5.8.2.3 Effect of Lipid II amidation on PBP2 transglycosylation 
 
PBP2-Δ59 demonstrates a clear preference for amidated Lipid II as a 
transglycosylase substrate. This was observed by SDS-PAGE analysis of glycan 
products, as efforts to observe activity by a continuous fluorescence assay were 
unsuccessful (Section 5.5.3). Lipid II amidation appears to affect processivity of 
PBP2-Δ59 polymerisation, however, a firm conclusion cannot be drawn as the 
reaction with Lipid II (Glu, Dans) did not go to completion overnight. This clearly 
identifies non-amidated Lipid II to be a poor substrate.  
 
The processivity of Staphylococcus aureus PBP2 transglycosylase activity has 
previously been studied (Rebets et al., 2014; Wang et al., 2008) with C35 non-
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amidated Lipid II substrate and full-length enzyme where glycan chains of ~15 
disaccharide units were observed. Based on previous gels and knowledge of chain 
length, an estimate of an average of 10 disaccharide units in length can be 
approximated for PBP2-Δ59 with amidated Lipid II, and much shorter (3-4 
disaccharides) with non-amidated Lipid II. A comparable study with full-length 
PBP2 is of great interest to identify any TM region mediated increase in processivity, 
as suggested for S. pneumoniae PBP2a (Helassa et al., 2012). Although the effect of 
detergent on this difference should be considered as discussed in Section 4.6.3.2. 
Interestingly, the average length of Staphylococcus aureus glycan chains in vivo is 6 
disaccharides, with a range from 3-10 (Boneca et al., 2000), which correlates well 
with the experimental data in this chapter. 
 
The work presented here testifies to the catalytic inefficiency of this enzyme with 
lipid II irrespective of amidation.  It is clear however, that this PBP functions in wild 
type Staphylococcus aureus not with lipid II but with lipid II carrying a pentaglycine 
branch on the ε-amino group of the stem peptide of this precursor. It is probable that 
PBP2 has a requirement for this branched precursor in order to catalyse 
transglycosylation fast enough to support cellular viability. This scenario is 
consistent with the observed essentiality of indirect cross-links in staphylococcal 
peptidoglycan  (Rohrer and Berger-Bächi, 2003).  
 
5.8.3 Combined transglycosylase activity of Staphylococcus aureus PBPs 
 
The Class B monofunctional transpeptidase PBP2a did not stimulate the processivity 
of Staphylococcus aureus PBP2-Δ59 activity (Figure 5.16), despite evidence for their 
functional interaction (Paulin et al., 2014; Pinho et al., 2001; Reed et al., 2011). 
However, both enzymes were truncated at the N-terminus to remove the 
transmembrane spanning domain. All evidence for the interaction of these proteins is 
with full-length versions and therefore the TM region may be important. It has been 
shown to be important in dimerisation of PBPs (Helassa et al., 2012 and Chapter 4) 
so likely also between proteins in complexes. Reed et al., (2011) identified other 
PBPs (SgtA, MGT and PBP1) involved in interactions and the experiments by Paulin 
et al., (2014) implicate the cell division protein FtsZ as well.  
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Therefore, it is likely that additional PBPs, cell division proteins and other 
interactions in the proposed cell wall synthesis complex (Section 5.8.4.2) are 
involved in functional interactions with PBP2. These may be able to stimulate the 
activity of PBP2; and an extensive range of experiments could be designed to test the 
many combinations. Consistent with this, MGT has recently been shown to extend 
glycan products of PBP2 (Rebets et al., 2014) and to have an optimal substrate of 
Lipid IV (Braddick et al., 2014), and therefore it would be of interest to identify if 
either PBP stimulates the activity of the other, along with working together to 
produce longer glycan chains (Rebets et al., 2014).  
 
Despite no observable effect on the processivity of PBP2, the rate of 
transglycosylase activity could not be studied due to issues in observing activity by 
the continuous fluorescence assay (Section 5.8.2.2).  
 
5.8.4 Biological implications 
 
5.8.4.1 The requirement for multiple transglycosylases 
 
Clear differences in the substrate specificity and processivity of Staphylococcus 
aureus MGT and PBP2 have been observed; with MGT producing longer glycan 
chains than PBP2 but being less affected by Lipid II amidation. Distinct 
requirements for observation of activity of the two enzymes have been seen 
previously (Abrahams, 2011; Barrett et al., 2005; Terrak et al., 2006). These make 
up two of the three transglycosylases in Staphylococcus aureus, with an additional 
nonessential monofunctional transglycosylase; SgtA (Reed et al., 2011). Multiple 
peptidoglycan transglycosylases are present in most bacteria, proposed to act at 
different stages of cell growth and division (Scheffers and Pinho, 2005). Indeed, 
PBP2 has been shown to localise to the septum during cell division in a substrate 
dependent manner (Pinho and Errington, 2005). The cellular localisation of MGT is 
as yet unknown. It has also been suggested that the structure of peptidoglycan varies 
at different locations in the cell, giving a requirement for different lengths of polymer 
(Wang et al., 2008). It was recently identified that glycan chain length plays a crucial 
role in determining Staphylococcus aureus morphology (Rebets et al., 2014) and that 
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the long chain lengths produced by MGT may be protective in cell wall stress, as 
gene expression of this monofunctional transglycosylases is upregulated (Balibar et 
al., 2010; Steidl et al., 2008). 
 
MGT transglycosylase activity becomes essential in the absence of an active PBP2, 
and whilst it is able to maintain cell viability, it cannot preserve β-lactam resistance 
in an MRSA background (Reed et al., 2011). This suggests that the long glycan 
chains produced by MGT are sufficient for correct growth and division but may not 
be a substrate for Staphylococcus aureus PBP2a transpeptidase activity, whereas 
those produced by PBP2 are a substrate for PBP2a, allowing coordinated synthesis of 
peptidoglycan in the presence of β-lactams. MGT and PBP2a have been shown to 
interact (Reed et al., 2011) but functionality of the complex has not been 
demonstrated to date and may be an artefact of the yeast two-hybrid system used. 
 
5.8.4.2 A cell-wall synthesis complex 
 
The cooperative function of Staphylococcus aureus PBPs in peptidoglycan synthesis 
is well documented (Leski and Tomasz, 2005; Pinho et al., 2001; Reed et al., 2011) 
and these are predicted to form part of a larger cell division complex (Steele et al., 
2011; Touhami et al., 2004). This is an increasingly disseminated hypothesis for 
many bacteria (see Section 1.7.2). MGT, SgtA, PBP1, PBP2 and PBP2a from 
Staphylococcus aureus have all been shown to interact (Reed et al., 2011). The 
monofunctional transglycosylase enzymes of Staphylococcus aureus have been 
shown to be non-essential in the presence of a functional PBP2 but it has been 
suggested that MGT and SgtA interact with PBP2 and other enzymes involved in cell 
wall synthesis as part of a larger, as-yet-uncharacterized cell wall-synthetic complex 
(Reed et al., 2011).  
 
It was recently observed that Staphylococcus aureus membrane particulates formed 
longer glycan chains when all transglycosylases were active than by MGT alone 
(Rebets et al., 2014), suggesting a combined effect of PBP2 and MGT mentioned in 
Section 5.8.4.1 and also the possibility of the involvement of the final 
transglycosylase (SgtA) or indirectly other cell-wall enzymes in increased 
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processivity. The combined effect of MGT and PBP2 was not studied here, but could 
be tested in further work. 
 
Additional evidence for the requirement of a peptidoglycan synthesis complex comes 
from the recent identification that formation of Lipid IV is rate limiting and more 
significantly so in Staphylococcus aureus MGT than any other enzyme tested (Wang 
et al., 2011). Combined with evidence for Lipid IV as the optimal substrate for MGT 
(Braddick et al., 2014) and that it can extend the polymers produced by PBP2 
(Rebets et al., 2014), a clear combined but ultimately non-essential (Reed et al., 
2011) role of at least these two transglycosylases at one or all stages of the cell cycle 
is suggested.  
 
5.8.4.3 Role of Lipid II amidation in Staphylococcus aureus 
 
Several explanations for the role of Lipid II amidation in Staphylococcus aureus 
viability have been suggested, including the requirement by peptidoglycan synthesis 
enzymes such as PBP2 and MGT (Figueiredo et al., 2012). Amidation has been 
shown to significantly affect growth rate, and resulting cells are of normal size but 
with fewer complete septa. Point mutations in the PBP2 active site cleft (in the 
extending polymer binding site) results in shorter glycan chains and septal 
abnormalities due to incorrect cell division regulation (Rebets et al., 2014). The 
morphology observed in mutants with depleted amidation of peptidoglycan 
intermediates could be explained by the ability of MGT to produce long chains with 
non-amidated Lipid II, and the presumed requirement for amidation for PBP2 
activity as demonstrated in this chapter. Experiments with PBP2-Δ59 suggest that 
stem peptide amidation affects PBP2 more significantly than MGT. If full-length 
PBP2 were to be less processive with non-amidated than amidated substrate, as the 
experiments with PBP2-Δ59 suggest, this may explain the septal abnormalities 
observed. Further work is required to confirm this as all of the literature to date 
concerns the non-amidated substrate, and full-length PBP2 was not studied here.  
 
The substrate for the MurT/GatD amidation complex has been identified as either 
Lipid II or Lipid II Gly5 (Münch et al., 2012). Recent work in our lab has shown that 
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FemX, FemA and FemB will append a pentaglycine branch to amidated Lipid II 
(Rebecca Bolton, personal communication). If FemXAB is shown to act 
preferentially on amidated Lipid II, then this could suggest that Lipid II amidation 
occurs before the addition of the pentaglycine branch. It would suggest an 
importance for amidation in Lipid II branching, and help to explain the requirement 
of both isoglutamine containing pentapeptides and Gly5 branch for full expression of 
methicillin resistance (Münch et al., 2012; Rohrer and Berger-Bächi, 2003). 
 
This may also help to explain the decrease in β-lactam resistance observed on 
depletion of amidation (De Lencastre et al., 1999). Alternatively it has been 
suggested that structurally abnormal cell wall peptides are poor substrates for PBP2a 
(Figueiredo et al., 2012; Strandén et al., 1997). This may be directly, or due to 
poorer utilisation of the non-amidated Lipid II by PBP2 to produce the polymerised 
substrate for cross-linking.  
 
At least one of the two peptidoglycan stem peptides must be amidated for cross-
linking to occur (Nakel et al., 1971), and very high cross-linking (> 95%) is required 
for Staphylococcus aureus survival. A reduction in cross-linking results in aberrant 
septum formation and deformed cells (Gally and Archibold 1993). The role of 
amidation in this could be; directly, through amidated Lipid II being a better 
substrate for PBP2a, PBP2 or PBP4 or through the increased branching of amidated 
Lipid II by FemXAB producing an optimal substrate for cross-linking by these 
enzymes.  
 
It is clear that many factors are involved in the observed phenotypes (reduced growth 
rate and increased susceptibility to lysozyme and methicillin) on depletion of 
amidation, and the results shown here support the evidence that the essentiality is at 
least in part due to the substrate specificity of the Staphylococcus aureus 
transglycosylases. 
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5.8.5 The characterisation of novel carbohydrate based transglycosylase 
inhibitors 
 
Two carbohydrate-based compounds were tested against Staphylococcus aureus 
MGT-Δ28(FL) as putative transglycosylase inhibitors. IC50 values of 26.1 µM ± 2.7 
(17 µg.ml-1) and 15.6 µM ± 2.0 (11 µg.ml-1) were established for ACL202015 and 
ACL20964 respectively, compared to 5.1 µM ± 0.729 (8 µg.ml-1) for moenomycin. 
These results suggest that ACL202015 and ACL20964 do not bind as strongly to the 
active site (binding site predicted by docking (Zuegg et al., 2015)) as moenomycin. 
Notably, the IC50 value obtained for moenomycin by this assay was higher than 
expected given its tight binding nature. Despite this, the results (in concert with 
others within the paper) clearly identify these compounds as inhibitors of 
transglycosylase activity.  
 
5.8.5.1 Limitations of the assay used 
 
The assumption of 100% turnover of Lipid II in the continuous assay was not made, 
as there was insufficient evidence to justify it (see section 4.6.2.2 for discussion). 
Therefore, in order to establish a Km for Lipid II (Glu, Dans) polymerisation by 
MGT-Δ28(FL) the initial rate in RFU/second was plotted against substrate 
concentration. This method allows comparison of the initial rates of fluorescence 
decrease due to incorporation of substrate into glycan chains, but does not enable 
rates as a factor of µM quantities of Lipid II per unit time to be established. 
However, the range of substrate concentrations tested did not allow the rate to 
plateau with respect to substrate concentration. Notably, the fit to Equation 4 
(Section 5.7.4) suggests cooperativity in activity with respect to substrate 
concentration, as was seen for S. pneumoniae PBP2a (Section 4.5.4). The recent 
identification of cooperativity in substrate binding to the donor and acceptor 
transglycosylase sites of S. aureus MGT (Bury et al., 2015), and the suggestion of 
cooperativity seen in this chapter highlights the need for further work in this respect. 
Due to substrate limitations, a published value was used to calculate substrate 
concentrations for inhibitor testing.  
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This calculation resulted in a 1.45:1 ratio of substrate:enzyme in subsequent assays 
which initially does not seem realistic given the requirement for two molecules of 
substrate for each molecule of enzyme. However, the initiation step of 
transglycosylation has been shown to be limiting in MGT (Wang et al., 2011) and 
long polymers were observed even at a 1:1 enzyme to substrate ratio, accounted for 
by slow initiation resulting in only a small amount of the available enzyme 
producing polymers with the available substrate. Therefore, the ratio of Lipid 
II:enzyme used here should enable polymer formation for digestion by N-
acetylmuramidase, but does mean that the active enzyme concentration is likely to be 
overestimated. This also has implications for any conclusions surrounding the 
tightness of binding of inhibitors, such as moenomycin, as the inhibitor will be 
binding to enzyme molecules that would otherwise not be actively polymerising.  
 
The structural similarity between the lysozyme and transglycosylase active site 
(Lovering et al., 2007; Yuan et al., 2007) raises an important point in the usefulness 
of this continuous assay for the identification of novel inhibitors of transglycosylase 
activity. The interaction of moenomycin with lysozyme is not reported in the 
literature. However, the presence of a large excess of lysozyme as a coupling enzyme 
in the assay would require its potent inhibition by moenomycin or the novel 
inhibitors observed tested here. Additionally, a sigmoidal relationship with respect to 
fluorescence decrease over time would be expected as active lysozyme concentration 
is reduced below that able to support a linear rate, but this was not observed. Finally,  
both ACL202015 and ACL20964 were shown to inhibit transglycosylation by an 
orthogonal assay without the need for a coupling enzyme (Zuegg et al., 2015) 
supporting the conclusions drawn from the fluorescence data reported here.  
 
Non-amidated Lipid II was used in this investigation due to substrate availability and 
previous experiments identifying no difference in rate of the continuous assay of 
MGT-Δ28(FL)  (Section 5.8.1.2). The previous experiments did not establish kinetic 
parameters for the two substrates, which may differ. Therefore a full analysis of 
MGT-Δ28(FL) activity with a range of Lipid II and enzyme concentrations would 
establish this. If a difference is observed, then a variation in the effect of the 
inhibitors may also be observed and should be tested. 
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5.8.5.2 Implications of the results  
 
Zuegg et al., 2015 (attached at the end of this thesis; Appendix 8) showed via a  
series of membrane based transglycosylase assays and membrane-disruption 
experiments that ACL202015 and ACL20964 were able to inhibit transglycosylase 
activity without disrupting the cell membrane. Both compounds showed good in 
vitro antibacterial activity against a range of Gram-positive bacteria, including drug 
resistant MRSA, GISA and VanA enterococci as well as good in vivo efficacy with 
no toxicity. Fluorescent NBD-Lipid II incorporation assays showed these compounds 
to inhibit Staphylococcus aureus MGT, and the dose response assays described here 
support and extend from this, providing IC50 data in a comparable range to that of 
moenomycin. The data reported here was consistent with virtual docking 
experiments showing that in comparison to moenomycin, both compounds partly 
occluded both the donor and acceptor binding site. Consequently the data reported 
here suggests that these molecules may be considered to be lead compounds in 
further transglycosylase directed antimicrobial drug discovery. 
 
5.8.5.3 Further work 
 
The discussion of the data covered in this section leads to the suggestion of a number 
of aspects of further work in the study of these inhibitors.  
 
Confirmation of the IC50 values by an alternative assay system such as the recently 
published Förster resonance energy transfer (FRET) method (Huang et al., 2013) 
could be used to confirm the results. This would be an essential step in adding weight 
to these findings, and could enable a kinetic analysis of the mode of inhibition 
(competitive, un-competitive (unlikely) or non-competitive) by ACL202015 and 
ACL20964 that could confirm their mode of action as inhibitors suggested by the 
virtual docking experiments. The inhibitors should also be tested with other 
transglycosylases, in particular bifunctional PBPs from pathogens of current clinical 
concern. 
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Co-crystallisation of MGT and other Gram-positive transglycosylases with the 
compounds would allow the predicted binding site to be confirmed. This knowledge 
could aid the design of future novel inhibitors and antibiotics. 
 
5.9 Conclusion 
 
Differences in processivity and substrate specificity of the Staphylococcus aureus 
transglycosylases have been identified, contributing to a new understanding of the 
role of Lipid II amidation in bacterial cell wall biosynthesis. Two novel carbohydrate 
based compounds were shown to be inhibitors of transglycosylase activity, aiding the 
hunt for new antimicrobials. 
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Chapter 6. Enzymology of transpeptidation: towards 
kinetic characterisation of the peptidoglycan cross-linking 
activity of Streptococcus pneumoniae PBPs 
 
6.1 Introduction 
 
The final step in the biosynthesis of peptidoglycan is the formation of a peptide bond 
between the third and fourth position amino acids of adjacent pentapeptide stems 
(Ghuysen, 1991). These crosslinks may be direct or indirect via a peptide branch, and 
are critical for structural rigidity of the final glycan sacculus (Vollmer et al, 2008). 
Formation of the peptide bond is catalysed by the transpeptidase activity of HMW 
bifunctional and monofunctional transpeptidase PBPs (Section 1.7.4)). The 
transpeptidase (penicillin-binding) domain of PBPs is the target for β-lactam 
antibiotics (Ghuysen, 1991), to which high levels of resistance have developed 
through several mechanisms in S. pneumoniae (Section 1.8.1). Investigating the 
peptidoglycan cross-linking activity of the PBPs is crucial in understanding the 
mechanisms of cell wall synthesis, as well aiding in the discovery of novel antibiotic 
agents.  
 
6.1.1 Streptococcus pneumoniae β-lactam resistance 
 
A primary factor in pneumococcal β-lactam resistance is the presence of low affinity 
PBPs. In addition, the presence of an L-Ala-L-Ala or L-Ser-L-Ala bridge on the third 
position lysine is associated with high level resistance and these strains exhibit 
elevated levels of inter-peptide branching (Garcia-Bustos and Tomasz, 1990) 
(Section 1.8.1). It has long been hypothesised that glycan chains with branched 
pentapeptides might be preferential substrates for the resistant PBPs, allowing them 
to maintain their cell wall synthetic activity and produce the high levels of branched 
cross-links observed whilst having a low affinity for the substrate mimic β-lactam 
ring (Filipe and Tomasz 2000). Mutations conferring resistance to β-lactams have 
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been associated with alterations in transpeptidase active site shape and charge. 
Greater flexibility is observed in the active site of PBP1a, PBP2b and PBP2x in 
resistant strains, through alterations in β3 and β4 of the β-sheet (Contreras-Martel et 
al., 2006; 2009; Job et al., 2008; Pernot et al., 2004). Crystal structures have shown 
the monofunctional transpeptidases (PBP2b and PBP2x) from some resistant 
pneumococcal strains to have more open active sites as a result of mutations 
(Contreras-Martel et al., 2009; Dessen et al., 2001; Pernot et al., 2004), with larger 
changes in the PBP2b active site associated with higher levels of resistance 
(Contreras-Martel et al., 2009). The biochemical characterisation of substrate 
specificity of these enzymes will enable the importance of the aforementioned active 
site changes to be investigated.  
 
6.1.2 Assays for transpeptidase activity 
 
The penicillin-binding domain of PBPs is responsible for both transpeptidase and 
carboxypeptidase activity, both of which result in the release of D-alanine (Section 
1.7.4.2). Most existing assay methods for studying the penicillin-binding domain do 
not distinguish between transpeptidase and DD-carboxypeptidase activity, and those 
that do are discontinuous in their nature. A sensitive, continuous assay of 
transpeptidase activity is required to enable detailed insight into the kinetic 
properties of this critical role of PBPs.  
 
6.1.2.1 Assay systems using substrate analogues 
 
Prior to the availability of physiologically relevant lipid-linked substrates, a thiol-
ester analogue of the stem peptide (S2d) was used as a donor along with amino acid 
acceptors in order to identify transpeptidation (Adam et al., 1991; Jamin et al., 1993; 
Wilkin et al., 1993). Analogue hydrolysis through thioesterase activity of PBPs is 
monitored spectrophotometrically. Additionally, substrate analogues or inhibitors 
can be used to determine the acylation and deacylation rates of PBPs by measuring 
the quenching of intrinsic protein fluorescence upon binding (Jamin et al., 1993; 
Josephine et al., 2006) and deacetylation alone was studied with [3H]-
benzylpenicillin labelling of PBPs, by monitoring the reduction in protein 
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radioactivity over time (Pagliero et al., 2004). A high throughput assay for binding to 
immobilised PBPs followed by treatment with biotin-ampicillin has been established 
(Stefanova et al., 2010). Subsequent addition of streptavidin-horseradish peroxidase 
(HRP) and a fluorogenic HRP substrate enables quantification of binding.  These 
latter techniques are not able to distinguish between transpeptidase and DD-
carboxypeptidase activities, and all use non-canonical substrates. 
 
6.1.2.2 Assay systems using native substrates 
 
Recent advances in synthesis of the native Lipid II substrates for PBPs (Breukink et 
al., 2003; Lloyd et al., 2008; VanNieuwenhze et al., 2002; Schwartz et al., 2001), 
has made direct assays of transpeptidase activity possible. Detection of cross-linked 
material is either directly through chromatographic separation of reaction products, 
or indirectly through the detection of released D-Ala as described in the following 
section.  
 
6.1.2.2.1 Chromatographic methods 
 
The products of peptidoglycan synthesis can be separated by HPLC or SDS-PAGE, 
with the former enabling quantitative analysis. Vinatier et al., (2009) separated 
peptidoglycan products by HPLC following incubation of E. coli membranes with D-
Cys containing UDP-MurNAc-pentapeptides. Products were labelled with 
fluorescein maleimide prior to digestion, HPLC separation, and mass spectrometry to 
confirm the presence of cross-linked peptide stems. More recently, radiolabelled 
products of peptidoglycan biosynthesis by E. coli PBP1a (Born et al., 2006) and 
PBP1b (Bertsche et al., 2005) were separated by HPLC. This enabled the 
investigation of acceptor strand specificity for transpeptidation. Biboy et al., (2013) 
give a detailed account of this technique. Analysis of the chromatogram and mass 
spectrometry of products allows identification of muropeptides, their relative 
abundance and the extent of cross-linking. Liquid-chromatography mass 
spectrometry (LC-MS) enables rapid identification of PBP products using 
completely native substrates (Lebar et al., 2013). 
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SDS-PAGE analysis of glycan chains has been used as an assay for transglycosylase 
activity previously (covered in more detail in Section 4.1.2). Through the use of 
either radiolabelled or a mix of 10% fluorescently labelled (90% non-labelled) Lipid 
II and a penicillin G control, cross-linking can occur and transpeptidase activity can 
be probed (Barrett et al., 2007; Helassa et al., 2012; Zapun et al., 2013). However, 
unlike the HPLC method, cross-links cannot be proven, as high molecular weight 
material is excluded from the gel regardless of whether it is long glycan chains or 
cross-linked peptidoglycan.  
 
6.1.2.2.2 Spectrophotometric assays 
 
Both transpeptidation and D,D-carboxypeptidation result in the release of the 
terminal D-Ala from the pentapeptide stem (Section 1.7.4.2), and therefore detection 
of D-Ala can be used to indirectly follow these enzymatic activities. The first use of 
this method was by Mirelman et al., (1972) through the incorporation of UDP-
MurNAc-L-Ala-D-Glu-L-Lys-D-Ala-[14C]-D-Ala into Micrococcus luteus 
membranes. The release of [14C]-D-Ala due to PBP activity was used to measure the 
composite transpeptidase and carboxypeptidase activities. Chromogenic assays are 
now available to follow D-Ala release in a continuous manner and could be used to 
follow transpeptidation, as described later in this chapter. (Section 6.4) 
 
6.1.2.2.3 D-amino acid exchange 
 
E. coli PBP1b will incorporate D-amino acids into the stem peptide in place of the 
terminal D-Ala in vitro, a phenomena which also occurs in vivo, and is thought to 
have a role in signalling (Lupoli et al., 2011). Lupoli et al., (2014) established an 
assay to monitor [14C]-D-Ala incorporation as method to study transpeptidation.  
 
6.1.3 Studying S. pneumoniae transpeptidase activity 
 
The assays described here have been used in attempts to study the mechanism of 
transpeptidation. However many fail to distinguish between this and D,D-
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carboxypeptidase activity, use a non-native substrate as a proxy or are discontinuous 
in their nature. Consequently, much more is known about the interaction of the 
penicillin-binding domain with β-lactams than kinetic parameters with native 
substrates (Lupoli et al., 2011). 
 
Progress has been slow, with the vast majority of published literature to date 
concerning only Gram-negative PBPs, in particular those from E. coli. 
Transpeptidase activity of these enzymes was identified in vitro by several methods 
(Bertsche et al., 2005, Born et al., 2006) and only very recently significant advances 
have been made in understanding the substrate specificity and kinetic parameters 
associated with it (Lebar et al., 2013, Banzhaf et al., 2012). Discovery of the role of 
the outer membrane lipoproteins LpoA and LpoB in E. coli PBP1a and PBP1b 
peptidoglycan assembly respectively (Lupoli et al., 2014) has in part helped to 
explain the reasons for difficulties encountered with in vitro reconstitution. LpoA 
was shown to stimulate PBP1a catalysed cross-linking by 4.5 fold in vitro. 
Additionally double knock-outs of PBP1a-LpoB and PBP1b-LpoA were lethal which 
demonstrates the critical role of these lipoproteins in vivo (Typas et al., 2010). 
 
Cross-linked peptidoglycan was observed in early work using both isolated 
membranes and purified PBPs from Bacillus megaterium and Bacillus 
stearothermophilus (Jackson and Strominger, 1984; Linnett and Strominger, 1974; 
Schrader et al., 1974; Wickus and Strominger, 1972), however reconstitution of 
peptidoglycan assembly in other Gram-positive bacteria has historically been 
problematic. Only very recently, the first in vitro observation of transpeptidase 
activity from S. pneumoniae was made (Zapun et al., 2013), and shown to be 
critically dependent on amidation of the stem-peptide. This discovery should 
facilitate the development of assays to study cross-linking in Gram-positive bacteria 
in more detail.  
 
6.1.4 Aims of this chapter 
 
Of the five synthetic PBPs in S. pneumoniae; PBP1a, PBP2a, PBP1b, PBP2b and 
PBP2x (Section 1.8.2), PBP2b and PBP2x are essential (Kell et al., 1993), and one of 
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either PBP2a or PBP1a must be functional for cell viability (Hoskins et al., 1999). 
Variants of all four are involved in β-lactam resistance, although mutations in PBP2a 
have only been described occasionally (Hakenbeck et al., 2012; Zapun et al., 2008).  
 
This chapter focuses on the in vitro detection of bifunctional PBP1a and PBP2a 
transpeptidase activity, concentrating particularly on PBP1a due to its more 
significant role in β-lactam resistance (Section 1.8.2; Barcus et al., 1995; Hakenbeck 
et al., 2012). The predominant objective was to observe cross-linking using a 
continuous assay for the first time, with the eventual aim of studying the substrate 
specificity of PBP1a from resistant and susceptible strains with the dipeptide 
branched substrates, in order to test the long standing hypothesis described in Section 
6.1.1. 
 
6.2 Experimental aims 
 
• To detect transpeptidase activities of S. pneumoniae PBP1a and PBP2a by 
SDS-PAGE analysis. 
• To observe S. pneumoniae PBP1a and PBP2a transpeptidase activity by a 
continuous spectrophotometric assay. 
• To investigate substrate specificity of the transpeptidase activity by PBPs 
from β-lactam susceptible and resistant S. pneumoniae strains. 
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6.3 Detection of transpeptidase activity by SDS-PAGE 
 
Zapun et al., (2013) first made observations consistent with in vitro transpeptidase 
activity of S. pneumoniae PBP1a and PBP2a by SDS-PAGE and mass-spectrometry. 
Full-length (including the transmembrane domain) variants of these enzymes were 
purified as described in Section 4.3.1 and 4.3.3 respectively, according to the 
protocol employed by Zapun et al., and therefore transpeptidase activity under the 
same conditions was expected. Tris-Tricine SDS-PAGE analysis of overnight 
reaction products was performed as described in Section 6.1.2.2.1 in order to confirm 
this.  
 
6.3.1 Demonstration of PBP1a and PBP2a in vitro peptidoglycan assembly 
 
A mix of 50 µM non-dansylated and 5 µM dansylated Lipid II (either Lipid II (Glu) 
or Lipid II (Gln)) was incubated with 1 µM PBP1a or PBP2a at 30°C overnight. 
Reactions were in the presence and absence of moenomycin (0.5 mM) or penicillin G 
(1 mM) as inhibitors of transglycosylation and transpeptidation respectively. 
Reaction buffers were, PBP1a; 50 mM HEPES pH 7.5, 10 mM MgCl2, 150 mM 
NaCl, 25% (v/v) DMSO, 0.02% (v/v) Triton X-100, and PBP2a; 50 mM HEPES pH 
7.5, 25 mM MgCl2, 200 mM NaCl, 25% (v/v) DMSO, 0.02% (v/v) Triton X-100 and 
products were analysed by SDS-PAGE (Section 2.8.2) (Figure 6.1).  
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Figure 6.1 demonstrates the same high molecular weight band observed by Zapun et 
al., (2013) with PBP1a, which is not detected in the presence of penicillin G. As 
previously described by Zapun and colleagues, this band is more significant in the 
presence of amidated Lipid II, consistent with the hypothesis that amidation was 
required for efficient peptidoglycan assembly. The same band was observed with 
incubation of amidated Lipid II and PBP2a, and not detected with non-amidated 
Lipid II. However, unlike in the earlier study, this high molecular weight band was 
not removed by the addition of penicillin G. Figure 4.6 also identified this species in 
an assay of transglycosylase activity with the same enzyme, thus demonstrating the 
clear limitation of this assay system for the differentiation between long polymers 
and cross-linked glycan chains, both of which are unable to enter the polyacrylamide 
gel matrix.  
PBP1a FL PBP2a FL 
Lipid II (Glu) Lipid II (Gln) Lipid II (Glu) Lipid II (Gln) 
Pen Moe Pen Moe - - - Pen Moe Pen Moe - 
i 
ii 
iii A B 
Figure 6.1 Assembly of peptidoglycan by S. pneumoniae PBP1a (A) and PBP2a (B) Mixture of 50 
µM Lipid II (Lipid II (Glu) or Lipid II (Gln)) and 5 µM dansylated Lipid II (Lipid II (Glu, Dans) or 
Lipid II (Gln, Dans) as labelled below the gel and 1 µM PBP1a or 1 µM PBP2a where indicated. -,no 
inhibitor; Pen, 1 mM penicillin G; Moe, 0.5 mM moenomycin. Products of reaction separated on a 
8.5% T/2.7% C Tris-Tricine SDS-PAGE gel. Dansyl fluorescence at 521 nm detected using a blue light 
converter and short pass filter on a GeneSnap Gel Doc. (i) denotes unpolymerised Lipid II; (ii) glycan 
chains of varying lengths and (iii) the very high molecular weight material, which does not enter the 
gel. 
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6.3.2 Time dependency of peptidoglycan assembly 
 
With the main aim of observing peptidoglycan cross-linking in a continuous assay 
format, the experiment in Section 6.3.1 was repeated with incubation for 1 hour, a 
reasonable time-course over which activity could be monitored in a 
spectrophotometric assay. Due to the clear preference for amidated substrate 
observed by Zapun et al., (2013), as well as in Chapter 4 of this thesis and Figure 
6.1, only this substrate was tested.  
 
A mix of 50 µM Lipid II (Gln) and 5 µM Lipid II (Gln, Dans) was incubated with 1 
µM PBP1a or PBP2a at 30°C for 1 hour in the presence and absence of moenomycin 
(0.5 mM) or penicillin G (1 mM). Reaction buffers were as described in Section 
6.3.1. Reaction products were analysed by SDS-PAGE (Section 2.8.2) (Figure 6.2).  
 
The band previously attributed to cross-linked peptidoglycan was observed following 
a 1 hour incubation with both PBP1a and PBP2a, and not in the presence of 
Penicillin G demonstrating that in principle, cross-linking could be monitored in a 
continuous assay format in a reasonable time frame.  
 
PBP1a is more biologically relevant than PBP2a in the context of antibiotic 
resistance (Barcus et al., 1995; Hakenbeck et al., 2012), and therefore was prioritised 
for further work in the first instance. Additionally Figure 6.2 shows that with 
amidated Lipid II, a single clean band is observed which does not enter the gel, as 
opposed to the smear seen with PBP2a, consistent with a mix of cross-linked and 
non-cross-linked material. This could complicate analysis, and supports the decision 
to carry out initial optimisation with PBP1a.  
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6.3.3 Characterisation of the high molecular weight species 
 
One significant limitation of the method used by Zapun et al., (2013), and the 
conclusions that could be drawn from by it, is that the band of product unable to 
enter the gel matrix was not characterised. The controls used allow an interpretation 
that it consists of cross-linked peptidoglycan, however, the same band has been 
observed within this thesis in assays of transglycosylase activity, where cross-linking 
cannot occur, such as with the Staphylococcus aureus monofunctional 
transglycosylase (MGT) and Streptococcus pneumoniae PBP2a (Chapter 4 and 5). 
Pen Moe Pen Moe - - 
i 
ii 
iii A B 
PBP1a FL PBP2a FL 
Figure 6.2 Time dependency of peptidoglycan assembly by S. pneumoniae 
PBP1a (A) and PBP2a (B) Mixture of 50 µM Lipid II (Gln) and 5 µM dansylated 
Lipid II (Gln, Dans) incubated with 1 µM PBP1a or 1 µM PBP2a where indicated 
for 1 hour. -,no inhibitor; Pen, 1 mM penicillin G; Moe, 0.5 mM moenomycin. 
Products of reaction separated on a 8.5% T/2.7% C SDS-PAGE gel. Dansyl 
fluorescence at 521 nm detected using a blue light converter and short pass filter on a 
GeneSnap Gel Doc. (i) denotes unpolymerised Lipid II; (ii) glycan chains of varying 
lengths and (iii) the very high molecular weight material, which does not enter the 
gel. 
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Zapun and colleagues carried out mass spectrometric identification of cross-linked 
product, however all reaction products were analysed, rather than the band from the 
gel. Additionally, the mass observed could represent a dimer of disaccharide-
pentapeptide and disaccharide-tetrapeptide cross-linked through the pentapeptide 
stem, or through a β-1,4-linkage between sugars (Figure 6.16). Furthermore the 
masses were inconsistent with the presence of a dansyl group, further reducing the 
support they give that the high molecular-weight fluorescent material unable to 
migrate on SDS-PAGE was cross-linked peptidoglycan. Positive ion fragmentation is 
required to differentiate the two. Therefore, two attempts were made to analyse the 
high molecular weight band from Figure 6.2 (A) by positive ion mass spectrometry 
in order to identify its composition. The method used is detailed in Section 2.8.3. 
 
The band was cut from the gel under UV illumination, the acrylamide dehydrated 
and N-acetylmuramidase digestion performed in gel (similar to that for tryptic digest 
of proteins for mass spectrometry). Initially, digestion was overnight with hen egg-
white lysozyme before removal of protein and acrylamide by heating and 
centrifugation. Lysozyme was chosen as its smaller molecular weight (14.3 kDa) 
compared to mutanolysin (27 kDa) was thought better for entering the acrylamide 
matrix and therefore accessing the peptidoglycan polymers. The supernatant was 
analysed by positive ion mass spectrometry, however no species identifiable to either 
polymeric glycan chains, or cross-linked peptidoglycan were observed. A repeat 
experiment using mutanolysin for digestion, and with removal of the undecaprenyl 
phosphate lipid linker by phosphoric acid hydrolysis was also unsuccessful. In both 
cases no species characteristic of either polymerised or cross-linked glycan chains 
were observed. 
 
The identity of the high molecular weight band observed could not be categorically 
proven, however the controls used both here and some of those executed by Zapun et 
al., (2013) are consistent with the presence of cross-linked peptidoglycan produced 
by the S. pneumoniae bifunctional PBPs; PBP1a and PBP2a.  
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6.4 Towards a continuous assay of S. pneumoniae PBP 
transpeptidase activity 
 
The Amplex Red assay for D-Ala release (Figure 6.3 (B)) can be used to follow both 
transpeptidase and DD-carboxypeptidase activity. Dr Adrian Lloyd (University of 
Warwick) has established this to be specific for the former through detailed work on 
E. coli PBP1b with the use of (transpeptidase) donor only and acceptor only 
substrates as well as appropriate controls. By incubation of a donor only Lipid II 
with PBP initially, any DD-carboxypeptidase activity can be accounted for before the 
addition of an acceptor that allows subsequent transpeptidase activity to be followed. 
Controls lacking Lipid II enable any background rate to be taken into consideration. 
Standard methods for the assay system are detailed in Section 2.8.4. 
 
Many of the experimental decisions detailed within this section are informed by on-
going unpublished data and personal communications with Dr A. Lloyd. As 
mentioned in Section 6.3.2, S. pneumoniae PBP1a was prioritised for initial work, 
due to its importance in β-lactam resistance. This section details the steps taken to 
observe PBP1a transpeptidase activity by the Amplex Red assay, the scheme for 
which is illustrated in Figure 6.3.  
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A 
B 
Native 
cross-link 
D-Amino acid 
exchange 
Figure 6.3 Amplex Red assay for D-Ala release as an assay for transpeptidase activity 
A:Schematic showing PBP catalysed transpeptidation between two stem peptides and incorporation of 
a simple glycine acceptor, both of which result in release of D-Ala. Use of a donor only substrate as 
Stem peptide 1 (not shown as not synthetically available at this point) allows D-Ala release due to 
transpeptidation and D,D-carboxypeptidation to be differentiated. B: Amplex Red assay for D-Ala 
release. D-amino acid oxidase (DAAO) catalyses the oxidation of D-Ala to pyruvate, with the release 
of hydrogen peroxide. Horseradish peroxidase (HRP) uses hydrogen peroxide to convert Amplex Red 
to resorufin, which absorbs strongly at 555 nm. 
 
  
242 
 
6.4.1 Initial attempts to detect transpeptidase activity 
 
E. coli PBP1b will incorporate D-amino acids into the stem peptide in place of the 
terminal D-Ala in a process known as D-amino acid exchange (Lupoli et al., 2011), 
and therefore the Amplex Red assay was optimised to use simple acceptors such as 
D-Lac and Glycine (Dr A Lloyd, Personal Communication). Combined with a Lipid 
II substrate that can only be a donor, and accounting for background D,D-
carboxypeptidase activity. Initial attempts to observe S. pneumoniae PBP1a 
transpeptidase activity were under the conditions used for SDS-PAGE analysis 
(Section 6.3.1). A donor only Lipid II substrate was not available and given the 
preference for amidated Lipid II for PBP1a transglycosylase (Chapter 4) and 
transpeptidase activity (Figure 6.2 and Zapun et al., 2013), Lipid II (Gln) was used as 
a substrate initially. This removes the ability to distinguish transpeptidation and 
carboxypeptidation as Lipid II (Gln) can be both a donor and an acceptor, but the 
identification of any rate at all was initially desired. L-Lys or L-Ala were added as 
additional acceptors in high excess, which was hoped to favour their incorporation. 
L-amino acids were chosen as the true acceptors in vivo are the ε-amino group of L-
Lys or the α-amino group of L-Ala rather than meso-DAP in E. coli. PBP1a was 
tested at 1, 5 and 10 µM with 20 µM Lipid II (Gln) and 0.1 M L-Lys or L-Ala. The 
experimental procedure was as described in Section 2.8.4.  
 
No change in absorbance at 555 nm was observed under any of the conditions 
attempted. The coupling enzyme system was tested with the addition of 5 µM D-Ala, 
which confirmed that the lack of observable activity was not due to the inability of 
the assay system to detect D-Ala release.  
 
6.4.2 Alternative substrates 
 
Previous (Abrahams, 2011; Helassa et al., 2012; Zapun et al., 2013) attempts to 
monitor PBP1a transpeptidase activity have shown a clear requirement for stem 
peptide amidation. However, the use of amidated Lipid II was unsuccessful in 
producing detectable activity in the Amplex Red assay with simple acceptors, as 
described in Section 6.4.1.  
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Dr A. Lloyd identified MurNAc-pentapeptide to be an efficient acceptor in the E. 
coli PBP1b assay system. MurNAc-pentapeptide is routinely made from UDP-
MurNAc-pentapeptide by acid hydrolysis, with approximately a 50% yield (Julie 
Todd, Personal Communication). In order to test this alternative acceptor, amidated 
UDP-MurNAc-pentapeptide (Gln)(Section 3.3) was hydrolysed by the standard acid 
method (Section 2.6.2.1), and an alternative enzymatic method (Section 2.6.2.2) 
investigated in an attempt to obtain a greater yield.  
 
6.4.2.1 Acid hydrolysis of UDP-MurNAc-pentapeptide 
 
10 mg UDP-MurNAc-pentapeptide (Gln) was hydrolysed with 0.1 M HCl and 
purified by anion exchange (Full details in Section 2.6.2.3). Figure 6.4 (A) shows the 
anion exchange chromatogram, identifying the MurNAc-pentapeptide (Gln) peak 
detected by its absorbance only at 218 nm (peptide bonds)(Figure 6.4 (A)(i)). 
MurNAc-pentapeptide absorbs at 218nm but not 254 nm or 280 nm due to the loss of 
the uridine ring. Peak (ii) is known to be UMP and (iii) UDP (Dr A. Lloyd, Personal 
Communication). Peak (i) was selected, freeze dried three times and resuspended in a 
small volume of H2O. Negative ion mass spectrometry (Figure 6.4 (B)) confirmed 
the presence of MurNAc-pentapeptide (Gln) (observed/expected m/z [m-H]- 
761.3578/761.3759) 
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6.4.2.2 Enzymatic hydrolysis of UDP-MurNAc-pentapeptide 
 
The acid hydrolysis method typically yields approximately 50%, and therefore an 
alternative enzymatic method was investigated in parallel, in an attempt to improve 
this. 10 units each of Phosphodiesterase from Crotalus adamanteus (Sigma-Aldrich;  
to cleave the phosphodiester linkage), and Shrimp alkaline phosphatase (SAP; NEB) 
(to remove the remaining phosphate) were used, based on their quoted specific 
activity, and a Tris.HCl buffer at pH 8.5 chosen as it is within the optimal pH range 
of both enzymes. Full methods are detailed in Section 2.6.2.2. Despite the poor 
separation by anion exchange (Figure 6.5 (A)), peak (i) was identified as MurNAc-
[M-H]- 
A 
B 
(i) 
(ii) 
(iii) 
Figure 6.4 Acid hydrolysis of UDP-MurNAc-pentapeptide (Gln). A. Anion exchange 
chromatography of acid hydrolysed UDP-MurNAc-pentapeptide. Blue; absorbance at 280 nm 
(mAu), Red; absorbance at 254 nm (mAu), Pink; absorbance at 218 nm (mAu), Black; conductivity 
(mS.cm-1). (i) MurNAc-pentapeptide (2.20 mS.cm-1), (ii) UMP (19.24 mS.cm-1), (iii) UDP (28.69 
mS.cm-1). B: Negative ion time-of-flight spectra of peak (i). Expected m/z [m-H]-=761.3759, 
observed [m-H]- 761.3578 
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pentapeptide (Gln) by negative ion mass spectrometry (observed/expected m/z      
[m-H]- 761.3756/761.3759) Peak (iii) was identified as MurNAc-pentapeptide 
monophosphate by negative ion mass spectrometry (not shown), remaining due to 
the inefficient activity of SAP. Peak (ii) was not analysed by mass spectrometry, but 
was assume to be either uridine or uracil due to its lack of negative charge and 
absorbance at all three wavelengths.  
 
 
 
 
[M-H]- 
A 
B 
(i) 
(ii) 
(iii) 
Figure 6.5 Enzymatic hydrolysis of UDP-MurNAc-pentapeptide (Gln). A. Anion 
exchange chromatography of UDP-MurNAc-pentapeptide hydrolysed with 10 units 
phosphodiesterase and 10 units shrimp alkaline phosphatase. Blue; absorbance at 280 
nm (mAu), Red; absorbance at 254 nm (mAu), Pink; absorbance at 218 nm (mAu), 
Black; conductivity (mS.cm-1). (i) MurNAc-pentapeptide (1.60 mS.cm-1), (ii) uridine 
(1.21 mS.cm-1), (iii) MurNAc-pentapeptide monophosphate (11.46 mS.cm-1). B: 
Negative ion time-of-flight spectra of peak (i). Expected m/z [M-H]-=761.3759, 
observed m/z [M-H]-=761.3756 
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6.4.2.3 Method choice 
 
MurNAc-pentapeptide was produced by both methods, as confirmed by negative ion 
mass spectrometry (Figure 6.4 (B) and 6.5 (B)). Removal of the uridine ring means 
that quantification by absorbance at 260 nm is no longer possible. Instead, the 
Amplex Red assay for D-Ala release was used coupled with E. coli DacB (Class C 
D,D-carboxypeptidase) to remove the terminal D-Ala from the MurNAc-
pentapeptide for detection (Section 2.6.2.5). 53% and 18% yields were achieved for 
the acid and enzymatic methods respectively. Notably, a 47% yield of MurNAc-
pentapeptide monophosphate was obtained from enzymatic hydrolysis, suggesting 
that optimisation of SAP activity has the potential to significantly improve yield. 
 
Purity of MurNAc-pentapeptide from both methods was established using a modified 
version of that for UDP-MurNAc-pentapeptides in Section 3.3 (Method details 
Section 2.6.2.4) (Figure 6.6). The lack of negative charge on MurNAc-pentapeptide 
required purity checking by cation exchange chromatography (MonoS) (rather than 
anion exchange) with a phosphoric acid buffer at pH 4 to promote a positive charge 
on contaminating species, therefore improving separation. Integration of the A218nm 
peaks established a purity of 95% and 59% for acid and enzymatic hydrolysis 
respectively. The low purity following enzymatic hydrolysis is due to the elution of 
two peaks that were unbound to the Source 30Q resin (Figure 6.5 (A (i) and (ii))). 
This might be alleviated in future through purification by cation exchange at a low 
pH (as the two peaks were separated in the MonoS purity check (Figure 6.6 (B) (i) 
and (ii)). Peak (i) was confirmed as MurNAc-pentapeptide (Gln) by negative ion 
mass-spectrometry. 
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The higher purity and yield of acid hydrolysis mean that this method was used to 
produce pure MurNAc-pentapeptide as a potential acceptor for the Amplex Red 
transpeptidase assay (see Section 6.4.5). 
 
6.4.3 Effect of purification detergent on PBP activity 
 
The detergent in which E. coli PBP1b is purified has significant consequences for its 
observed transpeptidase activity (Dr A Lloyd, Personal Communication). 
pET46::pbp1a with dodecahistidine tag was expressed and purified as before 
(Section 4.3.1) in DDM, as well as TX-100 and CHAPS in parallel. TX-100 was 
chosen as Lipid II is routinely presented in this detergent for both transglycosylase 
(Chapter 4) and transpeptidase (Zapun et al., 2013) assays. CHAPS has an extremely 
high CMC of 0.45% (w/v), and is therefore easily diluted below this to allow assays 
to be carried out in a different detergent if required, by eliminating the effect of 
detergent brought to the assay with the enzyme.  
 
6.4.3.1 Parallel purification of PBP1a FL in DDM, TX-100 and CHAPS 
 
PBP1a FL was expressed and solubilised from E. coli membranes in 1% (w/v) 
sodium deoxycholate as described in Section 4.3.1. Purification by IMAC was also 
as described with buffers containing 0.1% (w/v) DDM, 0.2% (v/v) TX-100 or 0.5% 
(w/v) CHAPS. The TX-100 concentration was at 10 × CMC, the same as that 
A B (i) 
(i) (ii) 
Figure 6.6: Purity checks of MurNAc-pentapeptide (Gln). Purity check by cation exchange 
chromatography on MonoS resin. A: MurNAc-pentapeptide from acid hydrolysis showing single peak 
(i) (eluting at a conductivity of 2.59 mS.cm-1). Blue; absorbance at 280 nm (mAu), Red; absorbance at 
254 nm (mAu), Pink; absorbance at 218 nm (mAu). Peak integration identified purity as 95%. B: 
MurNAc-pentapeptide from enzymatic hydrolysis showing two peaks (i) eluting at a conductivity of 
0.72 mS.cm-1 and (ii) at 8.39 mS.cm-1. Peak integration of (i) identified purity as 59%. 
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routinely used for DDM. However, the CHAPS concentration was just above the 
CMC due to the large quantities required to achieve 10 × CMC. CHAPS at this 
concentration has previously been successful for the purification of E. coli PBP1b 
(Dr A. Lloyd, Personal Communication). For gel filtration using a Superose 6 10/300 
column (Section 4.3.1), the DDM and TX-100 concentrations were reduced to 0.03% 
(w/v) and 0.02% (v/v) respectively, just above their CMC in order to reduce the 
numbers of micelles devoid of protein as much as possible. The CHAPS 
concentration was maintained at 0.5% (w/v).  
 
The purification of PBP1a in DDM was as described in Section 4.3.1, and final 
purity achieved is shown in Figure 4.2. For purification in TX-100, the 250 mM 
imidazole fractions from IMAC (Figure 6.7 (A)) were further purified by size 
exclusion chromatography (Figure 6.7 (B)), where two peaks but no aggregated 
material was observed. This was identified due to both peaks eluting outside of the 
void volume (9 mL) from the Superose 6 column. Peak (ii) was selected, as for the 
DDM purification (Figure 4.2) and the final purity is shown in Figure 6.7 (C).  
 
 
A Mr TM P S FT 
250 (fractions) 
15 1 2 3 4 1 2 3 4 
50 (fractions) 
[Imidazole] mM  
97 
45 
30 
66 
20 
(i) 
(ii) 
B C Mr 1a FL 
97 
45 
30 
66 
20 
- 
Figure 6.7: Purification of S. pneumoniae D39 PBP1a FL by IMAC and size exclusion 
chromatography in TX-100 detergent. A 12% SDS-PAGE Coomassie-stained gel showing the 
isolation of membranes, solubilisation in 1 % (w/v) sodium deoxycholate and subsequent IMAC 
purification of PBP1a FL in TX-100. Mr, molecular weight markers (kDa); TM, total membrane 
fraction; P, ultracentrifugation pellet following sodium deoxycholate solubilisation; S, 
ultracentrifugation supernatant containing soluble protein; FT, unbound protein following 3 h 
incubation of supernatant with cobalt-chelated sepharose resin; 15, wash with buffer containing 15 mM 
Imidazole; 50 (fractions) 1-4, elution with buffer containing 50 mM imidazole; 250 (fractions) 1-4, 
elution with buffer containing 250 mM imidazole. (b) Size exclusion chromatogram using the Superose 
6 10/300 GL column. Blue; absorbance at 280 nm (mAu), Red; absorbance at 254 nm (mAu) (i) shows 
the elution of a peak of higher molecular weight protein and (ii) the elution of lower molecular weight 
protein. (c) 12% SDS-PAGE Coomassie-stained gel of the final purity of PBP1a FL. Mr, molecular 
weight markers (kDa); -, empty lane; 1a FL, purity of PBP1a FL following both purification steps. 
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A large amount of protein precipitation occurred in the CHAPS sample following 
IMAC purification. This was removed by centrifugation at 3,000 × g in a bench-top 
centrifuge (Eppendorf Centrifuge 5810R) and the supernatant concentrated in a 
Vivaspin® centrifugal concentrator (10 kDa cut-off) before quantification of the 
remaining protein by BCA assay (Section 2.5.1). The yield was below detectable 
levels, and therefore purification in 0.5% (w/v) CHAPS was unsuccessful (discussed 
Section 6.5.2). Buffer exchange was attempted in order to obtain PBP1a in CHAPS 
for testing in the transpeptidation assay. 4 mg of pure PBP1a FL in 0.03% (w/v) 
DDM buffer (Figure 4.2 (c)) was bound to 2 mL TALON Metal Affinity Resin pre-
equilibrated in DDM buffer. The resin was washed with 5 × 20 mL 20 mM Tris pH 
7.5, 150 mM NaCl, 0.5% (w/v) CHAPS in order to obtain a 50 fold dilution of the 
0.03% (w/v) starting DDM concentration. PBP1a FL was eluted in 20 mL 20 mM 
Tris pH 7.5, 150 mM NaCl, 0.5% (w/v) CHAPS, 250 mM imidazole before 
concentration using a 10 kDa cut-off centrifugal concentrator and buffer exchange on 
a PD-10 Desalting column (GE Healthcare) to remove the imidazole (Figure 6.8). 
 
A negligible amount of DDM may remain following this method, however following 
a 50 fold dilution the amount remaining will be so low that it is unlikely to have an 
affect. Pure PBP1a in 0.5% (w/v) CHAPS buffer was obtained by this method. 
Mr FT W1 W2 W3 E 
PD10 
FT 
PD10 
elute 
97 
45 
30 
20 
66 
14 
Figure 6.8: Buffer exchange of S. pneumoniae D39 PBP1a FL by IMAC. 12% SDS-PAGE 
Coomassie-stained gel showing the buffer exchange of PBP1a FL from DDM to CHAPS by 
binding to IMAC resin, Mr, molecular weight markers (kDa); FT, Protein not bound to resin; 
W1, CHAPS buffer wash 1; W2, CHAPS buffer wash 2; W3, CHAPS buffer wash 3; E, Elution 
of PBP1a FL in CHAPS buffer plus 250 mM imidazole; PD10 FT, Flow through from loading 
on PD-10 Desalting column; PD10 elution from PD-10 column. 
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6.4.3.2 The effect of detergent on PBP1a activity 
 
The relative activity of PBP1a purified in DDM, CHAPS and TX-100 was evaluated 
using three established methods. Firstly the native conformation of the penicillin-
binding domain was investigated with binding of BOCILLIN FL; a fluorescently 
labelled penicillin. This is acylated by the active site serine, forming a covalent 
complex, which can be observed by fluorescence detection following SDS-PAGE 
analysis. PBPs in the three detergents were incubated at a 5:1 BOCILLIN: PBP ratio 
for 1 hour (in the dark to protect the fluorescent label) at 37°C (Section 2.8.1). 
Ampicillin will form a covalent complex with the active site and prevent BOCILLIN 
from binding if pre-incubated with the PBP, and was used as a control. DacB (E. coli 
PBP4) was used as a positive control. Samples were analysed by SDS-PAGE, 
BOCILLIN binding detected using a Typhoon FLA 9500 laser scanner (GE 
Healthcare) with Y520 filter and the gel was subsequently Coomassie-stained to 
detect all protein. Figure 6.9 shows both gels. 
 
The dominant BOCILLIN FL fluorescent bands on the SDS-PAGE gel (Figure 6.9 
(A)), correspond in size with the Coomassie-stained PBP1a FL (Figure 6.9 (B)), and 
are both indicated by an arrow. Samples were not heat denatured prior to SDS-PAGE 
analysis in order to maintain the interaction with BOCILLIN FL, and therefore 
several bands are observed above that of the indicated PBP1a FL upon Coomassie 
staining (Figure 6.9 (B)), suggestive of oligomerisation. The PBP1a FL band also 
runs slightly differently on the gel than that seen previously, likely due to the same 
reason. The contaminating protein observed just below PBP1a FL also binds to 
BOCILLIN, suggesting the presence of an E. coli PBP (discussed in Section 6.5.3). 
The intensity of BOCILLIN binding to PBP1a FL in CHAPS is less than that in 
DDM or TX-100, implying that its conformation may be affected and reducing the 
ability of BOCILLIN FL to access the active site serine. However, this could also be 
due to variation in protein quantification and therefore loading onto the gel. This 
result suggests that PBP1a FL in all three detergents should be active as a 
transpeptidase. 
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Additionally the transglycosylase and transpeptidase activity of all three were 
determined by a continuous fluorescence assay and SDS-PAGE analysis 
respectively. Transglycosylase activity was investigated by the continuous 
fluorescence assay used in Section 4.5 (Section 2.7.1). 1 µM of each enzyme was 
reacted with 10 µM Lipid II (Gln, Dans) and the initial rate of transglycosylase 
activity determined by calculating RFU change per second of dansyl fluorescence 
(Figure 6.10)(A)). Additionally, the transpeptidase activity of the three enzymes was 
probed by the SDS-PAGE system described in Section 6.3.2 (Section 2.8.2). The 
assay was exactly as described previously for PBP1a FL in each of the detergents 
(Figure 6.10 (B)). 
  
Mr (F) 
DacB 
Mr  
DDM TX-100 CHAPS 
+ A  - A  + A  - A  + A  - A  + A  - A  
97 
45 
30 
66 
20 
A 
B 
155 
65 
41 
100 
33 
12 
Figure 6.9: BOCILLIN FL labelling of PBP1a FL. Labelling of PBP1a FL in DDM, TX-100 
and CHAPS with fluorescent penicillin. A. BOCILLIN FL fluorescence of PBPs (PBP1a FL 
indicated by arrow). B:12% SDS-PAGE Coomassie-stained gel of PBPs stained with BOCILLIN 
FL (PBP1a FL indicated by arrow). Proteins labelled as DacB (control) or DDM (PBP1a FL in 
DDM), TX-100 (PBP1a FL in TX-100) and CHAPS (PBP1a FL in CHAPS). Inclusion of 
ampicillin as a control indicated as –A, no ampicillin; or +A; plus ampicillin. Mr, molecular 
weight markers (kDa), Mr (F), fluorescent molecular weight markers. Fluorescence detected using 
Typhoon FLA 9500 laser scanner (GE Healthcare) with Y510 filter. 
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PBP1a FL in CHAPS was less active in both the transglycosylase and transpeptidase 
assays, although the impact of buffer exchange on this is unknown (discussed 
Section 6.5.2), and results may be affected by variation in protein concentration 
determination. PBP1a in CHAPS was not used for further experiments in this 
chapter.  
A 
B 
DDM 
Pen Moe - Pen Moe - Pen Moe - 
TX-100 CHAPS 
i 
ii 
iii 
43.78 - 48.07 37.98 - 42.00 20.81 – 23.61 
Figure 6.10: Effect of detergent on PBP1a FL activity. A. Transglycosylation rates of PBP1a FL 
purified in DDM, TX-100 and CHAPS (as indicated on X axis) Rates are average of two replicates 
and the error bar shows the range of values (range additionally stated in bold below X axis). Rates 
calculated from continuous fluorescence assay of 1µM PBP1a FL and 10 µM Lipid II (Gln, Dans). 
B. Transpeptidase activity determined by SDS-PAGE analysis of reaction products. PBP1a FL 
purification detergent indicated below the gel. Mixture of 50 µM Lipid II (Gln) and 5 µM dansylated 
Lipid II (Gln, Dans) incubated with 1 µM PBP1a for 1 hour. -,no inhibitor; Pen, 1 mM penicillin G; 
Moe, 0.5 mM moenomycin. Products of reaction separated on a 8.5% T/2.7% C SDS-PAGE gel. 
Dansyl fluorescence at 521 nm detected using a blue light converter and short pass filter on a 
GeneSnap Gel Doc. (i) denotes unpolymerised Lipid II; (ii) glycan chains of varying lengths and (iii) 
the very high molecular weight material, which does not enter the gel. 
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6.4.4 Optimisation of assay conditions 
 
The acute sensitivity of in vitro transglycosylase activity to the buffer conditions has 
been well documented (Barrett et al., 2004; Offant et al., 2010; Schwartz et al., 
2002). Given that the transpeptidation substrate is polymerised peptidoglycan (Born 
et al., 2006; Lupoli et al., 2011; Zapun et al., 2013) and on-going transglycosylation 
is required for S. pneumoniae transpeptidase activity (Lupoli et al., 2014; Zapun et 
al., 2013), a thorough analysis of the conditions required to observe transglycosylase 
activity was needed in order to present the best chance of observing the subsequent 
cross-linking reaction. This was explored using the continuous fluorescence assay for 
transglycosylase activity (Section 2.7.1) as 8 fold less Lipid II is required per 50 µL 
reaction than for each  200 µL Amplex Red assay. The intention was to obtain the 
best conditions for transglycosylation as a starting point for optimisation in the 
transpeptidation assay.  
 
The buffer conditions used for S. pneumoniae PBP1a FL transglycosylase assays are 
50 mM HEPES pH 7.5, 10 mM MgCl2, 150 mM NaCl, 25% (v/v) DMSO, 0.02% 
(v/v) TX-100 as described in Chapter 4. Salt, detergent and DMSO concentration 
were varied and their effect on transglycosylase rate determined, following the 
observation of their significant effect on E. coli PBP1b transpeptidase activity (Dr A. 
Lloyd, Personal Communication). Assays were exactly as described in Section 4.5 
(details Section 2.7.1) with 1 µM PBP1a FL and 10 µM Lipid II (Gln, Dans). 
 
The effect of reducing the concentration of NaCl was investigated with DDM 
purified PBP1a FL (to allow continuity from previous assays in Chapter 4). The rate 
of transglycosylation fell as salt concentration was reduced (Figure 6.11 (A)). 
Following this, the concentration of NaCl was maintained at 150 mM, and the effect 
of detergent type and concentration studied. The reaction buffer and Lipid II were 
presented in a total of 0.02% (v/v) TX-100 as before, and enzyme in either DDM or 
TX-100 was added to give an additional final concentration of 1 × CMC or 0.1 × 
CMC. This was intended to investigate the necessity for enzyme detergent to be 
maintained above the CMC. CHAPS was not studied due to its poor activity 
observed in Figure 6.9. A significant bias was observed for both DDM and TX-100 
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purified enzyme, in favour of maintaining the concentration of detergent brought 
with the protein above the CMC in the assay (1 × CMC) (Figure 6.11(B)). No 
obvious difference was observed between 0.1 × CMC for DDM and TX-100 or 1 × 
CMC for DDM and TX-100, however, a lag phase was seen when enzyme was 
brought to the reaction in DDM, likely due to the presence of two different 
detergents in the assay. Enzyme purified in TX-100 was chosen for further 
optimisation for this reason.  
 
Finally, the DMSO concentration was varied from 0-25% (v/v), with PBP1a FL 
added to the assay in a final TX-100 concentration (including TX-100 from the Lipid 
II and reaction buffer (as before)) of 0.02% (v/v) (just above 1 × CMC) and 0.035% 
(v/v) (2.3 × CMC). At both detergent concentrations, DMSO concentration played a 
significant role in transglycosylation rate (Figure 6.11 (C) and (D)), with 10% (v/v) 
and lower resulting in very little activity. At 0.02% (v/v) final TX-100, optimal 
activity was observed at 20% (v/v) DMSO, whereas 25% (v/v) DMSO was required 
in the presence of 2.3 × CMC TX-100 in order to observe a reasonable level of 
activity. This could be because more DMSO is required to increase the rate of 
exchange between micelles at a higher detergent concentration, enabling Lipid II and 
enzyme to come into contact. The optimal buffer conditions taken forward following 
this investigation were 50 mM HEPES pH 7.5, 10 mM MgCl2, 150 mM NaCl, 20% 
(v/v) DMSO, 0.02% (v/v) TX-100.  
 
It should be noted that the rate observed here with dansylated Lipid II may not 
represent that with the non-labelled substrate in the Amplex Red assay (discussed 
further in Section 6.5.3). However, these conditions give a reasonable starting point 
for analysis of transpeptidase activity.  
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6.4.5 Detection of S. pneumoniae D39 PBP1a transpeptidase activity by the 
Amplex Red assay 
 
Following the optimisation carried out within this chapter, an Amplex Red assay was 
performed (Section 2.8.4) in 50 mM HEPES pH 7.5, 10 mM MgCl2, 150 mM NaCl, 
20% (v/v) DMSO, 0.02% (v/v) TX-100 final concentrations with 20 µM Lipid II 
(Gln) and 2 µM PBP1a FL purified in TX-100 (brought to the assay in 0.1 × CMC). 
The conditions were chosen to minimise the DMSO concentration used as this may 
affect the coupling enzymes. Lipid II (Gln) will act as both a transpeptidation donor 
and acceptor, meaning that any rate observed in the first instance cannot necessarily 
A 
D C 
B 
DDM TX-100 
Figure 6.11: Effect of buffer conditions on PBP1a FL transglycosylase activity. 10 µM Lipid II 
(Gln, Dans) and 1 µM PBP1a FL in all cases in a continuous fluorescence assay for transglycosylase 
activity. Initial rate calculated as RFU change per second and means of duplicate reactions (error bar 
= range) plotted against the condition. .A: PBP1a FL purified in DDM with NaCl concentrations from 
0-150 mM. B: PBP1a FL purified in either DDM or TX-100, and brought to the reaction with a final 
concentration of 0.1 × CMC or 1 × CMC (indicated below the figure), in addition to 0.02% (v/v) TX-
100 already in the assay. C: PBP1a FL purified in TX-100 and added to the assay in 0.1 × CMC, 
giving a final concentration of 0.02% (v/v) TX-100 in the assay. DMSO concentration varied from 0-
25% (v/v). D: PBP1a FL purified in TX-100 and added to the assay in 1 × CMC, giving a final 
concentration of 0.035% (v/v) TX-100 in the assay. DMSO concentration varied from 0-25% (v/v). 
All graph shown on the same scale for comparison. 
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be attributed to transpeptidase over DD-carboxypeptidase activity. However the 
initial aim was to observe any rate, and with the lack of a donor only substrate, Lipid 
II (Gln) was the best option. No rate was observed over the no Lipid II control, 
including after the addition of 20 µM MurNAc-pentapeptide (Gln)(Section 6.4.2) as 
an additional acceptor. The coupling enzyme system was tested with the addition of 
5 µM D-Ala, yielding an instantaneous increase in A555nm of 0.25 absorbance units, 
confirming that it was functional under the conditions used.  
 
The length of detergent ethylene glycol moieties has been observed to have a hugely 
significant effect on E. coli PBP1b transpeptidase activity (Dr A. Lloyd, Personal 
Communication). Triton X-100 contains a range of lengths from 5-20 ethylene glycol 
units, resulting in a mixture of positive and negative effects on enzyme activity. 
Therefore, based on this work, hexaethylene glycol dodecyl ether (E6C12)(CMC: 
0.0039% (v/v)) was trialled. In order to obtain the entire reaction as exclusively as 
possible in this detergent, DDM purified PBP1a FL (initial transglycosylase activity 
tests showed it to be similar to TX-100 purified enzyme (Figure 6.11 (B)) was used 
due to its significantly higher concentration. This allowed dilution into a buffer 
containing 10 x CMC E6C12, reducing the DDM concentration below its CMC. 20 
µM Lipid II (Gln) (in E6C12) and 2 µM PBP1a FL final concentrations in the cuvette 
were used as before, this time in 50 mM HEPES pH 7.5, 10 mM MgCl2, 150 mM 
NaCl, 20% (v/v) DMSO, 12 × CMC E6C12 (final) and also in 50 mM HEPES pH 7.5, 
10 mM MgCl2, 12 × CMC E6C12 (final). The decision was made in this parallel 
reaction to remove salt and DMSO despite the previous optimisation (Section 6.4.4). 
This was based upon work by Dr A. Lloyd showing the severe effect of these two 
components on E. coli PBP1b activity. The assay was performed as detailed in 
Section 2.8.4. 
 
This proved to be a pivotal decision as a significant rate was observed in the Amplex 
Red assay without DMSO and NaCl (Figure 6.12 (red)). A very slow rate was seen 
in their presence (not shown).  
 
A steady baseline was established by monitoring A555nm of a cuvette containing        
20 µM Lipid II (Gln) in 50 mM HEPES pH 7.5, 10 mM MgCl2, 12 × CMC E6C12 
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(plus Amplex Red coupling reagents (Section 2.8.4)), and rate observed following 
the addition of 2 µM PBP1a FL. The release of D-Ala was shown to be both Lipid II 
and enzyme dependent by the replacement of each with E6C12 Lipid II buffer, and 
enzyme storage buffer respectively (Figure 6.12 (red dashed and black solid 
respectively)). No reaction occurred in the presence of Lipid II (Glu)(not shown), 
showing a dependency on the stem peptide composition previously identified as 
important for PBP1a transpeptidase activity (Zapun et al., 2013, and Figure 6.2). 
Significantly, the observed reaction could be inhibited completely with 50 µM 
moenomycin, showing that it is dependent on the preceding transglycosylase activity 
(Figure 6.12 (blue solid)). Insufficient substrate was available to carry out a 
penicillin control within the time available.  
 
Moenomycin does not affect the Amplex Red coupling reagents at the concentration 
used (Dr A. Lloyd, Personal communication), and was shown not to inhibit binding 
of BOCILLIN FL to the penicillin-binding domain (Figure 6.13 (A)) of PBP1a FL or 
DacB. The BOCILLIN FL assay was as described in Section 6.4.4 (method Section 
2.8.1) with an additional 200 µM moenomycin control. The fact that DacB 
Figure 6.12. S. pneumoniae PBP1a D-Ala release. Amplex Red assay for D-Ala 
release by PBP1a, identified by an increase in A555nm due to Resorufin accumulation. 
50 mM HEPES pH 7.5, 10 mM MgCl2, 12 × CMC E6C12  with or without 20 µM Lipid 
II (Gln) allowed to reach a stable baseline. (a) addition of 2 µM PBP1a or equivalent 
volume of enzyme storage buffer. Black solid, 20 µM Lipid II and no PBP1a; Red 
solid, 20 µM Lipid II and 2 µM PBP1a, Red dashed; No Lipid II plus 2 µM PBP1a; 
Blue solid; 20 µM Lipid II, 2 µM PBP1a and 50 µM moenomycin.  
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BOCILLIN binding is unaffected, supports that moenomycin does not inhibit DD-
carboxypeptidase activity, and therefore supports that the rate observed is at least in 
part due to transpeptidation (following transglycosylation). The possibility of a 
contaminating transpeptidase from the purification was accounted for by the inability 
of E. coli PBP1b to use Lipid II (Gln)(Figure 6.13(B)), showing that E. coli 
transpeptidase activity has specificity for the stem peptide.  
 
D-Ala release by S. pneumoniae PBP1a at a rate of 0.246 µM/min was calculated 
with a turnover number of 0.123 min-1. These values are a composite of 
transpeptidase and carboxypeptidase activity. This is the first quantification of D-Ala 
release by a pneumococcal PBP using a native substrate, and is consistent with 
values required to observe microbial growth (0.05 min-1 required as a minimum 
based on a 20 minute doubling time). These values and the exciting plethora of 
further work now possible are discussed in more detail in Section 6.5. 
 
Notably, a continuous fluorescence assay for transglycosylase activity of PBP1a was 
conducted under the successful conditions for D-Ala release, and no rate was 
observed. This has important implications for the assay system used to study 
transglycosylation, as clearly PBP1a is capable of producing peptidoglycan under 
these conditions, as demonstrated by the moenomycin control (discussed further in 
Section 6.5.3).  
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(c) 
Figure 6.13. Confirmation of S. pneumoniae PBP1a transpeptidase activity. A series of 
controls confirming D-Ala release is due to transpeptidation by PBP1a. A: BOCILLIN FL 
fluorescence of PBP1a and DacB (control)(indicated by arrows) inhibited by ampicillin but 
not moenomycin. B: 12% SDS-PAGE Coomassie-stained gel of PBP1a and DacB labelled 
with BOCILLIN FL (indicated by arrows). Proteins labelled as DacB (E. coli PBP4 control) 
or Sp1aD (PBP1a FL purified in DDM). +A: plus 200 µM ampicillin, +M: plus 200 µM 
moenomycin. Mr, molecular weight markers (kDa), Mr (F), fluorescent molecular weight 
markers. Fluorescence detected using Typhoon FLA 9500 laser scanner (GE Healthcare) with 
Y510 filter.C: Amplex Red assay of E. coli PBP1b transpeptidase activity with amidated and 
non amidated lysine containing Lipid II. Assays in 50 mM BisTris propane pH 8.5, 2 mM 
MgCl2, 1.96 µM LpoB, 4.4 nM E. coli PBP1b (plus Amplex Red coupling reagents), 20 µM 
Lipid II Lys (black solid), 20 µM amidated Lipid II lys (red solid), or 20 µL 0.1 % TX-100 
(black and red dashed lines corresponding with amidated or non-amidated Lipid II) with 20 
µM MurNAc-L-alanyl-γ-D-glutamyl-meso-diaminopimelyl-D-alanyl-D-alanine (acceptor) at 
30°C. Absorbance of Lipid II in reaction buffer monitored, until PBP addition (a) followed by 
acceptor (b). A further 4.4 nM PBP1b was added at (c) to the plus or minus amidated Lipid II 
reactions.  
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6.4.6 Confirmation of transpeptidation by mass spectrometry 
 
The controls used in Section 6.4.5 strongly suggested that the D-Ala release detected 
is due to transpeptidation. Insufficient substrate was available to conduct a full range 
of controls and therefore Liquid Chromatography positive ion mass spectrometry 
(LC-MS) was performed on the contents of the cuvettes used to generate Figure 6.12 
to categorically confirm the presence of the cross-linked product. LC-MS is a mass 
spectrometry technique in line with liquid chromatography. Compounds are 
separated by liquid chromatography and positive ion (in this instance) mass 
spectrometry performed on each of the eluted peaks. This is useful for the detection 
of species with particular masses in the presence of other compounds.  
 
2.2 M Bis.Tris pH 6.2 was added to the cuvette contents from a successful reaction, 
plus a negative control and 1 mg.ml-1 Mutanolysin from Streptomyces globisporus 
added for 2 hours at 37°C to digest glycan chains. A further aliquot of Mutanolysin 
was added for 2 hours to ensure full digestion before the removal of protein by 
boiling. Products were incubated with 5.8 mg.ml-1 NaBH4 to reduce the sugar rings 
following cleavage and the undecaprenyl pyrophosphate linker removed with 2% 
(v/v) phosphoric acid. Samples were analysed by LC-MS in positive mode by Dr A. 
Lloyd. The total ion count (TIC), and detection of two peaks containing ions with a 
m/z value consistent with the anomeric structure of the cross-linked product are 
shown in Appendix 7 (Figures A7.1 and A7.2). Anomeric structures were observed, 
as the NaBH4 treatment was unsuccessful. Figures 6.14 and 6.15 show the mass 
spectra of the two eluted peaks (elution at 15.2 min and 15.5 min respectively; Figure 
A7.1) containing species with the expected mass of the unreduced cross-linked 
product, which is observed in the presence of Lipid II and not in the negative control. 
Masses consistent with the D,D-carboxypeptidase product and disaccharide-
pentapeptide from either Lipid II or its transglycosylation product were also 
identified in the Lipid II reaction and are shown in Appendix 7.    
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Doubly Charged (expected 921.9393) Singly Charged (expected 1842.8708) 
+ LII + LII 
- LII - LII 
A B 
C D 
Figure 6.14: Positive ion mass spectra of peak eluting at 15.2 min on liquid chromatography of Amplex Red cuvette contents. Expected m/z of cross-
linked disaccharide-pentapeptide-disaccharide-tetrapeptide: [M-Z]- 1842.8708, [M-2H]2- 921.9393. A, B: Spectra from analysis of cuvette contents with 
positive Amplex Red response including Lipid II (Gln) (+ LII Lys) showing mass of doubly charged (A) and singly charged (B) species. C, D: Spectra from 
analysis of negative control cuvette contents showing absence of the same species.   
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Doubly Charged (expected 921.9393) Singly Charged (expected 1842.8708) 
+ LII Lys + LII Lys 
- LII Lys - LII Lys 
A B 
C D 
Figure 6.15: Positive ion mass spectra of peak eluting at 15.5 min on liquid chromatography of Amplex Red cuvette contents. Expected m/z of cross-
linked disaccharide-pentapeptide-disaccharide-tetrapeptide: [M-Z]- 1842.8708, [M-2H]2- 921.9393. A, B: Spectra from analysis of cuvette contents with positive 
Amplex Red response including Lipid II (Gln) (+ LII Lys) showing mass of doubly charged (A) and singly charged (B) species. C, D: Spectra from analysis of 
negative control cuvette contents showing absence of the same species.   
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The masses observed in Figures 6.14 and 6.15, along with the controls used strongly 
suggests the presence of cross-linked species in the positive reaction from Figure 
6.12. However, the mass observed could be due to incomplete Mutanolysin digestion 
of glycan chains resulting in tetrasaccharide with a pentapeptide and tetrapeptide on 
each of the two MurNAc sugars. It could also be disaccharide-pentapeptide cross-
linked to disaccharide-tetrapeptide through the peptide stem. These two possibilities 
are shown in Figure 6.16.  
 
In order to confirm cross-linking, the samples were analysed by LC-MS in positive 
mode with subsequent isolation and collision induced fragmentation of the species 
with a mass consistent with the doubly charged cation of the product (Figure 6.17; 
TIC Appendix 7, 15.2 min peak isolated for fragmentation; carried out by Dr. A. 
Lloyd). Species were fragmented by increased voltage and collision-induced 
dissociation with argon. The results of this unambiguously show the in vitro 
detection of transpeptidation by a pneumococcal PBP for the first time, due to the 
presence of 10 species (indicated by * on Figure 6.17), which can only be reasonably 
explained by transpeptidation. 
A B 
Lac 
A 
Qi 
K 
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G 
Figure 6.16: Possible structures associated with observed mass by positive ion mass 
spectrometry. Two possible structures corresponding to exact mass of 1841.8630, and therefore not 
distinguishable by mass spectrometry. A: dimer of disaccharide-pentapeptide and disaccharide 
tetrapeptide as a result of transglycosylation and D,D-carboxypeptidation. B: cross-linked product of 
transpeptidation.  
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Figure 6.17: Positive ion fragmentation spectra of cross-linked species.  Corresponding structure with donor stem in blue and acceptor stem in green shown along with 
expected mass in red above the corresponding ion in the spectra. * indicated the 10 key species used to identify the species as a product of transpeptidation. Single letter code 
used to describe fragment corresponds to single letter labels in Figure 6.16 (B) for identification. Fragmentation pattern analysed and figure made by Dr A. Lloyd.  
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6.5 Discussion and future work 
 
This chapter has detailed the first conclusive evidence of in vitro transpeptidase 
activity by a pneumococcal PBP. This provides the foundation for future work aimed 
at answering long standing fundamental questions surround S. pneumoniae cell wall 
synthesis. This section discusses the presented work, and highlights particularly 
interesting areas of further work now possible.  
 
6.5.1 The need for a robust and conclusive transpeptidase assay 
 
The cross-linking of peptidoglycan is crucially important for structural integrity of 
the bacterial cell wall. The penicillin-binding domain of PBPs catalyses 
transpeptidation, and is a validated drug target as demonstrated by the success of the 
β-lactam class of antibiotics. However, high levels of resistance has developed to 
these agents, notably in S. pneumoniae through the modification of the PBP active 
site to give reduced β-lactam affinity. Understanding how these enzymes are able to 
continue cross-linking peptide stems despite losing affinity for the pseudosubstrate 
inhibitor is a long-standing and highly interesting biochemical question. A greater 
understanding of this current target, and the potential identification of new and 
related targets gives hope for the future of antibiotic discovery. This requires a robust 
assay that is specific for transpeptidation.  
 
The in vitro observation of cross-linking by Gram-positive PBPs has been 
historically difficult, and very little progress has been made since the pioneering 
work of Professor Jack Strominger in the 1970s (Section 6.1.3). Only very recently 
identification of the important role of stem peptide chemistry was identified, and this 
led to the first in vitro demonstration of transpeptidation by S. pneumoniae PBPs 
(Zapun et al., 2013).  
 
The work by Zapun and colleagues represented a significant step in the right 
direction, although is not without its flaws. The use of Penicillin G as a specific 
transpeptidase inhibitor, and active site mutants strongly suggests the products seen 
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by SDS-PAGE are as a result of peptidoglycan cross-linking. However, overnight 
incubations were required prior to SDS-PAGE separation of products to observe the 
high molecular weight species. In addition, as described in Section 6.4.6, the species 
identified by MALDI-TOF mass spectrometry could be interpreted in two ways in 
the absence of confirmation by positive ion fragmentation. The masses observed 
were characteristic of non-dansylated products, so their position on the SDS-PAGE 
gel (detected by dansyl fluorescence) could not be correlated. Donor stems can in 
principle be dansylated and cross-linked, and therefore this mass should have been 
present. Attempts were made to repeat the mass spectrometry analysis (Section 6.3.3) 
by removal of the high molecular-weight band from the gel, but these were not 
successful.  
 
This chapter aimed to develop the work published by Zapun and colleagues, 
providing mass spectrometric evidence for cross-linking as well as detection of 
cross-linking in a continuous format to enable higher throughput analysis.  
 
6.5.2 Efforts towards a continuous assay for transpeptidation 
 
Initial attempts to observe D-Ala release by the Amplex Red assay were 
unsuccessful, and several strategies were employed in an attempt to improve both the 
transpeptidase, and preceding transglycosylase activity. The decisions made were 
informed by on-going work by Dr A. Lloyd on E. coli PBP1b.  
 
MurNAc-pentapeptide (Gln) was made in reasonable yields and to high purity by 
acid hydrolysis as an alternative acceptor for transpeptidation. The lack of donor 
only substrate means that this was added as an additional acceptor in assays but will 
be of more use in future work as an acceptor only substrate (Section 6.5.4). 
Enzymatic hydrolysis was also attempted as an alternative method, which was hoped 
to increase yield. A significantly lower yield and purity was obtained by this method 
but increasing the amount of SAP added to the reaction, and purification by cation 
exchange has the potential to improve this. In the interest of time, acid hydrolysis 
was used, and the correct product was identified by mass spectrometry.  
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It was hypothesised that the N-terminal dodecahistidine tag on PBP1a may affect the 
ability of the protein to fold correctly, as well as its activity. Helassa et al., (2012) 
identified that S. pneumoniae PBP2a was inactive as a transglycosylase with a range 
of affinity tags on either the N- or C-terminus. Given that PBP1a and PBP2a are both 
bifunctional PBPs, and that on-going transglycosylation is required for 
transpeptidation (Zapun et al., 2013), the effect of removal of the N-terminal 
dodecahistidine tag on S. pneumoniae D39 PBP1a activity was investigated by two 
methods (not shown). PBP1a FL was cloned into the pET26b vector without an 
affinity tag, and calculation of the predicted isoelectric point (pI) of the cytoplasmic 
and extracellular domains suggested that purification by successive anion and cation 
exchange could be possible as for S. pneumoniae PBP2a (Helassa et al., 2012, and 
Section 4.3.3). Expression and purification by this method was successful, although 
the level of purity was poor. Subsequent gel filtration chromatography identified the 
protein to be aggregated as it eluted in the void volume. Cloning into a pProEX Hta 
vector with a TEV cleavable hexahistidine tag was attempted as affinity 
chromatography should result in greater purity. However, due to vector and E. coli 
cloning strain contamination this was not achieved in the time available. 
 
Based upon observation of the importance of detergent in E. coli PBP1b activity by 
Dr A. Lloyd, PBP1a was purified in DDM, TX-100 and CHAPS. Purification in 
DDM and TX-100 were successful but most of the protein precipitated between 
IMAC and gel filtration chromatography in CHAPS, probably due to the detergent 
concentration which was just above CMC. A higher concentration was not used 
because of the significant quantities required to make buffers for both stages of 
purification, and the concentration used has previously been successful for 
purification of active E. coli PBP1b.  Detergent exchange from DDM to CHAPS was 
subsequently performed for activity testing, although remaining trace amounts of 
DDM cannot be ruled out. PBP1a purified in DDM and TX-100 had comparable 
transglycosylase and transpeptidase β-lactam binding (determined by SDS-PAGE 
and BOCILLIN FL binding) activity. CHAPS purified protein was not as active. This 
could be affected by variation in the protein concentrations between the three 
enzyme preparations, but due to this and the precipitation observed, CHAPS purified 
protein was not used for further analysis. 
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Given the requirement for transglycosylase activity for the function of the 
transpeptidase active site and the requirement of amidation for transglycosylase 
activity (Chapter 4), optimisation of assay conditions were made for transglycosylase 
activity (Section 6.4.4). Salt, DMSO and detergent concentration were shown to have 
a substantial effect on the observed rate, and conditions were chosen to optimise this 
and limit the DMSO concentration used. 
 
6.5.3 The first conclusive demonstration of in vitro pneumococcal cross-linking  
 
Despite the attempts to improve activity discussed in Section 6.5.2, a combination of 
decisions based on parallel work by Dr A Lloyd, and an element of serendipity 
resulted in a positive Amplex Red result (Figure 6.11). The use of hexaethylene 
glycol dodecyl ether (E6C12) detergent and omission of DMSO and NaCl from the 
reaction proved to be a successful combination. The controls used showed this 
activity to be substrate dependent, enzyme dependent, require transglycosylase 
activity and to occur only in the presence of amidated substrate. LC-MS positive ion 
fragmentation (tandem LC-MSMS) gave conclusive evidence for the presence of 
cross-linked product, and therefore transpeptidase activity, for the first time.  
 
The Amplex Red coupling reagents had a linear response up to an absorbance change 
of 0.1 units per minute (Dr A. Lloyd, Personal Communication), and therefore it was 
clear that they were not limiting under the conditions used. Evidence of the 
requirement for on-going transglycosylase activity for at least part of the detected D-
Ala release came from moenomycin inhibition of the observed rate. The Amplex Red 
assay coupling system was not inhibited by moenomycin up to a concentration of 
1mM (Dr A. Lloyd, Personal Communication) and moenomycin binding was shown 
to not affect BOCILLIN FL interaction with the transpeptidase domain of PBP1a. 
Therefore the slight pause observed prior to acceleration of rate in Figure 6.12 was 
not due to limitations of the coupling system and was likely a result of the 
requirement for transglycosylation to produce glycan chains of sufficient length. 
 
The Amplex Red response corresponded to a D-Ala release of 0.246 µM/min and a 
turnover number of 0.123 min-1, which is a composite of transpeptidase and 
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carboxypeptidase mediated D-Ala release. In order to differentiate between the 
contributions of each enzymatic activity, a donor only transpeptidase substrate would 
be required. By incubating this with the PBP and observing A555, the background 
D,D-carboxypeptidase activity could be measured. The composite rate of 
transpeptidation and D,D-carboxypeptidation could then be measured on subsequent 
addition of acceptor (eg. see Figure 6.13) This would also remove the pause seen 
after addition of enzyme, as glycan chain polymerisation will occur during this 
period. Donor only substrates are produced by removing the ability of the ε-amino 
group of the lysine side chain to act as a nucleophile. This could be achieved through 
acetylation of the amine (Lupoli et al., 2014). Given the clear requirement for 
isoglutamine containing pentapeptide stems for transglycosylation by pneumococcal 
PBPs, amidation at this position must be present. Therefore it may be necessary to 
incorporate pre-acetylated lysine into the pentapeptide stem rather than carrying out 
chemical modification on the regular peptide stem, to avoid cross-reaction with the 
second position isoglutamine. S. pneumoniae MurE has been observed to incorporate 
a range of lysine analogues into the stem peptide in the place of lysine (Dr A. Lloyd 
and Anna York, Personal Communication). The isoglutamine amide is relatively 
stable and therefore less likely to react, but this should still be considered as a 
possibility. Alternatively DAP could be incorporated in the third position as the ε-D-
amino acid should not be a donor for S. pneumoniae PBPs. Whichever substrate is 
used must be checked as a transglycosylase substrate first to ensure sufficient rate 
can be achieved to support subsequent cross-linking.  
 
BOCILLIN FL binding to S. pneumoniae PBP1a (Figure 6.8) shows a contaminating 
lower molecular weight protein with a penicillin-binding domain. This could be due 
to degradation of PBP1a or a contaminating E. coli PBP.  E. coli PBP1b exhibited 
neither transglycosylase or transpeptidase activity with Lipid II (Gln) when tested, 
which suggests that the contaminating protein does not contribute to the 
transpeptidase activity observed. Any D,D-carboxypeptidase activity from the 
contaminating protein will be accounted for in future experiments using donor only 
controls, as previously described.  
 
Notably, activity could not be observed by the continuous fluorescence assay for 
transglycosylation under the conditions used for the successful Amplex Red assay. 
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Given that D-Ala release was inhibited by moenomycin, and on-going 
transglycosylation is required for transpeptidation, it is clear that glycan 
polymerisation can occur under these conditions. This suggests that the high salt and 
DMSO are required for PBP1a to be able to use dansylated Lipid II as a substrate, for 
lysozyme activity, or the conditions produce a fluorescence effect. This has 
important implications for the use of the fluorescence assay system, which is 
discussed in more detail in Section 4.6.2.2.  
 
6.5.4 Further work 
 
The work presented in this chapter provides the foundation for the future detailed 
study of transpeptidation by pneumococcal and potentially other Gram-positive 
PBPs. This section details some of the future work possible leading on from this.  
 
6.5.4.1 Optimisation of the observed rates 
 
Due to substrate and time limitations, a full optimisation of conditions was not 
carried out. Several strategies could be employed to investigate the effect of a variety 
of factors on rate.  
 
The buffer conditions used were significantly different to those optimised for 
transglycosylase activity (see Section 6.4.4) and contained neither salt or DMSO. A 
range of pH values, NaCl and metal ion types and concentration should be tested in 
order to identify any effect on the rate observed. All three conditions had a 
significant effect on E. coli PBP1b activity (Dr. A. Lloyd, Personal Communication). 
 
Work by Dr A. Lloyd identified a very strict dependency of E. coli PBP1b 
transpeptidase activity on detergent ethylene glycol polymeric state and chain length. 
This may be linked to the thickness of the cytoplasmic membrane in the native PBP 
environment. S. pneumoniae PBP1a was only tested with hexaethylene glycol 
dodecyl ether, the optimal detergent of this type for E. coli PBP1b, as substrate 
limitations meant no further experiments could be performed. The E. coli and S. 
pneumoniae cytoplasmic membranes have different compositions, which are 
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spatially, and temporally regulated throughout the cell and cell cycle (Barák and 
Muchová, 2013; Epand and Epand, 2009), so testing of a range of detergents will 
enable the identification of optimal conditions. It will be interesting to compare the 
in vitro detergent preferences of E. coli PBP1b and S. pneumoniae PBP1a. In future 
work, testing the specificity for detergent lengths between different PBPs from S. 
pneumoniae may help to identify differences in membrane composition and PBP 
localisation.  
 
The addition of cardiolipin and phosphatidylglycerol, the main components of the 
pneumococcal cytoplasmic membrane (Brundish et al., 1967) to the assay as well as 
the detergent used could improve enzyme activity due to an environment that is 
closer to that in vivo.  
 
A further attempt to obtain PBP1a without an affinity tag, which was previously 
unsuccessful (Section 6.5.2) could be attempted as this may result in a more active 
protein. 
 
6.5.4.2 Prospects for the Amplex Red assay system 
 
Following the investigation of conditions to ensure optimal transpeptidase activity 
(Section 6.5.4.1), and identification of the contribution of carboxypeptidase activity 
to the observed D-Ala release (Section 6.5.3), several interesting biochemical 
questions could be answered. Firstly, once the assay is optimised for PBP1a, the four 
other pneumococcal transpeptidases could be tested. For those that exhibit activity by 
this method, the first enzymological characterisation with their native substrate can 
be performed. PBP2a is bifunctional and previous work has suggested that it has both 
transglycosylase and transpeptidase activity in vitro (Zapun et al., 2013). However, 
monofunctional PBP2b and PBP2x will require glycan chains from another source. 
Both enzymes were reported to cross-link glycan chains formed concomitantly by a 
transpeptidase mutant of PBP2a (Zapun et al., 2013). Testing PBP2b and PBP2x 
with a combination of transpeptidase mutants of PBP1a, PBP1b or PBP2a may help 
in convincingly identifying the natural functional partners in the cell, as the glycan 
product of one may be the preferential substrate. PBP1a-PBP2x and PBP2a-PBP2b 
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interactions have previously been suggested but a high level of uncertainty still 
surrounds this theory, and very little is known about the activity and localisation of 
PBP1b (Liu et al., 2006). The requirement for stem peptide amidation of all four S. 
pneumoniae transpeptidases has previously been interpreted from SDS-PAGE 
experiments (Zapun et al., 2013), therefore with this substrate and the improved 
detergent, salt and DMSO conditions, which proved successful for PBP1a, there is 
hope for observation of activity in this system, to finally characterise the 
transpeptidase activity of the S. pneumoniae high molecular weight transpeptidases.  
 
As mentioned previously, no direct evidence exists for functional interactions of the 
S. pneumoniae PBPs with other PBPs or cell division proteins. However, several 
proteins have been assigned to either the septal or peripheral cell wall synthetic 
machineries (Massidda et al., 2013). Recent studies have isolated complexes of 
recombinantly expressed septal (Noirclerc-Savoye et al., 2013) and peripheral 
(Philippe et al., 2014) machinery proteins. Noirclerc-Savoye et al., (2013) purified 
several complexes containing DivIC, DivIB, FtsL, FtsW and PBP2x, and did not 
observe any increase in the transpeptidase activity of PBP2x by hydrolysis of the S2d 
thioester substrate analogue as part of the complex. This may be due to missing 
factors or non-functional interactions, or may have been masked by the intrinsic 
instability of this thiol ester substrate. MreC, MreD and PBP2b, RodA complexes 
were purified by Philippe et al., (2014) but larger complexes could not be obtained 
and the activity of PBP2b was not tested. It should be noted that functional 
interactions between proteins in these complexes may be transient in nature and at 
different points in the cell cycle. Therefore, although these complexes will co-purify 
following overexpression, they may not be representative of in vivo interactions. No 
transglycosylases were investigated in these experiments; PBP2a has been suggested 
to be part of the peripheral machinery and PBP1a both the septal and peripheral, 
however the localisation of PBP1b has not been investigated. Therefore the 
interaction of these bifunctional PBPs is of interest in the study of cell wall synthesis. 
 
Bertsche et al., (2006) successfully identified the interaction between the 
bifunctional PBP1b and monofunctional transpeptidase PBP3 from E. coli by 
immobilisation of PBP3 and affinity chromatography. The interaction was confirmed 
by surface plasmon resonance (SPR), bacterial two-hybrid and cross-linking/co-
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immunoprecipitation. However this study did not investigate the effect of this 
interaction on catalytic activity. Immobilisation of S. pneumoniae bifunctional PBPs, 
affinity chromatography using pneumococcal membrane preparations and 
subsequent SDS-PAGE could help to identify the range of proteins interacting with 
each PBP. Proteomic analysis of the co-eluted proteins will enable identification, and 
lead to experiments to confirm interactions both physically and functionally.  
 
6.6 Conclusion 
 
This chapter has shown the first unequivocal evidence for in vitro cross-linking by a 
pneumococcal PBP. The potential for the use of a continuous coupled assay for D-
Ala release as an assay for transpeptidation was demonstrated. This discovery sets 
strong foundations for the future enzymological characterisation of pneumococcal 
PBP transpeptidase activity, and greater understanding of the mechanisms of β-
lactam resistance (Discussed Section 7.2.2) in this important Gram-positive 
pathogen. 
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Chapter 7. General discussion and conclusions 
 
The current threat from highly- and multi-drug-resistant bacteria is significant and 
the long-term effects on modern healthcare could prove catastrophic. Therefore, in 
addition to improvements in diagnosis, prescription practices and education, it is 
vital that new antibiotics are developed and made available in the clinic. Antibiotic 
resistance is essentially natural selection and is therefore inevitable to some extent, 
but it is important that we do a much better job of producing and prescribing these 
drugs in the future in order to slow the process and protect this vital resource upon 
which the treatment of many acute illnesses and surgical procedures is entirely 
dependent.  
 
In addition to assisting drug discovery, a better understanding of bacterial 
biochemistry and physiology is interesting from the perspective of fundamental 
research. This thesis has focused on biosynthesis of the bacterial cell wall, which has 
for a long time been considered an Achilles heel and prime site for pharmacological 
intervention due to its importance for cellular viability and unique molecular 
composition. Key to this process are the penicillin-binding proteins (PBPs) that are 
responsible for synthesis of the sacculus surrounding the cell. As the site of action 
for penicillins and other β-lactams, PBPs are validated antibiotic targets. Amidation 
of the Lipid II stem peptide glutamate to isoglutamine is essential in several Gram-
positive bacteria including Staphylococcus aureus and S. pneumoniae, and this is 
predicted to be at least in part due to the substrate specificity of PBPs.   
 
The main aim of this thesis was to investigate the enzymology of peptidoglycan 
assembly, with a particular focus on the influence of stem peptide amidation on the 
activity of Gram-positive PBPs. This approach should further our knowledge of the 
fundamental science underlying this important physiological process, and may aid in 
the future development of novel PBP inhibitors.   
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7.1 Transglycosylase activity of Gram-positive Class A PBPs 
 
Two bifunctional Class A PBPs from S. pneumoniae (PBP1a and PBP2a), and 
another from Staphylococcus aureus (PBP2) were studied alongside the 
Staphylococcus aureus monofunctional transglycosylase MGT (Chapters 4 and 5).  
 
7.1.1 Effect of amidation on the transglycosylase activity of Gram-positive PBPs 
 
Almost all in vitro enzymological characterisation of Gram-positive PBPs reported to 
date has involved the use of non-physiological non-amidated Lipid II substrates, with 
the exception of one recent study that confirmed the importance of amidation in 
pneumococcal peptidoglycan assembly (Zapun et al., 2013). In this thesis, the 
activities of four transglycosylases from two Gram-positive bacteria were studied by 
two complementary assay systems. 
 
S. pneumoniae PBP1a, PBP2a and Staphylococcus aureus PBP2 all displayed a clear 
preference for amidated Lipid II, as demonstrated by kinetic data for the S. 
pneumoniae enzymes (Chapter 4) that revealed a higher affinity (lower Km/S0.5) and 
increased catalytic efficiency with amidated Lipid II. Although both enzymes 
displayed a preference for amidated substrate, the effect on PBP2a and PBP1a was 
different as a more marked decrease in Km was observed for PBP1a and a more 
significant increase in Vmax for PBP2a, resulting in an overall similar increase in 
catalytic efficiency for the two enzymes. Interestingly, cooperativity was also 
identified for S. pneumoniae PBP2a transglycosylase activity (Section 7.1.2), and to 
my knowledge this has not been previously reported through kinetic data for this 
enzyme class. Notably, possible cooperativity in MGT activity was identified in 
Chapter 5, although further work is required to confirm this. In addition, PBP2a 
acted in a more processive manner with the amidated substrate compared with the 
non-amidated substrate, although the SDS-PAGE assay system does not allow 
quantification in its current format. The sole bifunctional Class A PBP from 
Staphylococcus aureus (PBP2) also showed a clear preference for amidated Lipid II, 
although kinetic values were not established as the continuous fluorescence assay 
was unsuccessful. SDS-PAGE demonstrated an increase in both substrate usage and 
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processivity of PBP2. Notably, this preference for amidation was not observed for 
the full-length monofunctional transglycosylase MGT, although it became more 
important following removal of the TM region (Section 7.1.3), indicating a more 
subtle effect than that observed with the bifunctional PBPs. This is the first study to 
investigate the role of amidation on the activity of a monofunctional 
transglycosylase, and it will be of great interest in the future to determine if this is a 
general property of this enzyme class. These results, together with the requirement 
for on-going transglycosylation during transpeptidation (Zapun et al., 2013), the 
importance of amidation in transglycosylase activity, and the discovery that amidated 
stem peptides in S. pneumoniae are found mainly in cross-linked peptidoglycan (Bui 
et al., 2012), suggest that amidation of Lipid II may be more important for 
bifunctional PBPs than monofunctional transglycosylases to allow them to perform 
efficient peptidoglycan assembly.  
 
These results show the effect of amidation on transglycosylase activity for the first 
time and that this simple chemical modification has a large effect on PBP activity. 
Identifying the molecular mechanisms underlying the observed increase in affinity 
and catalytic efficiency with amidated Lipid II should be the focus of future work, 
and may be achieved through determination of crystal structures, molecular 
modelling, or a combination of these approaches together with further functional 
analysis.  
 
7.1.2 Cooperativity in transglycosylase activity 
 
Of particular note was the identification of positive cooperativity in the 
transglycosylase activity of S. pneumoniae PBP2a with respect to Lipid II (Section 
4.5.4), and possible positive cooperativity of Staphylococcus aureus MGT (Section 
5.7.2).  Cooperativity in substrate binding between the donor and acceptor sites in the 
active site of Staphylococcus aureus monofunctional transglycosylase (MGT) has 
been shown previously (Bury et al., 2015), but to my knowledge cooperativity 
between molecules in an oligomeric state, and the effect on catalytic activity has not 
been described. In contrast, PBP1a data did not suggest cooperativity, and similar 
experiments with Staphylococcus aureus PBP2 were not performed. Therefore this 
277 
 
study should be expanded to include other PBPs, and the work of Bury and 
colleagues should be repeated to determine if cooperativity between donor and 
acceptor sites is a factor of bifunctional PBPs as well as the monofunctional 
Staphylococcus aureus MGT.    
 
7.1.3 Importance of the transmembrane region in transglycosylase activity 
 
The hydrophobic TM region of S. pneumoniae PBP1a, PBP2a and Staphylococcus 
aureus MGT was shown to be important for transglycosylase activity. However, care 
must be taken here, as the results presented in this thesis show that previous 
conclusions by Helassa et al., (2012) on the importance of the TM region in              
S. pneumoniae PBP2a processivity are an artefact of the detergent concentration 
used, likely due to interaction with the hydrophobic membrane-interacting region (Di 
Guilmi et al., 1999). The role of the TM helix of MGT is of particular note because 
when it was absent (in the ∆67 enzyme variant), either amidated or a mixture of 
labelled and non-labelled Lipid II were required in order to observe any enzyme 
activity. It may therefore be important for interaction with hydrophobic regions of 
the substrate and/or in mediating access to the active site, which may be particularly 
crucial for the smaller monofunctional enzyme. This is also consistent with the 
important role of the pentapeptide stem in transglycosylase activity suggested in 
structural studies by Huang et al., (2012), and future structural and functional studies 
should be performed.  
 
The TM region was found to be essential for oligomerisation (presumably 
dimerisation) of PBP2a, and this enabled the first reported determination of the 
dissociation constant (Kd) of a Class A PBP from S. pneumoniae. Analytical 
ultracentrifugation (AUC) experiments could provide further confirmation of the 
oligomeric state. The observed cooperativity of PBP2a (Section 7.1.2) suggests that 
oligomerisation is important for enzymatic activity. With amidated Lipid II as a 
substrate, positive cooperativity was observed at an enzyme concentration 
significantly below the calculated Kd, suggesting substrate binding may contribute to 
cooperativity by encouraging and/or stabilising dimerisation. Whether this is a factor 
of the enzyme or substrate was not established, and a higher Hill coefficient was 
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observed when the enzyme concentration was double the Kd (in the presence of non-
amidated substrate), which may imply that oligomerisation is important for substrate 
binding. Further work should aim to distinguish the role of enzyme concentration, 
substrate specificity and the cooperativity between donor and acceptor sites, and has 
the potential to determine important mechanistic details involved in transglycosylase 
activity.  
 
7.1.4 PBPs as part of a larger cell wall synthesis complex 
 
Both Staphylococcus aureus and S. pneumoniae PBPs are believed to act as part of a 
large, as-yet not fully characterised cell wall synthesis complex (Sections 1.7.2, 4.6.5 
and 5.8.4.2), and this should always be remembered when studying isolated enzymes 
in vitro. The activity of E. coli PBPs are stimulated in vivo and in vitro by the outer 
membrane lipoproteins LpoA and LpoB (Lupoli et al., 2014; Paradis-Bleau et al., 
2010; Typas et al., 2010; 2012), and although direct equivalents cannot exist in 
Gram-positive bacteria due to the absence of an outer membrane, it is highly likely 
that important extracellular or membrane-associated interacting partners are present 
in vivo. Future work should focus on identifying potential interacting partners using 
yeast two-hybrid screening and ‘fishing’ experiments involving protein 
immobilisation as have proved successful for E. coli (Bertsche et al., 2006). 
 
It is important that the results of in vitro studies are correlated with in vivo 
approaches such as live cell imaging with fluorescent probes (Tsui et al., 2014). The 
bacterial cell wall and the machinery involved in its biosynthesis are highly complex, 
and both in vitro analysis and in vivo methods will be needed to fully understand the 
processes involved.   
 
7.1.5 Characterisation of novel carbohydrate-based transglycosylase inhibitors 
 
The potential for targeting transglycosylation with antibiotics has long been 
discussed (Galley et al., 2014; Halliday et al., 2006; Ostash and Walker, 2005), and 
two novel carbohydrate-based inhibitors were tested against Staphylococcus aureus 
MGT (Section 5.7), and this work was published recently (Zuegg et al., 2015) and is 
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attached at the end of this thesis (Appendix 8). The IC50 values determined were 
comparable to the highly potent transglycosylase inhibitor moenomycin, highlighting 
the potential for using the moenomycin pharmacophore as a starting point for the 
design of new, direct-binding transglycosylase inhibitors.  
 
7.1.6 The requirement for new assays for transglycosylase activity 
 
Both assay systems used in this thesis together provided valuable information on the 
catalytic rate and processivity of PBP transglycosylase activity, however both have 
clear limitations associated with them, as discussed in Sections 4.6.2 (and published 
recently in Galley et al., 2014, attached at the end of this thesis (Appendix 8)). There 
is a clear requirement for a complementary assay system using native, unmodified, 
non-fluorescent Lipid II that does not utilise an N-acetylmuramidase coupling 
enzyme (discussed in Sections 4.6.2.2 and 5.8.5.1). This will be important in the 
future study of transglycosylases and characterisation of novel inhibitors.   
 
 
7.2 Transpeptidase activity of S. pneumoniae PBP1a 
 
7.2.1 The first unequivocal evidence for in vitro transpeptidase activity of a       
S. pneumoniae PBP 
 
Chapter 6 described the observation of transpeptidase activity of a Gram-positive 
PBP by a continuous assay format for the first time, and the first unequivocal 
evidence for cross-linking by a S. pneumoniae PBP. This is a very significant 
development in the study of Gram-positive PBPs, as it will allow the kinetic 
characterisation of transpeptidase activity of Gram-positive HMW PBPs with their 
native substrates. However before the true potential of this development can be 
realised, it will be necessary to discriminate the contribution made to D-Ala release 
from carboxypeptidase compared to transpeptidase crosslinking activities (discussed 
in Section 6.5.3). 
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7.2.2 Branched substrates 
 
This important development, combined with progress made in the synthesis of native 
branched Lipid II substrates (described in Chapter 3), paves the way for investigation 
of a fundamental and long-standing question regarding β-lactam resistance mediated 
by pneumococcal PBPs. Several crystal structures have suggested that mutations in 
the transpeptidase domain of S. pneumoniae PBPs affect access to the active site 
(Sections 1.8 and 6.1.1), and this, along with the requirement for MurM and the 
elevated levels of interpeptide branching present in resistant strains, has led to the 
theory that branched Lipid II is the preferential substrate for PBPs from penicillin-
resistant strains. PBP1a, PBP2a, PBP2b and PBP2x from S. pneumoniae 5204 have 
now all been successfully expressed and purified in our lab. The 5204 strain isolated 
from sputum in Grenoble in 1999 is highly resistant to β-lactam antibiotics such as 
Penicillin G and cefotaxime (Chesnel et al., 2003; 2005). Progress on the synthesis 
of branched Lipid II substrates in this thesis (Chapter 3) and in other work on           
Staphylococcus aureus substrates (Rebecca Bolton, Personal Communication), along 
with the ability to detect cross-linking by PBP1a in a continuous assay format 
(Chapter 6) means that the investigation of substrate specificity of PBPs from 
penicillin susceptible and resistant strains will soon be possible.  
 
7.3 Conclusion 
 
The work presented in this thesis has made a significant contribution to 
understanding of the enzymology of Gram-positive PBPs from two important global 
pathogens. Future work that is now possible will enable the investigation of long-
standing fundamental questions surrounding bacterial cell wall synthesis and 
antibiotic resistance, and may assist the future development of much-needed 
antibiotics.  
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Appendix 1  
Preparation of Micrococcus flavus membranes 
 
M. flavus membranes for Lipid II synthesis were prepared by Julie Tod or Anita 
Catherwood (BaCWAN, UK) from frozen glycerol stocks. 100 mL of tryptone soya 
broth (TSB) was inoculated from a glycerol stock and cultured overnight at 37°C 
with 180 rpm agitation. Each of 8 × 650 mL TSB culture were inoculated with 10 
mL overnight culture and incubated at 37°C with agitation at 180 rpm until OD600nm 
reached 4.0 (mid-exponential phase). Cells were harvested by centrifugation at    
10,000 × g for 10 min using a Beckman JLA-8.100 rotor.  
 
Cell pellets were washed once in ice-cold membrane buffer (20 mM Tris, 1 mM 
MgCl2 and 2 mM β-mercaptoethanol, pH 7.5) and resuspended in 3 mL/g-1 of the 
same buffer plus 2.5 mg.mL-1 hen egg-white lysozyme in incubated for 15 min on 
ice. Cells were disrupted using a continuous cell disruptor (Constant Cell Disruption 
Systems) at 30 kpsi and centrifuged at 10,000 × g for 1 h at 4°C to remove cellular 
debris. The pellet was resuspended in three times the volume of membrane buffer 
and centrifuged at 50,000 × g for 1 h at 4°C. The pellet from this, containing the M. 
flavus membranes was resuspended in 3 mL membrane buffer and the protein 
concentration determined by the Bio-Rad assay (Section 2.5.1). Membranes were 
stored at -80°C until use. 
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Appendix 2  
Calculation of DAAO and Horseradish peroxidase catalytic 
concentrations  
 
Dr Adrian Lloyd calculated the catalytic concentration of DAAO and Horseradish 
peroxidase for use in the Amplex Red assay.  
 
DAAO:  DAAO was diluted to 54.13 nM in 50 mM Tris, 50 mM lactitol, 10% (v/v) 
glycerol and 5 mM EDTA, pH 7.5.  To a 0.2 ml cuvette was added (final 
concentration): 50 mM Bis.Tris propane pH 8.5, 0.1% (v/v) Triton X-100, 20 mM 
MgCl2, 5.8 units pyruvate kinase/lactate dehydrogenase mix, 0.3 mM NADH and 
1.35 nM DAAO.  The A340 was monitored at 30°C for 5 minutes, before 1mM D-
alanine was added to initiate the assay.  The DAAO initial rate was obtained from the 
difference between rates in the presence and absence of D-alanine (ε1cm, 340 nm = 
6,220 M-1.cm-1). 
 
Horsradish peroxidase: HRP was diluted 1 in 400,000 into 50 mM Bis.Tris propane 
pH 8.5.  To a 0.2 ml cuvette was added (final concentration): 158 µl water, 20 µl 0.5 
M BisTris propane pH 8.5 (50 mM), 2 µl  2 M MgCl2 (20mM), 1 µl 10 mM Amplex 
Red (50 mM) and 5 µl diluted HRP (18.5 pM). The absorbance of any residual 
resorufin at 555 nm was zeroed, and the A555 was monitored at 30°C for five 
minutes, before the addition of 4 µl 1 mM hydrogen peroxide (20 mM) to initiate the 
assay. The HRP initial rate was obtained from the difference between rates in the 
presence and absence of hydrogen peroxide (ε1cm, 555 nm = 55,000 M-1.cm-1).  
 
In both cases rates were calculated under these defined conditions as mMoles 
substrate consumed or product produced/ml enzyme/min which results in units of 
mM.min-1. This parameter (the catalytic concentration of enzyme activity) was then 
used to determine the exact enzymatic concentration of both DAAO and HRP 
coupling enzymes in Amplex Red assays of S. pneumoniae PBP1a, and other PBPs.  
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Appendix 3  
Negative ion mass spectrometry of UDP-MurNAc-
pentapeptide (Glu, Dans) and UDP-MurNAc-pentapeptide 
(Gln, Dans) 
 
 
UDP-MurNAc-pentapeptide (Glu, Dans) and UDP-MurNAc-pentapeptide (Gln, 
Dans) were synthesised by Julie Tod or Anita Catherwood of BaCWAN (UK; Clarke 
et al., 2009; Lloyd et al., 2008). Negative ion mass spectrometry was used to confirm 
the synthesis of dansylated intermediates (and amidated where required), and to 
ensure that no non-dansylated product was present. Mass spectrometry was 
performed by Warwick Proteomics Facility RTP.  
 
Figures A3.1 and A3.2 show the negative ion mass spectra for UDP-MurNAc-
pentapeptide (Glu, Dans) and UDP-MurNAc-pentapeptide (Gln, Dans) respectively, 
with inset images showing the predicted and observed isotope profiles of the [M-H]- 
species. The correlation between these, in addition to the m/z values observed 
allowed confirmation of synthesis of the required species. 
 
Note that the spectra shown in Figure A3.1 were acquired using an Orbitap Fusion 
mass spectrometer (Thermo Scientific) rather than the Synapt G2 HDMS (Waters, 
USA) used for all other spectra. This data cannot be opened in the same software, 
and this is the reason for the different formatting of figures A3.1 A and C. Isotope 
profile prediction (Figure A3.1 (B)) was in MassLynxTM (Waters, USA) as for all 
others.  
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[M-H]- 
[M-2H]2- 
A 
B 
C 
Figure A3.1: Negative ion mass spectra of UDP-MurNAc-pentapeptide (Glu, Dans) A: Mass spectra with [M-2H]2- (observed 690.1937, expected 690.1943), and 
[M-H]- (observed 1381.3966, expected 1381.3956) indicated. B: Predicted isotope distribution of [M-2H]2- based on the empirical formula of UDP-MurNAc-
pentapeptide (Glu, Dans) (predicted by MassLynxTM software (Waters, USA). C: Observed isotope distribution of [M-2H]2- (zoomed in view of [M-2H]2- peak in 
Ashowing exact match with the predicted distribution in B.  
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[M-H]- 
[M-2H]2- 
A 
B 
C 
Figure A3.2: Negative ion mass spectra of UDP-MurNAc-pentapeptide (Gln, Dans) A: Mass spectra with [M-2H]2- (observed 689.6926, expected 689.7203), and 
[M-H]- (observed 1380.4017, expected 1380.4116) indicated. B: Predicted isotope distribution of [M-2H]2- based on the empirical formula of UDP-MurNAc-
pentapeptide (Gln, Dans) (predicted by MassLynxTM software (Waters, USA). C: Observed isotope distribution of [M-2H]2- (zoomed in view of [M-2H]2- peak in A 
showing exact match with the predicted distribution in B.  
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Appendix 4  
Negative ion mass spectra of UDP-MurNAc-heptapeptide 
(Gln, AlaAla) 
 
Negative ion mass spectra from Figure 3.12 (B) is reproduced as a full page figure 
(Figure A4.1) due to low resolution of the original file. This is due to use of an open 
source mass spectrometer for which raw data is not available.  
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[M-2H]2- 
Figure A4.1: Negative ion electrospray time-of-flight mass spectra of UDP-MurNAc-heptapeptide (Gln, AlaAla). [M-2H]2- expected 644.2139 observed 644.2. 
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Appendix 5  
Collision induced fragmentation of UDP-MurNAc-
hexapeptide (Gln, Ala) and UDP-MurNAc-hexapeptide 
(Gln, Ser) 
 
In order to confirm the location of seryl and alanyl amino acid branching on the 
amidated UDP-MurNAc-pentapeptide stem, collision-induced fragmentation by 
positive mode electrospray mass spectrometry (ES-MS) was performed by Dr A. 
Lloyd. 
 
Figure A5.1 and A5.2 show the positive ion mass spectrum, isolation of the singly 
charged cation and fragmentation (with argon and a collision energy of 60 eV) for 
UDP-MurNAc-hexapeptide (Gln, Ala) and UDP-MurNAc-hexapeptide (Gln, Ser) 
respectively. A range of peaks were obtained for both which could be assigned to 
fragmentation of the UDP-MurNAc-hexapeptide (Gln, Ala) (Figure A5.3(A)) and 
UDP-MurNAc-hexapeptide (Gln, Ser) (Figure A5.3 (B)) specifically. Figure A5.3 
shows the annotation of the main peaks and fragment identities are detailed in the 
figure legend. The fragmentation patterns confirmed the addition of the seryl and 
alanyl groups onto the ε-amino group of the stem peptide lysine.   
 
It should be noted that the peaks attributed to having seryl amino acid branching in 
Figure A5.3 (B) have a mass 16 greater than the corresponding peak in Figure A5.3 
(A) for alanyl, consistent with the presence of an additional hydroxyl.  
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Figure A5.1: Positive ion mass spectra of UDP-MurNAc-hexapeptide (Gln, Ala). A: Positive ion 
mass spectrum showing the full range of peaks. B: Isolation of the positively charged cation (expected 
[m+H+] 1220.40; observed [m+H+] 1220.40). C: Positive ion mass spectrum of collision induced 
fragmentation at 60 eV with argon of the positively charged cation in B. C is annotated in Figure 
A5.3(A). Figure generated by Dr A. Lloyd.  
Figure A5.2: Positive ion mass spectra of UDP-MurNAc-hexapeptide (Gln, Ser). A: Positive ion 
mass spectrum showing the full range of peaks. B: Isolation of the positively charged cation (expected 
[m+H+] 1236.41; observed [m+H+] 1236.41). C: Positive ion mass spectrum of collision induced 
fragmentation at 60 eV with argon of the positively charged cation in B. C is annotated in Figure 
A5.3(B). Figure generated by Dr A. Lloyd.  
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Figure A5.3: Collision induced fragmentation of UDP-MurNAc-hexapeptide (Gln, Ala) (A) and 
UDP-MurNAc-hexapeptide (Gln, Ser) (B). A: UDP-MurNAc-hexapeptide (Gln, Ala): the singly 
protonated parent cation ([m+H+]; 1220.40 observed, 1220.40 expected) was fragmented. The 
expected mass of each observed mass is indicated in brackets and labelled with a number identifying 
each species. The observed fragments are assigned as follows where (A) denotes an alanyl group 
appended to the ε-amino group of the third position stem peptide lysine; 1: MurNAc-AQK(A)AA; 2: 
MurNAc-AQA(A)A; 3: lactyl-AQK(A)AA; 4: lactyl-AQK(A)AA-NH2; 5: lactyl-AQA(A)A; 6: 
QK(A)AA; 7: lactyl-AQK(A); 8: lactyl-AQK(A)-NH2; 9: QK(A)A; 10: K(A)AA; 11: QK(A); 12: 
lactyl-AQ. B: UDP-MurNAc-hexapeptide (Gln, Ser): the singly protonated parent cation ([m+H+]; 
1236.41 observed, 1236.41 expected) was fragmented. The expected mass of each observed mass is 
indicated in brackets and labelled with a number identifying each species. The observed fragments are 
assigned as follows where (S) denotes an seryl group appended to the ε-amino group of the third 
position stem peptide lysine; 1: MurNAc-AQK(S)AA; 2: MurNAc-AQK(S)A; 3: MurNAc-AQK(S); 
4: lactyl-AQK(S)AA; 5: lactyl-AQK(S)AA; 6: lactyl-AQK(S)A; 7: lactyl-AQK(S)A-NH2; 8: 
QK(S)AA; 9: lactyl-AQK(S); 10: lactyl-AQK(S)-NH2; 11: QK(S)A/AQK(S); 12: K(S)AA; 13: 
QK(S); 14: lactyl-AQ. Peak assignments and figure generation by Dr A. Lloyd.  
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Appendix 6  
Negative ion mass spectrometry of Lipid II (Glu), Lipid II 
(Gln), Lipid II (Glu, Dans) and Lipid II (Gln, Dans) 
 
Lipid II (Glu), Lipid II (Gln), Lipid II (Glu, Dans) and Lipid II (Gln, Dans) were 
prepared by Julie Tod, Anita Catherwood or Smita Chauhan of BaCWAN (UK; 
Clarke et al., 2009; Lloyd et al., 2008) as described in Chapter 3. Purity was 
confirmed by thin layer chromatography (TLC). 
 
The identity of Lipid II species were confirmed by negative ion electrospray mass 
spectrometry (ES-MS) performed by the Proteomics Facility RTP (School of Life 
Sciences, University of Warwick). Figures A6.1-A6.4 show the mass spectra 
obtained for Lipid II (Glu) ([M-2H]2- expected 936.52, observed 936.51), Lipid II 
(Gln) ([M-2H]2- expected 936.03, observed 936.02), Lipid II (Glu, Dans) (([M-2H]2- 
expected 1053.05, observed 1053.06) and Lipid II (Gln, Dans) ([M-2H]2- expected 
1052.56, observed 1052.54) respectively. Zoomed in views of the [M-2H]2- species 
are shown as an inset on each image (red) showing the isotope distribution observed. 
A second inset figure (blue) shows the predicted isotope distribution (predicted by 
MassLynxTM (Waters, USA) based on the empirical formula) for comparison. In all 
cases these match, enabling the species to be positively identified. 
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936.52 
A 
B 
C 
[M-2H]2- 
Figure A6.1: Negative ion mass spectra of Lipid II (Glu). A: Mass spectra with [M-2H]2- indicated (observed 936.51, expected 936.52). B: Predicted 
isotope distribution based on the empirical formula of Lipid II (Glu). C: Observed isotope distribution (zoomed in view of [M-2H]2- from A).  
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936.03 
A 
B 
C 
[M-2H]2- 
Figure A6.2: Negative ion mass spectra of Lipid II (Gln). A: Mass spectra with [M-2H]2- indicated (observed 936.02, expected 936.03). B: Predicted 
isotope distribution based on the empirical formula of Lipid II (Gln). C: Observed isotope distribution (zoomed in view of [M-2H]2- from A).  
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A 
B 
C 
[M-2H]2- 
Figure A6.3: Negative ion mass spectra of Lipid II (Glu, Dans). A: Mass spectra with [M-2H]2- indicated (observed 1053.06, expected 1053.05). B: Predicted 
isotope distribution based on the empirical formula of Lipid II (Glu, Dans). C: Observed isotope distribution (zoomed in view of [M-2H]2- from A).  
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A 
B 
C 
[M-2H]2- 
Figure A6.4: Negative ion mass spectra of Lipid II (Gln, Dans). A: Mass spectra with [M-2H]2- indicated (observed 1052.54, expected 1052.56). B: Predicted 
isotope distribution based on the empirical formula of Lipid II (Gln, Dans). C: Observed isotope distribution (zoomed in view of [M-2H]2- from A).  
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Appendix 7  
Liquid chromatography positive ion mass spectrometry of 
Amplex Red assay cuvette contents 
 
Amplex Red assay cuvette contents were prepared for liquid chromatography mass 
spectrometry (LC-MS) as described in Section 6.4.6. LC-MS in positive mode and 
subsequent data analysis was performed by Dr A. Lloyd.  
 
Figure A7.1 shows the total ion chromatogram and separate chromatogram of ions 
eluting with an m/z value consistent with the anomeric structure of the product of 
lipid II Lys transpeptidation (2 peaks). Both the α- and β- anomer are present due to 
failure of the NaBH4 treatment (these are structurally shown in Figure A7.1 (C)). 
Figure A7.2 shows the positive ion mass spectra of each of the two peaks, and 
spectra from the corresponding liquid chromatography elution time in the minus 
Lipid II control. The positive ion mass spectra of the singly and doubly charged 
product of both the 15.2 min and 15.5 min peaks are also shown in Chapter 6 
(Figures 6.14 and 6.15), along with the collision induced fragmentation pattern 
confirming the species as the product of transpeptidation (Figure 6.17).  
 
Masses corresponding to the PBP1a D,D carboxypeptidase tetrapeptide product and 
dissacharide-pentapeptide of lipid II or its transglycosylation product were also 
identified and are shown in Figure A7.3 and A7.4 respectively.  
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Figure A7.1: LC-MS (positive ion) chromatogram of ions eluting with an m/z value consistent with the anomeric structure of the product of lipid II Lys 
transpeptidation. A: Total ion chromatogram of +Lipid II and – Lipid II reactions. B: Elution of two peaks containing ions with m/z values consistent with the 
anomeric structure of the product of transpeptidation ([m+H+] 1842.87) in + Lipid II sample (absent in – Lipid II sample). C: Structure of the Lipid II (Gln) 
transpeptidation product highlighting the difference between the α and β anomeric forms. Figure generated by Dr A. Lloyd. 
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Mass spectrum of 15.2 min peak 
+Lipid II Incubation 
Mass spectrum of 15.5 min peak 
+Lipid II Incubation 
Mass spectrum of 15.2 min peak 
-Lipid II Incubation 
Mass spectrum of 15.5 min peak 
-Lipid II Incubation 
A 
B 
C 
D 
Expected [m+H+] = 1842.8708 Expected [m+H+] = 1842.8708 
Figure A7.2: Mass spectrum of putative PBP1a transpeptidation product ([m+H+) expected: 1842.8708) formed from Lipid II (Gln) in the 15.2 (A) and (B) 
and 15.5 (C) and (D) min LC-MS peaks containing ions with m/z values consistent with predicted structure. A: Positive ion mass spectrum of 15.2 min peak of 
+Lipid II incubation showing the m/z value consistent with the product ([m+H+] expected 1842.8707, observed 1842.8239) B. Positive ion mass spectrum of 15.2 min 
min elution of –Lipid II incubation. C: Positive ion mass spectrum of 15.5 min peak of +Lipid II incubation showing the m/z value consistent with the product 
([m+H+] expected 1842.8707, observed 1842.8376). D: Positive ion mass spectrum of 15.5 min elution of –Lipid II incubation. Figure generated by Dr A. Lloyd. 
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Elution of 895.42 m/z Combined mass spectrum between 13.6 and 13.8 min 
+ Lipid II Incubation 
Combined mass spectrum between 13.6 and 13.8 min 
-Lipid II Incubation 
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+Lipid II Incubation 
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Expected (m + H+) = 895.4260 
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B 
C 
D 
Figure A7.3: LC-MS (positive ion) detection of disaccharide-tetrapeptide (PBP1a D,D carboxypeptidase) A: Total ion chromatogram of +Lipid II and – Lipid II 
reactions. B: Elution of single peak containing ions with m/z consistent with disaccharide-tetrapeptide ([m+H+] 895.42) in + Lipid II sample (absent in – Lipid II 
sample). C: Positive ion mass spectrum of elution between 13.6 and 13.8 min of –Lipid II incubation. D: Positive ion mass spectrum of elution between 13.6 and 13.8 
min of +Lipid II incubation showing the m/z value consistent with the product ([m+H+] expected 895.4260, observed 895.4297). Figure generated by Dr A. Lloyd. 
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Figure A7.4: LC-MS (positive ion) detection of disaccharide-pentapeptide (from Lipid II or its transglycosylation product) A: Total ion chromatogram of 
+Lipid II and – Lipid II reactions. B: Elution of two peaks containing ions with m/z consistent with disaccharide-pentapeptide ([m+H+] expected 966.46) in + Lipid 
II sample (only one in – Lipid II sample). C: Positive ion mass spectrum of elution at 13.9 min of –Lipid II incubation. D: Positive ion mass spectrum of elution at 
13.9 min of +Lipid II incubation showing the m/z value consistent with the product ([m+H+] expected 966.46316, observed 966.4741). Figure generated by Dr A. 
Lloyd. 
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Appendix 8  
Publications 
 
This section contains the following publications (in the order listed): 
 
Review Article 
 
• Galley, N. F., O’Reilly, A. M., and Roper. D. I., Prospects for novel 
inhibitors of peptidoglycan transglycosylases. Bioorganic Chemistry 2014 
55: 16-26.  
 
Primary Literature 
 
• Paulin, S, Jamshad, M., Dafforn, T. R., Garcia-Lara, J., Foster, S. J., Galley, 
N. F., Roper, D. I., Rosado, H., Taylor, P. W., Surfactant-free purification of 
membrane protein complexes from bacteria: application to the staphylococcal 
penicillin-binding protein complex PBP2/PBP2a. Nanotechnology 2014, 25, 
285101-285108 
• Zuegg, J., Muldoon, C., Adamson, G., McKeveney, D., Le Thanh, G., 
Premraj, R., Becker, B., Cheng, M., Elliot, A. G., Huang, J. X., Butler, M. S., 
Bajaj, M., Seifert, J., Sing, L., Galley, N. F., Roper, D. I., Lloyd, A. J., 
Dowson, C. G., Cheng, TJ., Cheng, WC., Demon, D., Meyer, E., 
Meutermans, W., Cooper, M. A., Carbohydrate scaffolds as 
glycosyltransferase inhibitors with in vivo antibacterial activity. Nature 
Communications 2015 6, 7719-7730 
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DiscoveryThe lack of novel antimicrobial drugs under development coupled with the increasing occurrence of
resistance to existing antibiotics by community and hospital acquired infections is of grave concern.
The targeting of biosynthesis of the peptidoglycan component of the bacterial cell wall has proven to
be clinically valuable but relatively little therapeutic development has been directed towards the
transglycosylase step of this process. Advances towards the isolation of new antimicrobials that target
transglycosylase activity will rely on the development of the enzymological tools required to identify
and characterise novel inhibitors of these enzymes. Therefore, in this article, we review the assay meth-
ods developed for transglycosylases and review recent novel chemical inhibitors discovered in relation to
both the lipidic substrates and natural product inhibitors of the transglycosylase step.
 2014 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/3.0/).1. Introduction
In the search for new treatments of bacterial infections and to
combat the increasing threat of resistance to existing antimicrobi-
als, there is renewed interest in the exploitation of existing
validated targets with novel approaches. With respect to bacterial
cell wall biosynthesis, the validity of the peptidoglycan biosyn-
thetic apparatus is well established, particularly in consideration
of the fact that many of these antimicrobial targets exist at or
beyond the extra-cytoplasmic surface of the cell membrane and
are well conserved across all bacterial species [1,2]. The
biosynthetic pathway leading to peptidoglycan precursor lipid II
and the generalised scheme for its polymerisation into the
peptidoglycan layer is well documented. Brieﬂy, uridine 50-pyro-
phosphoryl-N-acetyl muramyl-L-alanyl-c-D-glutamyl-meso-diami-
nopimelyl-D-alanyl-D-alanine (UDP-MurNAc-L-Ala-D-Glu-L-(Lys/
meso-DAP)-D-Ala-D-Ala) or its L-lysine derivative (UDP-MurNAc-
L-Ala-D-Glu-L-(Lys)-D-Ala-D-Ala) is produced in the cytoplasmic
pathway before linkage at the cytoplasmic membrane surface to
an undecaprenyl (C55) carrier lipid, prior to the addition of GlcNAc,
forming lipid II [3]. This peptidoglycan precursor is then trans-
ferred to the outer surface of the cytoplasmic membrane whereit is polymerised by monofunctional transglycosylases and class
A bifunctional Penicillin Binding Proteins (PBPs) into long glycan
chains [4] (Fig. 1). The transpeptidase activity of Class A and B PBPs
then produce inter-strand peptide cross-links from pentapeptides
emanating from adjacent glycan chains. The resulting polymer
has the mechanical strength and rigidity required to resist cyto-
plasmic osmotic stress and forms a scaffold for a number of extra-
cellular structures and functions.
Both academic and industrial effort over many decades has
been directed towards the transpeptidase function of the penicil-
lin binding proteins (PBPs) in this context, with the development
of many generations of b-lactam-based antibiotics [5]. However,
there has been relatively little development directed towards
the essential transglycosylase function required to provide the
polymeric transpeptidase substrate, which can also be the product
of the same bifunctional peptidoglycan biosynthetic enzyme [6].
Dual inhibition of both transglycosylase and transpeptidase
functions would be a powerful antimicrobial strategy providing
therapeutic options in a variety of scenarios, including those cur-
rently untreatable. Since the active site of the transglycosylase
enzymes exist at the membrane surface where peptidoglycan
intermediates are presented to the enzymes, this has been viewed
as a difﬁcult interface to target [7]. In addition, consideration of
the catalytic function of the enzymes leads to the conclusion that
the transglycosylase enzymes have long extended active sites,
which traditionally have been viewed as more difﬁcult to target
[8]. Nevertheless, nature has already provided an exemplar
solution to this issue in the form of the moenomycin group of
antimicrobials, which appear to mimic the polymerised form of
Fig. 1. Schematic diagram of the transglycoylase active site showing doner and acceptor sites. Residue numbers in the acceptor sites refer to those determined for S. aureus
monofunctional transglycosylase in relation to lipid II analogue as described by Huang et al. [28].
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macokinetics prohibits the use of moenomycins in humans, yet
this group of antibiotics has been used for decades in agriculture,
principally in animal husbandry applications [9]. Remarkably,
there is almost no incidence of resistance to these compounds,
which implies that the transglycosylase activity may have signif-
icant attraction for future targeting.
Understanding the active site architecture of the transglyco-
sylase through X-ray crystallographic analysis along with
advances in biochemical study through the provision of native
substrate and chemically deﬁned probes, and the development
of assay technologies that can support industry standard screen-
ing techniques, provide a new prospect for inhibitor discovery for
new generation chemotherapy (Fig. 1). In this review article we
provide a perspective of the assay technologies available and
compounds recently discovered, that are pertinent in that
context.2. Assays for transglycosylase activity
Bacterial transglycosylases have been studied for over 50 years
[10]. The discovery and development of novel transglycosylase
inhibitors has been highly dependent on appropriate activity
assays. However, progress has been hampered by the lack of
quantitative and high throughput approaches capable of fast,
accurate enzyme activity measurement. In addition, such efforts
have been affected by the relative chemical complexity and lack
of availability of the transglycosylase substrate, lipid II. Chemical
and chemi-enzymatic approaches to overcome this hurdle have
been reported by several groups, [11–22]. In addition, lipid II
and other peptidoglycan intermediates have become available
from the UK Bacterial Cell Wall Biosynthesis Network (UK-BaC-
WAN). Since both the transglycosylase enzymes and substrate
are within a lipid membrane environment, assay conditions and
design needs to factor in these chemical properties and physical
limitations. The solution of several X-ray crystal structures of
mono-functional and bifunctional enzymes has enhanced struc-
ture based drug design efforts [7,23–28], an advance which has
depended upon the design and implementation of reliable and
accurate high-throughput assays. The following sections discuss
the main assay types currently available, whilst Fig. 2 and Table 1
provide concise summaries.2.1. Paper and thin layer chromatography
Paper chromatography was ﬁrst used to study the full polymer-
isation of peptidoglycan using particulate enzyme preparations
isolated from Staphylococcus aureus with radiolabelled UDP-
N-acetylmuramyl-pentapeptide and UDP-N-acetylglucosamine as
substrates [29]. The assay was adapted to use [14C]-labelled lipid
II with membrane protein preparations [22]. The use of penicillin
to inhibit transpeptidase and carboxypeptidase activities of bifunc-
tional PBPs facilitated analysis of the transglycosylation reaction,
and the assay has been used for several studies [30–34]. Whilst
scintillation counting allows collection of quantitative data in a
stopped assay format, paper chromatography remains a cumber-
some technique that is low throughput and lacks the ability to rap-
idly characterise the product post reaction.
Thin layer chromatography has also been used to study poly-
merisation, using ﬂuorescent lipid II for detection [35]. With the
ﬂuorescent substrate, a dansyl reporting group was linked to the
e-amino group of the lysine side chain of the pentapeptide via a sul-
fonamide linkage to generate ﬂuorescent dansyl lipid II. Transglyco-
sylase kinetic parameters have been shown to be unaffected by the
presence of this group (see Section 2.6 for further discussion).
The presence of a dansyl group prevents transpeptidation from
occurring on this molecule, which results in a transglycosylation-
speciﬁc assay when used as the sole substrate in a stopped assay
format. Paper and thin layer chromatography are both highly sen-
sitive techniques, allowing very small amounts of material to be
detected. However, the assay remained inherently low throughput
and qualitative.2.2. Polyacrylamide gel based techniques
Transglycosylase activity can also be studied using a polyacryl-
amide gel based assay developed from a technique initially used in
the late 1980s. Tricine–SDS–PAGE [36,37] is a variation on the
more commonly used glycine SDS-PAGE that has been optimised
for low molecular weight proteins. Glycan products made of
repeating disaccharide units have a net negative charge, allowing
their separation by electrophoresis, and shorter chain lengths in
particular are within the optimum separation size range. The sys-
tem was modiﬁed to separate the polymeric products of isolated
transglycosylase domains using [14C]-lipid II and lipid IV as
Fig. 2. Schematic of the main techniques currently available to assay transglycosylase activity allowing inhibitor discovery as discussed in Section 2. A cartoon representation
of a typical reaction trace is shown for each technique and section numbers corresponding to the text are included.
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full-length PBPs were used along with penicillin G to inhibit trans-
peptidase activity. These assays were able to detect the presence of
polymeric products, and also allowed visualisation of a range of
glycan chain lengths for the ﬁrst time. Fluorescently labelled lipid
II, as discussed above, can also be used as a substrate in gel-based
assays [39].
The main strength of this technique is the unique ability to visu-
alise discrete lengths of polymerised material. However this is only
possible for shorter chain lengths, with longer polymerised mate-
rial forming an unresolved smear or high molecular weight prod-
uct, which does not enter the resolving gel phase [38,39], thus
the techniques is not particularly sensitive. The main limitation
with this approach is the lack of quantitative data in a continuous
assay format. Unpolymerised and polymerised products can be
quantiﬁed using densitometry for both ﬂuorescent and radioactive
material, and rates can be crudely estimated using time-course
experiments. Nonetheless, gel-based assays are useful for studying
the processivity of enzymes, and they allow simple comparison
between different enzymes, which other systems cannot do at
present. It has been reported that separation of glycan chains using
this approach is not affected by other proteins, salts or additives in
reaction buffers [38].2.3. High-pressure liquid chromatography
High-pressure liquid chromatography (HPLC) has been used to
separate native muropeptides extracted from bacteria [40] and
adapted to identify the products of in vitro transglycosylase activity
using suitably labelled ﬂuorescent lipid II intermediates created
either pre or post reaction [18,41] In the method described by
Schwartz et al. 2001, reactions were in the presence of Penicillin
G and products are labelled post reaction with ﬂuorescamine
via the e-amino of lysine in the lipid II pentapeptide side chain
before being separated by anion exchange [18]. Size exclusion
chromatography has been used to separate mixtures of unlabelledand Alexa 647-ﬂuor labelled lipid II substrates and polymerised
products [26]. In these cases the reaction products were applied
directly to the column with no requirement for sample prepara-
tion, although N-acetylmuramidase digestion could also be used
prior to separation [28]. When the lipid II substrate is radiola-
belled, this technique can be adapted to monitor both transglyco-
sylase and transpeptidase products of the reaction by appropriate
post reaction enzymatic treatment of the resulting polymer
[42,43] since the e-group of lysine or DAP at position 3 of the pen-
tapeptide stem is free to participate in transpeptidation. HPLC
assays in this context are reasonably sensitive, allowing low levels
of material to be detected, although sensitivity is dependent on the
exact equipment being used and its capabilities.2.4. Fluorometric continuous assays
The ﬁrst continuous, coupled assay of transglycosylase activity
reported was based upon the increased quantum yield of ﬂuores-
cence signal from a dansyl ﬂuorophore when in a hydrophobic
micellar environment [41]. Under the assay conditions used, dan-
syl lipid II (see Section 2.1) is presented to the transglycosylase
in detergent micelles, and can be polymerised into glycan chains.
Whilst N-acetylmuramidase digestion of the glycan chains
generates aqueous soluble labelled monomers, resulting in a
reduction in ﬂuorescence as the environment of the ﬂuorophore
changes from hydrophobic micellar environment to the soluble
phase. The initial rate of this decreased ﬂuorescence was attributed
to incorporation of lipid II into glycan chains and was used to
determine kinetic parameters for Escherichia coli PBP1b transglyco-
sylase activity [41]. The presence of the dansyl group in the third
position of the lipid II pentapeptide, prevented subsequent trans-
peptidation by bifunctional enzymes, allowing measurement of
transglycosylation alone. This assay [41] has been converted to a
multi-well format, which enables the rapid parallel screening of
a range of reaction conditions [44]. This can allow, therefore, the
screening and determination of optimal conditions for multiple
Table 1
Summary of transglycosylase activity assays as discussed in the text.
Assay type Section number Stopped or continuous Sensitivity Inhibitor screens
Paper/thin layer chromatography 2.1 Stopped High No
Polyacrylamide gel 2.2 Stopped Low No
HPLC 2.3 Stopped Medium No
Fluorometric: continuous ﬂuorescence 2.4 Continuous High Yes
Fluorometric: FRET 2.4 Continuous High Yes
Moenomycin displacement 2.5 Continuous High Yes
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study of these membrane proteins. In addition, this demonstrated
the basis for utility of this assay in library screening of compounds
to identify potential novel inhibitors, as did a second study [45].
Whilst measuring changes in ﬂuorescence serve well for
efﬁcient enzyme and inhibitor characterisation, they are not
always suitable for high throughput, pharmaceutical industry stan-
dard, compound screening. Thus, the development of time resolved
Förster Resonance Energy Transfer (FRET) assays is of interest to
address these requirements since it is possible to avoid contami-
nating ﬂuorescence signals from compounds within the libraries
screened. Huang et al. utilised a FRET-Based Lipid II Analogue
(FBLA), with a Coumarin ﬂuorophore in the third position of the
peptide stem and a dimethylamino-azobenzenesulfonyl quencher
in the lipid chain of the same substrate molecule [46]. Prior to
polymerisation of the FBLA, the coumarin ﬂuorescence is
quenched, but once polymerised into glycan chains, the quencher
is lost as the polyprenyl lipid tail is released from the transglyco-
sylase-substrate complex, and the polymerised glycan product is
ﬂuorescent. Inclusion of N-acetylmuramidase to digest the glycan
product into smaller and more soluble intermediates enhanced
the ﬂuorescence changes observed. When adapted to a 1536-well
format, a very high throughput approach was achieved, and a
library of 120,000 compounds was screened. A number of
previously characterised inhibitors including moenomycin were
identiﬁed in screens utilising a variety of Class A PBPs (including
Acinetobacter baumannii PBP1b, Clostridium difﬁcile PBP, E. coli
PBP1b, Klebsiella pneumoniae PBP1b, and Mycobacterium tuberculo-
sis PonA1). This was the ﬁrst application of FRET in the study of
transglycosylation, and represents a new sensitive method for con-
tinuously following transglycosylation activity.
The high throughput nature of these assays is a clear advantage,
and the ability to continuously monitor enzyme activity and accu-
rately determine kinetic parameters for a wide range of conditions
and enzymes makes this a powerful approach. Both types of ﬂuo-
rometric assay described here measure overall transglycosylation
rates, and are capable of identifying inhibitors which interfere with
substrate availability as well as those that directly inhibit enzyme
activity, which may increase the range of possible lead compounds
identiﬁed. However, both assays use a modiﬁed lipid II substrate
that differs from the native substrate by addition of large ﬂuores-
cent groups, and this will be discussed further in Section 2.6.
2.5. High throughput screening based on moenomycin displacement
A different approach to high throughput assay design has been
taken by a number of groups, based upon chemically modiﬁed
derivatives of moenomycin, which binds to the transglycosylase
active site with high afﬁnity.
Following a surface plasmon resonance (SPR) study of various
immobilised Class A PBPs binding to moenomycin, Cheng et al.
designed a highly sensitive ﬂuorescence anisotropy based assay
utilising a ﬂuorescein labelled moenomycin (F-Moe) [47]. When
bound to the transglycosylase active site F-Moe displayed
ﬂuorescence anisotropy properties which decreased when theF-Moe was displaced by compounds binding competitively to the
active site at comparable or greater afﬁnity. Of all class A PBP
homologs tested, it was found that a combination of Helicobacter
pylori PBP1a with F-Moe had a Kd of 25 (±14) nM and anisotropy
reaching 0.2 upon binding of the ligand. This high throughput
assay was used to screen 57,000 compounds with a Z0 value of
0.895, which proved valuable as a robust initial screen and identi-
ﬁed a number of moenomycin derivatives and small molecules,
with 3 small molecule hits showing both antibacterial and trans-
glycosylase inhibitory action (HTS6-8) (Table 2). The major limita-
tion of this approach is the inability of compounds with relatively
low afﬁnity to displace high afﬁnity moenomycin, precluding for
example fragment based drug design or delineation of structure
activity relationships of transglycosylase inhibitors.
Gampe et al. described a ﬂuorescence polarisation, displace-
ment assay based upon the binding of a ﬂuorescently labelled,
truncated analogue of moenomycin that displayed weaker binding
than moenomycin A [48]. This ﬂuorescent probe represented a
minimal pharmacophore to speciﬁcally identify low micromolar
inhibitor binding to the transglycosylase active site and was
designed from a consideration of the X-ray crystal structures of
moenomycin in complex with transglycosylase active sites. This
probe was used in 1536-well plate format using non-essential
S. aureus monofunctional transglycosylase enzyme SgtB [49],
against 110,000 compounds in the Harvard Medical School screen,
resulting in a Z0 value of 0.78 and initially identifying 186 hits [48].
After dose response studies and the elimination of ﬂuorescent
compounds from the initial hits, a number of leads were identiﬁed
including one (Compound 10) with inhibition constants ranging
from 2.6 mM to 95 nM against transglycosylase enzymes from
S. aureus, Enterococcus faecalis, and E. coli (Table 2).
Both the assays described by Cheng et al. [47] and Gampe et al.
[48] utilise the properties of existing drug-enzyme interaction for
the basis of detection, eliminating the need for lipid II substrates
in the primary screen and the detection of the reaction products.
Both are also sensitive methods, which can detect low levels of dis-
placement. However these assays rely on chemical modiﬁcation of
the pharmacophore for detection in a ﬂuorescence mode and the
ability of library compounds to displace existing interactions
between enzyme and that pharmacophore.
2.6. Prospects for assay development in transglycosylase inhibitor
discovery
The transglycosylase activity of puriﬁed, recombinant PBPs is
highly sensitive to the conditions in vitro. In particular: tempera-
ture, DMSO, detergents and divalent cations can have signiﬁcant
effects [41,44,50,51]. Also, despite recent advances in membrane
protein biochemistry, the level of understanding of the separate
functions of Class A PBPs and MGTs and more importantly, their
coordinated activity with other cell wall biosynthetic proteins as
well as cell division is still somewhat lacking. Additionally, studies
have shown that the transmembrane portion of the PBPs may be
highly involved in substrate binding as well as in transglycosylase
activity [27,28,39]. In fact, enzyme activities of full-length enzymes
Table 2
Reference and chemical structure of transglycosylase inhibitors discussed.
Reference Compound name/features Year
Soﬁa et al.
[68]
1999
TS30153 TS30663
TS30888
He et al.
[72]
2000
AC326-a
Halliday
et al.
[6]
2006
ACL 19273
Cheng
et al.
[47]
2008
HTS-6 HTS-7 HTS-8
Gampe
et al.
[48]
2013
Compound 10
Garneau
et al.
[76]
2004
Compound 5
Cheng
et al.
[80]
2010
Compound 24
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Table 2 (continued)
Reference Compound name/features Year
Huang
et al.
[28]
2012
Analogue 3
Huang
et al.
[28]
2012
Compound 31
Dumbre
et al.
[78]
2012
Compound 21 Compound 62
Huang
et al.
[46]
2013
Compound 19 Compound 20
Compound 24 Compound 25
N.F. Galley et al. / Bioorganic Chemistry 55 (2014) 16–26 21are often higher than the truncated forms, which supports this
hypothesis. Assaying full-length enzymes in a membrane environ-
ment and in the presence of a full complement of cell wall proteins
may be a highly signiﬁcant factor in future inhibitor discovery, and
this is undoubtedly highly challenging.
It has been demonstrated that transglycosylase kinetic parame-
ters are largely unaffected by addition of side groups on the third
position lysine or DAP of the lipid II pentapeptide [16,41]. The
effects of ﬂuorophores on the lipid and peptide chains were com-
pared, and those on the lipid chain appear less likely to interfere
with enzyme-substrate recognition [52]. Even taking this into con-
sideration, the kinetic parameters measured still appear too low to
meet the demands of growing and dividing cells. In order to sup-
port growth, an E. coli cell would require 300 transglycosylase reac-
tions/minute/molecule, but published data on E. coli PBP1a (as a
representative example) in vitro gave only 0.8 transglycosylase
reactions/minute/molecule [53]. Thus, there is a signiﬁcant gap
between observed in vitro behaviour and that required to support
life in vivo, leading to the hypothesis that other regulatory and
coordinating factors are necessary for a more accurate reﬂection
of transglycosylase activity during in vitro analysis [54].Taking all of the above into account, it may be desirable to mea-
sure alternative product release, rather than polymerised product,
to follow transglycosylase reactions [13]. Despite this approach
being unsuccessful to date, the concept could pave the way for
new ideas on how to assay these biologically and pathophysiolog-
ically important enzymes. Eventually it may be advantageous to
move away from utilisation of highly modiﬁed substrates for
enzyme characterisation, and minimise the differences from the
physiological substrates. Furthermore, it is apparent that PBPs
function in a coordinated manner, and it may be intuitive to
includemultiple enzymes in assays. Several groups have developed
high throughput assays of the coupled transglycosylase-transpep-
tidase activities of peptidoglycan synthesis using membranes as a
source of PBPs [50,55,56], in which the transglycosylases can make
many of the interactions they would make in vivo, and are thus
being studied in a more physiologically relevant environment.
3. Known inhibitors of peptidoglycan transglycosylase enzymes
As previous eluded to, peptidoglycan transglycosylases are
under-exploited as antimicrobial drug targets, despite their key
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target for a number of existing antibiotics. Moreover, since most
pathogens have at least two transglycosylase enzymes required
for peptidoglycan biosynthesis which utilise the same mechanism,
resistance to novel compounds would require simultaneous and
multiple compensatory mutations. Additionally, the fact that the
natural product moenomycin has been used for several decades in
agriculture without reports for resistance [57], suggests promise
in the search for novel inhibitors targeting the same mechanism,
but requiring more acceptable pharmacokinetic properties for
human use. The structure, biosynthesis and chemical properties
of moenomycin have been reviewed extensively in the recent past
[9] and will not form part of this discussion except for reference
to the binding site within the transglycosylase active site. The
transglycosylases are processive enzymes utilising a donor site in
which the growing glycan chain resides anchored to the membrane
by the undecaprenyl chain of the previously appended lipid II, and
an adjacent acceptor site for the incoming lipid II monomer. As a
result, the enzyme active site is comparatively long and extended
and must accommodate at least four sugar binding sites. Similar
active site architecture is seen in lysozyme which also binds alter-
natingN-acetylglucosamine andN-acetylmuramic acid repeat units
[8]. In the following section, we summarise the latest advance-
ments in inhibitors of transglycosylation, including those based
on moenomycin and its analogues, as well as analogues of lipid II.
3.1. Moenomycin: The ‘blueprint’ transglycosylase inhibitor
The moenomycins are a family of glycolipid antibiotics natu-
rally produced as a complex of related compounds by Streptomyces
ghananensis with moenomycin A representing the major compo-
nent with antimicrobial activity [9,58]. Moenomycin consists of a
pentasaccharide of units B, C, D, E and F with a chromophore (unit
A) and a C25 lipid chain connected to the F saccharide via a phos-
phoglycerate linker (see Fig. 3). The C25 chain is required for anti-
microbial action and in essence the moenomycin structure
resembles that of the lipid IV product formed within the transgly-
cosylase active site [59].
Moenomycin has amphiphilic properties due to the hydrophilic
nature of the A to F carbohydrate units, the phosphate group of the
phosphorglycerate linker and the folded hydrophobic domain
formed by the lipid chain. Structure-activity relationships have
been carried out on the moenomycin A molecule through selective
degradation of its structure and the synthesis of di- and trisaccha-
ride analogues, resulting in an understanding of the minimal
pharmacophore [9,60,61]. The degradation of moenomycin to
chemical entities that retain the carbohydrate units C, E and F,
can be performed with retention of transglycosylase inhibition
and antibacterial activity [62,63]. Degradation to retain only the
E and F carbohydrate units, still yields transglycosylase inhibition
but with the loss of antibacterial activity [64]. The C25 lipid chain
is required to achieve full anti-bacterial activity of moenomycin,
but is also the origin of its long half-life and contributes to its poor
bioavailability and incompatibility for human consumption [9].
Decreasing the length of the lipid chain slowly reduces the inhibi-
tory ability of moenomycin [63], most likely due to loss of ability to
anchor itself into the cytoplasmic membrane. Modifying or trun-
cating the lipid chain improves pharmacokinetic properties but
the loss of activity needs to be compensated by maintaining essen-
tial polar active-site contacts or by utilisation of other hydrophobic
chemophores with acceptable properties.
3.2. The binding of moenomycin and lipid II to transglycosylase
The two natural molecules known to bind to the transglycosyl-
ase domain of PBPs are moenomycin and lipid II. The structuraldifferences between the two must be responsible for inhibition
(Fig. 1), as lipid II is the natural substrate for transglycosylation
and moenomycin is the most potent inhibitor. Understanding
how these two molecules interact and bind to the transglycosylase
domain is fundamental in pursuing structural analogues for
inhibition.
Moenomycin A binds with high afﬁnity to the transglycosylase
domain of several Class A PBPs and is the most potent inhibitor of
the transglycosylase function of PBPs with MICs in the region of
0.01–0.1 lg/mL [58]. The mode of inhibition of moenomycin is
such that it directly (and reversibly) binds to the active site of
the transglycosylase domain, preventing lipid II polymerisation. It
ﬁrst binds to the cytoplasmic membrane via its lipid chain, fol-
lowed by selective binding of the sugar moiety to the donor site
of the transglycosylase.
The transglycosylase domain contains ﬁve motifs representa-
tive of the GT51 fold-family [65] and which are conserved among
both mono- and bi-functional PBPs. Six residues in the transglyco-
sylase domain have been identiﬁed as important in the interaction
with moenomycin in Aquifex aeolicus PBP1A [24,25], and are con-
served across other species. These 6 interactions bind to the F-ring
and the phosphoglycerate portion of the drug. The transglycosylase
active site is buried in the membrane in order to access the lipid II
substrate, explaining the need for a lipid chain on moenomycin A
for its inhibitory potency. It is thought that the C25 chain of moe-
nomycin interacts with the transmembrane (TM) segment of E. coli
PBP1B [47], increasing the binding afﬁnity 5-fold of moenomycin
to the transglycosylase domain, highlighting the importance of
the TM domain for activity. The regions of moenomycin that make
essential contacts with the transglycosylase domain include the C2
on the E ring, C3 on the F ring, the phosphoglycerate moiety and
possibly the C10 region of the moenocinol lipid tail. The phos-
phoryl group and the carboxylate moiety form interactions with
conserved active site residues of the transglycosylase domain
[66]. The A unit chromophore is not essential for the interaction
but may provide higher binding afﬁnity [9].
At the time of writing, the only structural information available
for the interaction of lipid II with the transglycosylase domain is
that derived from the X-ray crystal structure of S. aureus non-func-
tional glycosyltransferase with an analogue of Lipid II [28]. The
lipid II analogue used in this study has an undecaprenyl lipid tail,
biotinylated ethylene glycol diethyl amine in place of the penta-
peptide stem and GalNAc in place of GlcNAc in the disaccharide
moiety and has a Kd of 12.9 lM. Despite the clear importance of
the undecaprenyl lipid tail of lipid II for location of the substrate
in relation to the enzyme active site, only a discrete section of
the disaccharide-pyrophosphate moiety of the lipid II is repre-
sented in the electron density at 2.3 Å resolution. The presence of
GalNAc within the lipid II analogue precludes its elongation in
the normal transglycosylation reaction, since the position 4 hydro-
xyl on the sugar ring is in the opposite orientation compared to
GlcNAc. but is proposed to bind more tightly to the active site as
the distance between that hydroxyl and main-chain carbonyl of
G130 is reduced [28].
In consideration of lipid II binding to both the donor and accep-
tor sites of transglycosylase, lipid II is thought to bind at a lower
afﬁnity for the donor site compared to that of lipid IV [14] and this
is consistent with the observation of a lag phase in catalysis, seen
with many transglycosylase enzymes in the presence of lipid II
substrate only. Many inhibitors that bind to transglycosylases
occupy the donor site, mimicking the elongating chain of polymer-
ised lipid II [7]. Lovering and co-workers have proposed that moe-
nomycin structurally mimics lipid IV [7,23], a supposition further
supported in that lipid IV and moenomycin are suggested to bind
to the same site on the transglycosylase domain [67] and that lipid
IV may bind to E. coli PBP1B with a higher afﬁnity than lipid II [14].
Fig. 3. The structure of Moenomycin A, the only known potent inhibitor for bacterial transglycosylases. The region highlighted in blue is the minimal inhibitory
pharmacophore, which is often used as a scaffold for the design of new potential inhibitors (discussed in Section 3.1).
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Finding that the moenomycin degradation products exhibit
inhibitory activity against transglycosylases prompted a study in
1999 by Soﬁa et al., to develop a combinatorial library of 1300 ana-
logues of the moenomycin disaccharide core [68]. These analogues
explored modiﬁcations at C2 of the E ring and C3 of the F ring (the
critical interaction points with the transglycosylase domain). Mod-
iﬁcations included aromatic groups attached to the E and F rings
and a lipid tail of 12 rather than 25 carbons. Three compounds
showed particular promise (Table 2: TS30663, TS30153 and
TS30888, with some being more active than the EF disaccharide.
These compounds were orders of magnitude less potent than the
parent molecule moenomycin, but had IC50 values in the range of
10–15 lM [69]. These putative inhibitors also exhibited activity
against Gram-positive strains including Enterococcus faecium
which have tolerance to moenomycin, highlighting that simple
degradation compounds show potency against clinically relevant
pathogens. The IC50 values obtained are within a similar range to
other cell wall inhibitors such as bacitracin, vancomycin and
ramoplanin. These compounds showed differing activities against
transglycosylases in different species, suggesting that they may
target different subsets of the transglycosylases [70] as is also seen
for b-lactams [71]. A new member of the moenomycin group
AC326-a was introduced by He et al. (2000) which has a cyclic
moenocinol chain, giving a diumycinol chain [72]. Branched chain
lipids show more potent antibacterial activity than linear chained
lipids. Putative inhibitors could be designed to mimic moenomycin
and could exhibit antibacterial activity to cyclic lipid chains.
Halliday et al. [6] presented a class of compounds from Alchem-
ia, based on the disaccharide scaffold of Soﬁa et al. [68] with a
focus on maintaining the important transglycosylase binding
regions. The hits had MIC values of 1–4 lg/mL, against a broad
range of Gram-positive organisms [6,68]. One example compound
from this class: ACL 19273, showed direct binding and inhibition of
the transglycosylase domain, potentially binding to either theacceptor or donor site of the enzyme [6]. Inhibitors that bind to
the transglycosylase acceptor site, which may be the case for these
small disaccharides, are binding to the contrary site to where moe-
nomycin binds. Determining whether inhibitors bind to the donor
or acceptor site of the transglycosylase is important is elucidating
their mode of action.
3.4. Lipid II analogues
In the early 1990s, efforts were focused on synthesizing trans-
glycosylase inhibitors based on monosaccharide and disaccharide
analogues of lipid II, but most were not very active [73–75]. A com-
bination of mono- and disaccharide analogues of lipid II and moe-
nomycin were synthesised by Garneau et al. based on the active
part of moenomycin and combining with structural features of
lipid II [76]. A lipid II monosaccharide analogue, Compound 5,
was designed to mimic the pyrophosphate of lipid II with a dicar-
boxylate group. Modest activity with just monosaccharide ana-
logues was exhibited, with 28% inhibition of transglycosylases at
100 lM [76]. Clearly the potency of such compounds is weak and
it may be that monosaccharide analogues do not have comparable
complexity to moenomycin, to sufﬁciently inhibit transglycosylas-
es [77].
Lipid I and lipid II substrate analogues (both mono- and disac-
charides) were synthesised by Terrak and co-workers [77–79] to
test the consequences of variations in the lipid chain length, the
pyrophosphate and the length of the peptide stem. The disaccha-
ride analogues were 2-fold greater inhibitors than their cognate
monosaccharides and as the length of the peptide stem increased
from no peptide to l-Ala-d-Glu, to l-Ala-d-Glu- l-Lys, inhibition
decreased. This was attributed to the presence of a peptide
preventing high afﬁnity binding between the GlcNAc and the trans-
glycosylase. Analogues were tested to highlight important moieties
for the future design of substrate-based inhibitors with two hits:
C16-phosphoglycerate-MurNAc-GlcNAc (Compound 21) and C16-
phosphoglycerate-MurNAc-(l-Ala-d-Glu)-GlcNAc (Compound 62).
Fig. 4. The structure of vancomycin and its derivative chlorobiphenyl vancomycin
(CBP-V), which showed antibacterial activity against vancomycin-resistant Entero-
cocci (VRE) [85] (discussed in Section 3.5).
24 N.F. Galley et al. / Bioorganic Chemistry 55 (2014) 16–26The latter was most active, exhibiting inhibitory activity against
the transglycosylase as well as antibacterial ability.
The continuous and quantitative FRET-based assay by Huang
and co-workers (as described in Section 2.4) was used to screen
a 120,000 compound library containing a variety of bioactive and
synthetic molecules, including lipid II analogues [46]. Initially, 25
primary hits were revealed which were subjected to secondary
screening. Dose-dependent studies using HPLC and other
FRET-based assays identiﬁed 7 compounds as transglycosylase
inhibitors. The antibacterial activities and MICs were acquired,
which showed activity against S. aureus and M. smegmatis, but
not Gram-negative bacteria tested (E. coli, Pseudomonas aeruginosa
and A. baumannii). Compounds 19 and 20 were competitive inhib-
itors of transglycosylase and compounds 24 and 25 were active
small molecule inhibitors, with 24 being a previously identiﬁed
hit [80] with a salicylanilide core structure.
Huang et al. solved the crystal structure of S. aureus MGT
(SaMGT) in complex with a lipid II substrate analogue, Analogue
3, designed with an inverted 4-OH group on the GlcNAc, which
can bind more tightly to the lipid II binding pocket [28]. The
compound was used as a donor substrate only, and bound to the
SaMGT acceptor site. The purpose of this analogue was primarily
as a means to understand binding interactions with the transglyco-
sylase domain, rather than as an inhibitor per se.
The role of the pentapeptide moiety in lipid II and its mode of
interaction with the transglycosylase has been explored [81]. Lipid
II analogues with an assortment of peptide stems were synthesised
to analyse their capabilities as transglycosylase substrates. Modiﬁ-
cations include incorporating a ﬂuorescent NBD label into position
3 of the peptide or a d-lactyl group at the hydroxyl group of
MurNAc. Surface Plasmon Resonance binding studies were con-
ducted to determine the binding afﬁnity of these analogues to
transglycosylase. The three main conclusions from this work were
(a) the terminal d-Ala-d-Ala is not essential for substrate binding
and does not signiﬁcantly interact with the transglycosylase
domain, (b) the ﬂuorescent probe NBD on the e-amino group of
the 3rd position lysine does not affect binding afﬁnity to transgly-
cosylase and (c) the minimum structural requirement for the pep-
tide moiety in lipid II as a transglycosylase is d-lactyl-l-Ala. Further
research has shown that only the d-lactyl of the MurNAc is
required for the substrate binding to transglycosylase [78].
3.5. Vancomycin derivatives bind to transglycosylase
The natural product antibiotic vancomycin normally inhibits
peptidoglycan polymerisation by binding to the terminal d-Ala-
d-Ala moiety on the lipid II pentapeptide stem, inhibiting trans-
peptidation. Controversially, hydrophobic vancomycin derivatives
have been shown to inhibit peptidoglycan polymerisation through
preventing transglycosylation, most likely through binding the
transglycosylase domain of PBPs and in the absence of dipeptide
and depsi-peptide binding [34,82–84]. Common examples of van-
comycin derivatives have lipid moieties at the aglycone or on the
carbohydrates. One is produced from alkylating vancomycin on
the vancosamine sugar with chlorobiphenyl, giving chlorobiphe-
nyl-vancomycin (CBP-V) [85] (Fig. 4). CBP-V showed antibacterial
activity against vancomycin-resistant strains, e.g. vancomycin-
resistant Enterococci (VRE), where the di-peptide moiety in lipid
II is substituted for d-Ala-d-lactate.
When the vancomycin N-terminal methyl leucine required for
binding d-Ala-d-Ala, was removed from chlorobiphenyl vancomy-
cin (yielding chlorobiphenyl desleucyl-vancomycin), the derivative
retained antibacterial activity for both sensitive and resistant bac-
teria, despite no longer being able to bind its di-peptide ligand
[85]. In contrast, when the N-terminal methyl-leucine was
removed from full-length vancomycin, it could no longer bind tothe d-Ala- d-Ala of lipid II and so was no longer active. The mech-
anism of action of chlorobiphenyl desleucyl-vancomycin on vanco-
mycin sensitive strains is through either binding the d-Ala-d-Ala
of lipid II, or by preventing transglycosylation. Chlorobiphenyl
desleucyl vancomycin is missing an important portion of the di-
peptide binding pocket [85]. Activity of the vancomycin derivatives
decreases when the peptide-binding pockets are damaged [34],
suggesting that inhibition is through a mechanism not involving
di-peptide binding [84].4. Prospects for new transglycosylase inhibitors
Developing new drugs with antibacterial properties through
inhibition of peptidoglycan transglycosylation is of current interest
to both academia and the pharmaceutical industry. Currently, most
compounds discovered, summarised in Table 2 have greater
potency against Gram-positive bacteria than Gram-negative
presumably due to accessibility, as is the case with many other tar-
geted compounds. Progress on the development of transglycosyl-
ase inhibitors has been slow historically due to complexity of the
active site of the enzymes, lack of suitable assays for high through-
put screening, provision of suitable substrates for such assays and
the difﬁculties surrounding the reconstitution of activity of these
membrane proteins. The availability of lipid II substrate from
chemi-enzymatic and total chemical synthesis domains allows
transglycosylases from various species to be studied along with a
growing literature detailing molecular architecture interactions
within the active site. Further understanding of substrate speciﬁc-
ity will aid the design of future substrate analogues, common fea-
tures of which are becoming apparent.
The development of glycolipids and glycopeptides as putative
transglycosylase inhibitors has shown that there are new prospects
for the combinatorial biosynthesis of phosphoglycolipid antibiotics
[86] and there are new generation glycopeptides currently in clin-
ical development that inhibit the transglycosylation process [87].
N.F. Galley et al. / Bioorganic Chemistry 55 (2014) 16–26 25In addition, research is on-going to determine the exact inhibitory
mechanism of moenomycin on transglycosylases, with a drive
towards ﬁnding novel inhibitory compounds with distinct struc-
tural features. Total synthesis of moenomycin A has been achieved
[88] and the biosynthetic pathway variants can be theoretically
generated which could help in the quest to design new compounds
with better pharmacokinetics [89].
We now have the ability to synthesise structurally diverse sub-
strates and to combine synthetic and biological compounds by
either enzymatic modiﬁcation of synthetic analogues or by chem-
ical modiﬁcation of biosynthetic intermediates. These capabilities
enable better comprehension of the role of lipid II in binding to
the transglycosylase domain and help to optimise structures for
the transglycosylase donor and acceptor sites. These sites have dif-
ferent requirements for lipid chain length, which is important for
the processivity of the transglycosylase, with the donor site requir-
ing a C20 lipid chain and the acceptor site tolerating shorter lipids,
so there is a compromise between lipid chain length and antibiotic
activity [90]. Walker and co-workers have predicted that lipid II
with four successive cis isoprene units in a 35-carbon chain is
the best transglycosylase substrate [21]. Investigating the optimal
substrate for transglycosylases such as lipid IV or longer as poten-
tial substrate inhibitors may be a worthwhile focus and could be
fruitful in generating moenomycin mimics, without the poor phar-
macokinetics [14]. Despite the evolution of structurally diverse
substrates, there is still more room to understand transglycosyl-
ase-substrate mimics.
The structures of transglycosylase domains resemble more clo-
sely the structures of glycosidases such as lysozyme, rather than
other glycosyl-transferases. Therefore, glycosidases may be better
representatives for inhibitor design and lessons may be learned
from several decades of experience with the great glycosyl-
transferase families [65]. Although there are now in the region of
ten structures of transglycosylase enzymes in the protein data-
bank, only a small subset are below 2.5 Å resolution and thus reli-
able for structure based drug design efforts. This does include
however the S. aureus monofunctional enzyme in apo (2.5 Å) and
lipid II analogue (2.3 Å) forms [28] and the 2.2 Å E. coli PBPIb
structure in complex with moenomycin [27]. Curiously, the latter
structure is monomeric whereas the enzyme in solution has been
shown to dimerise at a Kd well below that achieved in both crys-
tallisation and presumable in-crystallo [42]. The recent crystal
structures of transglycosylase domains in complex with moeno-
mycin have highlighted essential interactions but their signiﬁcance
in structure based drug design efforts must be viewed in the
context of the overall processive transglycosylase mechanism.
In the recent past, a number of robust high throughput assays
for screening have emerged that provide new prospects for inhib-
itor discovery. As with all such efforts, the quality and suitability of
such libraries must be carefully considered to maximise the poten-
tial outputs. The development of a ﬂuorescence polarisation based
assay utilising a weaker binding derivative of moenomycin in a dis-
placement assay scenario is particularly encouraging in this
respect [48]. Cell based screening assays are also worthy of discus-
sion in this context since they preselect those compounds with the
required properties to gain entry to the target cell and are selected
on bacteriostatic or bactericidal effects. A set of compounds with a
non-carbohydrate, salicylanilide core were identiﬁed by Cheng
et al. and showedmodest inhibitory action against transglycosylas-
es, providing an alternative starting point for medicinal chemical
approaches [80].
Further knowledge of the catalytic mechanism and in vivo reg-
ulation of transglycosylation activity may provide further insight
into the chemistry of potential novel lead compounds required
for effective chemotherapeutic intervention. Given the renaissance
of interest in antimicrobials, the growing concern by public andpolicy makers regarding antibiotic resistance, the development of
new approaches and collaborative efforts between academia and
pharma, progress in inhibitor design against transglycosylase
may be on the horizon.
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Abstract
Surfactant-mediated removal of proteins from biomembranes invariably results in partial or
complete loss of function and disassembly of multi-protein complexes. We determined the
capacity of styrene-co-maleic acid (SMA) co-polymer to remove components of the cell division
machinery from the membrane of drug-resistant staphylococcal cells. SMA-lipid nanoparticles
solubilized FtsZ-PBP2-PBP2a complexes from intact cells, demonstrating the close physical
proximity of these proteins within the lipid bilayer. Exposure of bacteria to (-)-epicatechin
gallate, a polyphenolic agent that abolishes β-lactam resistance in staphylococci, disrupted the
association between PBP2 and PBP2a. Thus, SMA puriﬁcation provides a means to remove
native integral membrane protein assemblages with minimal physical disruption and shows
promise as a tool for the interrogation of molecular aspects of bacterial membrane protein
structure and function.
S Online supplementary data available from stacks.iop.org/NANO/25/285101/mmedia
Keywords: Staphylococcus aureus, poly(styrene-co-maleic acid), lipid nanoparticles, antibiotic
resistance, immunoafﬁnity chromatography
(Some ﬁgures may appear in colour only in the online journal)
1. Introduction
Integral membrane proteins participate in a variety of activ-
ities essential for survival, homeostasis and division. Many
function only within dynamic multi-protein assemblages
embedded in specialized lipid microdomains of the bacterial
cytoplasmic membrane (CM). Thus, the bacterial cell division
machinery is localized at mid-cell within a divisome of more
than 20 proteins [1]; their dynamic and amphipathic nature
makes them difﬁcult to study in their native state, as their
removal by surfactants leads to decreased structural integrity,
complex disassembly and loss of activity. Advances in
membrane solubilization have enabled surfactant-free
extraction and puriﬁcation of functionally active membrane
proteins [2, 3]. Amphipathic poly(styrene-co-maleic acid)
(SMA), soluble at neutral and alkaline pH and insoluble at
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lower pH, auto-assembles at neutral or alkaline pH into
membranes to form discoidal nanostructures around mem-
brane proteins and associated lipids. Preservation of the native
lipid environment of embedded proteins yields correctly fol-
ded, functionally active protein. The technique has been used
to remove and purify functionally active proteins from lipo-
somes [2–4] and over-expressed proteins from isolated
membranes of eukaryotes and prokaryotes. SMA-lipid parti-
cles (SMALPs) have also been employed to remove respira-
tory enzyme complexes from mitochondrial membranes [5],
suggesting that SMALP encapsulation provides a tool to
identify and characterize protein complexes in which mono-
meric components are in close physical proximity.
Staphylococcus aureus rapidly acquires genes encoding
antibiotic resistance; strains resistant to β-lactam agents,
typiﬁed by methicillin-resistant S. aureus (MRSA), are
usually insensitive to other antibiotic classes and there are few
treatment options [6]. MRSA is resistant to β-lactam drugs
due to acquisition of the mecA gene encoding penicillin-
binding protein (PBP) 2a, an enzyme that takes over the
transpeptidase function of PBP2 following β-lactam inacti-
vation of the PBP2 transpeptidase, to ensure continued
synthesis of cell wall peptidoglycan [7]. PBPs are embedded
in the CM, which is comprised of an asymmetric array of
lipids with differing charge characteristics, in the main
phosphatidylglycerol (PG), lysyl-PG and cardiolipin [8]. It
has proven difﬁcult to determine the spatial proximity of
PBP2 and PBP2a in the CM, even though they form part of
the cell division machinery at the division septum; divisome
assembly is regulated by polymerization of the tubulin
homologue FtsZ to a ring-like structure that acts as a scaffold
for recruitment of other proteins, including PBPs [1, 9].
Membrane-intercalating agents that abrogate β-lactam resis-
tance disperse PBP2 from the septum [8] and conversion to
drug susceptibility may be due to disruption of functional and
spatial associations between these proteins. We used the
SMALP technique to determine that PBP2/PBP2a complexes
can be captured together in nanoparticles from normally
dividing MRSA cells and to demonstrate that the drug
resistance modiﬁer (-)-epicatechin gallate (ECg) alters the
spatial relationship between the two proteins.
2. Experimental details
Epidemic MRSA isolate EMRSA-16 was from a clinical
sample obtained at the Royal Free Hospital (London, UK).
Methicillin-susceptible S. aureus SH1000 was obtained from
Alex O’Neill (University of Leeds, UK). Bacteria were grown
in Mueller-Hinton broth (Oxoid) to mid-logarithmic phase at
35 °C with constant agitation and aeration; PBP2a was
induced with sub-inhibitory concentrations (125 μg l−1) of
oxacillin. Lysostaphin, a glycine–glycine endopeptidase, and
the protease and phosphatase inhibitor mixture HALT were
purchased from Sigma-Aldrich. Anti-PBP2 antiserum was
produced in rabbits with recombinant his6-tagged PBP2;
mouse anti-PBP2a antibody was purchased from My Bio-
source and 1,2-dimyristoyl-sn-glycero-3-phosphocholine
(DMPC) from Avanti Polar Lipids. Rabbit anti-FtsZ anti-
serum was a gift from Jeff Errington (Newcastle University,
UK). SMA was composed of styrene and maleic acid residues
in a ratio of 2:1 and was synthesized in-house; 5% stock
solutions of SMA were prepared in 1.0M NaCl and reﬂuxed
for 2 h followed by overnight dialysis at 4 °C in 50 mM Tris-
HCl (pH 8.0). The composition of the lyophilized product
was conﬁrmed by FTIR. ECg was a gift from Mitsui Norin,
Tokyo, Japan and was used at a concentration of 12.5 mg l−1.
Proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) on a 10%
acrylamide/ bis-acrylamide gel matrix and visualized with
Coomassie brilliant blue (Sigma-Aldrich) with a limit of
detection of 0.2 μg. N-(2-hydroxy-1,1-bis(hydroxymethyl)
ethyl) glycine (tricine) modiﬁcation of SDS-PAGE was also
used to avoid aggregation of membrane proteins in the gel,
essentially as described by Schägger [10]. Protein-containing
samples were concentrated in Vivaspin columns (<10
000 kDa) to approximately 20 mgml−1 protein. For Western
blotting, proteins were transferred by electrophoresis to Mil-
lipore polyvinylidene membranes and probed with antibodies
to proteins of interest. Binding was detected with monoclonal
secondary antibody conjugated to horseradish peroxidase
(HRP) followed by peroxide substrate and Supersignal West
Pico Chemiluminescent Substrate (Thermo Scientiﬁc), an
enhanced chemiluminescence HRP substrate. Different sec-
ondary antibodies were used for detection of PBP2 (anti-
rabbit) and PBP2a (anti-mouse). For transmission electron
microscopy (TEM), suspensions were dropped on a grid,
washed twice with 50 mM Tris buffer, stained with uranyl
acetate [2] and viewed and photographed using a Philips 201
microscope.
Protein content of nanoparticles was determined by
absorbance at 280 nm using a Nanodrop 2000 spectro-
photometer. The hydrodynamic particle size distribution of
SMALPs was measured by dynamic light scattering (DLS)
using a Zetasizer Nano ZS. Samples (1 ml) were placed in a
semi-micro PS disposable polystyrene cuvette (Fischer Sci-
entiﬁc) and equilibrated at 25 °C for 5 min to ensure tem-
perature homogeneity prior to taking 16 measurements for
each sample, repeated three times. Data was analyzed using
Zetasizer software (V. 6.20). SMALPs were further char-
acterized with respect to their capacity to induce forward light
scatter (FSC; reﬂecting predominantly size, but also refractive
index and shape) and side scatter (SSC; indicative of geo-
metry and internal structure, or ‘granularity’) using ﬂow
cytometry in tandem with ﬂuorescein isothiocyanate (FITC)-
coupled second antibodies and excitation at 488 nm, adapted
for the analysis of nanoparticles by van der Vlist et al [11].
SMALPs (500 μl aliquots) in buffer pH 7.6 were labeled with
60 μM Nile Red (Invitrogen) for 30 min in the dark and
detected using a Miltenyi MACSQuant Analyzer with voltage
set between 300 V and 500 V, gated for ﬂuorescence (trigger
3.0) and subsequently back gated for SSC and FSC. Twenty
thousand events were collected for each sample and data
analyzed with Miltenyi MACS Quantify Software. Fluores-
cence was used as the parameter for setting the acquisition
trigger and the trigger level was adjusted to minimize
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electronic noise. All assays were performed three times on
separate days.
To determine if PBP2 and PBP2a were present in close
proximity within nanoparticles and membrane preparations,
proteins were cross-linked with 3,3′Dithiobis (sulfosuccini-
midylpropionate) (DTSSP) linked by a spacer arm of 12Ǻ
(Thermo Scientiﬁc). DTTSP was dissolved to a ﬁnal con-
centration of 10 mM in 300 μl of SMALP solution (25
mgml−1 protein) and incubated at 4 °C for 30 min. The cross-
linking reaction was quenched by the addition of 2.5 μl of
1M Tris-HCl, pH 7.5 and incubated for 15 min [12]. Cross-
links were cleaved by addition of 5% 2-mercaptoethanol
(Sigma) in tricine sample buffer. For immunoafﬁnity chro-
matography (IAC), protein G HP spintrap columns (GE
Healthcare Life Sciences) were equilibrated in Tris-buffered
saline (TBS; 50 mM Tris-HCl, 150 mM NaCl; pH 7.5),
antibody bound to the column (0.5–1.0 mgml−1 in 200 μl
TBS) and excess removed by washing. SMALPs (maximum
volume 500 μl) were added to the column, maintained with
shaking at 4 °C for 60 min, washed extensively with TBS and
centrifuged at 150 g for 1 min at 4 °C. Bound material was
eluted from the column with 100 μl 0.1 M glycine pH 2.5 and
centrifuged for 1 min at 1000 g; pH was neutralized with 1M
Tris-HCl pH 8.0. For co-immunoprecipitation (Co-IP), para-
magnetic beads coated with protein G (Dynal) and complexed
with either anti-PBP2 or anti-PBP2a antibodies were used to
purify PBP2/PBP2a-containing nanoparticles; SMALPs
(200–400 μl protein) were mixed with the Dynabeads and the
mixture incubated at 4 °C for 2 h with constant agitation. The
complex was eluted following manufacturer’s instructions
and captured proteins analyzed by SDS-PAGE and Western
blotting.
3. Results and discussion
Initially, attempts were made to solubilize PBP2/PBP2a
complexes from EMRSA-16 membranes with Triton X-100.
Cells from 1 l cultures were suspended in 1–4 ml of ice-cold
distilled water and disrupted using a FastPrep FP120
Homogenizer (Thermo Scientiﬁc). Cell wall debris was
removed by centrifugation (5000 g; 10 min; 4 °C), CMs col-
lected (130 000 g; 1 h; 4 °C) and the pellet suspended in
∼200 μl of 10 mM Tris-HCl (pH 7.0) containing 2% Triton
X-100 [8]. Exposure of solubilized proteins to DTSSP fol-
lowed by Co-IP with anti-PBP2 antibody failed to elicit cross-
linked PBP2/PBP2a; only PBP2 could be detected in Western
blots of Co-IP eluents separated by SDS-PAGE (ﬁgure S1; in
the supplementary ﬁle, available at stacks.iop.org/NANO/25/
285101/mmedia). We also attempted unsuccessfully (data not
shown) to cross-link the two proteins after solubilization with
1% formaldehyde (95 °C; 5 min). We conclude that any
PBP2/PBP2a complexes are disrupted by detergent extrac-
tion; this accords with published reports demonstrating
recovery of PBPs by non-ionic detergents in exclusively
monomeric form [13, 14]. Consequently, we examined the
potential of SMA co-polymer solubilization to reveal the
presence of closely associated PBP2/PBP2a.
As the composition of the staphylococcal CM is unusual,
we determined if SMA was able to solubilize proteins from
puriﬁed EMRSA-16 membranes. Cells were suspended in
3 ml 20% sucrose, 0.05 M Tris-HCl, 0.145M NaCl (pH 7.6)
and the cell wall digested with 80 μg lysostaphin (with 25 μg
DNase I and protease inhibitors) for 10 min at 37 °C. SMA
was added to ﬁnal concentration of 2.5% and the mixture
(6 ml) incubated for 1 h at 37 °C; membranes were collected
by centrifugation (100 000 g; 1 h; 4 °C). Proteins were sepa-
rated by tricine-SDS-PAGE. Western blotting revealed the
presence of both PBP2 and PBP2a in SMALPs. As the pre-
paration of bacterial membranes may lead to redistribution of
bilayer protein and lipid, we modiﬁed this procedure to enable
solubilization of PBPs from intact cells; the lysostaphin
digestion components were added to 3 ml bacterial suspen-
sion from 2 l culture and incubated for 10 min at 37 °C prior
to addition of SMA. Omission of this cell wall digestion step
resulted in failure to extract membrane proteins; lysostaphin,
which disrupts the pentaglycine cross-bridges of peptidogly-
can [15], breached the integrity of the cell wall as determined
by TEM (ﬁgure 1(B)). After addition of SMA and further
50 min incubation, SMALPs were recovered from the
supernatant (100 000 g; 1 h; 4 °C). TEM showed that partial
digestion of the cell wall was necessary to allow ingress of
SMA and egress of SMALPs (ﬁgure 1(C)). Initial experi-
ments included sonication of bacteria and 16 h incubation at
37 °C prior to centrifugation, as these steps were considered
essential to obtain homogeneous preparations of SMA lipo-
somal extracts [2, 3], but neither were found to be necessary
for membrane protein extraction and were omitted from our
optimized protocol, as sonication is likely to disrupt physical
associations between membrane proteins. The amount of
membrane protein extracted from EMRSA-16 by SMA was
comparable to that extracted by 2% Triton X-100 (ﬁgure S2).
TEM images of material solubilized by SMA from
DMPC vesicles, S. aureus SH1000 and EMRSA-16 revealed
monodispersed, homogeneous suspensions (ﬁgure 2) with
mean diameters of 12 ± 2 nm (±1SD) for particles from pro-
tein-free DMPC vesicles and 18 ± 3 nm and 24 ± 5 nm (all
n = 75) for those from SH1000 and EMRSA-16, indicating
that incorporation of proteins results in SMALPs of increased
size. Nanoparticle size distribution and dispersion were
investigated by DLS and ﬂow cytometry (ﬁgure 3). DLS
conﬁrmed the monodispersed nature of SH1000 and
EMRSA-16 preparations and indicated that hydrodynamic
diameters of SMALPs were 17.4 ± 2.23 nm and
24.5 ± 2.64 nm, in good agreement with measurements from
TEM. Although these nanoparticles are close to the lower
limits of detection, they were readily quantiﬁed and analyzed
by ﬂow cytometry, employing ﬂuorescence threshold trig-
gering to discriminate ﬂuorescently labelled SMALPs from
non-ﬂuorescent noise [11]. Figure 3(A) shows the forward-
(inﬂuenced by size, refractive index, shape) and side-scatter
distribution (geometry, internal structure) of nanoparticles
from EMRSA-16, visualizing both Nile Red-labeled
SMALPs and noise events. SMALPs labeled with the lipo-
philic dye Nile Red could be discriminated from non-ﬂuor-
escent noise (ﬁgure 3(B)); raising the ﬂuorescence threshold
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to eliminate noise (ﬁgure 3(C)) showed that the majority of
particles formed a homogeneous population with respect to
forward- and side-scatter but with a short tail of small ﬂuor-
escent particles (ﬁgures 3(C) and (D)). When particles were
stained with Nile Red (for lipid) and Bocillin FL (for PBPs)
and examined by ﬂuorescence microscopy, the two stains co-
localized, indicating successful protein extraction. PBP2 and
PBP2a were detected in unfractionated SMALPs from
EMRSA-16 by Western blotting.
Protein-containing SMALPs were enriched by IAC or
Co-IP; prior to enrichment, proteins separated by 12Ǻ or less
were cross-linked with DTSSP. IAC was employed to
determine if PBP2 or PBP2a could be detected in protein
complexes recovered using antibodies raised against FtsZ.
Western blotting of proteins from EMRSA-16 SMALPs
reacting with anti-FtsZ antibodies contained PBP2, PBP2a
and FtsZ (ﬁgure 4), indicating that these proteins exist on or
within the CM in close spatial proximity. IAC and Co-IP with
both anti-PBP2 and anti-PBP2a antibodies yielded nano-
particles in which PBP2 and PBP2a, but not FtsZ, could be
detected in Western blots with the appropriate antibodies, but
the bands were less prominent in comparison to blots of anti-
FtsZ-recovered nanoparticles, almost certainly reﬂecting the
low number of copies of PBPs in each S. aureus cell [16].
ECg completely abolishes β-lactam resistance in clinical
MRSA isolates; it reduces the minimum inhibitory con-
centration of oxacillin required to prevent growth of EMRSA-
16 from 512 to <1 mg l−1, due to its capacity to intercalate
deep within the CM, fundamentally altering the biophysical
characteristics of the bilayer and forcing the bacteria to
respond by reconﬁguration of CM architecture [8, 17]. The
polyphenol induces partial delocalization of PBP2 from the
septal divisome [8], indicating that reversible sensitization to
β-lactam antibiotics may be due to dissipation of the PBP2/
PBP2a-facilitiated resistance machinery. In this study, it is
clear that 12.5 mg l−1 ECg alters the spatial relationship
between these two proteins, as PBP2a can no longer be
recovered by SMA extraction and capture with anti-FtsZ
antibodies (ﬁgure 4), providing support for this supposition.
Eluents from Co-IP were also investigated by analytical
ﬂow cytometry. SMALPs were enriched with anti-PBP2
antibodies, lipid labeled with Nile Red and probed with anti-
PBP2a antiserum and FITC-conjugated second antibody.
Conversely, nanoparticles enriched with anti-PBP2a were
probed for the presence of PBP2. In both cases, the partner
protein was readily detected, with 8260 of 20 000 reacting
with anti-PBP2a antibodies after enrichment with anti-PBP2
antibodies and 7260 of 20 000 with anti-PBP2 antibodies after
enrichment with anti-PBP2a antibodies (ﬁgure 5). These data
provide strong evidence that PBP2 and PBP2a are in close
spatial proximity following recruitment by FtsZ and are
recovered from the CM in ∼40% of SMALPs. It is likely that
this reﬂects the proportion of PBP2/PBP2a complexes
actively involved in cell division, with the remainder
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Figure 1. TEM of (A) EMRSA-16 cell, (B) after 10 min exposure to lysostaphin (26.7 mg l−1), (C) after 10 min lysostaphin digestion
followed by 2.5% SMA and incubation for 50 min. Two SMALPs of diameter 37.9 nm and 32.8 nm can be seen. Scale bar = 100 nm.
Figure 2. TEM of (A) DMPC, (B) SH1000 membranes and (C) EMRSA-16 membranes incorporated into SMALPs. Bacterial membranes
were solubilized directly from viable bacteria with no intermediate membrane puriﬁcation step. Scale bar = 100 nm.
recovered from regions of the membrane other than those
accommodating divisome complexes. Flow cytometry pro-
vided further evidence that exposure of EMRSA-16 to 12.5
mg l−1 ECg caused partial dissociation of PBP2/PBP2a
complexes. Co-IP of SMALPs from control and ECg-exposed
cells was undertaken with anti-PBP2 and anti-PBP2a anti-
bodies and PBP2 and PBP2a quantiﬁed with the appropriate
antibody combinations. With anti-PBP2 Co-IP pull down,
there was a 1.76-fold reduction in the PBP2/PBP2a ratio
following ECg exposure, reﬂecting a reduction in PBP2a
FITC ﬂuorescence (normalized against PBP2 Nile Red
ﬂuorescence) from 231.6 arbitrary ﬂuorescence units (AFU)
to 131.6 AFU. With anti-PBP2a Co-IP, a 1.43-fold reduction
was observed, corresponding to a reduction in normalized
PBP2a ﬂuorescence from 53.7 AFU to 37.6 AFU. Flow
cytometry scatter plots from these experiments are shown in
ﬁgure S3. Flow cytometry was used as it is a highly sensitive,
quantitative method with a much lower limit of detection
compared to semi-quantitative Western blotting. In this con-
text, we were unable to detect a band corresponding to PBP2a
by Western blotting of SMA-extracted proteins from ECg-
exposed EMRSA-16 cells; ﬂow cytometry clearly indicated
residual PBP2a, in agreement with a study showing partial,
rather than complete, disruption of the complex [8]. Also of
note was our ability to obtain ﬂuorescence data by ﬂow
cytometry from nanoparticles of 20–25 nm diameter, using
methods [11] designed for detection and analysis of vesicles
of ∼100 nm.
We show for the ﬁrst time that SMA trapping of mem-
brane domains can be used to extract native membrane-
embedded protein complexes directly from intact bacteria.
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Figure 3. Size determination of SMALPs from EMRSA-16 membranes. Upper panel: distribution of hydrodynamic radii determined by DLS.
Lower panel: ﬂow cytometry of SMALPs labeled with 60 μM Nile Red by (A) size (forward scatter; FSC-A) and granularity (side scatter;
SSC-A), no discrimination between ﬂuorescent and non-ﬂuorescent nanoparticles, all arbitrary units; (B) ﬂuorescence intensity of Nile Red
within SMALPs (red) and non-ﬂuorescent SMALPs (black); (C) separation of SMALPs labeled with Nile Red by ﬂuorescence sorting;
number of particles in the scatter plot follow the transition from blue (low) through green to red (high); (D) size distribution (FSC-A) of Nile
Red-labeled SMALPs.
Figure 4. Western blots of EMRSA-16 SMALP proteins recovered
by anti-FtsZ IAC. Bacteria were grown in the absence (−ECg) or
presence (+ECg) of the drug resistance modiﬁer ECg (12.5 mg l−1)
and proteins probed with anti-PBP2 (A), anti-PBP2a (B) and anti-
FtsZ (C) antibodies. Arrows indicate the target protein in each blot.
Other studies [2–4] have effected removal of single proteins
within model lipid bilayers or over-expressed proteins from
protoplasts of viable bacteria. The latter approach would not
be suitable for SMALP enrichment of divisome proteins as
key components remain at the septum due to interactions with
D-alanyl-D-alanine termini on nascent peptidoglycan chains
[18]; removal of the cell wall will destroy this anchor and
delocalize proteins. It was necessary to minimally digest the
cell wall whilst retaining overall architecture and we estab-
lished that 10 min lysostaphin digestion of whole cells led to
optimal cell wall perturbation compatible with protein
extraction. SMA solubilized substantial amounts of protein
from the membrane but native PBP2 and PBP2a copy num-
bers are low and this restricted our capacity to purify enough
protein using PBP-speciﬁc antisera for analysis by Western
blotting, but not by the more sensitive ﬂow cytometry tech-
nique. In contrast, there are many more copies of FtsZ, the
major cytoskeletal protein, within the membrane bilayer [19].
The presence of FtsZ within PBP2/PBP2a-containing nano-
particles could only be demonstrated when anti-FtsZ
Nanotechnology 25 (2014) 285101 S Paulin et al
6
A
C D
B
FI
TC
 fl
uo
re
sc
en
ce
FI
TC
 fl
uo
re
sc
en
ce
FI
TC
 fl
uo
re
sc
en
ce
FI
TC
 fl
uo
re
sc
en
ce
102
102
101
101
100
100
10-1
102
101
100
10-1
102
101
100
10-1
102
101
100
10-1
10-1
10210110010-1 10210110010-1
10210110010-1
FSC-A
FSC-A FSC-A
FSC-A
Figure 5. Flow cytometry of EMRSA-16 SMALPs enriched for PBP2 and PBP2a by Co-IP. Nanoparticles were labeled with Nile Red and
size (forward scatter; FSC-A) and granularity (side scatter; SSC-A) determined after pull down with (A), (B) anti-PBP2 and (C), (D) anti-
PBP2a antibodies. Nanoparticles from A were labeled with murine anti-PBP2a antibodies followed by FITC-conjugated anti-mouse IgG
secondary antibody (B) and those from B with rabbit anti-PBP2 antibodies and FITC-conjugated anti-rabbit IgG second antibody (D). In each
experiment, 20 000 Nile Red-labeled nanoparticles; 8260 reacted with anti-PBP2a antibodies when enriched with anti-PBP2 antibodies (B)
and 7260 with anti-PBP2 antibodies when enriched with anti-PBP2 antibodies (D).
antiserum was used for puriﬁcation by IAC. SMALP capture
of FtsZ, PBP2 and PBP2a with antiFtsZ antiserum shows that
the procedure can remove large protein complexes. The S.
aureus division machinery is comprised of many membrane-
located and cytosolic proteins that interact with the FtsZ
scaffold: removal of functionally active components of the
divisome in a spatially relevant manner will provide a new
tool for elucidation of their complex interactions.
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Carbohydrate scaffolds as glycosyltransferase
inhibitors with in vivo antibacterial activity
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The rapid rise of multi-drug-resistant bacteria is a global healthcare crisis, and new antibiotics
are urgently required, especially those with modes of action that have low-resistance
potential. One promising lead is the liposaccharide antibiotic moenomycin that inhibits
bacterial glycosyltransferases, which are essential for peptidoglycan polymerization,
while displaying a low rate of resistance. Unfortunately, the lipophilicity of moenomycin
leads to unfavourable pharmacokinetic properties that render it unsuitable for systemic
administration. In this study, we show that using moenomycin and other glycosyltransferase
inhibitors as templates, we were able to synthesize compound libraries based on novel
pyranose scaffold chemistry, with moenomycin-like activity, but with improved drug-like
properties. The novel compounds exhibit in vitro inhibition comparable to moenomycin, with
low toxicity and good efﬁcacy in several in vivo models of infection. This approach based on
non-planar carbohydrate scaffolds provides a new opportunity to develop new antibiotics
with low propensity for resistance induction.
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P
eptidoglycan glycosyltransferases (GT) and transpeptidases
(TP) are two key enzymes in the ﬁnal steps of
peptidoglycan (PG) biosynthesis essential for bacterial cell
wall integrity and stability. GTs catalyse the polymerization of
lipid II disaccharide units, forming a long chain of alternating
b-1,4-linked N-acetylglucosamines and N-acetylmuramic acid,
leading to a linear glycan chain and the release of undecaprenyl-
pyrophosphate carrier1–3. These carbohydrate chains are
further crosslinked by TP enzymes, forming linkages between
the peptide chain and the D-alanine of a neighboring unit
(Fig. 1). GT and TP enzymes are unique to bacteria and
are expressed either as individual domains, monofunctional
GT (MGT) and penicillin-binding proteins (PBP), respectively or
as bifunctional proteins that possess both GT and TP domains
(class A PBP)4,5.
Inhibition of extracellular bacterial cell wall synthesis has been
a very successful strategy in the development of many important
antibacterial agents, with teixobactin6, one of the most
recently reported. The b-lactam class, which includes
cephalosporins, monobactams and carbapenems, inhibit PG
crosslinking by covalently binding to the TP enzyme, while
glycopeptides such as vancomycin bind directly to the lipid II unit
and sterically inhibit further polymerization and crosslinking of
PG. Bacteria developed resistance to cell wall inhibitors via
b-lactamases, thickened cell walls and modiﬁcation of the lipid II
unit, with extended-spectrum b-lactamases such as NDM-1
and vancomycin-resistant enterococci representing a signiﬁcant
health threat7. Glycolipopeptides (for example, ramoplanin),
cyclic peptides (for example, AC98-6446) and lantibiotics
(for example, nisin or NVB302) also bind to lipid II of
Gram-positive bacteria8. Only nisin has reached the market,
and then only as a food preservative9.
Antibacterial compounds that bind directly to GT have never
been developed for human use. Of the few examples reported in
the literature, moenomycin is by far the best described10.
Moenomycin is produced by various streptomyces species and
has a broad-spectrum activity against a range of Gram-positive
bacteria. The poor pharmacokinetic properties of moenomycin
have prevented further clinical development10,11, and it has been
commercialized only as a ‘growth promoter’ within animal feed
stocks (Flavomycin and Flavophospholipol). Despite evidence
that regular application of antibiotics as growth promoters in
animals in general leads to increased antibiotic resistance12,13,
remarkably no moenomycin-resistant bacteria in animals
have been reported to date14,15. In vitro resistance induction
experiments showed extremely slow development of resistance
with low-resistant frequencies16, as well as no transferable
resistance between organisms17,18, no cross-resistance to other
antimicrobials or co-selection of resistant strains19. Intrinsic
resistance in moenomycin-producing organisms is not associated
with the biosynthesis cluster, but is likely to arise from the
presence of GT’s with low afﬁnity for moenomycin, or some
peculiarities of their cell wall organization10. Further,
moenomycin is primarily accumulated inside of the cells, while
its target is located on the cell surface20,21. In vitro-induced
resistance with S. aureus showed mutations in the binding
site of PBP2 with reduced afﬁnity for moenomycin as well as its
ligand, resulting in strains with shorter PG polymers and
major cell division defects16. The lack of a speciﬁc resistance
mechanism and the paucity of antibiotics that speciﬁcally
mimic the carbohydrate portion of bacterial lipid II suggest that
direct GT inhibition remains an attractive strategy for the
development of novel antibacterial agents with low potential for
resistance development.
Moenomycin A is a highly functionalized pentasaccharide
attached via a phosphoglycerate linkage to a polyprenyl chain22
(Fig. 1) that binds competitively to GT enzymes by mimicking the
disaccharide–pyrophosphate–prenol linkage of the donor lipid
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II10,23,24. Although the E and F rings and the phosphoglycerate
(G) portion of moenomycin A are important for GT
inhibitory activity, analogues of this pharmacophore subunit
did not maintain whole cell antibacterial activity25,26. Attempts
to mimic the EFG structural fragment with disaccharide
derivatives27–30 resulted in compounds (such as TS30153
(ref. 17)) with cell-based activity, that is, minimum inhibitory
concentration (MIC) of 3.12 and 12.5 mgml 1 against
staphylococci and enterococci, but with no in vivo activity.
Compound TS30153 (ref. 17) has three hydrophobic binding
elements that mimic the acyl and alkyloxy moieties of
moenomycin A (Fig. 2b). Attempts to mimic directly lipid II31,
or the ring F of moenomycin32, with monosaccharide scaffolds
gave compounds with only low to medium activity (MIC¼ 60 mM
against Bacillus cereus31). More recently, de novo inhibitors for
GT discovered using high-throughput screening33–35 or in silico
methods36, were shown to have improved in vitro activity
(MIC¼ 0.25 mM against MRSA33), but no in vivo activity.
In this study, we explore novel chemistry based on a
monosaccharide scaffold37 to mimic the essential structure
features of moenomycin and to improve the drug-like properties,
in particular reduced molecular weight and hydrophobicity.
Compared with other scaffolds, the monosaccharide scaffold
approach provides structural diversity using up to ﬁve chiral
attachment points within a small volume38. This allows for more
efﬁcient pharmacophore optimization, while still enabling the
generation of a broad structural diversity to scope and improve
activity and physicochemical properties. Here we use the approach
to produce moenomycin-focused libraries and select compounds
with in vitro antibacterial activity and in silico potential to inhibit
the GT enzyme. We demonstrate the strength of this strategy with
two of the most promising candidates showing inhibition of GT
and PG synthesis in in vitro assays, as well as in vivo efﬁcacy in
eliminating S. aureus infection from a mouse mammary gland.
Results
Design and synthesis. We synthesized a small library of
compounds by replacing the phosphoglycerate/phosphate
moieties (G, Fig. 1) with simpler lipophilic substituents (that is,
phenyl, biphenyl or naphthyl groups linked via a urea) and
changing the orientation and nature of ring F. This approach
yielded compounds like ACL19378 (Fig. 2a, Supplementary
Figs 1–8) and ACL19333 (Supplementary Fig. 1), with MICs
against Gram-positive bacteria in the range of 2 mgml 1, but
with limited activity in the presence of 50% serum. In the second
stage, we used the disaccharide structure–activity relationship
information to design more synthetically feasible and smaller
monosaccharide molecules. A versatile solid-phase method was
developed to rapidly synthesize the representatives of three dif-
ferent core chemotypes M1 to M3, starting from a single
monosaccharide building block, that is, 1,5-anhydro-galactitol
(see Fig. 3). Chemotype M1 explored the option of using only two
of the hydrophobic elements, whereas the other two, M2 and M3,
used a benzimidazole moiety as the third hydrophobic group
(Fig. 3).
Five hundred compounds were thus synthesized combinatorially
on solid-phase resin, puriﬁed using high-performance liquid
chromatography, and tested for their MIC activity against two
Gram-positive staphylococcal strains (methicillin-sensitive (MSSA)
and methicillin-resistant S. aureus (MRSA)), three enterococcal
strains and Escherichia coli as a Gram-negative control. Although
most compounds were inactive against E. coli, many compounds
displayed activity against the Gram-positive strains. The derivatives
with Gram-positive antibacterial activity generally contained a
lipophilic substituent such as an alkyl moiety (minimum length
of 10 carbon atoms) or a biaryl, and one or two electron-deﬁcient
aryl groups. All active compounds were then tested for haemolytic
activity and, after ﬁltering out the haemolytic compounds, a
series of compounds of chemotype M3 containing substituted
amino-benzimidazoles were selected for further study
(Supplementary Table 1). Two compounds (Fig. 4), ACL20215
(Supplementary Figs 10–15) and ACL20964 (Supplementary
Figs 16–20), showed broad activity against a range of drug
resistant S. aureus strains, including MRSA, GISA (glycopeptide-
intermediate S. aureus), VRSA (vancomycin-resistant S. aureus)
and DRSA (daptomycin-resistant S. aureus) and multi-drug-
resistant S. pneumoniae, with low haemolytic activity against
human red blood cells (Table 1). ACL20215 was assayed for
resistance potential and showed a spontaneous mutation frequency
against S. aureus (ATCC 13709; Smith strain) of less than
2.5 10 10 at four times its MIC value.
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Evaluation of mode of action. To elucidate the mode of action of
the inhibitors, we conducted various GT enzyme inhibition
assays. We ﬁrst examined the inhibitory effect of the compounds
in a bacterial membrane environment, comparing ACL20215 and
ACL20964 in an in vitro assay for bacterial PG biosynthesis,
using crude Bacillus megaterium membrane preparations.
This assay monitors [14C]UDP-GlcNAc incorporation into
lipid II and mature PG, in the presence of different concentra-
tions of antibiotics39,40. Owing to the sequential nature of the
glycosyltransfer and transpeptidation, it is not possible to
determine at which step PG biosynthesis is blocked in this
assay. The low concentration of lipid II can be detected by
thin-layer chromatography (TLC) separation and subsequent
phosphorimaging of pre-solubilized membranes, which was
incubated with the cytoplasmic PG precursors UDP-MurNAc-
pentapeptide and UDP-[14C]GlcNAc41,42. As shown in Fig. 5
(and Supplementary Table 2 and Fig. 21), both ACL20215 and
ACL20964 caused an inhibition of mature PG production at a
concentration of 200 mgml 1, to a similar extent as the controls,
vancomycin and moenomycin A. Both inhibitors also caused an
accumulation of lipid II, although to a lesser extent compared
with vancomycin or moenomycin A.
Membrane-disruption experiments were performed using
S. aureus (ATCC 25923) in combination with membrane
potential-sensitive cyanine dye diSC35 (ref. 43). Neither
compounds showed membrane disruption (Supplementary
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Table 1 | In vitro activity data of ACL20215 and ACL20964.
Organism Strain/type Vancomycin Moenomycin A ACL20215 ACL20964
MIC (mgml 1)
S. aureus MSSA, ATCC 25923 1 4 4
MRSA, ATCC 43300 1 4 4 8
Newbould 305 2 1
NRS 17—GISA 8 16–32 8 32
NRS 1—GISA 4 1 4 16
VRS 1 464 8 4 8
mMRSA, DRSA, ci 4 16 4 8
E. faecium ATCC 35667 16 2
VanA, ATCC 51559 464 32 8 464
E. faecalis ATCC 29212 4 8
VanA, ci 464 464 8 64
S. pneumoniae MDR, ATCC 700677 2 8–16 4 8–16
E. coli ATCC 25922 464 464 464 464
Mutation frequency
S. aureus (at 4MIC) ATCC 13709 2.5 10 10
HC50 (mgml 1)
Human RBC 74 4100
IC50 (mgml 1)
S. aureus MGT 17.1 11.1
ci, clinical isolate; DRSA, daptomycin-resistant S. aureus; GISA, glycopeptide-intermediate S. aureus; HC50, half maximal haemolytic concentration; IC50, half maximal inhibitory concentration; MDR, multi-
drug-resistant; MGT, monofunctional glycosyltranferease; MIC, minimum inhibitory concentration; mMRSA, multi-drug-resistant methicillin-resistant S. aureus; Moenomycin A (Sigma, 32404); MRSA,
methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus; RBC, red blood cells; Vancomycin (Sigma, 861987); VRS, vancomycin-resistant S. aureus.
All values are mgml 1.
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Figure 5 | Inhibition of PG synthesis. The inhibitory effect in bacterial PG biosynthesis within a crude B. megaterium membrane is shown for
(a) vancomycin, (b) moenomycin A, (c) ACL20215 and (d) ACL20964, showing the relative change of lipid II and PG isolated from the crude membrane
by TLC, after 3 h, compared with non-antibiotic treatment. Error bars show s.d. for n¼ 3.
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Fig. 22) compared with a positive control Citropin 1.1
(refs 44–46), which suggested that the GT inhibitors disrupt PG
biosynthesis without disrupting the cell membrane.
We then monitored the transformation of ﬂuorescent
NBD-lipid II by two different GT enzymes, PBP1 from
Clostridium difﬁcile and MGT from S. aureus. The single
concentration test at 200mgml 1 revealed that both
inhibitors showed an inhibitory effect against MGT S. aureus,
while showing only moderate effect against PBP1 C. difﬁcile
(Supplementary Fig. 23). Conﬁrmative dose–response assays
were subsequently conducted with continuous ﬂuorescent activity
assay using a dansyl-labelled, lysine-lipid II substrate47. The assay
revealed that both ACL20215 and ACL20964 were able to inhibit
MGT from S. aureus with an IC50 of 17 and 11mgml 1,
respectively (Fig. 6). In the same assay, moenomycin A was used
as positive control showing an IC50 of 5 mM or 8 mgml 1.
Virtual docking. Several crystal structures of GT domains
have been reported for Gram-positive (MGT48,49 and PBP2
(refs 50,51) from S. aureus) and Gram-negative bacteria (PBP1
(ref. 52) from E. coli and PGT11,53 from Aquifex aeolicus),
showing a high structural similarity between the difference
species. One main feature of the structures is a binding site loop
(MGT S. aureus Phe120–Gly130; PBP2 S. aureus Gly134–Gly145)54
located between the donor-binding site, occupied by
moenomycin, and the acceptor binding site occupied by the
incoming lipid II molecule. This binding site loop is highly
ﬂexibly and partly disordered in most of the crystal structures (see
Supplementary Table 3). Even when the loop is resolved, it can
occupy different conformations, either separating the donor from
the acceptor sites or opening a groove between the sites (see
Supplementary Fig. 24 and Supplementary Note 1). We have
carried out in silico virtual docking with the monosaccharides
ACL20215 and ACL20964, choosing the receptor model (and
loop conformation), which best reproduced the binding
orientation of moenomycin. A receptor model based on the
crystal structure of MGT from S. aureus with a loop
conformation blocking the access to the acceptor site, 3HZS48,
was thereby selected (see Supplementary Fig. 25). As shown in
Fig. 7, the benzimidazole group of both inhibitors was located
similarly to portion G of moenomycin, with one of the other
hydrophobic groups located in the donor-binding site (similar to
ring E of moenomycin), and the other was located towards the
acceptor site not occupied by moenomycin. While the virtual
docking experiments were able to reproduce the binding
orientation of moenomycin, a degree of uncertainty remained
due to the ﬂexibility of the binding site loop (Fig. 7), and its
ability to adopt different conformations depending on the ligand
49. However, the docking experiments clearly indicated the
potential of the inhibitors to extend to the acceptor binding site
not occupied by moenomycin.
In vivo studies. ACL20215 testing with in vitro metabolic stability
assays showed no degradation of the compound using both human
and mouse liver microsomes. The in vivo pharmacokinetic
properties of ACL20215 and ACL20964 were investigated using
intravenous (i.v.) administration at 3.5mgkg 1 to male rats
(Table 2 and Supplementary Table 4). Both compounds had a high
apparent half-life (t1/2) of 27.2 and 33.8 h, respectively. They also
showed a very high volume of distribution (VD) and a high
clearance (Cltotal). No urinary excretion was detected for either
compound, and no metabolites were observed in plasma. The
maximum tolerated dose for both compounds (see Supplementary
methods) was determined following intraperitoneal (i.p.)
administration of the compounds to mice, and showed good
tolerance up to 60mgkg 1, with no mortality up to 100mgkg 1.
Both compounds induced some minor changes to central/
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Figure 6 | Inhibition of glycosyltransferase. The inhibition of MGT from S. aureus is shown for ACL20215 (a) and ACL20964 (b), by measuring the
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Figure 7 | Virtual docking studies of ACL20215 and ACL20215. The
virtual docking poses are shown for ACL20215 (pink) and ACL20964
(blue) within the GT domain of MGT S. aureus (pdb: 3HZS48) shown as
ribbon (green) and surface representation. Binding orientation of
moenomycin is shown as found in the corresponding crystal structure
(grey). The structure illustrates that both inhibitors are able to occupy the
donor, as well as part of the acceptor sites. The dotted line is illustrating the
suggested membrane interface49,50. BS loop marks the region of the
binding site loop with high conformational variation or disorder in the
different crystal structure, while E100 marks the active site residue Glu100.
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autonomic responses at the higher dose of 100mgkg 1. No
adverse effects were observed in a single-dose study (4mgkg 1)
following i.v. administration.
ACL20215 and ACL20964 were subsequently tested in a mouse
model of septicemia, using 10 male CD-1 (Crl.)-derived mice,
inoculated i.p. with a LD90–100 of S. aureus (Smith; 3.7 105 c.f.u.
per mouse). Both compounds administered i.p. 10min after
inoculation at 50mgkg 1 resulted in 100% survival rate after
7 days. However, same studies with i.v. administration of the
compounds (4mgkg 1, 10min after inoculation) showed no
antibacterial effect, resulting only in a 10% survival rate, compared
with 90% for ampicillin (0.1mgkg 1). The lack of efﬁcacy
following i.v. administration is most likely due to a lower dose
(4mgkg 1, limited by solubility) combined with the high volume
of distribution and serum-binding properties of the compounds,
which effectively lowers the free drug concentration at the site of
infection. When a higher dose (50mgkg 1 as a suspension) was
administered i.p. at the site of infection, the high local concentration
of the drug ensures effective clearance of the bacterial infection.
Further optimization of compound properties, dose or formulation
is required for parenteral administration.
Additional in vivo studies were conducted with ACL20215 and
ACL20964 using a mouse mammary gland infection (mastitis)
model with intraductal inoculation of S. aureus (Newbould 305,
ATCC 29740). Each compound was instilled at different doses
into the teat canal of both contralateral glands from the fourth
mammary gland pair of lactating mice at 4 h after bacterial
inoculation. Mice were killed at 14 h post infection and both
glands were analyzed for c.f.u. counts (Fig. 8, Table 2 and
Supplementary Tables 5 and 6). The effective dose to reduce the
bacterial load by 2 log(c.f.u.) (ED2log) were 730 and 510 mg per
gland, for ACL20215 and ACL20964, respectively, indicating that
both compounds cleared 99% of the staphylococci from the
infected mammary gland at a moderate dose. Similarly, the
protective doses to clear all bacteria in 50% (PD50) and 100%
(PD100) of the glands, respectively, indicated that a high dose of
ACL20964 very efﬁciently cleared S. aureus from the infected
glands (Table 2). In contrast, no PD values could be determined
for ACL20215 as the latter compound was unable to eradicate all
bacteria in 50 or 100% of the glands in the analyzed doses to at
least the detection limit of the assay.
Discussion
Using moenomycin A and previously reported GT inhibitors27,28,
we designed and synthesized a small library of disaccharide-based
compounds with a smaller, more drug-like, hydrophobic tail29.
These compounds (such as ACL19378) showed good in vitro
antibacterial activity but had unfavourable physicochemical
properties that limited their in vivo application. Nevertheless,
this set of active compounds gave valuable structure–activity
relationship information, which was used to design libraries of
compounds based on a smaller monosaccharide scaffold37. This
strategy also reduced compound hydrophobicity and chemical
complexity, enabling the synthesis of the ﬁrst reported direct GT
inhibitors with in vivo efﬁcacy against bacteria.
A reductionist approach, moving from disaccharide mimics of
the moenomycin EFG fragment to a smaller monosaccharide
scaffold, maintains the key pyranose scaffold and the substitution
pattern derived from the disaccharide actives. Chemical chirality
inherent in the pyranose scaffold ensures a rigid three-
dimensional positioning of substituents that is maintained in
the series. Second, the solid-phase synthetic method allowed
us to make substantial libraries of chemotypes designed to mimic
the disaccharide series. In this way, we identiﬁed a series of
compounds, corresponding to the amino-benzimidazole chemo-
type, which showed clear antibacterial activity against a range of
drug-resistant Gram-positive bacteria. While the cell-based
activity suggests a preference for more hydrophobic substituents,
some structural variations are not reﬂected in their activity, such
as the difference in activity between a 2- and 1-naphthyl group
and the lack of activity of the corresponding biphenyl compound.
The two most promising compounds from this monosacchar-
ide library, that is, ACL20215 and ACL20964, showed good
in vitro antibacterial activity against a range of Gram-positive
bacteria, including those resistant to common antibiotics, that is,
MRSA, GISA and VanA enterococci. PG biosynthesis assay data,
taken together, suggests that both compounds trigger an
accumulation of lipid II and a decrease of mature PG, as is the
Table 2 | Pharmacokinetic properties and in vivo efﬁcacy of ACL20215 and ACL20964.
ACL20215 ACL20964
Pharmacokinetic properties
Metabolic stability (in vitro) No degradation ND
Rat (i.v.)
Dose (mg kg 1) 3.5 3.5
t1/2 (h) 27.2 33.8
Plasma Cltotal (mlmin
 1 kg 1) 42.1 17.9
Blood Cltotal (ml min
 1 kg 1) 48.9 21.5
VZ (l kg
 1) 97.2 53.0
Mice (i.p.)
MTD (mg kg 1) 100 100
In vivo efﬁcacy
Mouse (i.p.)
Survival 7 days (%) 100 100
Mouse (i.v.)
Survival 7 days (%) 10 10
Mouse (mastitis)
ED2logc.f.u. (mg per gland) 730 510
ED4logc.f.u. (mg per gland) 1,400 770
PD50 (mg per gland) 41,000 800–1,000
PD100 (mg per gland) 41,000 41,000
Cl, clearance; ED2logc.f.u., effective dose to reduce bacterial load by 2 log(c.f.u.); ED4logc.f.u., effective dose to reduce bacterial load by 4 log(c.f.u.); i.p., intraperitoneal injection; i.v., intravenous injection;
MTD, maximal tolerated dose; ND, not determined; PD50, 50% protective dose; PD100, 100% protective dose; t1/2, half-life; VZ, volume of distribution.
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case for moenomycin A. Compounds can inhibit the function of
GT with IC50 values similar to that determined for moenomycin.
The virtual docking experiment suggest that the compounds are
able to bind in the catalytic site of the GT by occupying part of
the donor lipid II-binding site (similar to moenomycin A) as well
as part of the acceptor lipid II-binding site (not occupied by
moenomycin A).
Both hit compounds can be tolerated in mice up to a dose of
100mg kg 1, while showing good metabolic stability in rats.
Even though the library design aimed to reduce the lipophilicity,
it is apparent that GT inhibitory compounds require a certain
degree of hydrophobicity to be active in vitro and in vivo. The
monosaccharide scaffold is an excellent scaffold for drug design,
as it is able to present various substituents or binding elements (in
this case, three hydrophobic elements) in diverse spatial
orientation using up to ﬁve chiral attachment points38. The
scaffold is also able to present those substituents in a
conformational rigid form, indicated by the fact that both
monosaccharide compounds, ACL20215 and ACL20964, existed
as two atropisomers55,56 (see Supplementary Fig. 1 and
Supplementary Note 1), conformational restricted isomers or
rotamers, which would not occur if the carbohydrate scaffold
itself was ﬂexible. Virtual docking experiments show both
atropisomers among the top ranked poses. It is reasonable to
assume that one isomer will be the preferred binding partner for
the GT active site, but our in silico and in vitro experiments were
unable to distinguish them.
The membrane-associated nature of the GT enzyme and the
hydrophobicity of its natural substrate lipid II necessitates a
certain degree of lipophilicity for a compound with an inhibitory
effect. While serum binding could not be eliminated in this pilot
series, ACL20215 and ACL20964 showed in vivo efﬁcacy without
toxicity. GT inhibition hence remains a very attractive drug
discovery target3, as the current inhibitor moenomycin shows
extremely low induction of antibiotic resistance14,15, and also
inhibits the conjugative transfer of resistance plasmids19,57;
signiﬁcant advantages given the current background of
increased antimicrobial resistance.
Methods
Solid-phase synthesis. All monosaccharide compounds were synthesized on
solid-phase using an orthogonally protected galactitol-building block attached to
WANG resin. The synthesis of ACL20215 and ACL20964 is given in
Supplementary Fig. 9 and below as a representative example.
DTPM removal: the resin was treated with a solution of 5% hydrazine hydrate in
dimethylformamide (DMF; 10ml g 1 of resin), shaken (1 h, RT), drained and
washed (3 DMF, 3 DCM, 3 DMF). Urea formation: the resin was treated
with a solution of 4-chloro-3-triﬂuoromethyl-phenyl isocyanate (0.15M) in DMF
(10ml g 1 of resin), shaken (O/N, RT), drained and washed (3 DMF, 3 DCM).
The resin was taken up in a solution of sodium methoxide (0.15M) in MeOH
(5ml g 1 of resin) and tetrahydrofuran (20ml g 1 of resin), shaken (3 h, RT),
drained and washed (3 tetrahydrofuran, 3 MeOH, 3 DCM, 3 DMF).
Azide reduction: the resin was treated with a solution of lithium tert-butoxide
(0.2M) and DL-dithiothreitol (DTT, 0.2M) in DMF (15ml g 1 of resin), shaken
(O/N, RT), drained and washed (3 DMF, 3 MeOH, 3 DCM, 3 DMF).
Formation of the substituted benzimidazoles: the resin was treated with a
solution of 4-ﬂuoro-3-nitro-benzotriﬂuoride (0.36M) and DIPEA (0.36M) in
DMF (10ml g 1 of resin), and heated at 50 C. The resin was drained and washed
with (3 DMF, 3 DCM, 3 DMF). Reduction the nitro group: the resin was
treated with a solution of SnCl2.2H2O in DMF (2.0M, 10ml g 1 of resin), shaken
(O/N, RT), drained and washed (3 DMF, 3 DMF/MeOH 1:1, 3 DCM,
3 DMF, 3 DMF/MeOH 1:1, 3 DCM).
To form the benzimidazole, the resin was treated with DIPEA (0.5M) in DCM
(10ml g 1 of resin), shaken (1 h, RT), drained and washed (3 DCM), followed
by a solution of cyanogen bromide (1.0M, 10ml g 1 of resin), shaken (O/N, RT),
drained and washed (3 DCM, 3 MeOH, 3 DCM). To alkylate the 2-amine,
the resin was treated with a solution of benzyl bromide or 1-(bromomethyl)
naphthalene (0.4M) and DIPEA (0.8M) in DMF (10ml g 1 of resin), shaken
(O/N, RT), drained and washed (3 DCM, 3 MeOH, 3 DCM).
Cleavage and puriﬁcation: each resin was treated with 10% TFA, 20%
triethylsilane in dry DCM (1.5ml), allowed to stand at RT for 3 h, drained into a test
tube and washed (3 DCM). The concentrated samples were treated with a solution
of saturated ammonia in methanol (1.0ml) and left to stand at RT for 2 h, and
concentrated by vacuum. Crude samples were puriﬁed using preparative high-
performance liquid chromatography on a C-18 column (water/acetonitrile gradient).
Analytical data for ACL20215. The analytical data for ACL20125 are given as
1H-NMR, temperature dependent 1H-NMR, 13C-NMR, COSY, edCOSY and
HMBC NMR spectra in Supplementary Figs. 10–15, respectively. The structure
of ACL20215 exists as two distinctive rotamers or conformational isomers that can
be detected in NMR experiments. Transition between the two isomers, or
atropisomers, can be achieved by heating the sample to 45 C (see Supplementary
Fig. 11). In silico analysis of the structure and conformation of ACL20125 indicate
restricted torsional rotation of the C4–NBenzimidazole bond, due to size of the
benzimidazole group. Energy barrier calculation indicate an upper range of 25
kcal/mol for this rotational barrier (see Supplementary Fig. 3), which, in relation to
other known atropisomers, corresponds to an interconversion rate from a few
hours to a few days56.
1H-NMR (600MHz, dimethylsulphoxide (DMSO)-d6): major rotamer d 9.20
(br s, 1H, 7-NH), 8.10 (d, J¼ 8.0Hz, 1H, H-20), 8.02 (d, J¼ 2.2Hz, 1H, H-9), 7.50
(d, J¼ 8.9Hz, 1H, H-13), 7.48 (dd, J¼ 2.2, 8.9Hz, 1H, H-12), 7.42 (s, 1H, H-17),
7.39 (d, J¼ 7.3Hz, 2H, H-25, H-29), 7.27 (dd, J¼ 7.3, 7.3Hz, 2H, H-26, H-28), 7.22
(d, J¼ 8.0Hz, 1H, H-19), 7.19 (dd, J¼ 7.3, 7.3 Hz, 1H, H-27), 7.14 (t, J¼ 5.8Hz,
1H, 15-NH), 6.34 (d, J¼ 6.0Hz, 1H, 2-NH), 5.41 (d, J¼ 5.8Hz, 1H, 3-OH), 4.91
(m, 1H, H-4), 4.91 (t, J¼ 5.1Hz, 1H, 6-OH), 4.63 (m, 2H, H-23), 4.27 (dd, J¼ 5.2,
11.2Hz, 1H, H-1b), 4.00 (m, 2H, H-3, H-5), 3.87 (dddd, J¼ 5.2, 5.8, 11.2, 11.2Hz,
1H, H-2), 3.40 (m, 1H, H-6a), 3.39 (m, 1H, H-1a), 3.18 (dd, J¼ 5.8, 5.8, 11.2Hz,
1H, H-6b); minor rotamer d 9.25 (br s, 1H, 7-NH), 8.10 (d, J¼ 2.2Hz, 1H, H-9),
7.78 (t, J¼ 5.2Hz, 1H, 15-NH), 7.54 (m, 2H, H-12, H-13), 7.54 (d, J¼ 7.3Hz, 2H,
H-25, H-29), 7.45 (s, 1H, H-17), 7.36 (d, J¼ 8.0Hz, 1H, H-20), 7.35 (dd, J¼ 7.3,
7.3 Hz, 2H, H-26, H-28), 7.27 (dd, J¼ 7.3, 7.3Hz, 1H, H-27), 7.21 (d, J¼ 8.0Hz,
1H, H-19), 6.36 (d, J¼ 6.0Hz, 1H, 2-NH), 5.29 (d, J¼ 6.1Hz, 1H, 3-OH), 5.00 (m,
1H, H-4), 4.96 (t, J¼ 5.2Hz, 1H, 6-OH), 4.65 (m, 1H, H-23a), 4.63 (m, 1H, H-23b),
4.24 (dddd, J¼ 5.2, 5.8, 11.2, 11.2Hz, 1H, H-2), 4.16 (dd, J¼ 5.2, 11.2Hz, 1H,
H-1b), 4.07 (m, 2H, H-3, H-5), 3.48 (ddd, J¼ 5.2, 5.2, 11.2Hz, 1H, H-6a), 3.39
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Figure 8 | In vivo efﬁcacy in mastitis mouse model. S. aureus c.f.u. counts (c.f.u. g 1 gland) at 14 h post treatment in infected mouse mammary glands
treated with increasing doses of ACL20215 (a) and ACL20964 (b). Signiﬁcance compared with control (parafﬁn oil) are given as Po0.001 (***) and
Po0.0001 (****), calculated by one-way analysis of variance followed by Holm–Sidak post hoc test. Dashed line represents the detection limit at 1.7
log10c.f.u. Data values are given in Supplementary Table 5.
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(m, 1H, H-1a), 3.27 (dd, J¼ 5.8, 5.8, 11.2Hz, 1H, H-6b); 13C-NMR (150MHz,
DMSO-d6): major rotamer d 158.9 (C-15), 154.9 (C-7), 143.0 (C-16), 140.1 (C-24),
139.9 (C-8), 137.4 (C-21), 131.8 (C-12), 128.0 (C-26, C-28), 126.8 (C-25, C-29),
126.4 (C-27), 125.5 (q, 1JCF¼ 271Hz, C-22), 122.9 (q, 1JCF¼ 273Hz, C-14), 122.6
(q, 2JCF¼ 31Hz, C-10), 122.3 (C-13), 121.5 (C-11), 121.0 (q, 2JCF¼ 31Hz, C-18),
116.1 (C-9), 115.0 (C-19), 112.1 (C-20), 111.4 (C-17), 77.7 (C-5), 70.7 (C-3),
68.8 (C-1), 60.3 (C-6), 55.2 (C-4), 48.8 (C-2), 46.0 (C-23); minor rotamer d 155.8
(C-15), 155.0 (C-7), 142.1 (C-16), 140.9 (C-21), 139.9 (C-8), 139.0 (C-24), 131.9
(C-12), 128.4 (C-26, C-28), 127.5 (C-25, C-29), 127.0 (C-27), 125.5 (q, 1JCF¼
271Hz, C-22), 122.9 (q, 1JCF¼ 273Hz, C-14), 122.6 (q, 2JCF¼ 31Hz, C-10), 122.3
(C-13), 121.5 (C-11), 121.0 (q, 2JCF¼ 31Hz, C-18), 116.1 (C-9), 115.0 (C-19),
109.4 (C-20), 111.1 (C-17), 77.9 (C-5), 70.8 (C-3), 69.0 (C-1), 59.9 (C-6),
56.4 (C-4), 48.5 (C-2), 46.8 (C-23); HRESIMS (m/z): [MþH]þ calcd. for
C29H27Cl1F6N5O4, 658.1650; found, 658.1659.
Analytical data for ACL20964. The analytical data for ACL20964 are given as
1H-NMR, 13C-NMR, COSY, edCOSY and HMBC NMR spectra in Supplementary
Figs 16–20, respectively. Similar to ACL20215, ACL20964 exists as two
conformational isomer, due to rotational restriction of the C4–NBenzimidazole bond,
caused by the large benzimidazole group.
1H-NMR (600MHz, DMSO-d6): major rotamer d 9.26 (br s, 1H, 7-NH), 8.14 (d,
J¼ 8.2Hz, 1H, H-32), 8.13 (d, J¼ 8.2Hz, 1H, H-20), 8.04 (s, 1H, H-9), 7.94
(d, J¼ 8.2Hz, 1H, H-29), 7.81 (d, J¼ 8.2Hz, 1H, H-27), 7.63 (d, J¼ 8.2Hz, 1H,
C-25), 7.54 (m, 2H, H-30, H-31), 7.51 (m, 2H, H-12, H-13), 7.42 (s, 1H, H-17), 7.39
(dd, J¼ 8.2, 8.2Hz, 1H, H-26), 7.22 (d, J¼ 8.2Hz, 1H, H-19), 7.19 (t, J¼
5.7Hz, 1H, 15-NH), 6.34 (br s, 1H, 2-NH), 5.47 (br s, 1H, 3-OH), 5.09 (m, 2H, H-23),
4.97 (m, 1H, H-4), 4.95 (br s, 1H, 6-OH), 4.28 (dd, J¼ 4.8, 11.2Hz, 1H, H-1b), 4.01
(m, 2H, H-3, H-5), 3.92 (m, 1H, H-2), 3.45 (m, 1H, H-6a), 3.39
(m, 1H, H-1a), 3.23 (m, 1H, H-6b); minor rotamer d 9.26 (br s, 1H, 7-NH), 8.21
(d, J¼ 8.2Hz, 1H, H-32), 8.10 (s, 1H, H-9), 7.96 (d, J¼ 8.2Hz, 1H, H-29), 7.87
(d, J¼ 8.2Hz, 1H, H-27), 7.78 (t, J¼ 5.1Hz, 1H, 15-NH), 7.73 (d, J¼ 8.2Hz, 1H,
C-25), 7.60 (dd, J¼ 8.2, 8.2Hz, H-31), 7.55 (m, 2H, H-12, H-13), 7.54 (m, 1H, H-30),
7.47 (s, 1H, H-17), 7.50 (m, 1H, H-26), 7.37 (d, J¼ 8.2Hz, 1H, H-20), 7.22 (d,
J¼ 8.2Hz, 1H, H-19), 6.36 (br s, 1H, 2-NH), 5.31 (br s, 1H, 3-OH), 5.16 (dd, J¼ 5.6,
15.3Hz, 1H, H-23a), 5.11 (dd, J¼ 4.8, 15.3Hz, 1H, H-23b), 5.01 (m, 1H, H-4), 4.95
(br s, 1H, 6-OH), 4.24 (m, 1H, H-2), 4.16 (dd, J¼ 5.2, 11.2Hz, 1H, H-1b), 4.05 (m,
1H, H-3), 4.01 (m, 1H, H-5),3.48 (m, 1H, H-6a), 3.39 (m, 1H, H-1a), 3.27 (m, 1H,
H-6b); 13C-NMR (150MHz, DMSO-d6): major rotamer d 158.7 (C-15), 154.9 (C-7),
143.1 (C-16), 140.0 (C-8), 137.5 (C-21), 134.9 (C-33), 134.2 (C-28), 131.9 (C-12),
130.9 (C-24), 128.5 (C-29), 127.0 (C-27), 126.6 (q, 2JCF¼ 31Hz, C-10), 126.1 (C-31),
125.6 (C-30), 125.5 (C-26), 125.4 (q, 1JCF¼ 271Hz, C-22), 124.6 (C-25), 123.4 (C-
32), 122.8 (q, 1JCF¼ 273Hz, C-14), 122.3 (C-13), 121.5 (C-11), 121.0 (q,
2JCF¼ 31Hz, C-18), 116.1 (C-9), 115.0 (C-19), 112.1 (C-20), 111.4 (C-17), 77.6 (C-
5), 70.7 (C-3), 68.8 (C-1), 60.3 (C-6), 55.1 (C-4), 49.0 (C-2), 44.3 (C-23); minor
rotamer d 155.8 (C-15), 154.9 (C-7), 142.1 (C-16), 140.9 (C-21), 140.0 (C-8), 134.2
(C-33), 133.2 (C-28), 131.8 (C-12), 130.9 (C-24), 128.6 (C-29), 127.7 (C-27), 126.6 (q,
2JCF¼ 31Hz, C-10), 126.5 (C-31), 125.8 (C-30), 125.6 (C-26), 125.4 (q,
1JCF¼ 271Hz, C-22), 125.4 (C-25), 123.4 (C-32), 122.8 (q, 1JCF¼ 273Hz, C-14),
122.3 (C-13), 121.5 (C-11), 121.0 (q, 2JCF¼ 31Hz, C-18), 116.1 (C-9), 115.0 (C-19),
111.1 (C-17), 109.5 (C-20), 77.8 (C-5), 70.9 (C-3), 68.5 (C-1), 59.8 (C-6), 56.4 (C-4),
48.5 (C-2), 44.7 (C-23); HRESIMS (m/z): [MþH]þ calcd. for C33H29Cl1F6N5O4,
708.1807; found, 708.1797.
Virtual docking. The virtual docking of inhibitor and moenomycin structures into
the binding site of MGT from S. aureus were done using the software Glide
(version 6.5, Schro¨dinger, LLC, New York, 2014 (ref. 58)) and using several
different crystal structures with different binding site loop conformations. In
addition, the induced ﬁt protocol in the Schro¨dinger software package (Induced Fit
Docking protocol 2014-4, Glide version 6.5, Prime version 3.7, Schro¨dinger,
LLC59,60) was used to allow conformational ﬂexibility of the GT domain. The
docking experiments were all done using the standard precision (SP) in Glide and
deﬁning a binding site with 13Å around the crystal structure of moenomycin, large
enough to include also the acceptor site which is not occupied by moenomycin. For
the structure of moenomycin, a truncated version was used, without the fatty acid
chain and only a lactic acid attached to the phosphate group. Models for inhibitors
were built in four different conformations, 4C1 and 1C4 chair conformation for the
galactose moiety, and two different orientations for the benzimidazole moiety
compared with the galactose ring. All structure models were built using Maestro
(version 10.0, Schro¨dinger, LLC, New York, 2014).
The different approaches, that is, crystal structures and protocols, were
validated and the best one selected by comparing the docking orientation of
moenomycin with the one found in the crystal structures, by visual inspection. The
following models for MGT from S aureus have been used for the docking
experiments: 3HZSm–3HZS48 changing to wild type, by mutating Asn100 to Asp,
3VMRm–3VMR49 modelling the missing loop residues (2 residues) with loop
search, 3NB6sa-Homology model of MGT S. aureus sequence using 3NB6 (ref. 11)
(PGT from A. aeolicus) with complete loop as template, 3VMSm–3VMS49
modelling missing loop (7 residues) using the loop in 3NB6 (ref. 11) as template.
From these receptor models, 3HZSm was able to reproduce the binding
orientation of moenomycin A as found in the crystal structure (see Supplementary
Fig. 25; a, green: crystal structure; grey; docked structure). The 3VMRm model
produced similar orientations for moenomycin but with different orientation of the
D ring. In 3NB6sa model, moenomycin was binding in the same binding pocket
but its orientation was always different, with phosphoglycerate (G) portion of the
molecule facing either to the solvent, the donor or acceptor binding site. In the
3VMSm model, which has the most open groove between the donor and acceptor
site, moenomycin was actually oriented partly across the acceptor binding site.
Induced ﬁt protocol on those models did not produce better moenomycin binding
orientations compared with the standard docking protocol.
In vitro PG biosynthesis. The cell-free particulate fraction of B. megaterium KM
(ATCC13632), capable of catalysing the polymerization of PG from UPD-linked
precursors was performed as described previously61. B. megaterium was grown
in standard medium, harvested and washed with Tris-buffer by centrifugation.
Resuspended bacteria were subjected to three freeze/thaw cycles (5min
dry ice, followed by 10min at RT), homogenized by the glass homogenizer and
centrifuged all at 4 C, leaving most of the cell wall in the pellet. Resuspended
pellet was combined with UDP-N-acetylmuramyl-pentapeptide, [14C]UDP-N-
acetylglucosamine and individual compounds or antibiotics (that is, vancomycin
hydrochloride or moenomycin A), and incubated at for 3 h at RT, placed in a
boiling water bath for 3min to inactivate enzymes and to prevent any further lipid
II transformation, and analysed by TLC on silica gel plates. After separation, plates
were dried, exposed to phosphorimaging screen (1 week), scanned by Typhoon
8600 calculating the integrated density value of each band on silica gel. Changes of
PG or lipid II were calculated as a percentage from negative control (for more
details see Supplementary Methods).
Inhibition of glycosyltransferase. Inhibition of glycosyltransferase was measured
using a ﬂuorescence detection method62 by adding 1 mM S. aureus MGT to
1.45 mM ﬂuorescent dansyl-Lys Lipid II and different concentration of inhibitors,
all in a buffer of 50mM Tris pH 8 containing 10mM MnCl2, 0.08% (v/v) decyl
PEG, 10% (v/v) DMSO, 100mgml 1 hen egg-white lysozyme, in 96-well microtiter
plates. Initial rates were measured as a decrease in ﬂuorescence (ex/em: 340/
521 nm) and calculated as a percentage compared with no inhibitor as negative
control (0% of rate inhibition) and moenomycin A (Sigma, Cat. no.: 32404) as
positive control (100% of rate inhibition). The data were ﬁtted to a simple
saturation model of inhibitor binding to a single site, from which IC50 values were
extracted. Moenomycin A showed an IC50 of 5 mM in this assay.
Minimal inhibitory concentration (MIC) determination. The compounds along
with standard antibiotics were serially diluted twofold across the wells of 96-well
standard polystyrene non-treated plates (Corning 3370). Compounds and standard
antibiotic controls ranged from 1.28mgml 1 to 0.06 mgml 1 with ﬁnal volumes
of 50ml per well. Bacteria were cultured in Brain–Heart Infusion (Bacto labora-
tories, Cat. no. CM1135B) at 37 C overnight. A sample of each culture was then
diluted 40-fold in fresh brain–heart infusion broth and incubated at 37 C for
2–3 h. The resultant mid-log phase cultures were diluted to 5 105 c.f.u. ml 1 then
50 ml was added to each well of the compound-containing 96-well plates giving a
ﬁnal compound concentration range of 64 mgml 1 to 0.03mgml 1 in 2.5
105 c.f.u. ml 1. All the plates were covered and incubated at 37 C for 24 h. MICs
were determined visually as the lowest concentration showing no visible growth.
Antibiotic control compound vancomycin (Sigma, Cat. no.: 861987) was
prepared as water solution, while moenomycin A (Sigma, Cat. no.: 32404) was
dissolved in DMSO and 20mM ammonium acetate, due to solubility issues. The
average MIC for moenomycin for S. aureus was, however, within the range of
recent literature35.
In vivo mouse mammary gland infection model. For the infection of the mice,
S. aureus Newbould 305 (ATCC 29740) isolated from a clinical mastitis cases63 was
used and prepared. The procedure for mouse mammary gland infection has been
recently described64. CD-1 lactating mice were utilized 12–14 days after giving birth,
with pups weaned 1–2h before bacterial inoculation of the mammary glands.
Inoculation of both left (L4) and right (R4) glands of the fourth abdominal mammary
gland pair of anesthetized mice with 150 c.f.u. of S. aureus, was done using 32-gauge
syringes (blunt needle). The antimicrobial formulation was instilled into the
mammary gland of anesthetized mice at 4 h after bacterial inoculation, followed by i.p.
administration of postoperative analgesic Buprecare. Mice were killed 14 h post
treatment, mammary glands (two per mouse) were harvested, weighed and
homogenized. Bacterial c.f.u. counts were obtained after quantiﬁcation of serial
logarithmic dilutions of mammary gland homogenates on TSA. The detection limit
(DL) was 1.7 log10 c.f.u. g 1 gland weight (for more details see Supplementary
Methods). The animal experiments were approved by the Ethical Committee of the
Faculty of Veterinary Medicine, Ghent University (EC2009/133).
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